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Nathalie Mestdagh, Joël Mercier, Frédéric Mievis, Fabrice Giacomelli, 
Christian Lemaire, Eric Salmon, André Luxen and Alain Plenevaux
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Preface to ”Radiolabelled Molecules for Brain
Imaging with PET and SPECT”
Positron emission tomography (PET) and single-photon emission computed tomography 
(SPECT) are in vivo molecular imaging methods which are widely used in nuclear medicine for 
diagnosis and treatment follow-up of many major diseases. These methods use target-specific 
molecules as probes, which are labeled with radionuclides of short half-lives that are synthesized 
prior to the imaging studies. These probes are called radiopharmaceuticals. Their design and 
development is a rather interdisciplinary process covering many different disciplines of natural 
sciences and medicine. In addition to their diagnostic and therapeutic applications in the 
field of nuclear medicine, radiopharmaceuticals are powerful tools for in vivo pharmacology 
during the process of preclinical drug development to identify new drug targets, investigate 
pathophysiology, discover potential drug candidates, and evaluate the in vivo pharmacokinetics and 
pharmacodynamics of drugs.
The use of PET and SPECT for brain imaging is of special significance since the brain controls 
all the body’s functions by processing information from the whole body and the outside world. It is 
the source of thoughts, intelligence, memory, speech, creativity, emotion, sensory functions, motion 
control and other important body functions. Protected by the skull and the blood–brain barrier, 
the brain is somehow a privileged organ with regard to nutrient supply, immune response, and 
accessibility for diagnostic and therapeutic measures. Invasive procedures are rather limited for the 
latter purposes. Therefore, noninvasive imaging with PET and SPECT has gained high importance for 
a great variety of brain diseases, including neurodegenerative diseases, motor dysfunctions, stroke, 
epilepsy, psychiatric diseases, and brain tumors. This Special Issue focuses on radiolabeled molecules 
that are used for these purposes, with special emphasis on neurodegenerative diseases and brain 
tumors.
Molecular imaging of neurodegeneration has become a useful noninvasive clinical tool to early 
detect pathophysiological changes in the brain and is regarded to be of special importance for 
prognostic purposes, therapeutic decision making, and therapy follow-up. Alzheimer’s disease (AD) 
and Parkinson’s disease (PD) are regarded as the most common and known neurodegenerative 
disorders, with a growing impact especially in countries with rapidly increased life expectancies 
during the last decades. Misfolded proteins such as β-amyloid, τ -protein, α-synuclein together 
with neuronal dystrophy characterize the main pathology of these diseases. Furthermore, multiple 
neurotransmitter systems are affected and involved in the cellular pathology.
The initial review written by Uzuegbunam, Librizzi, and Yousefi provides an overview of the 
currently available PET radiopharmaceuticals, examining the timeline and important moments that 
led to the development of these tracers and offering an outlook that is especially focused on the design 
of α-synuclein-targeting radiotracers.
This review is followed by a number of articles describing other potential targets for diagnostic 
and/or therapeutic approaches towards AD and PD. Neuronal dystrophy in AD is accompanied 
by a reduced glucose metabolism, which can be measured with PET using the radiopharmaceutical 2-
deoxy-2-[18F]fluoroglucose ([18F]FDG). However, at the time at which significant reductions of 
[18F]FDG accumulation in brain regions become evident, AD has usually progressed into the clinical 
stage. In order to prevent and/or start early treatment of AD, disease diagnosis during the preclinical 
stage is needed. To address this issue, a novel metabolic brain network analysis of FDG-PET using
ix
kernel-based persistent features was proposed by Kuang et al. The FDG imaging data from 140 
subjects with AD, 280 subjects with mild cognitive impairment, and 280 healthy normal controls 
suggest that the approach has the potential of an effective preclinical AD imaging biomarker.
Synaptic loss is well established as the major structural correlate of cognitive impairment 
in AD. The ability to measure in vivo synaptic density could accelerate the development of 
disease-modifying treatments for AD. The synaptic vesicle protein 2 (SV2) is involved in synaptic 
vesicle tracking and regarded as a potential biomarker for the measurement of synaptic density. It 
consists of the three isoforms, A, B, and C, whereby SV2A, in particular, has been closely related 
to AD. Therefore, the selectivity of a radiopharmaceutical towards these different isoforms is an 
important issue. The article of Serrano et al. evaluates the in vivo specificity of [18F]UCB-H, a 
radiotracer with nanomolar affinity for human SVA2, by comparing the SV2A protein with SV2B 
and SV2C using microPET in rats.
The potential of nicotinic acetylcholine receptors (nAchRs), as indicators of cholinergic neuronal 
functions, has previously been reported by a variety of papers, including those of our group, to be 
reduced in AD and PD. In this Special Issue, the dibenzothiophene derivatives [125I]Iodo-ASEM and 
[18F]ASEM, isomers of our own ligand [18F]DBT10 (previously published in Molecules 20, 18387-421, 
2015), were preclinically characterized in pigs as suitable radiotracers for the imaging of homo- and 
heteromeric α7 nAchRs with PET and SPECT.
The sleep–wake cycle in patients with AD has been associated with τ pathology and the 
dysregulation of the neuropeptide orexin, which exerts its action by binding to orexin receptors 1 
and 2. There is evidence that the OX2R gene’s rs2653349 and rs2292041 polymorphisms may be 
associated with AD. The FDA has approved orexin as a drug to treat insomnia. For these and 
other reasons, imaging of the orexin receptor status with PET and/or SPECT appears to be highly 
impactful. Bai et al. report a new PET radiotracer for orexin receptors neuroimaging which was 
preclinically used for PET investigations in mice and monkeys.
The following article deals with the adenosine A2A receptor (A2AR), which is regarded as a 
particularly appropriate target for the non-dopaminergic treatment of PD. Schröder et al. selected the 
known A2AR-specific radiotracer [18F]FESCH and developed a simplified two-step one-pot 
radiosynthesis, in order to promote its clinical applicability. The radiotracer was used to investigate 
the suitability of rotenone-treated mice as an animal model of PD.
In a previous issue (Molecules 21, 650, 2016), the development of 18F-labelled PET ligands for the 
molecular imaging of the cyclic nucleotide phosphodiesterase 2A, a key enzyme in the cellular 
metabolism of the second messengers cAMP and cGMP, was reviewed, and PDE2 was proposed as a 
viable target for future drug development for AD, PD, Huntington’s chorea and psychiatric diseases. 
Two articles by Ritawidya et al. dealing with fluorine-containing benzoimidazotriazine-based 
PDE2A-selective ligands for potential PET imaging are included in this Special Issue—the first 
describes the synthesis and in vitro evaluation of 8-pyridinyl-substituted benzo[e]imidazo[2,1-c]
[1,2,4]triazines as selective PDE2A inhibitors, and the second describes the radiosynthesis and 
biological evaluation of [18F]BIT1, the best candidate among this series.
Usually, it is broad basic and clinical research on the involvement of potential imaging targets in 
brain diseases that strongly support the development of related PET/SPECT radiotracers. However, 
the review of Cummings et al. about the molecular imaging of opioid receptors (ORs) and 
opioid-receptor-like receptors (ORL) concludes that, in this field, it applies only to μOR, while there 
is scant documentation of δOR, κOR or ORL1 receptors in healthy human brain or in neurological
x
and psychiatric disorders. Here, clinical PET research must catch up with the recent progress in 
radiopharmaceutical chemistry.
With the development of radiolabeled amino acids for PET and SPECT imaging, a completely 
different set of targets for molecular brain imaging was facilitated: brain tumors. The identification 
of LATI, the sodium- independent L-type amino acid transporter 1, as a light chain of the CD98 
heterodimer which is strongly overexpressed in C6 glioma cells, stimulated the radiolabeling of 
a great variety of amino acids for the purpose of brain tumor imaging. The review by Werner 
et al. summarizes the clinical value of a variety of tracers that have been used in recent years, 
for the following indications: the delineation of tumor extent (e.g., for planning of resection or 
radiotherapy), the assessment of treatment response to systemic treatment options such as alkylating 
chemotherapy, and the differentiation of treatment-related changes (e.g., pseudoprogression or 
radiation necrosis) from tumor progression. It also provides an overview of promising newer tracers 
for the investigation of these questions. The authors conclude that currently, the best-established PET 
tracers in neuro-oncology are radiolabeled amino acids targeting L-system transporters.
A thematically related review by Drake et al. on brain tumor imaging by PET is focused on 
glioblastoma. It includes most recent experimental approaches such as sigma receptor imaging, 
as well as PET imaging of the programmed death ligand 1 (PD-L1), the ADP-ribose polymerase 
(PARP) and the mutated form of isocitrate dehydrogenase (IDH). The authors conclude that these 
new PET imaging targets have the potential to enhance diagnosis, staging, and treatment approaches 
for glioblastoma.
In summary, I regard this to be an interesting collection of papers to get an overview on 
radiolabeled molecules which are preclinically and clinically used for molecular brain imaging. 
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Abstract: Ironically, population aging which is considered a public health success has been
accompanied by a myriad of new health challenges, which include neurodegenerative disorders
(NDDs), the incidence of which increases proportionally to age. Among them, Alzheimer’s disease
(AD) and Parkinson’s disease (PD) are the most common, with the misfolding and the aggregation of
proteins being common and causal in the pathogenesis of both diseases. AD is characterized by the
presence of hyperphosphorylated τ protein (tau), which is the main component of neurofibrillary
tangles (NFTs), and senile plaques the main component of which is β-amyloid peptide aggregates
(Aβ). The neuropathological hallmark of PD is α-synuclein aggregates (α-syn), which are present as
insoluble fibrils, the primary structural component of Lewy body (LB) and neurites (LN). An increasing
number of non-invasive PET examinations have been used for AD, to monitor the pathological
progress (hallmarks) of disease. Notwithstanding, still the need for the development of novel detection
tools for other proteinopathies still remains. This review, although not exhaustively, looks at the
timeline of the development of existing tracers used in the imaging of Aβ and important moments
that led to the development of these tracers.
Keywords: Alzheimer’s disease; Parkinson’s disease; β-amyloid plaques; neurofibrillary tangles;
α-synucleinopathy; positron emission tomography (PET); diagnostic imaging probes
1. Introduction
Of all the causes of dementia, AD stands in first place and makes up the largest part—about
two-thirds—of all differential diagnoses [1–3], and it is the most common form of dementia in persons
older than 65 years [4]. Others have vascular dementia, mixed dementia, PD, Lewy body dementia
(LBD) or frontotemporal degeneration (FTD) [2]. Although AD and PD present markedly different
clinical and pathological features, many mechanisms involved in AD and PD may be the same, such
as mutation in genes, the roles of α-synuclein and tau protein aggregates in oxidative stress and
mitochondrial dysfunction, dysregulation in the brain homeostasis of iron [5].
The WHO in 2012 named the prevention and control of neurocognitive disorders (mild cognitive
impairment (MCI) or Alzheimer’s type dementia) a global public health priority. As of 2012, it was
estimated that worldwide 35.6 million people are living with dementia. By 2030 this number will
double and by 2050 triple [3]. The World Alzheimer Report also in 2018 estimated that there are
50 million people in the world with dementia. This number by 2050 is likely to rise to about 152 million
people [2] a projection not far from that made by the WHO way back in 2012.
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In the pathogenesis of AD two proteins are implicated β-amyloid peptide aggregates (Aβ) and
tau. Based on several scientific evidences, AD is histopathologically characterized by the progressive
deposition of Aβ peptides into the interneuronal space [2,6,7]. The pathogenic pathways leading to AD
involve several mechanisms which include the dysfunction of cholinergic neurons and the aggregation
of tau, however, it has been shown that the amyloid cascade plays a significant role.
The amyloid cascade assumes that the pathogenesis of AD is as a result of a dysfunction in
the synthesis and the secretion of the amyloid precursor protein (APP), usually cleaved by the
proteases in the secretase family. Normally, the cleavage of APP by α-secretase within the Aβ domain
releases soluble APP-α which is non-pathologic, whereas, in pathology, Aβ is generated from APP via
successional cleavages by β-secretase followed by the γ-secretase complex, which cuts the γ-site of
the carboxyl-terminal fragment of APP producing two major Aβ isoforms: Aβ1-42 and Aβ1-40, which
subsequently aggregate to form β-amyloid plaques [8,9]. Aβ1-42 comprises a major part of amyloid
plaques owing to its low solubility and tendency to form aggregates with β-pleated sheet structure [9].
Neurodegeneration and neuronal dysfunction are caused by the binding of extracellular Aβ
oligomers to the neuronal surface, leading to functional disruption of a number of receptors, finally
culminating in dysfunction and neurodegeneration [2,10]. The accumulation of hyperphosphorylated
tau protein in neurons, which normally is a microtubule-associated protein (MAP) abundantly
expressed in the central nervous system, is another key player in the pathogenesis of AD. As a result
of abnormal hyperphosphorylation the protein self-aggregates and forms paired helical filaments
(PHF), which leads to the formation of intracellular neurofibrillary tangles, which ultimately block the
neuronal transport system [2,11,12].
A definitive diagnosis of AD still requires a histological examination of post-mortem brain
sample [13–15]. However, in living patient’s cerebrospinal fluid (CSF) biomarkers and positron
emission tomography (PET), in combination with several new clinical criteria can assist in the
diagnosis [16,17], and for symptomatic patients with familial early-onset AD, it is recommended to
undergo clinical genetic testing together with their asymptomatic relatives [18–20].
The European Medicines Agency has presented the measurement of Aβ peptides and total tau
protein levels in the CSF as a complementary usable tool in the diagnosis and monitoring of AD [21,22].
Albeit a less expensive method of evaluation, the method is invasive and carries the risks of adverse
effects and discomfiture associated with a lumbar puncture [23–25].
Non-invasive modern imaging techniques allow to identify either patients who are at risk of
developing AD, and also to monitor disease progression or both [26–28]. Positron emission tomography
(PET) imaging especially, which is superior to other imaging techniques in terms of sensitivity, since
only picomolar concentrations of the radiotracers are required allows to visualize, characterize and
quantify physiological activities at molecular and cellular levels [29,30]. Hence, it may serve as an
important diagnostic tool in the field of drug discovery and development, in order to monitor disease
progression and the interaction of ligands with their targets.
Aβ is the most studied and first target for the neuroimaging of AD [31], hence it is no surprise
that there are already selective PET radiotracers for its imaging. In 2003, Mathis et al. reported the
carbon-11 labeled Pittsburgh compound B ([11C]PiB), and the first successful Aβ-selective PET radioligand,
which is a derivative of thioflavin (Th-T) an amyloid-binding histological fluorescent dye [32,33].
The discovery of [11C]PiB led to further tracer development of other Aβ tracers. Three of which
are already FDA approved and are 18F-labeled [27] (a radioisotope with a relatively longer half-life of
109.7 min [34], in comparison to carbon-11 with a shorter half-life of 20.3 min, a property that logistically
limits its use to centers with cyclotron on-site [35]): [18F]florbetaben (Neuraceq) [36]; [18F]florbetapir
(Amyvid) [37]; [18F]flutemetamol (Vizamyl) [38].
So far, there are other findings that the density and neocortical spread of NFTs correlate better with
neurodegeneration and cognitive decline in AD patients [39–42], in spite of Aβ pathology temporarily
preceding tau pathology [27]. Recent evidence further corroborates initial findings of the dominant role
2
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of tau in the pathogenesis of AD [39,43,44], backing this protein as a diagnostic as well as a therapeutic
target [45].
Moreover, since apart from AD there are other NDD associated with amyloid pathology, amyloid
imaging is not enough to differentiate dementia subtypes [27]. Nevertheless, NFTs are also present in
other dementias, like FTD, some neurodegenerative movement disorders like corticobasal degeneration
(CBD) and progressive supranuclear palsy (PSP) [45]. More recently, Vanhaute et al. reported that the
loss of synaptic density in the medial temporal lobe is linked to an increased tau deposition in AD [46,47].
Hence, a radiotracer, that could quantify NFTs would help to understand the pathophysiology and
clinical management not only of AD, but these other NDD. Furthermore, when done in conjunction
with amyloid diagnosis, PET imaging of NFTs might provide a way to distinguish between AD
dementia (when there are NFTs and Aβ present) and non-AD dementia (when NFTs and Aβ are absent).
Furthermore, the application of Aβ imaging is just approved for the exclusion of AD in patients with
cognitive impairment but amyloid PET-negative [48]. Also, it is being evaluated as a diagnostic tool
for the definition of the preclinical stages of AD [49]. Due to the abovementioned reasons, several
academic and industrial groups are currently making efforts to develop tau aggregate tracers, which
are not only selective, but also with minimal or no off-target binding [50–53].
The α-synucleinopathies: PD, LBD, multiple system atrophy (MSA) have their pathological hallmark
as α-syn aggregates included in Lewy body (LB), Lewy neurites (LN), and glial cytoplasmic inclusions
(GCI) in MSA [54–57]. α-Synuclein is a small (140 amino acid residues) highly soluble presynaptic protein
that normally exists in a native unfolded state. In PD, there is formation of highly ordered insoluble
aggregates known as α-syn fibrils, which are stabilized by β-sheet protein structure [58–61].
The identification of point mutations in the SNCA gene in familial cases of PD nearly 23 years
ago first linked α-syn to PD [62], and this was corroborated by the additional discovery that increased
genetic copies of α-synuclein in the form of duplications and triplications of the SNCA gene are
enough to cause PD; the higher gene copy, the earlier the age of disease onset and the more severe the
disease [63–65]. More recently, further investigation into the genetic aspects of the disease culminated
in genome-wide association studies (GWAS), and candidate gene association studies which have
repeatedly validated that statistically relevant signals linked to PD are common variants near the
SNCA, LRRK2, MAPT and low-frequency coding variants in GBA (glucocerebrosidase) genes [66].
Moreover, in GWAS so far, not less than 41 risk loci for PD have been identified [67,68]. Even in
the sporadic forms of the disease, α-syn as a candidate risk gene has shown significant associations
between variation within the SNCA gene and a higher risk of developing PD [69].
It has been known for some time now based on fairly strong evidence that the motor phase of
classical PD occurs after a premotor period that could last for a considerable number of years if not
decades [70]. Before the appearance of motor symptoms, at least 50% of substantia nigra (stage 3 of the
Braak staging) cells have to be lost [71,72] and likely a loss of a higher percentage of dopaminergic
nerve endings in the putamen [73]. Based on the findings of Braak et al., there are 6 stages in which the
deposition of α-syn in LBs and LNs occurs sequentially and additively [74]. Overall, it is evident that
pathophysiological changes in the central nervous system in PD involves the abnormal deposition
of α-syn occurs early in PD, hence the earliest definition and most precise detection of premotor PD
should be based on the imaging of aggregate α-syn, not dopaminergic alterations.
Despite the high abundance of α-syn in the nervous system, where it constitutes 1% of all cytosolic
proteins [75], the amount of α-syn aggregates, however, in LBD and MSA brain is 10-fold or lower than
that of Aβ in AD brain, and in advanced cases in the range of 50–200 nM in brainstem and subcortical
regions, and moreover, they typically have a small size, which complicates detections [76,77].
Unlike Aβ, but similar to NFTs, LBs are intraneuronal and GCI are intraglial, hence any tracer for
the detection α-syn must readily pass through the blood-brain barrier (BBB), and subsequently the cell
membrane to access its target [77,78]. Unfortunately, due to the structural similarity of β-pleated sheets
amongst different species of amyloid fibrils, and the colocalization of α-syn aggregates with other
aggregating amyloid proteins like Aβ plaque and tau fibrils tracer, selectivity for α-syn aggregates
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over the others is a desired quality. This explains why non-selective ligands are more common than
selective tracers [79–82].
Generally, good PET radiotracers for brain amyloid imaging should have the qualities prerequisite
for successful central nervous system ligands [83,84]. A good brain penetration via passive diffusion,
relatively small molecular weight (< 700 Da), moderate lipophilicity 1–3 at physiological pH (7.4), lack
of P-glycoprotein substrate activity, lack of BBB permeable radioactive metabolites or intracerebral
radiometabolites, etc. Most importantly, they should with high affinity selectively and reversibly bind
to targets in the brain. Target selectivity an important trait depends on factors such as the relative
affinities of the tracer to target (specific binding) and non-target (non-specific binding) sites, its brain
distribution and the relative concentration of the binding sites. Both target and non-target binding
sites should be considered when developing a brain tracer [77,81,82,85,86].
Additionally, a slow and reversible off-rates coupled (koff) with relatively high on-rates (kon),
which is reflected by an equilibrium dissociation constant (Kd) in the range of 1 nM. A low Kd
value in the nanomolar (nM) range could guarantee that the radioligand-amyloid complex remains
intact long enough for a washout of non-specifically bound tracers to occur, hence allowing good
signal-to-noise contrast. It is also needed especially when dealing with short-lived PET radioisotopes
like 11C with a half-life of 20.3 min and 18F half-life 109.8 min. A standard uptake value (SUV) in the
brain > 1.0 within a few min of intravenous injection is also required. Large molecules, antibodies,
and nanobodies can cross the BBB, however they are unable to attain an SUV value > 1.0 a few min
post-injection (p.i), and this has been a disqualifying criterion for large ligands labeled with short-lived
radioisotopes [81,85,86].
2. PET Imaging Agents for the Diagnosis AD and PD
2.1. PET-Tracers for the Imaging of Aβ Plaques
2.1.1. First Generation of Aβ PET Tracers
Benzothiazole (BTA) Derivatives
The development of amyloid-specific imaging compounds is based mostly on conjugated dyes
like Th-T (Figure 1) and Congo red, that are used in postmortem AD brain sections for the staining
of plaques and tangles [87–90]. The synthesis of the hundreds of the derivatives of the latter by the
Pittsburgh group gave rise to a series of pan-amyloid imaging agents that showed nanomolar binding
affinities for Aβ, tau, α-syn, and prion aggregates. Notwithstanding, a number of these compounds
ionize at physiological pH, and for this reason did not achieve high brain uptake ( > 1 SUV) a few min
post intravenous injection [32,91].
 
Figure 1. Structures of thioflavin-T, [11C]PiB, and the FDA approved Aβ-PET tracers: [18F]florbetaben,
[18F]florbetapir, and [18F]flutemetamol.
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The examination of the derivatives of Th-T derivatives followed: making the dye neutral by the
removal of the methyl group attached to the benzothiazole ring via the nitrogen atom of the ring,
hence the positive charge on the benzothiazole ring gave rise to compounds (known as benzothiazole
anilines or BTAs) with improved lipophilicity, [11C]6-Me-BTA-1 (Figure 2) being the best in the series.
It was 6-fold more lipophilic, and readily crossed the BBB in brains of rodents, and showed 44-fold
more affinity for synthetic Aβ fibrils (Table 1) than did Th-T [92,93].
 
Figure 2. Structures of the predecessors of FDA approved Aβ-PET tracers: [11C]6-Me-BTA-1, [11C]SB-13,
[18F]FMAPO.
Further manipulation of the benzothiazole ring by derivatizing the C-6 position and varying the
degree of methylation of the aniline nitrogen gave a series of ligands with high affinity for Aβ fibrils.
Of these radiotracers, the monomethylated-aniline derivative ([11C]PiB [11C]6-OH-BTA-1 (Figure 1),
was selected (which will be referred to as just PiB throughout the paper). It showed a combination of
favorable pharmacokinetics as PiB, the highest brain clearance 5 times faster than at 30 min and a high
binding affinity to Aβ plaques approximately 207-fold than Th-T [94] (Table 1), with a very low binding
affinity to aggregated tau, with a ratio of tau-to-Aβ ((Kitau/KiAβ) greater than 100-fold [33,95–97].
Clinical study with PiB showed that AD patients retained PiB in areas of association cortex known
to contain large amounts of amyloid deposits [33]. Further clinical studies to confirm if there is abnormal
binding of PiB in clinically healthy individuals showed that PiB-PET not only was able to detect
Aβ deposits in AD patients but also in some nondemented patients, hence suggesting that amyloid
imaging might be useful in the detection AD in its preclinical stages [98]. Additionally, it was confirmed
that there is a direct correlation of the retention of PiB in vivo with region-matched quantitative
analyses of Aβ plaques in the same patient, upon post-mortem examination of clinically diagnosed
and autopsy-confirmed AD subjects [99]. This too additionally validated PiB-PET as a method for
evaluating the amyloid plaque burden in AD subjects [33].
In an experiment carried out by Serdons et al. it was discovered that more than 80% of the
tracer remains intact 60 min p.i [100,101]. The radiometabolites of PiB found in animal and human
blood, due to their high polarity did not easily pass through the BBB [94,100]. One of the identified
radiometabolites 6-sulfato-O-PiB, and others produced in rat brain, built up over time and complicated
pharmacokinetic analyses [95,102]. Fortunately, the intracerebral metabolism of PiB is limited only to
rats and was not observed in mice, humans, and other nonhuman primates [95].
The success of PiB for in vivo imaging of Aβ plaque deposition led to the development of an 18F
analog, which would perform similarly. The development of 18F-labeled radiotracers for the imaging
of amyloid deposits in AD was on the basis that, as previously mentioned, carbon-11 with which PiB
was labeled has a half-life 20.3 min, and this limits its use to PET centers with cyclotron on-site and
with experience in 11C-radiochemistry [33,36].
A variety of structural analogs were developed and evaluated both in vitro [103] and preclinically,
out of which flutemetamol also known as [18F]GE067 ([18F]3′F-PiB) (Figure 1) was selected [104].
In vivo studies in rats and mice showed that it has similar pharmacokinetics as PiB. They both readily
entered the brain, however, flutemetamol which is more lipophilic was washed out more slowly from
the brain approximately 1.4 times slower (Table 1), especially from the white matter [105].
Initial human studies, in which flutemetamol and PiB were compared in AD and control subjects,
the former showed similar uptake and specific binding attributes as PiB [104]. A phase-III trial
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demonstrated that it is safe with high specificity and sensitivity for the in vivo detection of brain Aβ
density [106,107]. It was approved by the FDA in 2013 [108].
The Stilbene and Styrylpyridine Derivatives
The discovery of [3H]SB-13, a stilbene derivative which showed a high binding affinity to
postmortem AD brain homogenates [109], led to subsequent labeling with carbon-11 to afford
[11C]SB-13 (4 methylamino-4′-hydroxystilbene) (Figure 2). The tracer displayed a good brain uptake
and brain clearance (Table 1) [110]. In vivo human PET-imaging it displayed properties similar to PiB
in discriminating between AD and non-AD patients [111].
The similarities between PiB and SB-13 in addition to their similar biological properties are also in
their chemical structures: the presence of a highly conjugated aromatic ring with an electron-donating
group (N-methylamine (-NHCH3) or hydroxyl (-OH)) at the end of the molecule and the relative
planarity of both ligands [90].
Early attempts at the development of 18F-labeled SB-13 was unsuccessful, due to the high
lipophilicity and high nonspecific binding in the brain shown by [18F]SB-13 derivatives with a fluoroalkyl
group on either ends of their structures. In order to reduce the lipophilicity of the ligands, the stilbene
scaffold was further modified by the introduction of different functional groups. Based on in vitro and
in vivo biological assays a NH-CH3 derivative [18F]FMAPO, with a 2-fluoromethyl-1,3-propylenediol
group tethered to the phenol end of molecule (Figure 2) was selected for not only exhibiting a selectivity
and specific binding to Aβ plaques in AD brain homogenate binding studies but also for showing a
higher brain penetration in 2 min, which was nearly three times higher than that of flutemetamol in
5 min (Table 1). Although it displayed a slower washout than the latter, at 60 min p.i. the concentration
in the brain was less than 1%ID/g [103,112].
In order to circumvent the complication of in vivo metabolism, which might result due to the
presence of a chiral center in the fluorine containing side chain, another series of stilbene derivatives
were synthesized with polyethylene glycol (PEG) units of different lengths (n = 2–12) tethered to the
4′-OH group, with 18F attached at the end of PEG side-chain. This also provided a way to maintain
a small molecular weight, adjust lipophilicity and facilitate a simple 18F-labeling by nucleophilic
substitution. Structure-activity relationship (SAR) studies showed that high binding affinity was
maintained when n < 8, and from 8 and above there was a significant reduction in binding affinity.
There was a noticeable decrease in brain penetration as shown by in vivo biodistribution studies when
n > 5 [113–115], perhaps partly due to increased molecular weight and total polar surface area (tPSA).
Of the four ligands which performed well in in vitro and in vivo assays, florbetaben (Figure 1) also
known as AV-1, or BAY94-9172 with n = 3, was selected. Although the tracer did not have the highest
affinity for Aβ in comparison with its structural analogs or the fastest washout rate (Table 1) from the
brain of healthy mice [114], it, however, showed selectivity for Aβ and non-appreciable binding to
NFTs, Pick bodies, LBs and GCIs [112]. Furthermore, binding to postmortem cortex of subjects with
FTD or postmortem brain tissue from other NDDs like tauopathies and α-synucleinopathies was not
observed [114]. With no observable effects at 100x the expected human dose in preclinical toxicity
studies in a different animal species, florbetaben was deemed suitable for human studies [116]. In 2014,
it was approved by the FDA [117].
In order to obtain an Aβ tracer with improved in vivo biological properties of targeting Aβ
plaques, so that a high signal to noise ratio is quickly and more efficiently achieved, some critical and
competing factors were taken into consideration: initial brain uptake, washout from non-afflicted brain
regions, in vivo metabolism, and optimal time in the accomplishment of the highest target-to-non-target
ratio. For this reason, the stilbene ring was further explored. The fluoropegylation discussed above
was extended from stilbene to styrylpyridine series. This was achieved by exchanging one of the
stilbene benzene rings for a pyridine ring. This led to the development of florbetapir also known as
[18F]AV45 [118]. It displayed 2-fold more binding affinity to Aβ in postmortem AD brain homogenates
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than florbetaben. Nevertheless, it showed a slightly lower initial uptake and washout rate from the
brain of healthy mice than florbetaben (Table 1) [114,119].
An initial clinical trial with a tertiary amine derivative, which was similar to florbetapir but for
the dimethylation of the aniline nitrogen suggested lower than expected brain uptake, probably due to
a fast in vivo metabolism by N-demethylation. Of all the evaluated ligands, faster brain kinetics was
exhibited more by florbetapir, and it also displayed an excellent brain uptake and washout in humans.
The signal to noise ratio in the brain approaches an optimal level in 40–60 min post intravenous
injection. In vitro metabolic stability assay also demonstrated that it is more stable towards microsomal
degradation than florbetaben [115,118].
In AD patients, florbetapir from 30 min p.i. showed a clear separation between cortical
and cerebellar activity, hence making it possible to start brain PET scan 30–50 min p.i. [120].
Significant elevations of tracer uptake in several brain regions of AD patients in comparison with controls
were observed upon visual evaluation and analysis using semiquantitative methods. Results from
phase III clinical trial showed a distinct correlation between the distribution of Aβ and florbetapir PET
images at postmortem examination. Furthermore, no serious side effects were recorded in any of the
clinical trials of the tracer [121]. It was approved by FDA in 2012 [31,122].
2.1.2. Second Generation of Aβ PET Tracers
Benzofuran, Benzoxazole and Imidazobenzothiazole Derivatives
Other notable Aβ tracers include flutafuranol, also known as [18F]AZD4694 ([18F]NAV4694)
(Figure 3) a benzofuran derivative, developed by researchers at AstraZeneca in Sweden [123].
Its development, amongst other second generation of 18F-labeled Aβ imaging agents [124] was
spurred by the report that flutemetamol and florbetaben, have high level of non-specific white matter
retention [116,125,126], which could be a limitation in situations when insoluble Aβ levels are low,
due to a spillover effect of radioactivity to adjacent cortical regions from nonspecific binding in white
matter. Hence, they may not be useful for correct mapping of Aβ plaque load in low-density regions
and in prodromal phases of AD.
 
Figure 3. Structures of second generation Aβ-PET tracers: [18F]AZD4694, [18F]MK-3328, [18F]AD-269,
[18F]FIBT.
Using the intravenous cassette dosing technique to compare the pharmacokinetics of flutafuranol
and flutemetamol, it was seen that they were both readily taken up in the brain tissue and washed out
of the brain normal rats between 2 and 30 min, but with less than 10% of concentration of flutafuranol
at 2 min remaining at 30 min, a time point at which flutemetamol still had up to 28% of the initial
concentration at 2 min (Table 1) [103]. With its fast binding kinetics, it could perform better than other
Aβ tracers, like PiB, which display, based on time-activity curves, slower kinetics with a blunt peak of
specific binding accompanied by a slower decline [95,127]. Consequently, its rapid binding kinetics
makes quantification using data based on short acquisition possible. Furthermore, using the cerebellum
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as a reference region in approaches like reference Logan, valid estimates of Aβ binding could be easily
acquired [128]. It is presently in its phase III of clinical trial for the evaluation of its efficacy and safety
for the detection of cerebral Aβ in comparison with postmortem histopathology [129,130].
A benzoxazole derivative [18F]MK-3328 (Figure 3), which was selected amongst four other
fluoroazabenzoxazoles owing to its favorable kinetic profile, shown in rhesus monkey PET studies,
a relatively low binding potential in white matter and cortical grey matter, which is approximately
2× lower than that of florbetapir, a relatively lower lipophilicity at log D 2.91, in comparison with an
analog [18F]AD-269 with similar properties, but more (1.21 fold) lipophilic (Table 1).
In autoradiography studies, it was observed that in an AD patient brain slice that MK-3328 showed
punctuate, displaceable binding in the cortical gray matter, with no noticeable binding in the
cerebellum [131]. Investigation of the tracer in healthy human volunteers and AD subjects was
also being carried out at the time until the premature termination of the clinical trial after the
completion of phase 1 of its clinical trial [132].
The best imidazobenzothiazole derivative [18F]FIBT (Figure 3) was reported by the Yousefi et
al. group and it was described as the first high-contrast Aβ-imaging agent on par with florbetaben
(Figure 4). It also displayed excellent pharmacokinetics, selectivity and high binding affinity to Aβ
fibrils in vitro and in vivo comparable to the gold standard PiB [133–135].
Their results also showed that FIBT has a better pharmacokinetic profile and specific binding
affinity to Aβ than florbetaben in transgenic mice. This could be expected from a tracer with >300-fold
selectivity for Aβ in comparison to the other amyloid protein aggregates a Ki >> 1000 nM to recombinant
tau and Ki >> 1000 nM to α-syn aggregates [114,136]. Further investigations of the tracer in human
subjects are however yet to be carried out [133,135].
 
Figure 4. Exemplary sagittal PET images of the FDA approved Aβ PET-tracers of Alzheimer’s
disease patients with other select featured tracers, [11C]PiB, [18F]Florbetaben, [18F]Flutemetamol,
[18F]Florbetapir, [18F]Flutafuranol, and [18F]FIBT (reproduced with permission as agreed by Newlands
Press Ltd. [135]).
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2.1.3. The Clinical Utility and Consequences of Clinically Approved PET-Aβ Radiotracers
Since the clinical approval of the abovementioned three FDA approved PET-Aβ tracers as
diagnostic tools for the detection of neuritic (Aβ) plaques in live patients, there have been studies to
determine their clinical usefulness in the diagnosis AD. These studies have been subsequently and
specifically well-reviewed by Kim et al. [137], Barthel et al. [138], Chiotis et al. [139].
In general, the studies have showed that the use of the Aβ-PET tracers led to a moderate to
significant change in diagnosis, diagnostic confidence [140–145], and had a substantial impact on
change in the treatment and management plan of AD [137,144,146]. It is likely that the new generation
of Aβ-PET tracers with improved pharmacokinetics will allow for improved signal-to-noise ratio,
hence will be more suitable for the quantification of disease progression and therapeutic monitoring.
2.2. PET-Tracers for the Imaging of Tau Aggregates
As mentioned earlier, the tau protein plays a key role in the pathogenesis of AD [2,6,11,12].
The predominant aggregation of certain MAPT (tau gene) isoforms, either the 4-repeat (4R tau) or
the 3-repeat (3R tau) isoforms have been widely described in tauopathies. So, in addition to the
already mentioned properties every CNS tracer should possess [65,67,68,73,74], tau tracers must also
address 3R and 4R tau deposits. 3R and 4R tau proteins are the classifications of the 6 tau isoforms
according to their tubulin-binding domains [147,148]. In a normal brain, there are equal amounts
of the 3R and 4R tau proteins, as well as in AD. An imbalance in tau ratio can lead to abnormal tau
accumulation and lead to NDD as in tauopathies. For instance, there is an ample amount 4R tau in PSP,
CBD, and argyrophilic grain disease, in contrast, there is an abundance of the 3R tau in Pick’s disease
(PiD) [149]. Furthermore, tau tracers should also be able to bind to different tau folds, all of which will
facilitate the detection of tau pathology in both AD and non-AD tauopathies [150,151].
The identification of lead compounds for the imaging of Aβ proteinopathies has been relatively
easier since most β-sheet binding ligands have a high affinity for Aβ fibrils, with which NFTs coexist in
AD and both are colocalized in the gray matter structures [42,152]. In spite of controversy surrounding
the subject, PHFs predominantly found in NFTs in in vitro experiments suggest a β-sheet structured
core similar to that characteristic of Aβ and α-syn fibrillar aggregates [42]. There are recent reports
that there are α-syn containing aggregates present in AD [79,153]. Therefore, tau PET tracers should be
selective for tau aggregates over these aggregates as well.
In AD, there is a distinct difference in the concentration of Aβ relative to tau aggregates.
The concentration of Aβ is approximately 5–20 times higher than that of tau aggregates [154]. In spite of
this inequality in quantity, there is however a clear-cut regional pattern of Aβ and tau deposition in the
neocortex. The frontal cortex has the highest concentration of Aβ aggregates, while the temporoparietal
cortices have the highest concentrations of tau aggregates. Different distributions of tau aggregates are
also found in the different phenotypes. Although this has its own merits as it will facilitate differential
diagnosis of tauopathies, it means that it is unlikely a single tau PET tracer could bind to the whole
spectrum of tau polymorphism [42]. In this review, some select selective tau tracers already evaluated
in human subjects will be examined, together with other notable tau tracers.
2.2.1. First Generation of Tau-PET Tracers
The Arylquinolines
The THK-compounds (Figure 5) were as a result of the structural modification of the lead
compounds BF-158 and BF-170, arylquinoline derivatives. Even though in vitro fluorescence binding
affinity assay data and neuropathological suggested that they are good tau ligands, they showed poor
selectivity over amyloid plaques, and furthermore were unable to bind to tau present in non-AD
tauopathies. However, autoradiographic studies in AD brain section showed an uptake BF-158 in
brain regions which were NFT-rich. Biodistribution studies, analyzed using HPLC with a fluorescence
detector, showed a good uptake BF-158 (11.3% ID/g at 2 min p.i.) of BF-158 in the brain of normal
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mice but a slow washout with only 27.4% of the concentration at 2 min washed out at 30 min, which
suggested a high unspecific binding (Table 2). In contrast BF-170 performed better in the biodistribution
studies with good brain uptake, as well as a faster washout at 30 min than BF-158 [155] (Table 2).
 
Figure 5. Structures of the first generation tau-PET tracers: BF-158, BF-170, [18F]THK-523,
[18F]THK-5105, [18F]THK-5117, [18F]THK-5317(17), (S)-[18F]THK-5117 ([18F]THK-5351), [11C]PBB3,
[18F]Flortaucipir (AV-1451, [18F]T807), [18F]T808.
Structural modification of BF-170 led to the development of [18F]THK-523 (Figure 5) a
[18F]fluoroethoxy derivative. The introduction of an alkylether in the C6 position of the
arylquinoline structure improved its affinity and selectivity for tau aggregates relative to BF-170 [156].
However, competition studies showed that it has a relatively low affinity for recombinant tau fibrils (Ki
59.3 nM) and even lower for PHF in AD brain homogenates (Kd 86.5 nM) than synthetic heparin-induced
tau polymers (HITP) Kd 1.67 nM (Table 2), an evidence of the inadequacies of synthetic tau preparations,
which fails to completely replicate native tau aggregates in vivo [156,157].
Notwithstanding, it performed better in vivo than it did in vitro. In comparison to healthy controls,
it showed higher cortical retention in AD subjects and was distributed in the brain in accordance with
reported histopathological brain distribution of PHF in AD. Unfortunately, due to its high white matter
retention, a clear visualization of PET scans was not possible, and for this reason, it was not further
developed [158].
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Introduction of a secondary alcohol in the fluoroethoxy chain in BF-170 and the monomethylation
[18F]THK-5117 and dimethylation [18F]THK-5105 (Figure 5) of the aniline moiety gave tracers with
higher in vitro affinities (Kd) for both synthetic HITP tau fibrils and for human AD-PHF tau aggregates
than [18F]THK-523: they showed a 16-fold and 32-fold increase in affinity for human AD-PHF
tau aggregates in comparison to their direct predecessor [18F]THK-523, a higher in vitro selectivity
for tau versus Aβ; a coincidence with Gallyas-Braak staining and immunoreactive tau staining in
autoradiography staining of human AD brain sections but not with the distribution of PiB and an good
initial brain uptake and washout in normal mice than [18F]THK-523 [157] (Table 2).
An improved selectivity could be due to the secondary alcohol present, a polar terminus in
the molecules. Likewise the presence of a secondary amine in [18F]THK-5117 and a tertiary amine
in [18F]THK-5105 seemed to be behind the enhancement of tau affinity and better pharmacokinetic
profile [35].
However, the N-dimethylation of [18F]THK-5105 appeared to be its undoing: due to its
relatively higher lipophilicity (1.3x) than [18F]THK-5117 (Table 2), it showed in vivo nonspecific
binding in the brainstem, thalamus and subcortical white matter, which hinders interpretation.
Notwithstanding, it was still able to differentiate between AD patients and healthy control in its
first-in-human PET studies. Its distribution in the mesial and lateral lobes of AD patients is in
accordance with the reported NFT distribution in AD brain. Nevertheless, due to its inadequacies in
comparison to other known tau-PET tracers, it was not used further [159,160].
On the other hand, first human PET studies with [18F]THK-5117, demonstrated that it has faster
kinetics and better signal to noise ratio than seen in [18F]THK-5105, in comparison to which it is less
lipophilic. Clinical studies have been conducted with the (S)-enantiomer [18F]THK-5317, owing to
its better signal-to-noise ratio and pharmacokinetics than the (R)-enantiomer, a trait observed in the
quinoline derivatives [159,161–163]. One of the shortcomings of [18F]THK-5117 and its S-enantiomer
[18F]THK-5317 is their significant white matter binding, which might be owing to binding to β-sheet
structures of myelin basic protein [164].
In order to reduce white matter binding a feature common among 18F-labeled amyloid tracers,
a structural modified (S)-[18F]THK-5117 was developed, the phenyl ring was replaced with a pyridinyl
ring, which made [18F]THK-5351 more hydrophilic [164]. It not only displayed a quicker white matter
washout (lower white matter retention) and higher specific binding to AD tau-associated regions of
interest than [18F]THK-5317, but also its retention correlated with extra-hippocampal sub-regional
atrophy rather than hippocampal subfields, proffering hence different underlying mechanisms of
atrophy in early AD. Another remarkable advantage it has over other tau tracers was the lack of
significant retention in the choroid plexus or venous sinus, which could probably lead to a spill-in of
tracer signals into the brain [165,166].
Unfortunately, it has been reported to have high affinity to monoamine oxidase-B (MAO-B) (an
isoform of monoamine oxidase whose function is to catalyze the oxidation of monoamines [167,168])
in contrast with [18F]THK-5117, and also showed a greater off-target binding in the midbrain, thalamus
and the basal ganglia [169,170].
The Phenylbutadienylbenzothiazoles (PBB)
Following the observation that ligands with a π-electron-conjugated backbone longer than 13Å
showed affinities for pathological inclusions in a several tauopathies Maruyama et al. investigated
the affinities of a series of compounds with a different structural dimension to tau aggregates
and concluded that a core structure with specific distance from 13–19 Å contributes to affinity for
non-AD inclusions. Additionally, since ligands with a slender and flat backbone have the ability
to transverse and attach to channel-like channels in β-pleated sheets they developed a class of
compounds phenyl/pyridinyl-butadienyl-benzothiazoles/benzothiazoliums (PBBs) [171]. They are
structural analogs of fluorescent amyloid dye Th-T, with an all-trans butadiene bridge between the
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aniline and benzothiazolium moieties. Interestingly the resulting tracers were also able to detect tau
inclusions in non-AD tauopathies like CBD, Pick’s disease and PSP [172].
Amongst a series of analogs, [11C]PBB3 (Figure 5) was selected as the best candidate with an
affinity Kd for HITP 2.55 nM and nearly 50 folds selectivity for tau versus Aβ fibrils [35,172] (Table 2).
Based on preclinical findings in mice, the tracer was further evaluated in humans. It showed in
comparison with control accumulation in the medial temporal region of AD subjects. Its distribution
in AD human brains differed from that of PiB, suggesting minimal nonspecific binding to white matter,
although in both controls and AD brains it accumulated in dural venous sinuses. The use of the
tracer in a CBD patient showed its retention in the basal ganglia, hinting that it could be useful for the
imaging non-AD tauopathies additionally [172].
The compound although it seemed to be a likely candidate for the in vivo imaging of tau pathology,
regrettably had some in vitro and in vivo instability problems. The in vitro instability was due to
its photoisomerization tendencies: the quick interconversion of E/Z isomers in the presence of light.
Although, this can be suppressed by shielding it from light during radio- and chemical synthesis it
still is an inconvenience. In vivo, it gets quickly metabolized in mice and humans, with 2% remaining
unchanged in mice at 1 min p.i. and 8% at 3 min p.i. in humans. Although this radiometabolite is
polar, in mice it still made image analysis difficult [173]. It also displayed off-target binding in the
basal ganglia, the choroid plexus and the longitudinal sinus [172]. Nevertheless, a new fluorinated
PBB compound [18F]PM-PBB3 (Figure 6) has been developed and is being clinically investigated to
find out if there would be an improvement in the shortcomings of [11C]PBB3 [51].
 
Figure 6. Structures of the selected second-generation tau-PET tracers. [18F]GTP1, [18F]PM-PBB3
(APN-1607), *9, [18F]MK-6240, *12, [18F]RO-948 (RO6958948), [18F]PI-2620, [18F]JNJ64349311(JNJ311).
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Interestingly, in in vitro fluorescent study using postmortem DLB and MSA brain sections
PBB3 was colocalized on α-syn in LBs, LNs, and GCIs. In contrast, autoradiographic labeling with
[11C]PBB3 at 10 nM only showed significant binding in MSA cases in regions with a high density of
GCIs in the absence of tau or iron deposits. Since the maximum concentration of [11C]PBB3 in human
PET scans is roughly 10 nM as presented by Koga et al., it means that α-syn is only detectable by
[11C]PBB3 in MSA patients with a high density of GCIs [174]. A later in vivo human PET study on
MSA patients by Perez-Soriano et al. was consistent with the work carried out by Koga et al., that
[11C]PBB3 binds to α-syn [175,176].
The Carbazole and Benzimidazole Derivatives
A screening campaign at Siemens MI Biomarker Research led to the discovery of these classes of
lead series [177]. Further optimization led to the development of flortaucipir (AV-1451, [18F]T807) and
[18F]T808 (AV-680) (Figure 5). They both have sufficient affinity for tau (AD-PHF) 14.6 nM and 22nM
based on a Scatchard analysis of autoradiography staining of human PHF-AD brain sections, with
Kd(Aβ)/Kd(tau) 25 and 27 respectively, meaning a higher selectivity of tau aggregates over Aβ fibrils
(Table 2). The binding of [18F]T808 to only one type of binding site of the tau aggregates as seen from
the degree of linearity in its Scatchard plot further confirmed its selectivity for tau aggregates over
Aβ. Most importantly, they have minimal white matter binding and a good pharmacokinetic profile
(Table 2) [178,179].
Initial PET scans of flortaucipir in controls and subjects with AD and mild cognitive impairment
demonstrated an accumulation of the tracer with a distinct increasing neocortical distribution in
tandem with the severity of dementia [180] according to the known mode of spread of PHF in the
brain in agreement with Braak’s staging [181]. In other tauopathies such as PSP and CBD, it was
shown in a head-to-head comparison of [11C]PBB3 and flortaucipir, that the former binds more
avidly to neuronal and glial tau lesions relative to the vague binding of flortaucipir [182]. Similar to
[11C]PBB3, it is suspected that flortaucipir significantly binds to α-syn in the posterior putamen MSA
patients. This, however, is not consistent with in vitro autoradiography results, which so far has proven
otherwise [183,184].
First-in-human PET studies with [18F]T808 showed similar results as flortaucipir, but with more
rapid kinetics. As early as 30 min p.i. [18F]T808 images stabilized, but flortaucipir SUVR values
after 80 min still fluctuated. Notwithstanding, flortaucipir was selected over [18F]T808 for clinical
development, because of the metabolic defluorination observed in some cases, and the significant
accumulation of fluorine-18 in the skull especially in late time points, that could confound PET images.
This prevented further in vivo use of the tracer [185].
Off-target binding has been seen in flortaucipir PET studies in the meninges, striatum, choroid
plexus and midbrain. In the analysis of autopsy brain samples, it was found out that flortaucipir also
binds to vessels, iron-associated regions, substantia nigra, the leptomeningeal melanin and calcifications
in the choroid plexus [186]. Another important off-target of flortaucipir is to both isoforms of the MAO
enzyme [167,168,187,188]. Furthermore, there was difficulty in quantification due to the fact that it
does not reach a steady-state during a typical imaging duration [189,190].
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2.2.2. Second Generation of Selective Tau Tracers
Even though several goals were achieved with the first-generation selective tau tracers
like improvement in affinity to both 3R and 4R tau deposits, selectivity of the tracers to
tau aggregates versus Aβ plaques, and pharmacokinetics, there remains still the problem of
lack of selectivity over other protein aggregates, and brain contents: subcortical white matter
accumulation, in conjunction with off-target binding especially to MAO-B enzyme in the basal
ganglia. Findings in which the THK-radiotracers and flortaucipir have been implicated following
in vitro assessments [169,170,184,188]. Clinical validity could be limited in tauopathies where the
accumulation of tau is expected in regions with a high concentration of MAO-B, like in PSP and CBS.
There has, furthermore, also been mounting evidence that the binding of certain tracers such
as flortaucipir and 18F-labeled THK tracers is not only limited to tau deposits but to other protein
deposits, like TDP-43 (transactive response DNA binding protein 43 kDa) predominantly present in
patients with semantic dementia. Flortaucipir as well as [11C]PBB3 showed in vivo binding in patients
expected to have α-synuclein deposits [174–176,183,184].
Consequently, efforts are being made by various pharmaceutical companies and research institutes
to optimize the binding selectivity and enhance the pharmacokinetic profile of tau PET tracers.
Hence, more focus will be paid in this section to improvements in the pharmacokinetic profile and
specificity of the new tracers in comparison to their predecessors.
Optimized First Generation Tau Tracers
As mentioned earlier [185], [18F]T808 had a propensity to metabolic defluorination, which led to the
selection of flortaucipir (AV-1451, [18F]T807) over it, despite its faster kinetics (Table 2). For this reason,
it was deuterated to improve its in vivo stability to defluorination, which resulted in the development of
[18F]GTP1 (Figure 5). This modification prevented the accumulation of free 18F-flouride in the skull in
clinical PET study, in which it also distinctly differentiated AD subjects from healthy controls [189,192,193].
In addition to its low nanomolar affinity to tau aggregates and excellent selectivity to Aβ plaque
(Table 3), it was reported to bind to non-AD tau aggregates. It also showed no off-target binding
especially to MAO-B. Both preclinical and clinical in vivo kinetic studies showed that the tracer has a
good pharmacokinetic profile which allows imaging some minutes earlier than flortaucipir [190,194].
Further investigations however still need to be carried out to properly compare these two tracers [193].
An introduction of fluorine-18 in the structure of the first-generation tracer [11C]PBB3 gave rise
to [18F]PM-PBB3 (APN-1607) (Figure 6). In human subjects, it showed in less than 5 min a peak ~2.5
[18F]PM-PBB3 SUV in the brain. It has less off-target signals in the basal ganglia than [11C]PBB3, and a
greater signal-to-background ratio. It showed no significant off-target binding in the basal ganglia
and thalamus. Furthermore, it did not show radiometabolites in the brain as did its predecessor
[11C]PBB3 [192,195]. Phase 0 of its clinical evaluation was completed not so long ago in 2018 [196].
A structurally modified version of flortaucipir whose inadequacies were already
discussed [186,187,197], [18F]RO-948 (RO69558948) (Figure 6) was developed and selected from
three lead compounds. Of the selected three which also displayed good brain uptake, fast brain
clearance, high affinity for NFT (Table 3) and excellent selectivity against Aβ plaques in AD brain tissue,
lower affinity for MAO-A and MAO-B in comparison to [18F]T807 and [18F]THK-5351, and based
on preclinical binding study RO-948 was selected for further development. This was because in
comparison to the other analogs it displayed better pharmacokinetics and metabolic properties both
in mice and non-human primates. Moreover, it showed a better signal-to-background ratio than the
others in AD patients. Notwithstanding, three of them gave results from their first-in-human study,
which were consistent with preclinical data [198–200].
Upon the discovery that affinity for MAO-A is significantly attenuated and high affinity for
aggregated tau improved in the presence of pyrrolo[2,3-b:4,5-c’]dipyridine core structures in comparison
to pyrido[4,3-b]indole core structure a series of fluoropyridine regioisomers were developed from which
the 4-pyridine regioisomer [18F]PI-2620 (Figure 6) a regioisomer of RO-948 was selected. In AD brain
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homogenate competition assays, it demonstrated a high affinity for tau deposits pIC50 8.4 nM (Table 3),
and a superior binding to both 3R and 4R tau aggregate folds in self-competition experiments using
recombinant K18 fibrils (representing 4R tau pathology) as well as human PSP and PiD brain homogenates.
Besides, it is selective over Aβ and has no off-target binding towards either MAO-A as
[18F]RO-948 or MAO-B as flortaucipir, and furthermore showed low off binding in brains of
non-demented controls, with rapid and complete washout. It also showed selective binding to
pathological tau present in Braak I, III and V human brain sections in autoradiography experiments.
In autoradiography studies it also showed to tau aggregates/folds in PSP brain sections, which of
course has been controversial, since many tau tracers has been reported not to be bind to tau deposits in
PSP in autoradiography experiments. However, off-target binding was observed in the pars compacta
portion of the substantia nigra in human brain sections, consistent with the affinity of some tau tracers
like flortaucipir, [18F]MK-6240 to melanin-containing cells [52,53,201].
Clinical data are needed to confirm the usefulness of [18F]PI-2620 in non-AD patients.
Nonetheless, it is presently being examined in several clinical trials in order to establish its
pharmacokinetic profile in humans, and decide its application in in vivo PET-imaging of tau
aggregates/folds both in non-AD and AD tauopathies [53].
The Azaindole-Isoquinoline and Naphthyridine Derivatives
Following an SAR study, an azaindole-isoquinoline derivative was developed. The study showed
that the azaindole core (*9) (Figure 6) with a 2,4-substituted pyridine shown below was the minimum
pharmacophore needed for a high binding affinity to NFTs. The insertion of fluorine in the minimal
pharmacophore led to a loss in affinity by >10 fold. This was also observed when either pyridinyl rings
were fluorinated. A phenomenon, which hinted at a specific electronic contribution of the basic nitrogen
to NFT binding. In [18F]MK-6240 there is a minimum effect of fluorine on the basicity of the heterocyclic
nitrogen in the isoquinoline ring and the presence of a primary amine, an additional stronger basic
center, must have improved its affinity to NFTs, Kd 0.36, in comparison to the 1,6-naphthyridine
derivative (*12), with both basic centers in the ring, with affinity to NFTs, Kd 52.6 [202] (Table 3)
It exhibited favorable pharmacokinetics, with a fast brain uptake and clearance (Table 3). Uptake was
higher in AD subjects and was considerably higher in brain regions expected to have NFT like in the
hippocampus, but very low uptake in the cerebellar gray matter suggests a potential use of the cerebellar
gray matter as a reference region. Based on reliability analysis simplified quantitative approaches could
offer informed estimates of NFT load [203]. Furthermore, the spatial patterns of binding of the tracer were
in accordance with the neuropathological staging of NFT, as reported from recent clinical studies [204].
Preclinical findings confirmed a lack of binding to MAO-A and MAO-B [203]. Unlike flortaucipir
and [18F]THK-5351 off-target binding was not seen in the choroid plexus and basal ganglia [204], but like
flortaucipir and various tau PET tracers, off-target binding to neuromelanin- and melanin containing
cells like the pigmented neurons in the substantia nigra, and meninges was observed [52,187,201].
To confirm initial observations, there are ongoing clinical trials on non-AD patients. The phase I of its
clinical trial was completed in 2016 [205].
A 1,5-napthyridine derivative, [18F]JNJ64349311(JNJ311) (Figure 6) was also reported. It showed
moderate initial brain uptake but a fast brain clearance in biodistribution assay using wild-type mice
(Table 3). It is quickly metabolized as was seen in NMRI mice and a rhesus monkey 30 min after
intravenous injection, where only 22% and 35% respectively of the recovered activity was the intact
radioligand. However, all the detected radiometabolites were more polar than the tracer, and none
was found in the brain even at 60 min after injection. Furthermore, no bone uptake was detected in
a rhesus monkey during a 120 min scan, in the duration of a microPET scan, which also showed a
moderate initial brain uptake (SUV of 1.9 at 1 min p.i.) with a rapid wash-out.
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Semi-quantitative autoradiography studies on post-mortem tissue sections of human AD brains
displayed highly displaceable binding to NFT-rich regions, but it showed no specific binding to human
PSP and CBD brain slices. Based on its in vitro and in vivo preclinical profiling, it was deemed a
promising candidate for quantitative tau PET imaging in AD [206]. There is presently no in vivo
human data for the tracers of the JNJ series.
2.3. Selective PET-Tracers for the Imaging of α-syn
Most of the PET/SPECT tracers developed and approved so far for the differential differential
diagnosis of PD have been geared towards the evaluation of the function of the dopaminergic
system [207]. As was mentioned earlier, 50% of substantia nigra cells (stage III of the Braak staging)
and a probable loss of a higher percentage of dopaminergic nerve endings in the putamen have to be
lost before the appearance of motor symptoms [71–73], in contrast, based on the findings of Braak et
al., there is deposition of α-syn in LBs and LNs, which occurs sequentially and additively throughout
the VI stages of disease progression [74], therefore the most accurate and earliest detection of premotor
PD should be based on imaging α-syn instead of dopaminergic changes [208].
The development of α-syn PET tracers is still an unmet need and in its early stages.
Regardless, efforts have been made in the past decades and are still being presently made to develop
tracers with a high affinity and selectivity for α-syn over Aβ and tau aggregates.
2.3.1. The Phenothiazine Derivatives
In 2011, to discover selective α-syn tracers Yu et al. synthesized a series of phenothiazine
derivatives. Three of the tricyclic compounds (Figure 7) based on in vitro Th-T competition assay to
recombinant α-syn fibrils were selected: [11C]SIL5, [125I]SIL23, and [18F]SIL26 based on the fact that
they displayed an affinity (Ki) to the α-syn fibrils less than 60 nM [209] (Table 4).
In further tests, [125I]SIL23 with a ki of 57.9 nM [209] was able to bind to α-syn fibrils in
postmortem PD brain homogenates, which indicated that the tracer binding affinity in PD brain
samples is comparable to its affinity to recombinant α-syn fibrils. It also displayed 5-fold and 2-fold
less affinity for Aβ1-42 and tau aggregates respectively in comparison to α-syn fibrils, however this
selectivity was insufficient for in vivo imaging. Moreover, a high nonspecific binding in white matter
seems to limit autoradiography with the tracer initial experiments. Furthermore, its affinity for α-syn
fibrils Kd 148 nM, is also not optimal for the in vivo imaging of α-syn fibrils [210].
[11C]SIL5 and [18F]SIL26 with binding affinities (Ki) 1.8× and 1.2× more than that of
[125I]SIL23 respectively, showed a low initial brain uptake in healthy Sprague-Dawley rats 5 min p.i.
0.953%ID/g and 0.758%ID/g respectively, and slow washout with [18F]SIL26 performing poorer of
the 2 tracers with not less than 50% of the initial brain concentration at 5 min remaining at 60 min.
[11C]SIL5 still had at 60 min 16.57% of its initial brain uptake at 2 min, which suggested a slow washout
of the tracer or a lot of unspecific binding (Table 4).
In vivo microPET imaging in a healthy cynomolgus macaque confirmed that [11C]SIL5, with
a faster washout kinetics of the two was able to penetrate the BBB into the brain, and also has a
homogeneous distribution and fast washout kinetics. The authors believe that both compounds require
further structural optimization in order to make them a more suitable α-syn tracer [211].
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Figure 7. Structures of selective α-syn-PET tracers: [11C]SIL5, [125I]SIL23, [18F]SIL26, *6a, *14, *20,
*46a, *11a, *11b, [125I]IDP-4, [18F]FS3-1 ([18F]DABTA-11). *numbers given to the tracers in their
respective publications.
2.3.2. The Indolinone and Indolinonediene Derivatives
An SAR study by structural modifications of an indolinone derivative *6a [212] (Figure 7),
by the introduction of different alkyl and arylalkyl groups substituted at the indolinone nitrogen
led to the identification of an aza-analog-*14 (Figure 7), which was the most successful in this series
(Table 3). With a binding affinity Ki 79 nM to recombinant α-syn fibrils less than that of the select
3 phenothiazine tracers [209,213], with 1,4- and 11-fold selectivity over recombinant Aβ and tau
aggregates. Another major limitation of the series was the presence of E/Z isomers, which re-equilibrate
after separation.
A homologation of the double bond in *6a by the addition of an additional double (to form
diene group) bond, in order to increase affinity to α-syn fibrils over the other aggregates gave a
series of compounds, which were a mixture of stereoisomers with either an E,E or Z,E configuration,
which quickly re-equilibrated after chromatographic purification. *20 (Figure 7) was however selected
from the series based on its improved affinity (Ki) for recombinant α-syn fibrils 1.9×more than *14,
but unfortunately affinity Ki 27.6 nM for Aβ increased as well, with 1.3-fold selectivity over tau
aggregates (Table 4). However, its strong fluorescent attributes allowed for a performance of fluorescent
microscopy studies of postmortem AD and PD brain samples. Results showed that it labels both LB
20
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and Aβ plaques. Regardless, this showed that indolinonediene derivatives can label α-syn fibrils
in LBs.
Introduction of a para nitro group into the pendant benzene ring of the diene moiety made it
possible to isolate both the E,E and Z,E stereoisomers, and further explore their in vitro properties.
The Z,E regioisomers were generally more active than the corresponding E,E configuration in terms of
higher affinity for α-syn over Aβ and tau fibrils. The best in this series was [18F]46a with the highest
affinity (Ki) for α-syn fibrils 2 nM, 70-fold and 40-fold less affinity for Aβ and tau fibrils respectively
(Table 4).
Unfortunately, due to its high lipophilicity log D 4.18, which prevented obtaining a reliable and
reproducible results from binding assays to insoluble α-syn acquired from PD brain and the possible
reduction of the nitro group to an amino group in vivo makes it an unsuitable PET probe for imaging LB
and LN in PD subjects. In spite of the shortcomings of the compound it showed interesting selectivity
for α-syn fibrils over Aβ and tau, and could serve as a good lead for further development of α-syn
fibril tracers [213].
2.3.3. Chalcone Derivatives and Structural Cogeners
Hsieh et al. went further to investigate a series of chalcone derivatives, whose enone moiety serves
as an isosteric replacement of the diene group in the indolinonediene derivatives while precluding
the E,E and Z,E isomerization problem. The indole ring was further replaced with a benzothiazole
ring system, based on a previous SAR study, which revealed that an electron-deficient ring like the
aza-indole system has a higher affinity for α-syn fibrils relative to the indole ring system and to prevent
the Michael-acceptor properties associated with the chalcone system they replaced the enone moiety
with an isoxazole and a pyrazole ring system. The results of a competition in vitro binding studies
with Th-T led to the identification of a compound *11a,b (37 a,b) (Figure 7), isoxazole derivatives with
a modest affinity in comparison to [18F]46a (36) for α-syn at Ki 18.5 nM over Aβ and tau fibrils with
5-fold and over 54-fold less affinity respectively (Table 4). Although the compounds described in
their report have modest affinity to serve as a PET radiotracer for in vivo imaging studies, they could,
however could be used for further SAR studies [214].
Based on previous research, it was discovered that flavonoids could inhibit not only the formation
of Aβ [215–217] but also of α-syn [218–220] aggregates, an indication that they could also bind with
α-syn aggregates. With this in mind, Ono et al. developed some α-syn imaging tracers based on
the chalcone scaffold: they developed four prospective chalcone derivatives (IDP compounds) with
varying molecular lengths made possible by conjugated double bonds. A longer molecular length and
a long conjugated π system were believed to lead to increased affinity of probes to Aβ [221], and tau
aggregates as was seen in the PBB compounds [172,222].
All the IDP-compounds, unfortunately, displayed almost as much affinity for Aβ as they displayed
for α-syn (Table 4), with affinity for α-syn increasing proportionately to molecular length, with not
really much change in the selectivity to Aβ, which means that [125I]IDP-4 with a tetraene structure
was the best in this regard. It had a high binding affinity to α-syn Kd of 5.4 nM and 3-fold selectivity
to recombinant Aβ fibrils, which nevertheless was not as high as [18F]46a, which the authors believe
could be attributed to different binding assay conditions.
[125I]IDP-4 (Figure 7) in vivo biodistribution in normal mice performed poorer than the other
IDP-compounds, with a brain uptake of 0.45%ID/g at 2 min p.i. and a low brain clearance, 93.3% of the
concentration at 2 min still remaining at 60 min (Table 4). The suboptimal pharmacokinetics could be
due to the lipophilicity, high molecular weight and chemical structure of the tracer. In any case, this
property makes it an unlikely tracer for in vivo imaging of α-syn aggregates. Still, it could be a useful
probe for in vitro screening of compounds for affinity to α-syn and Aβ fibrils in vitro [222].
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2.3.4. Diarybisthiazole Compounds
More recently, highly innovative small molecules utilized as diagnostic probes, based on
4,4’-diaryl-2,2’-bithiazole, called DABTAs were developed by Yousefi et al. as sensitive, selective
and specific tracers. According to pilot data these compounds suitable for the visualization and
quantification of α-syn pathology by nuclear medicine imaging. With the help of these newly
developed ligands, the presence, distribution and progression pattern of α-syn can be investigated
in the living brain, reflecting the disease entity and stage. Preliminary results with the [18F]FS3-1
([18F]DABTA-11) (Figure 7) in a rat model overexpressing human E46K mutated α-syn are promising
regarding sensitivity [223,224]. In addition, in vivo imaging of the progression and spreading of
α-synuclein pathology over time with the tracer greatly motivates the authors to develop tracers for
aggregated α-syn in PD, DLB or MSA.
3. Conclusions
Several Aβ PET tracers have been developed and promoted discussion on their clinical values.
Among these three tracers have been already approved by the FDA and EMA. Research on tau PET
yielded several tau-tracers already entered into clinical investigations, however, still inherent are
challenges in selective tau imaging. The lack of any consented and approved tracer for aggregated
α-syn greatly motivated scientists in the field to develop tracer for aggregated α-syn in PD, DLB or
MSA. Remarkable progress has been made so far in order to fulfill the unmet need for α-syn PET tracers
with suitable pharmacokinetics, binding affinity and selectivity. Lately, innovative small molecules
have been identified with excellent binding affinity and selectivity for α-syn fibrils relative to Aβ and
tau aggregates. Utilizing high-throughput binding assays, in-silico design in the conventional tracer
development may accelerate the identification of new leads for a specific α-syn PET imaging.
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Abstract: Recent research of persistent homology in algebraic topology has shown that the altered
network organization of human brain provides a promising indicator of many neuropsychiatric
disorders and neurodegenerative diseases. However, the current slope-based approach may not
accurately characterize changes of persistent features over graph filtration because such curves are
not strictly linear. Moreover, our previous integrated persistent feature (IPF) works well on an
rs-fMRI cohort while it has not yet been studied on metabolic brain networks. To address these issues,
we propose a novel univariate network measurement, kernel-based IPF (KBI), based on the prior IPF,
to quantify the difference between IPF curves. In our experiments, we apply the KBI index to study
fluorodeoxyglucose positron emission tomography (FDG-PET) imaging data from 140 subjects with
Alzheimer’s disease (AD), 280 subjects with mild cognitive impairment (MCI), and 280 healthy normal
controls (NC). The results show the disruption of network integration in the progress of AD. Compared
to previous persistent homology-based measures, as well as other standard graph-based measures
that characterize small-world organization and modular structure, our proposed network index KBI
possesses more significant group difference and better classification performance, suggesting that it
may be used as an effective preclinical AD imaging biomarker.
Keywords: Alzheimer’s disease (AD); network measure; graph theory; brain network; positron
emission tomography (PET); persistent homology
1. Introduction
Alzheimer’s disease (AD) is one of the most common neurodegenerative neurological diseases and
is the most common form of dementia in the elderly [1]. Its clinical manifestations include long-term
memory loss, cognitive decline, language disorders, and other symptoms. AD seriously affects the
normal life of the elderly. However, the pathology of AD is not yet clear [1]. Some existing imaging
technologies are used to explore the mechanisms of human brain function. Compared to magnetic
resonance imaging (MRI), fluorodeoxyglucose positron emission tomography (FDG-PET) has been
demonstrated to be a more precise predictor of both AD and mild cognitive impairment (MCI), and
is more suitable for monitoring disease progression [2]. It collects and measures changes in glucose
metabolism values in brain regions or local brain cells. The signals are then converted into effective
three-dimensional images and the connectivity between brain regions are analyzed.
The topological organization of metabolic brain networks have been successfully characterized in
many cases using various measures based on graph theory [3–5], such as characteristic path length
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(CPL) [6], global efficiency [7], modularity (Mod) [7,8], and network diameter (ND) [9], to name but
a few. Specifically, in patients with AD and MCI, several research groups have reported topological
alterations in the whole-brain connectome, including a loss of small-worldness [10], a redistribution
of hubs [9,11], and a disrupted modular organization [12]. Traditionally, weighted networks usually
require defining a set of thresholding values before quantifying network topology [13–15], which may
result in inconsistent network features when the thresholding values vary. Generally, the choice of
threshold is rather arbitrary and there are no widely accepted criteria [16,17].
Recently, persistent homology [18] in algebraic topology has been studied to detect persistent
structures generated over all possible thresholds [19–23] in brain network analysis. There have been
significant efforts to model evolution of brain networks and to link network topology to network
dynamics. This method constructs multiscale network for all possible thresholds wherever the
persistent topological features over the evolution of the network changes are identified. Its ability
to handle noisy data and provide homological information has turned it into a successful tool for
the analysis of brain network structures [24]. One typical application of persistent homology is in a
Betti number plot (BNP) [18], which has been successfully applied to the brain network research on
epilepsy [20], autism spectrum disorder, and attention-deficit hyperactivity disorder [19,23]. As BNP
ignores the association between persistent features and forthcoming thresholding value changes,
we proposed an integrated persistent feature (IPF) by integrating an additional feature of connected
component aggregation cost with BNP, and applied it to measure an AD network using resting state
functional MRI (rs-fMRI) in our prior study [25]. However, both BNP and IPF applied linear regression
analysis for computing the slope of the plot over all thresholds as a univariate network index. Such a
slope-based approach may not accurately characterize the changes of persistent features over graph
filtration because the curves are not strictly linear. Moreover, our previous IPF works well on an
rs-fMRI cohort though it has not been used to study metabolic brain networks yet.
In this paper, we borrow the idea of kernel methods [26,27] on persistent homology and propose
a kernel-based IPF (KBI) index based on our prior work on IPF. We hypothesized that our KBI index
may help to better reveal the difference between brain networks. With the cross-sectional FDG-PET
imaging data of 140 AD, 280 MCI, and 280 normal control (NC) individuals, we set out to test this
hypothesis by computing the KBI indices that measure the differences between AD, MCI, and NC
groups. We further perform statistical inference and classification to validate the power of KBI.
2. Results
In this section, we use FDG-PET data to evaluate statistical power and classification performance
of our proposed KBI index for the analysis of brain metabolic networks related to AD. We further
compared it with prior persistent features, BNP [19,21,23] and SIP [25], as well as some other standard
graph-based indices.
2.1. Metabolic Brain Networks
After data preprocessing, the summarized point cloud were extracted from PET 3D imaging
using predefined automated anatomical labeling atlas with 90 (AAL-90) regions of interests (ROI) [28].
We obtained the SUV matrix for all 700 subjects in all 90 ROIs and plot three histograms, in Figure 1,
to show the global distributions of FDG uptake in AD, MCI, and NC. As the number of AD is half of
MCI and NC, we have normalized the SUV distribution of AD by doubling its statistics. We observed
that the AD cohort has lower glucose metabolism than MCI and NC, but no significant differences were
detected in the statistical inference of permutation test. We calculated the Pearson-based correlation
distance of FDG uptake between each pair of brain regions using Equation (1) and constructed
group-wise brain metabolic networks. The three multiscale networks of AD, MCI, and NC groups are
shown in Figure 2, which visualizes the evolution of brain networks over different thresholds.
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Figure 1. The fluorodeoxyglucose (FDG) uptake distribution of AD, MCI, and NC groups.
Figure 2. The constructed multiscale networks of AD, MCI, and NC by graph filtration λ, and the node
color represents the ROI index predefined in AAL-90 atlas.
2.2. Brain Network Features
We computed the values of graph-based network indices (CPL, ND, and Mod) in three groups
based on their weighted networks after filtering their edges, whose corresponding p-values passed a
statistical threshold (Bonferroni corrected p < 0.05). We then obtained the multiscale network according
to graph filtration and computed the BNP and IPF index (i.e., SIP), as well as KBI index. Figure 3 shows
three separate IPF plots of AD, MCI, and NC. All brain network index values are shown in Table 1.
The differences between groups need to be further verified by statistical inference and classification.
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Figure 3. The proposed integrated persistent feature (IPF) plot for three group-wise networks of AD,
MCI and NC, respectively.
Table 1. The network index values of three groups.
Cohort KBI SIP BNP CPL ND Mod
AD 0.577 0.790 268.7 1.20 1.601 1.289
MCI 0.826 0.842 265.2 1.17 1.457 0.770
NC 0.988 0.882 245.5 1.15 1.436 1.004
2.3. Statistical Group Difference Performance
In this study, we use the permutation test for 10,000 permutations between any two groups, and
show the resulting p-value in Table 2. Only the proposed KBI index obtained a significant difference in
any between-group at the significance level of 0.05.
Table 2. Statistical p-values for between-group differences by different graph indices on an AAL-90 atlas.
Cohort KBI SIP BNP CPL ND Mod
AD vs. MCI 0.017 0.036 0.048 0.058 0.397 0.074
AD vs. NC 0.002 0.042 0.054 0.285 0.266 0.063
MCI vs. NC 0.036 0.076 0.339 0.062 0.031 0.458
Only the proposed KBI index detected significant difference in any between-group (any p-value < 0.05).
2.4. Classification Performance
Furthermore, we resampled the networks 5000 times for each group with the resampling rate of
0.5, and obtained 5000 values of each network index for each group. We then performed leave-one-out
crossvalidation to evaluate the classification powers of two-label (Figures 4 and 5) and three-label
(Figure 6) by SVM. Our KBI shows better classification performance than prior persistent features, SIP
and BNP, as well as other standard graph-based features, including CPL, ND, and Mod.
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Figure 4. Comparison of ROC curves of different network indices for MCI vs. NC.
 
Figure 5. Comparisons of ROC curves of different network indices for AD vs. NC.
 
Figure 6. Three-label classification.
3. Discussion
3.1. Present Findings
This study has three main findings.
First, from Figure 1, we found that the AD cohort has lower glucose metabolism than MCI and NC.
This may imply cognitive impairment in AD and MCI. Such an inference is further partly confirmed by
graph theory analysis because a larger CPL is present in AD and MCI, while the network with smaller
CPL is considered to be efficient.
Second, in our previous study [25], we had developed a univariate network index, SIP, based on
homology to model graph dynamics over all possible scales and applied it to study the rs-fMRI data of
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AD. We found the SIP values of AD were lower than MCI and much lower than NC. In the current
PET data, we still find the SIP values show the same pattern AD <MCI < NC, suggesting a slower
network integration rate in AD and MCI groups. Thus, the results from both independent cohorts
provide consistent empirical evidence for decreased functional integration in AD dementia and MCI.
Finally, we propose a novel univariate network index KBI to enhance our previous study based
on persistent homology. With our univariate KBI index, the difference of persistent features between
cognitive dysfunction and NC brain network can be measured more accurately. Our preliminary
experimental results demonstrate that the proposed KBI may greatly boost prior SIP and BNP power
in both statistical inference and classification analyses. The KBI also outperforms other standard
graph-based methods, such as CPL, ND, and Mod, suggesting that our method may serve as a valuable
preclinical AD imaging biomarker.
3.2. Exploring Other Connectivity Definitions
There are many types of distance functions to construct weighted networks in brain network
analysis [29], such as Pearson correlation, partial correlation, psycho–physiological interactions, ReHo,
partial least squares, wavelet-based correlation, mutual information, synchronization likelihood,
principal component analysis, independent component analysis, cluster analysis, dynamic causal
modeling, Granger causality modeling, structural equation modeling, and multivariate autoregressive
modeling, among others. At present, it is difficult to put forward the evaluation criteria of these
methods, and few studies have compared them comprehensively. Although the Pearson correlation
that we used in this study may be the most practical scheme to define the connectome in AD studies,
there is still debate about the choice of connectivity definition [29,30]. Therefore, we performed four
other connectivity definitions to explore more potentials in defining connectivity network. They were
Kendall correlation [31], Spearman correlation [32], partial least squares [33], and Granger causality
modeling [34]. The obtained p-values of our proposed KBI with these distance functions are shown in
Table 3. There was no significant difference if Granger causality modeling was used, while the other
three methods detected at least one significant difference. It should be noted that none of these methods
performed significantly better than Pearson correlation (Table 1) in our current dataset. Moreover,
when we checked all measures to discriminate AD, MCI, and NC by these methods, we found that the
three-label classification accuracy of BNP (88.3%) was improved greatly if the partial least squares
method was applied, while the performances in other cases have not been improved significantly. Such
an empirical study may justify the connectivity definition adopted in our current work.
Table 3. Statistical p-values for between-group differences of KBI by different connectivity definitions.
Between-Group









AD vs. MCI 0.003 0.007 0.159 0.399
AD vs. NC 0.005 0.003 0.047 0.375
MCI vs. NC 0.109 0.224 0.198 0.238
3.3. Ways of Network Construction
Graph-based brain connectome analyses are sensitive to the choice of parcellation schemes.
To assess the effects of different parcellation strategies, we carried out the same set of analyses with
another commonly employed atlas, the Harvard–Oxford atlas [35,36] with 110 ROIs (HOA-110).
The detailed statistical significances of between-group difference on HOA-110 are presented in Table 4.
Again, our proposed KBI achieved better statistical power.
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Table 4. Statistical p-values for between-group difference of different network indices on HOA-110 atlas.
Between-Group KBI SIP BNP CPL ND Mod
AD vs. MCI 0.022 0.032 0.063 0.092 0.424 0.035
AD vs. NC 0.013 0.053 0.033 0.458 0.290 0.081
MCI vs. NC 0.042 0.051 0.242 0.088 0.076 0.404
Similarly, only the proposed KBI index detected significant difference in any between-group.
In the metabolic network construction, the common practice is building a group-wise brain
network for each group as there is only one summarized value (average SUV) in each ROI. However,
we notice that some studies [37] constructed subject-wise networks by dividing each ROI of a subject
into blocks to obtain the correlation distance between any two ROI. Thus, subject-wise networks were
constructed. We did not study this method in as it would require additional discussion that would
exceed the scope of this paper.
In addition, we defined the connectivity between two brain regions as 1-Pearson correlation in
Equation (1) in our study. Although some existing studies [19,23] also define such kinds of connectivity
in analyzing brain network properties, the common practice in brain network analysis based on
graph theory is to directly specify the Pearson correlation as the edge weight. To assess the effect of
different connectivity definitions on other graph-based measures, we performed statistical inference
on the brain networks whose edges were defined as directly based on Pearson correlation, and the
statistical p-values of graph-based measures are shown in Table 5. We found the results were different
from the previous results in Table 2, suggesting that graph-based measures could be affected by way
of connectivity definition. We also found that none of the graph-based measures could detect all
between-group differences significantly in either connectivity definition.
Table 5. Statistical p-values for between-group differences by specifying Pearson correlation as
connectivity directly.
Between-Group CPL ND Mod
AD vs. MCI 0.214 0.040 0.081
AD vs. NC 0.063 0.083 0.173
MCI vs. NC 0.004 0.281 0.005
3.4. Limitations and Future Work
Despite the promising results obtained by applying our proposed network index KBI based on
persistent homology to PET, there are three important caveats. First, the current study only takes the
zeroth persistent homology into account. Higher-order persistent features are also worth studying.
In future, we will try to improve the performance of our method by considering higher dimensional
persistent homology, such as the first Betti number, which is designed to calculate the number of
holes in a graph and may boost the performance, especially in sparse networks that tend to have
more holes. Then, although the subject-wise network is more convenient, efficient, and useful than
group-wise network for brain network analysis, as we discussed in our prior study [25], we only
measured the group-wise metabolic brain network according to regular practice in PET data analysis.
In future, we will validate the KBI in a subject-wise metabolic network. Finally, this study was based on
cross-sectional PET analysis, and we compared their network indices. With longitudinal PET analysis,
we may further study the evolution between longitudinal brain networks by quantifying the difference
of their persistent features.
4. Materials and Methods
Figure 7 shows the pipeline of our framework, where the data flow from FDG-PET brain images
to some network indices. The details are described in following subsections.
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4.1. Participants
Data used in the preparation of this article were obtained from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu) [38,39]. ADNI was launched in 2003
as a public–private partnership led by Principal Investigator Michael W. Weiner, MD. The primary
goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission
tomography (PET), other biological markers, and clinical and neuropsychological assessment can be
combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s
disease (AD).
In this study, we chose 700 subjects with FDG-PET data from ADNI2. To match the three research
cohorts of AD, MCI, and NC in gender and age, 140 AD, 280 MCI, and 280 NC subjects from 57 sites
across North America were selected. The detailed cohort information is described in Table 6.
 
Figure 7. The pipeline of the brain network analysis based on a group of subjects. SUV, support vector
machine; BNP, Betti number plot; SIP, slope of IPF plot; KBI, kernel-based IPF; CPL, characteristic path
length; ND, network diameter; Mod, modularity.
Table 6. Demographic information of the subjects in this study.
AD (n = 140) MCI (n = 280) NC (n = 280) p-value c
Age a 74.2 ± 7.8 73.9 ± 8.0 75.0 ± 6.6 0.20
Gender b 70/70 140/140 140/140 1
CDR ≥ 1 0.5 0 –
Key: AD, Alzheimer’s disease; MCI, mild cognitive impairment; NC, normal control; a mean ± SD; b male/female
number; c statistical group significance using ANOVA test.
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4.2. FDG-PET Data Acquisition and Preprocessing
All FDG-PET scans were obtained using Siemens, GE, and Philips PET scanners. Details of the
PET data acquisition is described at http://adni.loni.usc.edu/methods/pet-analysis/pre-processing/.
All FDG-PET scans used in this research are preprocessed (step 1 of Figure 7) as follows [40]. First,
in order to eliminate the individual differences in brain morphology between subjects such that
they can completely coincide and be subject to effective statistical analysis, we used the software
toolkit Statistical Parametric Mapping (SPM8) [41] in MATLAB (Mathworks Inc, Natick, MA, USA)
to linearly align the images into the Montreal Neurological Institute (MNI) space using the TPM.nii
template file released with SPM. Second, we borrow a brain mask from SPM, exclude the brain stem
and only keep the cerebral cortex (because the cerebral cortex is the object of this study), and then
segmented all the images with this cerebral mask. Third, we conducted spatial smoothing with a
Gaussian kernel of the full width at half maximum (FWHM) equal to (8,8,8) in three directions (x,y,z)
to improve signal-to-noise.
4.3. Network Construction
A weighted graph is a natural and efficient way to represent metabolic brain network because it
represents a discretized version of original PET images. In computer graphics, polygon meshes, as a
class of graphs with particular connectivity restrictions, are extensively used to represent the topology
of an object [42]; however, the mesh representation may not be the most suitable representation for
analyzing PET images because of connectivity restrictions [43]. Here, we extend polygon meshes to
general graphs by relaxing the connectivity restrictions. Such graphs are easier to construct and are
flexible enough to capture metabolic information. We construct a weighted network by encoding the
metabolic information through an adjacency matrix W = {wij}. The node corresponds to the brain
regions, and the edge corresponds to the interregional correlation of brain metabolism. Specifically,
the region parcellation in brain imaging is usually defined based on an anatomical atlas. In this
study, we applied a predefined atlas, an automated anatomical labeling atlas with 90 (AAL-90) regions
of interests (ROI) [28]. Once an ROI is specified, an overall summary measure within it can be
calculated to assess the response as a whole, rather than on a voxel-by-voxel basis (step 2 of Figure 7).
The most straightforward way to do so is by taking the average standard uptake values (SUV) of all
voxels within the ROI. The SUV of a specific ROI is 1M
M∑
p = 1
vp, where M is the total voxel number
in a given ROI and vp is the FDG uptake value of voxel p. Given K subjects and N brain regions,
let SUVi = {SUVi1, SUVi2, . . . , SUViN,}(1 ≤ i ≤ N) be the vector of average SUV in i-th ROI of all K
subjects (step 3 of Figure 7), and the edge weight wij between two brain regions is defined as 1-Pearson








where SUVi, SUVj are the average SUV in i-th and j-th brain region respectively, cov is the covariance,
σ is the standard deviation, and
cov(SUVi,SUVj)
σSUViσSUVj
is coefficient of Pearson correlation.
4.4. Network Indices
In clinical settings, doctors prefer single indices as biomarkers because a single neuroimaging
index provides a practical reference for evaluating disease progression and for effective treatments.
Generally, there are some available network indices based on graph theory that measure brain global
attributes. In addition, we focus on some univariate indices that were developed from persistent
homology in algebraic topology, and compare them with the network indices from traditional graph
theory in our experiments.
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4.4.1. Traditional Graph Theory Indices
Traditionally, graph theoretical analysis has been applied to measure brain network topological
features. In this study, three global network indices based on graph theory are investigated, including
characteristic path length (CPL) [6], network diameter (ND) [9], and modularity (Mod) [7].
Briefly, CPL can be understood as indicating a network with “easily” transferred information.




di, j, where di,j is the shortest path length between nodes i and j. Note that
infinitely long paths (i.e., paths between disconnected nodes) are not included in computations. ND
is the greatest distance between any pair of nodes, and is defined as ND = max
i∈V maxj∈V di, j. It enables
understanding of the size of a network. A graph with a large ND and small CPL would therefore
be considered an efficient network. Mod describes the extent to which a network has modules that
differ from others, each of which is independent and functionally specialized [7]. Computationally, it is









2⎤⎥⎥⎥⎥⎥⎦, where i and j are individual modules in the set of all modules
M, and c is the proportion of existing connections between two modules.
In practice, we filtered the weighted network before computing these graph-based indices by only
selecting the edges whose corresponding p-values passed through a statistical threshold (Bonferroni
corrected p < 0.05) and then adopted the Brain Connectivity Toolbox (https://sites.google.com/site/
bctnet/) [7] for their implementation (step 6 (right) of Figure 7).
4.4.2. Persistent Features Based on Persistent Homology
Persistent homology is an emerging mathematical concept for characterizing shapes in complex
data, and the persistence features based on BNP are widely recognized as a useful feature descriptor.
BNPs can distinguish robust and noisy topological properties over a wide range of graph filtrations
based on the connectivity of k-dimensional simplicial complexes [18] (step 6 (left) of Figure 7).
Graph filtration is an important tool [24] in persistent homology that constructs nesting subnetworks
in a coherent manner and avoids thresholding selection (step 5 of Figure 7). BNPs have been
successfully applied to measure brain networks based on FDG-PET and structural MRI data [23] in
some neurodegenerative diseases. In our previous study [25], we proposed an integrated persistent
feature (IPF) by integrating an additional feature of connected component aggregation cost with BNP







λk, 0 ≤ i ≤ m− 2
0, i = m− 1
, (2)
where the maximal graph filtration is λ0 = 0 < λ1 < λ2 < · · · < λm−1. As the IPF plot over all possible
filtration values is a monotonically decreasing convergence function, the absolute value of the slope of
IPF plot (SIP) was defined as a univariate network index and was successfully applied to quantify
brain network dynamics on rs-fMRI data of AD. Both the BNP and SIP indices indicate the rate of
connecting components converging over the filtration value, and can be thought as the information
diffusion rate or the convergence speed with said network.
4.4.3. The Kernel-Based IPF (KBI) Index
Although the SIP has been developed as a univariate network index in our previous study, it may
not be the most appropriate way to describe IPF plot as it is nonlinear, strictly speaking. Recently, some
kernel methods [26,27] have been defined on persistent homology to measure the distance between
persistence diagrams, which are not only provably stable but also discriminative. Therefore, we employ
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the framework of kernel embedding of the IPF plot into reproducing kernel Hilbert spaces [26]. Given
a point set of IPF plot X = {x1, x2, · · · xN} and a template T = {t1, t2, · · · tN} that are obtained from an































are both increasing functions with respect to maximal graph
filtrations λ(X) of X and λ(T) of T, and are used for weighting the persistence (λ is a sequence of
persistence of zeroth homology in fact). Hence, an essential persistence gives a large weight and a
noisy persistence produces a small weight. By adjusting the parameters p, σ, and C, we can control the
effect of the persistence. In our practice, we set p = 5,









so that they take close values to many ‖xi − ti‖ and λXi , respectively.
4.5. Statistical Analysis
We applied a group-wise statistical analysis of permutation test to all network indices in the last
section between AD, MCI, and NC groups. As there are no prior studies on the statistical distribution
of any network index, it is difficult to construct a parametric test procedure. Moreover, as there is only
one group-wise network for each group, it is necessary to empirically construct the null distribution
and determine the p-value. The steps of our permutation test are described as follows. First, the actual
network index difference in means between two groups is calculated according to the actual grouping
of their subjects. Second, the subjects are randomly assigned to two groups, each of which is assigned
the same group size. We then construct two group-wise networks based on such permutated groups
and recalculate their indices, whose difference is recorded. This process is repeated 10,000 times and
10,000 permuted differences are obtained. Finally, the total number of permuted differences larger than
the actual difference is counted and divided by 10,000. The obtained value is the probability of no
difference between the groups, that is, the p-value.
4.6. Classification
We evaluate the power of our method by classification analysis. In this study, our proposed
KBI index and other comparison network indices have only one univariate feature to discriminate
the global brain network structure. Since the samples are limited, we apply resampling technology
beforehand. For a specific group, half subjects are removed randomly at a time and the remaining
subjects are used to construct a group-wise network. Resampling all subjects for n times repeatedly
in each group until the results are stable, we can obtain n group-wise networks. Each group-wise
network is an average of all involved subjects graphs. In our practice, the number of resampling times
is set to 5000 (n = 5000) and we obtain 5000 resampled networks for each group. Each network can
yield a KBI index and other comparable network indices. Then, we compute the values of proposed
KBI index, as well as other network measures for all resampled networks, and run support vector
machine (SVM) [44] on them. We conduct leave-one-out crossvalidation experiments to evaluate the
classification performance. The classification accuracy, sensitivity (i.e., true positive rate), specificity
(i.e., true negative rate), and area under the curve (AUC) of receiver operating characteristic (ROC) are
severed as criterion of classification performance.
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5. Conclusions
This work proposed a novel network index KBI based on our prior work of persistent feature IPF
to measure the metabolic brain network of FDG-PET on cognitively impaired cohort. The proposed
KBI encoded a great deal of dynamic information over all possible scales that may be inaccessible by
standard graph-based measures. Compared to previous slope-based approaches of persistent homology,
our kernel-based network index is more accurate regarding the characterization of differences between
persistent features. Our current results show that the slope of IPF plot present a pattern AD <MCI <
NC in a FDG-PET cohort, consistent with our prior finding in an rs-fMRI cohort, and indicate a slower
network integration rate in AD dementia and MCI. Moreover, the enhanced measurement KBI greatly
boosted the performance of prior persistent features and outperformed some standard graph-based
network indices in both statistical inference and classification experiments, suggesting that our method
may serve as a valuable preclinical AD imaging biomarker.
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Abstract: The synaptic vesicle protein 2 (SV2) is involved in synaptic vesicle trafficking. The SV2A
isoform is the most studied and its implication in epilepsy therapy led to the development of the
first SV2A PET radiotracer [18F]UCB-H. The objective of this study was to evaluate in vivo, using
microPET in rats, the specificity of [18F]UCB-H for SV2 isoform A in comparison with the other
two isoforms (B and C) through a blocking assay. Twenty Sprague Dawley rats were pre-treated
either with the vehicle, or with specific competitors against SV2A (levetiracetam), SV2B (UCB5203)
and SV2C (UCB0949). The distribution volume (Vt, Logan plot, t* 15 min) was obtained with a
population-based input function. The Vt analysis for the entire brain showed statistically significant
differences between the levetiracetam group and the other groups (p < 0.001), but also between the
vehicle and the SV2B group (p < 0.05). An in-depth Vt analysis conducted for eight relevant brain
structures confirmed the statistically significant differences between the levetiracetam group and the
other groups (p < 0.001) and highlighted the superior and the inferior colliculi along with the cortex
as regions also displaying statistically significant differences between the vehicle and SV2B groups
(p < 0.05). These results emphasize the in vivo specificity of [18F]UCB-H for SV2A against SV2B and
SV2C, confirming that [18F]UCB-H is a suitable radiotracer for in vivo imaging of the SV2A proteins
with PET.
Keywords: SV2A; SV2B; SV2C; microPET; [18F]UCB-H; epilepsy; PBIF; distribution volume; blocking
assay; preclinical imaging
1. Introduction
The synaptic vesicle protein 2 (SV2) is an integral membrane protein with twelve transmembrane
domains and three N-glycosylation sites in the intravesicular loop. The SV2 protein is ubiquitously
present in the nerve terminals of the central and peripheral nervous systems, and in several types
of endocrine cells [1]. This protein is critical for the adequate functioning of the central nervous
system, acting as a modulator of synaptic transmission [2,3]. Moreover, it has been associated with the
pathophysiology of epilepsy [4–6].
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Previous studies have identified three SV2 isoforms: SV2A, SV2B and SV2C, characterized by
different expression levels during rodent brain development [7] and adulthood [8]. While the SV2A
isoform is present across all brain areas, the SV2C isoform can only be found in specific regions, such
as the striatum, pallidum, midbrain, brainstem, substantia nigra, and the olfactory bulb [9]. The
SV2B isoform is particularly present in the cerebral cortex, and the cornu ammonis sub-region of
the hippocampus [10]. The three isoforms present large similarities in their structure: 65% between
isoforms A and B, 62% between A and C, and 57% between B and C [8].
Of these three isoforms, SV2A is the most investigated. The antiepileptic drug levetiracetam
(Keppra®) binds to SV2A, suggesting a role for SV2A in the pathology underlying certain forms of
epilepsy [11–14]. Several studies have shown a correlation between the brain expression of this isoform
and the clinical efficacy of this drug [5,13].
To investigate the role of SV2A in vivo, in 2013 [18F]UCB-H was presented as an imaging agent
with a nanomolar affinity for human SV2A [3,15–17]. Since then, other PET radiotracers, such as
[11C]UCB-J, or [11C]UCB-A, have been synthetized to study this protein [3,18–20] (see Figure 1).
These PET radiotracers appear to be more specific than [18F]UCB-H (pIC50 = 7.8) [3,16], based on
their respective affinity measured in vitro, with pIC50 = 8.2 for [11C]UCB-J [18] and pIC50 = 7.9 for
[11C]UCB-A [20]. The three radiotracers have demonstrated potential for use as synaptic density
biomarkers not only in animals, but also in humans [3,21–23]. However, despite the valuable properties
of [11C]UCB-J and [11C]UCB-A in assessing brain synaptic density in vivo, their clinical application
is limited to facilities with a cyclotron due to the short half-life of 11C (20.3 min) compared to the
half-life of 18F (110 min). In addition, the use of a PET radiotracer with a longer half-life (such as 18F)
allows the evaluation of a greater number of patients per day with just one production. Therefore,
different fluorine-18-labelled derivatives of UCB-J are currently being developed and characterized,
such as [18F]SDM-8 [24]. The potential of [18F]UCB-H for detecting variations in SV2A has already
been demonstrated in vivo [25,26]. Nevertheless, as the actual specificity of [18F]UCB-H for SV2A
against SV2B and SV2C has never been addressed in vivo, we consider that this point deserves more
careful evaluation.
Figure 1. Chemical structures of [18F]UCB-H, [11C]UCB-J and [11C]UCB-A.
This paper, therefore, aims to evaluate for the first time the specificity of [18F]UCB-H for the SV2A
isoform against SV2B and SV2C using microPET imaging in rats, by means of a blocking assay between
this radiotracer and specific competitors for the three SV2 isoforms. The results will provide highly
valuable information about the actual potential of [18F]UCB-H as a radiopharmaceutical candidate to
study the SV2A protein with PET in research or clinical practice.
2. Results
Table 1 summarizes the results obtained from the in vitro binding assays. We observe that SV2BL
presents a high affinity for SV2B (pIC50 = 7.8), but also has an affinity for SV2A similar to that of SV2AL
(pIC50 = 5.6).
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Table 1. pIC50 of the competitors used for the different SV2 isoforms. Binding affinities measured for
human SV2 proteins at 37 ◦C. Data are presented as mean (n = 3 to 10) from non-linear regression
analysis of raw data using a sigmoidal dose-response model. Additional data for SV2BL (UCB5203)
solubility: 0.1 mg/mL, route of administration: ip (suspension in 5% DMSO–1% methyl cellulose in
water), CEREP @ 10 μM: all targets < 50% inhibition, mouse brain fraction unbound: 37%, mouse brain
exposure (3 mg/kg, 30–60 min): ~1.8 μM total→ 0.66 μM free→ ~100 fold IC50 SV2B. Additional
data for SV2CL (UCB0949) solubility: 0.055 mg/mL, route of administration: ip (suspension in 5%
DMSO—1% methyl cellulose in water), CEREP @ 10 μM: all targets < 50% inhibition, mouse brain
fraction unbound: 54%, mouse brain exposure (3 mg/kg, 30–60 min): ~8 μM total→ 4.3 μM free→
~270 fold IC50 SV2C.
Synaptic Vesicle Protein Isoforms
SV2A SV2B SV2C
SV2AL 5.2 −3.1 −3.2
SV2BL 5.6 7.8 5.5
SV2CL <5 5.9 7.8
In Figure 2, [18F]UCB-H parametric Vt maps are presented for the vehicle group and the three
pre-treated groups (SV2AL, SV2BL and SV2CL). These pictures highlight a clear reduction of the
[18F]UCB-H binding throughout the entire brain induced by levetiracetam (SV2AL) pre-treatment at
10 mg/kg (PET image corresponding to the SV2AL group).
 
Figure 2. Example of an individual parametric Vt map of [18F]UCB-H binding in rat brain (PET),
along with the corresponding individual MRI and the overlay of both images (PET +MRI). Rats were
pre-treated 30 min before the 60 min PET acquisition with either vehicle, SV2A competitor (levetiracetam
[SV2AL] at 10 mg/kg), SV2B competitor (UCB5203 [SV2BL] at 3 mg/kg) and SV2C competitor (UCB0949
[SV2CL] at 3 mg/kg).
In Figure 3A, we can observe the time activity curves (TACs) corresponding to the four different
treatments (vehicle, SV2AL, SV2BL and SV2CL), for one of the regions of interest (ROIs): the whole brain.
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The four TACs reveal a high initial uptake of [18F]UCB-H, which peaks around 5 min post-injection.
Subsequently, the radioactivity is quickly washed out of the brain. Some differences can be observed
in the kinetic of the TAC after pre-treatment with the respective ligands: The highest peak activity is
observed after pre-treatment with the vehicle and with SV2CL. Interestingly, the pre-treatments with
SV2AL and SV2BL display the same peak of initial uptake. In the case of SV2BL, the kinetics of the
TAC from 15 to 60 min are similar to the kinetics of the radiotracer after pre-treatment with either the
vehicle or SV2CL. The TACs for all the ROIs are included in Supplementary Figure S1. In addition, the
area under each TAC (the AUC) is represented in Figure 3B, where we can observe the differences
between the [18F]UCB-H uptake after pre-treatment with SV2AL, and after pre-treatment with the
other compounds.
Figure 3. Representative time activity curves (TACs) and AUC (area under each TAC) for the different
regions of interest (ROIs). (A) TACs extracted from the whole brain as ROI, and normalized by the
injected activities and the body weight. Lines represent the [18F]UCB-H uptake over a 60 min acquisition
after pre-treatment with the vehicle, SV2AL, SV2BL, or SV2CL. (B) The bar plots represent the AUC in
the eight ROIs (mean ± SEM, n = 5).
Figure 4 presents the mean Vt values for the eight selected brain structures, calculated from
the previous TACs and the population-based input function (PBIF). Comparing Figures 3B and 4,
the differences between groups in AUC and in Vt are similar, with the highest value associated to
pre-treatment with the vehicle, and the lowest value for pre-treatment with SV2AL.
Table 2 summarizes, for the same regions, the impact on the Vt induced by the blocking experiments,
expressed as the relative difference in Vt between the vehicle group and the pre-treated groups. In the
whole brain, mean Vt values of 10.4 ± 0.7, 6.0 ± 0.3, 8.3 ± 0.2 and 9.8 ± 0.3 were obtained for the vehicle
(control) group, the SV2AL pre-treated group, the SV2BL pre-treated group and the SV2CL pre-treated
group, respectively. For the eight ROIs, a statistically significant difference was observed between the
SV2AL pre-treated group and all the other groups (p < 0.001). Furthermore, for the whole brain, the
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cerebral cortex and the inferior and superior colliculus, a statistically significant difference was also
detected between the vehicle group and the SV2BL pre-treated group (p < 0.05).
Figure 4. Vt values for the eight selected brain structures. Bars represent the mean ± SEM (n = 5).
One-way ANOVA and Scheffe post-hoc tests were performed, with ***p < 0.001 and *p < 0.05.
Table 2. Illustration of the impact induced by the blocking experiments, expressed as percentage of
reduction calculated from the mean Vt values (n = 5) for the eight selected ROIs.
ROIs Vehicle vs. SV2AL Vehicle vs. SV2BL Vehicle vs. SV2CL
Whole brain 42.3 19.9 5.6
Cortex 42.7 21.1 9.1
Hippocampus 46.8 16.9 2.1
Inferior colliculus 49.1 23.7 8.5
Midbrain 46.3 19.1 5.1
Caudate/Putamen 46.2 20.2 6.2
Superior colliculus 50.4 23.4 7.6
Thalamus 45.9 19.7 4.4
Mean 46.2 20.5 6.1
SEM 1.0 0.8 0.8
3. Discussion
The SV2 protein is critical for the adequate functioning of the central nervous system, acting as
a modulator of synaptic transmission by priming vesicles in quiescent neurons [4]. The divergent
roles of the three isoforms which comprise this family have yet to be clarified, although different
pathologies have been associated with them. As previously stated, the SV2A isoform is associated
with the physiopathology of epilepsy [5,27]. In contrast, the SV2B isoform is related with prostate
small cell carcinoma [28] and the SV2C isoform is generally associated with the correct functioning of
basal ganglia nuclei [9,29,30]. Some studies have evaluated the possible relation between SV2C and
Parkinson’s disease, as SV2C modulates dopamine release [29,31].
This paper’s goal was to evaluate, for the first time, in vivo the specificity of the [18F]UCB-H
radiotracer in targeting the SV2A isoform compared to SV2B and SV2C. The relevance of such a study
stems from the fact that in vivo SV2A quantification can be considered to be an indirect measure of the
synaptic density [2,3,18], which is a key parameter for fundamental research and for the clinic.
Before discussing the results obtained during these blocking experiments, we have to address
some general considerations. Firstly, the results presented issue from the microPET imaging technique.
Like many other microPET cameras, the Focus120 used during this work has a spatial resolution
of 1.5 mm, at best hampering the study of brain structures of small size due to the partial volume
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effect [32,33]. Secondly, the rat brain distributions of the three SV2 protein isoforms [7–9] indicate that
almost all major brain structures express at least two SV2 protein isoforms. SV2A, the most extensively
studied, is ubiquitously distributed [1,8]. Like SV2A, SV2B can be found in almost all the rat brain
structures with few subtle differential expressions in some hippocampal substructures like CA3 and
the dentate gyrus, along with the reticular nucleus of the thalamus and some small areas in the brain
stem [8,9,34]. Unfortunately, these regions are far too small to be correctly quantified with microPET.
Janz and Sudhof showed that unlike SV2A and SV2B, the SV2C protein is characterized by much
more restricted localization in brain regions considered to be evolutionarily well preserved in rats:
The olfactory bulb, the striatum, the substantia nigra, and some nuclei in the pons and the medulla
oblongata [9]. As we can see, it is impossible to find well defined brain structures for in vivo microPET
quantification in which one of the three isoforms is uniquely or even mostly expressed. Another
important point is that we do not have a clear picture of the respective proportions of each isoform
present in the main rat brain structures. All these considerations will have to be taken into account in
the following discussion. Accordingly, we have decided to select eight major ROIs to ensure robust
in vivo quantification with microPET: Whole brain, cortex, hippocampus, inferior colliculus, superior
colliculus, midbrain, caudate putamen and thalamus.
The [18F]UCB-H Vt values obtained during this study for the vehicle pre-treated group, calculated
using the PBIF [35] were in good agreement with those previously published for rats [35,36]. This is
important in order to establish the consistency of the proposed methodology. The blocking experiments
realized with SV2AL at 10 mg/kg demonstrated a clear significant competition (46.2%) between
levetiracetam and [18F]UCB-H in eight selected ROIs. These values are of the same order of magnitude
as those previously reported in rats [36]. According to the potency of levetiracetam for SV2A against
SV2B and SV2C (Table 2), we can conclude that SV2A is one of the main target of [18F]UCB-H in vivo
in rats.
After performing a blocking experiment with SV2CL at 3 mg/kg, we obtained TACs with similar
peaks and kinetics to the TAC corresponding to pre-treatment with the vehicle, in all ROIs. The
quantification of the radiotracer uptake, using the Vt, highlighted no statistically significant in vivo
competition between SV2CL and [18F]UCB-H in any of the eight selected ROIs. From this we can
infer that SV2CL pre-treatment has either no impact or an impact of very small size. The population
used (n = 5) is not sufficient to demonstrate an effect of small size (f = 0.10), but is optimal to detect
medium (f = 0.25) and large effect sizes (f = 0.5). Another important point is that a highly potent SV2C
competitor like UCB0949 (pIC50 of 7.8) was unable to modify [18F]UCB-H binding in brain structures
with a high expression of SV2C, like the midbrain or the caudate/putamen [9]. The reduction measured
in these regions was of the same order of magnitude as that found in the other structures. These
considerations support the theory that SV2C does not seem to be the main target of [18F]UCB-H in rats.
The pre-treatment with SV2BL at 3 mg/kg resulted in a TAC with a peak as high as that obtained
after pre-treatment with SV2AL. However, it features kinetics which are similar to those obtained after
pre-treatment with the vehicle or SV2CL. This lower peak could be attributed to an initial non-specific
binding of SV2BL to the SV2A protein, for which it presents an affinity which is similar to that of
SV2AL, with a pIC50 = 5.6. After the peak, the SV2BL TAC follows a similar shape and level to those of
pre-treatment with the vehicle and SV2CL, indicating a washing out effect of this fraction of non-specific
binding of SV2BL to the SV2A protein. In order to confirm this hypothesis, a similar experiment with a
SV2BL with a lower affinity for SV2A should be performed. However, the SV2BL used in this paper is
currently the only one available. In addition to the previous analysis, we evaluated the changes in
Vt after pre-treatment with SV2BL. In these results, we can observe a consistent mean reduction of
20.5% of the Vt values in the eight selected ROIs. The SV2BL is characterized by a pIC50 of 7.8 for the
SV2B isoform. Such a highly potent competitor is expected to effectively impede the binding of any
radioligand to the SV2B isoform. If SV2B was the main target for [18F]UCB-H, the blocking induced
with this highly efficient SV2BL would have been very pronounced and much higher than the 20%
measured. In order to explain the 20% reduction of [18F]UCB-H Vt values, we have to take into account
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that SV2BL also presents some potency for SV2A. SV2BL has a pIC50 of 5.6, which is of the same order
of magnitude as that of levetiracetam. Thus, the SV2BL ligand has some affinity for SV2A, which could
lead to partial blocking of SV2A. Hence, the 20% reduction observed is most likely linked to SV2A
blocking induced by SV2BL. Accordingly, we can conclude that SV2B does not seem to be the main
target of [18F]UCB-H in vivo in rats.
We are aware that the respective affinities of SV2BL and SV2CL are a problem for the interpretation
of the data, but we have to consider that today UCB5203 and UCB0949 are the only compounds that
can be used for this purpose.
4. Materials and Methods
4.1. Animals
Twenty male Sprague Dawley CD rats (five weeks old) were used, bred by Janvier Laboratories
(France). The animals were housed in pairs for three weeks under standard 12:12 h light/dark conditions,
maintaining room temperature at 22 ◦C, and humidity at approximately 50%. Standard pellet food
and water were provided ad libitum.
The experimental procedures and protocols used in this investigation (“Synap-SV2A project” files
14-1753 and 13-1573) were reviewed and approved by the Institutional Animal Care and Use Committee
of the University of Liege, according to the Helsinki declaration, and conducted in accordance with
the European guidelines for care of laboratory animals (2010/63/EU). Moreover, the Animal Research
Reporting In Vivo Experiments (ARRIVE) guidelines [37] were followed as closely as possible to confer
a minimal intrinsic quality to the study.
4.2. Radiopharmaceutical Production and Drugs
[18F]UCB-H was produced through one-step radiolabeling of a pyridyliodonium precursor. This
method provides 34% ± 2% of injectable [18F]UCB-H (uncorrected radiochemical yield) from up to
285 GBq (7.7 Ci) of [18F]fluoride (specific activity of 815 ± 185 GBq/μmol and measured purity of
99.8 ± 0.5 wt %); this has previously been reported in Warnier et al. [17].
The ligand for the SV2A isoform (SV2AL) was purchased as an injectable solution (levetiracetam,
Keppra®, UCB Pharma S.A. Brussels, Belgium). At the present time, there are no commercially
available specific ligands for the other two SV2 isoforms (SV2B and SV2C). The competitors used were
obtained from UCB Pharma s.a.: UCB5203 for SV2B (SV2BL, MW: 236.238 g/mol) and UCB0949 for
the SV2C (SV2CL, MW: 281.197 g/mol). The information on these compounds was supplied by UCB
Pharma s.a. The respective affinities for the different SV2 isoforms are presented in Table 2.
The competitors were prepared daily in a vehicle composed of distilled water containing 1%
methyl cellulose (viscosity: 15 cP, Sigma-Aldrich, Overijse, Belgium) and 5% dimethyl sulphoxide
(DMSO, Sigma-Aldrich, Belgium). The concentrations differed depending on the product specifications
and their respective pharmacokinetics, provided by UCB Pharma s.a. The dosing used was 10 mg/kg
for SV2AL, 3 mg/kg for SV2BL, and 3 mg/kg for SV2CL. All solutions were administered through the
intraperitoneal (i.p.) route in a total volume of 1 mL per kg of body weight. The animals used as a
control group (vehicle) received an equal volume of vehicle through the same route of administration.
4.3. In Vitro Binding Assays
Reagents and reference compounds used were of analytical grade and obtained from various
commercial sources. All cell culture reagents were obtained from Invitrogen (Merelbeke, Belgium).
Radioligands (3H-UCB30889, 1184 GBq/mmol; 3H-UCB1418435, 925 GBq/mmol; and 3H-UCB101275-1,
1110–1480 GBq/mmol) were obtained from G.E Healthcare, Amersham, UK (now Perkin Elmer,
Zaventem, Belgium) and reference compounds (levetiracetam, UCB108649-1 and UCB101275-1) were
custom synthesized and stored according to manufacturer’s recommendations. Test and reference
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compounds were dissolved in 100% DMSO or H2O to give 1 or 10 mM stock solution. The final DMSO
concentration in assays was 0.1% unless otherwise stated.
Cell lines generated at UCB Biopharma were human embryonic kidney (HEK) 293 cells expressing
human SV2A, SV2B or SV2C proteins. Cells were cultured in Dulbecco’s Modified Eagle medium. The
culture medium was supplemented with foetal bovine serum (FBS, 10%), 2 mM l-glutamine, 50 to
100 U/mL penicillin, 50 to 100 μg/mL streptomycin, and 200 μg/mL hygromycin B. Cells were grown at
37 ◦C with 95% air. Confluent cells were detached by 10 min incubation at 37 ◦C in phosphate buffered
saline (PBS) containing 0.02% EDTA. Culture flasks were washed with 15 mL of ice-cold PBS. The
cell suspension was centrifuged at 1500× g for 10 min at 4 ◦C. The pellet was homogenized in 15 mM
Tris-HCl buffer (pH 7.5) containing 2 mM MgCl2, 0.3 mM EDTA, and 1 mM EGTA (buffer A) using a
glass/teflon homogenizer. The crude homogenate was subjected to a freeze and thaw cycle in liquid
nitrogen and DNAse (1 μL/mL) was then added. The homogenate was further incubated for 10 min at
25 ◦C before being centrifuged at 40,000× g for 25 min at 4 ◦C. The pellet was re-suspended in buffer A
and washed once under the same conditions. The final crude membrane pellet was re-suspended at a
protein concentration of 1–3 mg/mL in 7.5 mM Tris-HCl buffer (pH 7.5 at 25 ◦C) containing 250 mM
sucrose and stored in liquid nitrogen until use.
Membranes were incubated in binding buffer (see Table 3) containing test compound or positive
control in the presence of the radioligand. The non-specific binding (NSB) was defined as the residual
binding observed in the presence of a high concentration (1000 fold its Ki) of a specific unlabeled
reference compound. Membrane-bound and free radioligands were separated by rapid filtration
through glass fiber filters (GF/C). Samples and filters were rinsed using at least 6 mL of washing buffer.
The entire filtration procedure did not exceed 10 s per sample. The radioactivity trapped on the filters
was counted by liquid scintillation in a β-counter. To determine the affinity of a compound for a given
target, competition curves were performed with at least 10 concentrations of compound spanning at
least 5 log units.
Table 3. Details of the in vitro binding assay determination. Percentage of inhibition was calculated
as follows: % INHIBITION = 100 − [((BI − NSB)/(B0 − NSB)) × 100], where B0 and BI represent
the binding observed in the absence and presence of the test compound, respectively (dpm),
NSB is the radioligand non-specific binding (dpm). Raw data were analyzed by non-linear
regression using XLfitTM (IDBS, London, Great Britain) according to the following generic equation:
B = NSB + [(B0 − NSB)/(1 + (((10X)/(10−pIC50))nH))], where B is the radioligand bound in the presence
of the unlabeled compound (dpm), NSB is the radioligand non-specific binding (dpm), B0 is the
radioligand bound in the absence of unlabeled compound (dpm), X is the concentration of unlabeled
compound (log M), pIC50 is the concentration of unlabeled compound that inhibits the radioligand
specific binding by 50% (−log M), and nH is the Hill coefficient.
In Vitro Binding Details hSV2A Assay hSV2B hSV2C
Binding buffer 50 mM Tris-HCl (pH 7.4) containing 2 mM MgCl2
Filtration buffer Ice-cold 50 mM Tris-HCl (pH 7.4)
Incubation time 120 min at 37 ◦C in 0.5 mL 120 min at 37 ◦C in 0.5 mL 120 min at 37 ◦C in 0.2 mL
















The animals (n = 5 per group) were anesthetized using 4% isoflurane in air at a flow rate of
1 L/min during induction and 1.5% to 2% isoflurane in air at 0.6 L/min during maintenance. Respiration
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rate and rectal temperature were continuously measured using a physiological monitoring system
(Minerve, France). The temperature was maintained at 37 ± 0.5 ◦C using an air warming system.
MicroPET scans were performed with a Siemens FOCUS 120 microPET (Siemens, Knoxville, TN,
USA). The animals were anesthetized and pre-treated i.p. with vehicle, SV2AL, SV2BL, or SV2CL.
Thirty minutes later, they were installed in the microPET scanner and [18F]UCB-H was injected via the
lateral tail vein (44.7 ± 3 MBq, 0.55 mL), simultaneously starting a 60 min emission scan, in list mode.
Finally, a 10 min transmission scan was performed in a single event acquisition mode, using a 57Co
source. The acquired data were then reframed as follows: 6 × 5 s, 6 × 10 s, 3 × 20 s, 5 × 30 s, 5 × 60 s,
8 × 150 s, and 6 × 300 s. For each frame, a total of 95 trans-axial slices were obtained using Fourier
rebining (FORE), followed by 2D ramp filtered backprojection (FBP), in 256 × 256 matrix. The slice
thickness was 0.796 mm and the in-slice pixel size was 0.433 mm.
Immediately after the PET acquisition, the anesthetized rats were transferred into a 9.4 Tesla MRI
horizontal bore system (Agilent Technologies, Palo Alto, CA, USA), with a 72 mm inner diameter
volumetric coil (Rapid Biomedical GmbH, Würzurg, Germany). Anatomical T2-weighted brain
images were obtained using a fast spin echo multi-slice sequence with the following parameters:
TR = 2000 ms, TE = 40 ms, matrix = 256 × 256, FOV = 45 × 45 mm, 30 contiguous slices of
thickness = 0.80 mm and in-plane voxel size = 0.176 × 0.176 mm.
4.5. Imaging Data Processing
PMOD software (Version 3.6, PMOD Technologies, Zurich, Switzerland) was used to process
the imaging data. The structural MRI images were firstly co-registered to the corresponding PET
images, and subsequently spatially normalized into the PMOD MRI T2 template. Finally, the inverse
normalization parameters were calculated and applied to the PMOD rat brain atlas to bring it in the
individual PET space. From this atlas, eight relevant regions of interest (ROIs) were chosen according
to their differential expression of SV2A, SV2B and SV2C: whole brain, cortex, caudate/putamen,
hippocampus, inferior colliculus, superior colliculus, midbrain and thalamus.
Individual time-activity curves (TACs) were extracted for each ROIs and normalized by the
body weight and the injected dose of radiotracer to be expressed as standardized uptake value (SUV).
A population-based input function (PBIF) published by our laboratory [35] was used to avoid arterial
blood sampling during the acquisitions. The distribution volume (Vt), was determined by Logan plot
kinetic modelling using the TACs and the PBIF. The equilibration time (t*) was fixed at 15 min (starting
point of the range used in the multi-linear regression analysis).
4.6. Statistical Analysis
The results are presented as mean (Vt) ± standard error of the mean (SEM). All the data were
tested for normal distribution with Levene’s test for homogeneity, and with a Kolmogorov–Smirnov
test for normality. Data were analyzed using one-way analysis of variance (ANOVA) followed by
Scheffe post-hoc tests.
All statistical analyses were performed with the statistics software Statistica 12 (Statsoft, France)
and GraphPad Prism (version 6, GraphPad software, Inc., San Diego, CA, USA). The critical level of
statistical significance was always set at p < 0.05.
5. Conclusions
For the first time, the specificity of a radiopharmaceutical compound for the three SV2 protein
isoforms was assessed in vivo, in rats. The results obtained clearly indicated that SV2A was the
main target of [18F]UCB-H, and confirmed that [18F]UCB-H is a suitable radiotracer for in vivo
imaging of the SV2A proteins with PET. Consequently, [18F]UCB-H is an interesting candidate to study
SV2A-associated pathologies.
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Supplementary Materials: The following are available online. Figure S1: TACs extracted from the eight ROIs,
and normalized by the injected activities and the body weight. Lines represent the [18F]UCB-H uptake over a
60 min acquisition after pre-treatment with the vehicle, SV2AL, SV2BL, or SV2CL (mean ± SEM; n = 5).
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Abstract: The α7 nicotinic acetylcholine receptor (α7 nAChR) is involved in several cognitive and
physiologic processes; its expression levels and patterns change in neurologic and psychiatric diseases,
such as schizophrenia and Alzheimer’s disease, which makes it a relevant drug target. Development
of selective radioligands is important for defining binding properties and occupancy of novel
molecules targeting the receptor. We tested the in vitro binding properties of [125I]Iodo-ASEM
[(3-(1,4-diazabycyclo[3.2.2]nonan-4-yl)-6-(125I-iododibenzo[b,d]thiopentene 5,5-dioxide)] in the
mouse, rat and pig brain using autoradiography. The in vivo binding properties of [18F]ASEM
were investigated using positron emission tomography (PET) in the pig brain. [125I]Iodo-ASEM
showed specific and displaceable high affinity (~1 nM) binding in mouse, rat, and pig brain. Binding
pattern overlapped with [125I]α-bungarotoxin, specific binding was absent inα7 nAChR gene-deficient
mice and binding was blocked by a range ofα7 nAChR orthosteric modulators in an affinity-dependent
order in the pig brain. Interestingly, relative to the wild-type, binding in β2 nAChR gene-deficient
mice was lower for [125I]Iodo-ASEM (58% ± 2.7%) than [125I]α-bungarotoxin (23% ± 0.2%), potentially
indicating different binding properties to heteromeric α7β2 nAChR. [18F]ASEM PET in the pig showed
high brain uptake and reversible tracer kinetics with a similar spatial distribution as previously
reported for α7 nAChR. Blocking with SSR-180,711 resulted in a significant decrease in [18F]ASEM
binding. Our findings indicate that [125I]Iodo-ASEM allows sensitive and selective imaging of α7
nAChR in vitro, with better signal-to-noise ratio than previous tracers. Preliminary data of [18F]ASEM
in the pig brain demonstrated principal suitable kinetic properties for in vivo quantification of α7
nAChR, comparable to previously published data.
Keywords: alpha 7; nicotinic acetylcholine receptors; PET; nAChR; autoradiography
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1. Introduction
The α7 nicotinic acetylcholine receptor (α7 nAChR) belongs to the superfamily of ligand-gated ion
channels and is expressed across all mammalian species [1–4]. The receptor plays an important role in
cognition [5], mood [6] and consistent with this, α7 nAChR are particularly abundant in hippocampus
and prefrontal cortex [7,8]. Furthermore, α7 nAChR are implied in neuro-immune [9] and immune
functions [10] under homeostatic conditions.
Changes in protein and mRNA levels of α7 nAChR have been reported in a number of
neuropsychiatric and neurodegenerative diseases [1,11–15]. Notably, certain polymorphisms in the
promoter region of the α7 nAChR gene (CHRNA7) [16] are probable risk factors for neuropsychiatric
diseases, such as major depression [17] and schizophrenia [18] and are associated with developmental
disorders and cognitive impairments [19]. Additionally, α7 nAChRs are expressed by several central
and peripheral immune cells and activation via agonists and positive allosteric modulators showed
neuroprotective and immunomodulatory efficacy in different preclinical disease models [20–24].
Changes of α7 nAChR in the healthy and diseased brain can only be detected in vivo by molecular
imaging, such as positron emission tomography (PET) using specific radiotracers. A clinically usable
radiotracer requires sufficient selectivity, specificity and suitable affinity, depending on the target [25].
Most of the previously described α7 nAChR PET tracers, among those [18F]NS14490, [11C]NS14492,
[11C]CHIBA-1001 and [11C]A-582941 (Table 1), studied in mice, pigs and non-human primates exhibited
some shortcomings, such as poor specific and/or high nonspecific binding or radiometabolites crossing
the blood–brain barrier [26–32]. Furthermore, the specificity of novel α7 nAChR tracers has not always
been tested in respective gene-deficient mice, e.g., using in vitro autoradiography.
While development of novel tracers from different lead structures is still ongoing [33–37],
tilorone [38] provided a lead-structure for a number of derivatives subsequently developed into α7
nAChR PET tracers. From those, [18F]ASEM (JHU82132) [39] and the structurally related [18F]DBT-10
(JHU82108) [40] have been most widely investigated. Initial studies have shown that ASEM is a
potent antagonist [39] with subnanomolar affinity and high selectivity [39,41], further substantiated
by the radiolabelled compounds [18F]ASEM [26] and [125I]Iodo-ASEM [42] as tested in human and
rat recombinant α7 nAChR. [18F]ASEM and [125I]Iodo-ASEM readily enter the mouse brain, are
displaceable, and accumulate in regions with highest α7 nAChR density [26,39,42,43].
More recent studies using [18F]ASEM and [18F]DBT-10 further supported the suitability of the
tracers, showing high and reversible brain uptake with a regional binding pattern consistent with
the distribution of α7 nAChR receptors in the non-human primate brain [39,44,45]. Favourable
brain pharmacokinetics, excellent test-retest reproducibility and regional uptake [18F]ASEM pattern
consistent with post-mortem α7 nAChR distribution have been reported in human PET studies [43,46].
Several recent studies extended the available data in human subjects, showing good agreement
with previous distribution volumes (VT) and test-retest values in nonhuman primates and healthy
volunteers [44]. A study in ageing subjects showed a significant positive correlation between age
and [18F]ASEM VT in striatum and several cortical regions [47], however without any correlation
between VT and cognitive measures. A small sample of individuals with schizophrenia on stable
antipsychotic medication showed lower [18F]ASEM VT in cingulate cortex and hippocampus [46]
and individuals with recent onset of psychosis were also reported to show lower [18F]ASEM VT in
hippocampus, after controlling for age [48]. Interestingly, patients with mild cognitive impairment
showed higher [18F]ASEM VT when adjusted for age as compared to the control group [49], consistent
with post-mortem findings from patients and animal models. Additionally, [18F]ASEM has been
employed in a rat 6-OHDA lesion model of Parkinson’s disease, showing an initial increase of
[18F]ASEM SUVr in the ipsilateral striatum and substantia nigra between 3 and 7 days, which coincided
with several histology markers of glia activation [50].
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While this data shows the general applicability of [18F]ASEM, binding properties and interpretation
of novel α7 nAChR tracers might be complicated by the fact that α7 subunits can form heteromeric
receptors together with other subunits, specifically β2 [51]. These receptors can be heterologously
expressed in oocytes and are found in the rodent and human basal forebrain and cortex [52,53].
While these heteromeric receptors display different pharmacological properties [52,54], it is not clear
how this translates to radiotracer binding. In vitro binding studies of [18F]ASEM or [125I]ASEM in
gene-deficient mice could answer the question, and would also reveal the suitability of [125I]ASEM for
in vitro autoradiographic studies. The latter would offer a better comparability to in vivo PET data
over the current gold-standard tracer [125I]α-bungarotoxin. We therefore investigated the potential
of [125I]ASEM for in vitro studies of the α7 nAChR, by comparing binding of [125I]Iodo-ASEM in rat,
mouse and pig brain sections. Furthermore, [18F]ASEM was characterized for in vivo brain uptake
and target selectivity in a PET study conducted in the pig.










2.1. In Vitro Autoradiography
Cerebral binding of [125I]Iodo-ASEM was investigated across several mammalian species, i.e.,
rat (Figure 1A, upper row), mouse (Figure 2A) and pig brain (Figure 1A, lower row) and compared to
[125I]α-bungarotoxin (Figure 1B/2B). Total cortical [125I]Iodo-ASEM binding was highest in the pig, and
lower in the rat and mouse (Figures 1C and 2C), as compared to [125I]α-bungarotoxin. [125I]Iodo-ASEM
binding was displaceable with (-)-nicotine (1 mMol/L, data not shown) and SSR-180,711 (10 μMol/L,
Figures 1A and 2A, nonspecific binding) in all species.
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Figure 1. (A,B) Representative autoradiographs showing [125I]Iodo-ASEM and [125I]α-bungarotoxin
total and non-specific binding (determined with 1 mMol/L (-)-nicotine for [125I]α-bungarotoxin and
10 μMol/L SSR-180,711 for [125I]Iodo-ASEM) in 12 μm sections of the rat (upper row) and pig brain
(lower row). Arrowheads indicate residual white matter binding. (C) Comparative quantitative analysis
of specific binding (± S.E.M.) of [125I]Iodo-ASEM and [125I]α-bungarotoxin from autoradiography in
the rat (n = 1) and pig cortex (n = 2). All autoradiographic experiments and quantifications are carried
out in 3-4 sections per animal.
A non-specific binding component remained detectable under the described experimental
conditions at low levels in white matter structures (arrowheads, Figures 1A and 2A). The distribution
pattern of [125I]Iodo-ASEM binding in the rat, mouse and pig brain was comparable to that of
[125I]α-bungarotoxin (Figures 1B and 2B). In the pig, [125I]Iodo-ASEM showed a laminar binding
pattern in the frontal cortex, with highest density in cortical layers (1–3) (Figure 1A, lower row), while
in the rat, binding in motor, cingulate and somatosensory cortex was more prominent in layers 5–6.
However, this species difference was also observed for [125I]α-bungarotoxin (Figure 1B).
Figure 2. (A,B) Representative autoradiographs showing total [125I]Iodo-ASEM (A) and [125I]a-bungarotoxin
(B) and non-specific (determined with 1 mMol/L (-)-nicotine for [125I]α-bungarotoxin and 10 μMol/L
SSR-180,711 for [125I]Iodo-ASEM) binding in 12 μm brain sections of α7 and β2 nAChR wild-type
vs. corresponding gene-deficient (def) mice (n = 1 each). Arrowheads indicate residual white matter
binding. (C) Comparative quantitative analysis of specific binding (± S.E.M.) of [125I]Iodo-ASEM and
[125I]a-bungarotoxin in α7 and β2 nAChR wild-type vs. corresponding gene-deficient mice (n = 1).
All autoradiographic experiments and quantifications are carried out in 3-6 sections per animal.
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The specificity of [125I]Iodo-ASEM to α7 nAChR is further substantiated by tracer binding
experiments in α7 nAChR gene-deficient mice. Specific [125I]Iodo-ASEM binding was lacking in α7
nAChR gene-deficient mice (Figure 2A), as indicated by the overall reduction in total binding by
93% ± 1.7%, compared to wild-type animals (Figure 2C). Similarly, [125I]α-bungarotoxin total binding
(Figure 2B) was 96% ± 0.4% lower in α7 nAChR gene-deficient mice (Figure 2C). In wild-type mice, no
difference in [125I]Iodo-ASEM and [125I]α-bungarotoxin binding was observed (Figure 2A,B). However,
traces of nonspecific binding were again noted in white matter structures (arrowheads in Figure 2A).
[125I]Iodo-ASEM binding in β2 nAChR gene-deficient mice was different compared to
[125I]α-bungarotoxin. An overall 58% ± 2.7% lower specific [125I]Iodo-ASEM binding was observed,
as compared to corresponding wild-type controls (Figure 2C). In contrast, [125I]α-bungarotoxin binding
was reduced by 23% ± 0.2%, being less affected by β2 nAChR gene-deficiency as compared to the
reduction in [125I]Iodo-ASEM binding.
Saturation binding in rat and pig brain sections indicated that [125I]Iodo-ASEM binding was
saturable. In the rat, non-linear regression analysis revealed an equilibrium dissociation constant (Kd)
of 1.14 nM (cortex, Figure 3B) and 1.17 nM (hippocampus, Figure 3A) with corresponding receptor
density (Bmax) of 0.70 fmol/mg protein (cortex) and 1.44 fmol/mg protein (hippocampus), respectively
(Figure 3A,B). In comparison, the pig cortex showed a Kd of 1.21 nM with a Bmax of 5.47 fmol/mg
protein (Figure 3C). The non-specific binding of [125I]Iodo-ASEM at concentrations near the Kd was
low (rat hippocampus, 20%; rat cortex, 30%; pig cortex, 10%).
Figure 3. Saturation binding of [125I]Iodo-ASEM (0.02-10 nMol/L) to 12 μm sections from the rat
hippocampus and cortex (A, B, n = 1) and pig frontal cortex (C, n = 1) brain. Non-specific binding
was determined in the presence of 10 μMol/L SSR-180,711. Optical density of the autoradiograms was
converted into ligand binding (fmol/mg protein ± S.E.M.) from a representative experiment. Data from
saturation binding experiments were analysed by non-linear regression. Individual Kd and Bmax values
are indicated in Section 2.1. All autoradiographic experiments and quantifications are carried out in
2–4 sections per animal using 10 radioligand concentrations.
A range of selective α7 nAChR ligands (10 μMol/L each), including the α7 nAChR preferring
antagonist methyllycaconitine (MLA), were used to test whether in vitro [125I]Iodo-ASEM binding
(0.5 nMol/L) could be blocked in the pig cortex (Table 2). The partial agonists, NS14492, TC-5619,
EVP-6124, A-582941, and SSR-180,711, showed almost complete (>90%) blocking of [125I]Iodo-ASEM
binding in receptor dense areas of the cortex, e.g. layers 1–3. In contrast, GTS-21 (weak α7 nAChR
agonist, ~70% reduction) and MLA (α7 nAChR preferring antagonist, ~80% reduction) exhibited less
efficacious blockade of [125I]Iodo-ASEM binding in the pig cortex.
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Table 2. Blocking of [125I]Iodo-ASEM binding in the pig cortex by a series of α7 nAChR ligands.
Ligand
(10 μMol/L)
[125I]Iodo-ASEM Binding in the
Pig Cortex, Layers 1–3
(%, mean ± S.E.M.)
[125I]Iodo-ASEM Binding in the
Pig Cortex, Layers 4–6
(%, mean ± S.E.M.)
NS14492 4.04 ± 0.55 9.25 ± 0.83
TC-5619 7.88 ± 1.65 7.60 ± 0.30
EVP-6124 2.50 ± 0.20 5.50 ± 0.07
A-582941 3.22 ± 0.28 4.44 ± 0.93
SSR-180,711 2.92 ± 0.35 3.53 ± 0.50
GTS-21 30.92 ± 2.55 31.39 ± 2.15
MLA 20.46 ± 2.18 18.16 ± 2.41
Results are given in % remaining binding of total binding (mean ± S.E.M.).
2.2. In Vivo PET Imaging in the Pig Using [18F]ASEM
[18F]ASEM readily entered the pig brain and highest tracer accumulation was found in the
thalamus followed by cortex, striatum and cerebellum (Figure 4A,C). [18F]ASEM uptake in the white
matter was initially lower than in the grey matter regions, however the tracer kinetics were also
slower, resulting in lower grey to white matter ratio at the end of the scans. The metabolism of
[18F]ASEM in pigs was relatively slow, with 60% of the radioactivity at 120 min still being parent
radioligand (data not shown). Kinetic modelling was performed to quantify the tracer uptake. Baseline
VT values varied between animals but after correcting for free fraction in plasma(fP), there was only a
5% difference in VT/fP values between the two baseline animals (Table 3). This also suggest that VT/fP
values are unaffected by relatively large differences in injected mass (0.35 μg and 1.78 μg).
Table 3. Kinetic modelling of [18F]ASEM with the Logan Graphical Analysis model in different pig
brain regions.
Comparison of Baseline VT Values.
Kinetic Modelling Animal 1 Animal 2
0–90 min VT VT/fP VT VT/fP
Frontal cortex 7.87 43.70 3.75 41.66
Somatosensory cortex 8.33 46.27 4.15 46.14
Occipital cortex 8.03 44.63 3.77 41.86
Remaining cortex 7.63 42.37 3.78 41.94
Thalamus 8.83 49.06 4.12 45.73
Striatum 7.41 41.17 3.77 41.94
Hippocampus 7.53 41.83 3.59 39.93
Cerebellum 6.66 36.99 3.16 35.07
Comparison of VT Values at Baseline and After Pre-treatment with SSR-180,711
Kinetic Modelling Animal 1 Animal 3
0–150 min VT VT/fP VT VT/fP
Frontal cortex 6.73 37.38 3.61 22.57
Somatosensory cortex 7.26 40.35 3.94 24.60
Occipital cortex 6.96 38.65 3.90 24.40
Remaining cortex 6.68 37.08 3.60 22.50
Thalamus 7.42 41.24 4.34 27.15
Striatum 6.51 36.19 3.83 23.92
Hippocampus 6.55 36.41 3.37 21.09
Cerebellum 5.55 30.82 3.39 21.17
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In a third animal, we evaluated the specificity of [18F]ASEM binding in vivo, by administering
SSR-180,711 (1 mg/kg) prior to injection of [18F]ASEM. Compared to the baseline studies, we found an
increase in [18F]ASEM uptake in all brain areas investigated (Figure 4A). Quantification of uptake and
subsequent correction for fP revealed that SSR-180,711 administration decreased the VT/fP compared
to baseline (Table 3). Occupancy was computed with the Lassen plot using VT/fP values comparing
baseline data from animal 1 and blocking data from animal 3 (0-150 min scan data). We found that the
1 mg/kg SSR-180,711 dose resulted in a 49% occupancy (Figure 4B).
From the Lassen plot, the volume of non-displaceable binding (VND/fP) was found to be 9.2 mL/cm3.
When comparing the VND/fP to the VT/fP in the thalamus, we found that 78% of the signal observed in
the thalamus is specific binding, leaving 22% as non-displaceable binding.
In one animal, [18F]ASEM acquisition time was 240 min, which allowed subsequent analysis of
the time-stability of the parameters estimated with kinetic modelling. Again, the LGA model was
used to determine VT with different scan length and VT values were found to decrease with more time
included in the kinetic modelling. Using all data (0–240 min), VT values were 5.4 mL/cm3 (thalamus),
5.0 mL/cm3 (frontal cortex) and 4.0 mL/cm3 (cerebellum).
The upper half of the table shows the baseline distribution volumes (VT) values with and without
correction for free fraction in plasma (fP) in two different animals. Bottom part of the table describes
VT values with and without correction for (fP) at baseline (animal 1) and after pre-treatment with
SSR-180,711 (animal 3). See Table 4 (Material and Methods) for fP values in the individual animals.
Because animal 2 was only scanned for 90 min, the acquisition time of animal 1 was truncated to 90 min
to allow for comparison.
Figure 4. [18F]ASEM binding in the pig brain. (A) Time-activity curves of [18F]ASEM in three different
animals: Animal 1, bsl, blue; Animal 2, bsl, black; Animal 3, SSR-180,711 pre-treated, red. The regions
shown are: Thalamus (tha, triangles) and cerebellum (cb, circles). (B) Lassen plot with total distribution
volumes (VT) corrected for free fraction in plasma (fP) using values from animal 1 and animal 3.
Each point represents one region of interest (ROI), please refer to the method section for the complete
list of ROIs. (C) Summed PET image (0–240 min) from animal 1 showing the distribution of [18F]ASEM
in the pig brain. SUV: standard uptake value. Bsl: baseline. SSR: SSR-180,711 (1 mg/kg).
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3. Discussion
In this study, we investigated binding properties of radiolabelled ASEM in vitro ([125I]Iodo-ASEM]
and in vivo ([18F]ASEM). Autoradiography was used to determine the applicability of [125I]Iodo-ASEM
for in vitro assessment of α7 nAChR receptor distribution and occupancy in the mammalian brain.
[125I]Iodo-ASEM showed high-affinity and specific binding to α7 nAChR in the rat, mouse and pig
brain. Specific binding was absent in α7 gene-deficient mice, indicating high specificity and selectivity.
Saturation binding experiments in rat and pig brain sections revealed low nanomolar Kd values
(approximately 1 nM) in both species. Bmax in the pig cortex was considerably higher as compared to
the binding found in the mouse and rat brain cortex. Such species differences are well documented in
the literature, e.g., for metabotropic glutamate 5 receptors and the 18 kDa translocator protein between
monkey and humans [55,56]. As affinity and selectivity are major criteria for radiotracers, our data
further substantiates the suitability of ASEM derivatives as favourable α7 nAChR tracers [57,58]
We found that the affinity of [125I]Iodo-ASEM in the pig brain as determined with autoradiography
was in a similar range as [3H]NS14492 [59]. In contrast, higher affinities and receptor densities are
reported for radioligand binding assay in brain homogenates for a number of different α7 nAChR
ligands, such as [3H]NS14492 and [3H]A-585539 [60], including other dibenzothiophenes [26,38].
Across the brain and specifically regions with high α7 nAChR expression, such as hippocampus
and superficial cortical layers, non-specific binding of [125I]Iodo-ASEM at concentrations near the Kd
was low (10%–30% of total binding) and produced a robust specific signal. However, a consistent
nonspecific binding component in white matter was observed in all investigated species, in particular
the corpus callosum and subcortical tracts. This is supported by previously reported in vivo findings
in human and non-human primate subjects [39,43], where tracer uptake was lowest in white matter
structures, such as the corpus callosum. Furthermore, we also observed slower in vivo kinetics in
white matter structures in the pig brain. This could be caused by lower perfusion or kinetics may be
different when the tracer interacts with lipid membranes, compared to interaction with the receptor.
As in vitro binding conditions are distinctly different due to absent metabolism and blood flow, it is
possible that these effects may limit pronounced non-specific white matter binding in vivo or that
the nonspecific binding exhibits much slower kinetics. Under the employed incubation conditions,
[125I]α-bungarotoxin shows no white matter residual binding. However, under the same conditions,
the overall non-specific binding in grey matter for [125I]α-bungarotoxin is approximately 45% in human
(data not shown) and 55% in pig brain tissue, where it is much lower for [125I]Iodo-ASEM (~10%–30%).
[125I]Iodo-ASEM binding enables an important distinction between grey and white matter
structures, e.g., the distinct cortical laminar binding pattern observable in the pig. While
[125I]Iodo-ASEM binding was prominent in the deeper cortical layers in the mouse and rat, superficial
cortical layers were intensely labelled in the pig. Using in vitro autoradiography, similar laminar
cortical binding pattern in the pig brain has also recently been reported for a structurally different
α7 nAChR radioligand, [3H]NS14492 [61]. Binding of both tracers was matching the pattern of
[125I]α-bungarotoxin, the in vitro gold-standard radioligand for α7 nAChR. However, the spatial
binding pattern in the rodent brain was only similar between [125I]Iodo-ASEM and [125I]α-bungarotoxin,
but not for [3H]NS14492, suggesting different binding profiles of antagonists and agonists, or species
differences in affinity.
[125I]Iodo-ASEM proved specific to the α7 nAChR, as evidenced by the lack of specific binding in
α7 nAChR gene-deficient mice and a virtually complete block of cortical [125I]Iodo-ASEM binding by a
wide range of structurally different α7 nAChR selective ligands and MLA, with the rank order being
NS14492=TC-5619=EVP-6124=A-582941=SSR-180,711>MLA>GTS-21. While this corresponds well
with the individual high affinities in the nanomolar range (NS14492, TC5619, EVP-6124, A-582941,
SSR-180,711) [31,62–65], as compared to the lower affinity of a partial agonist (GTS-21) [66], it could also
reflect the general differences between antagonists and agonist in terms of binding sites and kinetics.
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When comparing to [125I]α-bungarotoxin, the specific binding of [125I]Iodo-ASEM was lower in
the rat and mouse brain, but higher in the pig cortex. While species differences in receptor structure
may account for the discrepancies, it should also be considered that different incubation protocols
were used for the determination of optimal [125I]Iodo-ASEM and [125I]α-bungarotoxin binding. Hence,
a relatively high detergent concentration was required in the experiments to obtain optimal total
tissue binding of [125I]Iodo-ASEM, which may potentially affect binding of the radioligand in the
mammalian species tested, e.g., through differences in lipid content and myelination. For example,
[125I]Iodo-ASEM showed some degree of non-displaceable binding to white matter structures, which
could be caused by the ligands’ lipophilicity and/or different kinetics in white matter structures.
Interestingly, radioligand binding in β2 nAChR gene-deficient mice was more strongly reduced
for [125I]Iodo-ASEM than [125I]α-bungarotoxin. This observation suggests different binding properties
and subtype selectivity to heteromeric α7β2 nAChR, compared to the homomeric receptors. In the CNS,
heteromeric α7β2 nAChR are identified in the mouse forebrain and hippocampal neurons, rat basal
forebrain cholinergic neurons, as well as in the human basal forebrain and cerebral cortex. Importantly,
α7β2 nAChR display distinct functional properties as compared to homomeric α7 nAChR [51,67],
owing to their slower whole cell decay kinetics and current amplitudes in both transfected cell
systems and native rodent neurons [53,54,68–70]. Accordingly, co-expression of α7 and β2 nAChR
subunits in Xenopus oocytes also results in lower maximal responses (evoked current amplitudes) of
selective α7 nAChR agonists but does not shift pharmacology to a more β2-like profile [52–54,71].
These in vitro studies in transfected cell systems therefore suggest that α7 nAChR agonists bind
to the α7-α7 subunit interface, and β2 subunits likely do not contribute to the ligand binding site
on heteromeric α7β2 nAChR [67,71]. When using selective α7 nAChR antagonists, including MLA
and α-bungarotoxin, to alter the response to some nicotinic agonists in either homomeric α7 and
heteromeric α7β2 nAChR, results have been less consistent, as they show unaltered [54] or reduced
potency [52] and efficacy [53] in comparison to homomeric α7 nAChR expressed in Xenopus oocytes.
The functional significance of heteromeric α7 nAChR expression is not well understood, with recent
work suggesting that this subtype combination might be more sensitive to inhibition by oligomeric
amyloid β1–42 [68,69] and isoflurane [72], as compared to homomeric α7 nAChR. Our finding that
binding of [125I]Iodo-ASEM, an antagonist, was markedly reduced in the forebrain of β2 gene-deficient
mice therefore may suggest that [125I]Iodo-ASEM binds to heteromeric α7β2 nAChR in the brain,
as opposed to [125I]α-bungarotoxin. Whether this is due to different affinity for homomeric α7 and
heteromeric α7β2 nAChR requires further in vitro studies. Although speculative, this may offer a
chance to probe the binding of amyloid β1–42 to heteromeric α7β2 nAChR in vivo using PET.
In vivo uptake of [18F]ASEM into the pig brain occurred rapidly within the first 10–20 min
and a reversible but slower washout was found, as observed in human and non-human primate
subjects [39,43]. The in vivo distribution of [18F]ASEM found here is very similar to that of [11C]NS14492
and importantly, also in accordance with the distribution of α7 nAChR in the pig brain [31,73].
Furthermore, our data with [18F]ASEM matches previous reports with the structurally similar analogue
[18F]DBT-10 in piglets [40].
We found variations in brain uptake and fP in the two baseline animals, and this result is consistent
with the interpretation that lower fP will lead to lower brain uptake [74]. Due to the limited number of
animals in this study, this observation merits further investigations. Our finding is however supported
by PET studies in non-human primates with [18F]ASEM and [18F]DBT-10, where VT/fP was shown to
be a more stable outcome measure than VT [44,45]. This has also been shown for radiotracers binding
to other neurotransmitter receptors [75].
VT was found to increase slightly when the scan time was prolonged. This phenomenon was
most pronounced in the thalamus and least pronounced in the white matter and is evident from the
TACs (Figure 4A), where the ratio between e.g., thalamus and cerebellum was lower at 240 min than
at 90 min. This finding is in contrast with the non-human primate and human data, where VT was
underestimated when reducing the PET data from 180 to 60 min [44]. Given that ASEM is an antagonist,
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it is unlikely that internalization of the receptor-ligand complex is an explanation for the decrease in
VT. We cannot exclude that other receptor adaptations, such as (de)sensitization, could be responsible
for this observation. Desensitization could occur if experiments were not conducted at tracer dose, i.e.,
but we did not attempt to identify the mass dose limit of unlabelled ASEM. Although the injected
doses of ASEM varied in the two baseline animals, we only found a 5% difference in the calculated
VT/fP, which suggest that the studies were conducted at tracer doses. The injected doses in this study
(0.007–0.085 ug/kg) are higher than the doses used in the non-human primate evaluation of [18F]ASEM,
where injected doses ranged from 0.009 to 0.056 μg/kg [44]. Further studies are needed to identify the
mass dose limit of unlabelled ASEM.
While pre-treatment with 1 mg/kg SSR-180,711 resulted in an increased uptake of [18F]ASEM,
kinetic modelling for quantification of tracer uptake showed that SSR-180,711 at this dose resulted
in 49% occupancy. A similar phenomenon has also been reported in piglets when [18F]DBT-10 was
blocked by the weak agonist NS6740, which was ascribed to a potential blood flow-driven effect of
NS6740 leading to greater central uptake of [18F]DBT-10 [40]. The increased tracer uptake could also
be a result of peripheral α7 nAChR binding sites having been blocked by SSR-180,771. The occupancy
found by us is in line with previous work of Horti et al., reporting 39% and 81% occupancy for doses
of 0.5 and 5 mg/kg SSR-180,711, respectively [39]. The occupancy computed in this study should be
interpreted with care, as the baseline and blocking study is conducted in two different pigs. Due to the
half-life of [18F]ASEM, it was not possible to conduct the study in the same animal on the same day.
A further limitation to this in vivo study is the low number of PET scans and animals and thus we can
only provide a descriptive presentation of the data, without statistical evaluations.
From our results, [125I]Iodo-ASEM therefore offers several advantages over [125I]α-bungarotoxin:
1) low nonspecific binding, 2) similar high affinity and selectivity and 3) in vivo applicability and direct
comparison of PET data with autoradiographic data. The lower nonspecific binding of [125I]Iodo-ASEM
is advantageous primarily in vitro, as it allows for a better signal-to-noise ratio over [125I]α-bungarotoxin
at very similar affinities. While a low nonspecific binding would also be favourable under in vivo
conditions (e.g., PET), having two nearly identical molecules as tracers offers interesting avenues,
especially for preclinical studies. In vivo PET/SPECT imaging data can be acquired through [18F]ASEM,
[18F]DBT10 or [123I]Iodo-ASEM and results can be validated or extended by using the advantages of
in vitro autoradiography (e.g. resolution) with [125I]Iodo-ASEM.
In conclusion, [125I]-Iodo-ASEM is applicable for visualizingα7 nAChR binding in vitro, its binding
is different between species, and may potentially bind to heteromeric α7β2 nAChR. In addition,
[18F]ASEM is demonstrated to have suitable kinetic properties for in vivo quantification of α7 nAChR
in the pig.
4. Materials and Methods
4.1. Compounds and Radioligands
[125I]Iodo-ASEM [(3-(1,4-diazabycyclo[3.2.2]nonan-4-yl)-6-(125I-iododibenzo[b,d]thiopentene
5,5-dioxide)] was labelled according to previously published procedures [42]. Mean molar activity
was 59.94 ± 6.25 TBq/mmol. [125I]Tyr-54-mono-Iodo-α-bungarotoxin (81.4 TBq/mmol) was purchased
from Perkin-Elmer (Skovlunde, Denmark). (-)-nicotine tartrate was purchased from Sigma-Aldrich
(St. Louis, MO). Unlabelled ASEM and precursor for radiosynthesis was provided by DanPET (Malmoe,
Sweden). The α7-selective ligands were purchased from Sigma-Aldrich (MLA) or provided by DanPET
(NS11492) or NeuroSearch A/S (Copenhagen, Denmark) (SSR-180,711, TC-5619, EVP-6124, A-58294,
and GTS-21.
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4.2. Tissue Origin and Sectioning for In Vitro Autoradiography
All animal procedures were approved by the Danish Animal Experimentation Inspectorate (J. No.
2012-15-2034-00156) and treated in concordance with the European Communities Council Directive of
24th November 1986 (86/609ECC).
One female Sprague-Dawley rat (250 g, obtained from Charles River, Sulzfeld, Germany) was
euthanized with an intraperitoneal overdose of pentobarbital, the brain was quickly removed and
snap-frozen in −50 ◦C 2-methylbutane, then stored at −80 ◦C until further processing.
Mice deficient for the α7 subunits (The Jackson Laboratory) and β2 (Institut Pasteur, Paris,
France) and their corresponding wild-type littermates were bred (C57BL/6J background) in an animal
care facility at Virginia Commonwealth University. Brains from α7 and β2 gene-deficient mice
and corresponding wild-type littermates were kindly provided by Dr. M. Imad Damaj (Dept. of
Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA).
One two-month old female Danish domestic pig (Landrace x Yorkshire x Duroc, 22 kg) was
euthanized with an intravenous injection of pentobarbital, the brain was quickly excised, separated in
two hemispheres and frozen on dry ice, before being stored at −80 ◦C.
All brain specimens were cut in 12 μm serial sections on a cryostat (Microm HM 500 OM, Walldorf,
Germany), thaw-mounted onto Super Frost slides (Thermo Scientific, Hvidovre, Denmark), briefly air
dried and stored at −80 ◦C until further processing. Protein concentration was determined from single
or three sections with the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA) based on the method of
Bradford [76].
4.3. In Vitro Autoradiography with [125I]Iodo-ASEM
Initial optimization of assay conditions was performed to maximize total binding while keeping
non-specific binding low. Adjustments included buffer composition and pH, detergent concentration,
wash and incubation time and temperature. An assay buffer with 50 mMol/L Tris-HCl pH 7.4, 21 ◦C
(termed Tris-HCl buffer) provided best preserved tissue integrity and lowest non-specific binding,
as compared to physiologic Tris, Tris-EDTA-EGTA or HEPES-KRH buffer (data not shown). For all
further experiments, tissue from 1–2 animals was used, with experiments and quantifications carried
out using 3–4 sections for pig and rat tissue and 3–6 sections for mouse tissue. Adjacent sections
were used for autoradiography for all similar experiments (e.g. saturation binding). Sections were
brought to room temperature and pre-incubated for 20 min in Tris-HCl buffer (pH 7.4, 21 ◦C), then
incubated for 60 min in the same buffer (21 ◦C) containing 1.5% Triton X-100 (v/v) and 0.5-1.0 nMol/L
[125I]Iodo-ASEM in a humidified chamber. Non-specific binding of [125I]Iodo-ASEM was assessed
in the presence of 10 μMol/L SSR-180,711, added to the buffer. Blocking of [125I]Iodo-ASEM binding
was investigated with a series of individual α7 nAChR selective compounds (10 μMol/L) added to the
incubation buffer, i.e., methyllycaconitine (MLA) [77], SSR-180,711 [63], NS14492 [31], TC-5619 [64],
EVP-6124 [65], A-582941 [62], and GTS-21 [66]. Following incubation, slides were rinsed in Tris-HCl
buffer (pH 7.4, 21 ◦C), washed 2 × 5 min in Tris-HCl buffer (pH 7.4, 4 ◦C) and rinsed (5 sec) in ice-cold
distilled water. Slides were gently dried under an air stream and exposed to 4% paraformaldehyde
vapour overnight at 4 ◦C, followed by another drying step in a desiccator for 1 h. Adjacent sections
were used for autoradiography.
4.4. In Vitro Autoradiography with [125I]α-bungarotoxin
Slides were thawed at room temperature (21 ◦C) for 30 min, followed by 30 min of rehydration in
50 mMol/L Tris buffer with 0.1% BSA (w/v), pH 7.3 (binding buffer). For assessment of α-bungarotoxin
binding, the binding buffer contained 0.5 mMol/L [125I]α-bungarotoxin and 4.5 nMol/L unlabelled
α-bungarotoxin (Tocris, Denmark) yielding a total of 5 nMol/L α-bungarotoxin (incubation buffer).
Total binding was determined using one set of slides incubated with the radioligand for 2 h at
room temperature in a humidified chamber. Non-specific binding was determined in the presence
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of 1 mMol/L (-)-nicotine added to the incubation buffer. Afterwards, slides were briefly rinsed in
binding buffer, followed by 2 × 30 min of washing in ice-cold binding buffer (4 ◦C). Finally, slides
were briefly rinsed (5 sec) in ice-cold distilled water, dried under a gentle air stream and exposed
to 4% paraformaldehyde vapour overnight at 4 ◦C. On the next day, the slides were dried for 1 h in
a desiccator.
4.5. Saturation Binding and Kinetic Analysis Using In Vitro Autoradiography
Saturation binding was carried out in rat and pig brain sections as described above (Section 4.3).
Sections were incubated with ten serial dilutions of [125I]Iodo-ASEM ranging from 0.02 to 10 nMol/L,
with concentrations measured by gamma-counting. Non-specific binding was determined in adjacent
sections in the presence of 10 μMol/L SSR-180,711 for each radioligand concentration. Binding was
terminated by washing the sections in ice-cold binding buffer. The equilibrium dissociation constant
(Kd) and maximum number of binding sites (Bmax) were determined by non-linear regression analysis
of a one-site saturation binding model using GraphPad Prism 6.0 (GraphPad Software, Inc., San Diego,
CA, USA).
4.6. Autoradiographic Image Acquisition and Analysis
BAS SR2040 phosphor imaging plates (Fujifilm, Toyko, Japan) were exposed to the samples along
with [125I] standards (ARI 0133A; American Radiolabeled Chemicals, St. Louis, USA) for 24-72 hours.
Imaging plates were scanned using a Phosphor Imager BAS-2500 (Fujifilm Europe GmbH, Düsseldorf,
Germany). Images were converted to TIF-files using the manufacturer’s software and analysed in
QuantityOne (BioRad, Waltham, MA, USA). Regions of interest (ROIs) were drawn over grey and
white matter structures, depending on the investigated species. High intensity circular spots were
occasionally observed in [125I]Iodo-ASEM autoradiographs and were excluded from the analysis.
For α7 and β2 gene-deficient mice, only one ROI was drawn over the whole brain, again excluding
spots and irregular white matter binding. In the rat brain, the ROIs were drawn over cortex and
hippocampus. From the pig brain, only frontal cortex sections were cut, the ROIs therefore contained
the frontal cortex and white matter tracts. The mean values of optical density per mm2 (averaged from
the replicates) were converted to radioactive concentration using a linear regression derived from the
[125I] radioactive standards. A global background of the imaging plate and individual non-specific
binding were subtracted. Final values were expressed as fmol/mg protein, based on the protein
measurements from individual sections.
4.7. Radiosynthesis of [18F]ASEM
The radiosynthesis of [18F]ASEM was performed as previously published [26]. No-carrier-added
aqueous 18F-fluoride from the target was collected at a non-conditioned activated (10 mL ethanol,
20 mL water and dried with air) anion-exchange cartridge (QMA). A solution of 20 mg of
1,10-diaza-4,7,13,16,21,24-hexaoxabicyclo[8.8.8]hexacosane (Kryptofix-222) and 3.3 mg of K2CO3
dissolved in a 0.65 mL methanol-water mixture (97/3 v/v) was used to elute the 18F-fluoride off the
cartridge. The elute was thereafter dried by evaporation at 90 ◦C under nitrogen and then further dried
twice with 1 mL dry acetonitrile. To the dried Kryptofix®222/[18F]fluoride complex, 2.4 mg (0.006
mmol)/L of 3-(1,4-Diazabicyclo[3.2.2]nonan-4-yl)-6-nitrodibenzo[b,d]- thiophene 5,5-Dioxide dissolved
in 0.8 mL DMSO was added. The reaction was performed at 160 ◦C for 15 min and afterwards the
crude was quenched with 3.5 mL H2O. Reactants and by-products were separated from [18F]ASEM
by semi-preparative HPLC [Luna column, Phenomenex Ltd. Aschaffenburg, Germany; 10 μm C18(2)
10×250 mm column, flow rate 6 mL/min, eluent: Ethanol/0.1% H3PO4 in water (25:75) with 6 mM
ascorbic acid to prevent radiolysis]. The retention time for [18F]ASEM was 400-450 s and the product
was collected into a vial containing 9 mL of PBS (phosphate-buffered saline). The product was visually
inspected for clarity, absence of colour and visible particles. Chemical and radiochemical purities were
assessed by analytical HPLC [Kinetex column, Phenomenex Ltd. Aschaffenburg, Germany; 2.6μ C18
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4.60 × 50 mm, eluent: ACN/0.1% H3PO4 in water (25:75) RT: [18F]ASEM = 1.3 min; nitro precursor = 1
min; flow rate 1.5 mL/min]. Molar activity (Am) of the radiotracer was determined as follows: the area
of the UV absorbance peak corresponding to the radiolabelled product was measured (integrated) on
the HPLC chromatogram. This value was then converted into a molar mass by comparison with an
average of integrated areas (triplet) of a known standard of the reference compound.
4.8. In Vivo Imaging in the Pig
Three female pigs (21, 22 and 23 kg) were used for in vivo PET imaging on a HRRT PET scanner
(Siemens Healthcare, Erlangen, Germany). All animal procedures were approved by the Danish
Council for Animal Ethics (journal no. 2012-15-2934-00156).
4.8.1. Animal Procedures
Before scanning, anaesthesia was induced with i.m. injection of 0.13 mL/kg Zoletil veterinary
mixture (Virbac, Kolding, Denmark; 10.87 mg/kg xylazine + 10.87 mg/kg ketamine + 1.74 mg/kg
methadone + 1.74 mg/kg butorphanol + 10.87 mg/kg tiletamine + 10.87 mg/kg zolezepam). Hereafter,
anaesthesia was maintained with constant propofol infusion (1.5 mg/kg/h intravenous (i.v.); B. Braun,
Melsungen, Germany). An arterial i.v. catheter was employed for blood sampling from the right
femoral artery and two venous i.v. catheters for injections were placed in the left and right mammary
veins. During anaesthesia, animals were endotracheally intubated and ventilated. Vital parameters
(heart rate, body temperature, blood pressure, oxygen saturation and end tidal CO2) were continuously
monitored during the scan.
4.8.2. PET Scanning
[18F]ASEM was given as intravenous i.v. bolus, with experimental details described in Table 4.
Table 4. Experimental details of [18F]ASEM PET scans in pigs.
Details Animal 1 Animal 2 Animal 3
Type of experiment Baseline Baseline SSR-180,711; 1 mg/kg
Scan length 240 min 90 min 150 min
Molar activity 20 GBq/μmol 345 GBq/μmol 388 GBq/μmol
Injected activity 99 MBq 335 MBq 189 MBq
Injected mass 1.78 μg 0.35 μg 0.18 μg
Free plasma fraction 18% 16% 9%
4.8.3. Blood Sampling
During the first 30 min of the scans, radioactivity in the whole blood was continuously measured
using an ABSS autosampler (Allogg Technology, Mariefred, Sweden) counting coincidences in a
lead-shielded detector. Concurrently, arterial whole blood was sampled manually at times 2.5, 5, 10, 20,
30, 40, 50, 70, 89, 91, 120 and 150 min after injection of [18F]ASEM. Total radioactivity in plasma (500 μL)
and whole blood (500 μL) was measured in a well counter (Cobra 5003; Packard Instruments, Meriden,
CT, USA), which was cross-calibrated to the HRRT scanner and autosampler. All measurements of
radioactivity were decay corrected to the time of radioligand injection.
4.8.4. Metabolite Analysis
Radiolabelled parent compound and metabolites were determined by direct injection of plasma
into a radio-HPLC system (Dionex Ultimate 3000; Thermo Fisher Scientific, Hvidovre, Denmark)
configured for column switching. Manually drawn arterial whole blood samples were centrifuged
(1500 g, 7 min, 4 ◦C), and plasma was filtered through a syringe filter (Whatman GD/X 13 mm or 25 mm,
PVDF membrane, 0.45 μm pore size; Frisenette ApS, Knebel, Denmark) prior to the analysis by HPLC
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as previously described [78]. To increase sensitivity on gamma counts from samples with low levels
of radioactivity, eluent from the HPLC was collected into fractions (10 mL) using a fraction collector
(Foxy Jr FC144; Teledyne, Lincoln, NE, USA) and counted offline in a well counter (2480 Wizard2
Automatic Gamma Counter, Wallac Oy, Turku, Finland).
4.8.5. Determination of Free Fraction
The free, non-protein bound fraction of [18F]ASEM in pig plasma, fp, was estimated using an
equilibrium dialysis chamber method as previously described [79].
4.8.6. Reconstruction and Pre-Processing of PET Data
150 -minute list-mode PET data were reconstructed in 58 dynamic frames (6 × 10, 6 × 20, 6 × 30,
6 × 60, 4 × 120, 14 × 300, 8 × 150, 8 × 300 s). One animal was scanned for 240 min using the mentioned
framing protocol but adding 9 frames of 600 s). Images consisted of 207 planes of 256 × 256 voxels of
1.22 × 1.22 × 1.22 mm. A summed picture of all counts in the 150-min scan was reconstructed for each
pig and used for co-registration to a standardized MRI-based atlas of the domestic pig brain, similar to
that previously published [80]. The time activity curveds (TACs) were calculated for the following
volumes of interest (VOIs): thalamus, striatum, hippocampus, cerebellum, white matter, frontal cortex,
somatosensory cortex, occipital cortex, rest of the cortex. Radioactivity in all VOIs was calculated as
the average of radioactive concentration (Bq/mL) in the left and right sides. Outcome measure in the
TACs was calculated as radioactive concentration in VOI (in kBq/mL) normalized to the injected dose
corrected for animal weight (in kBq/kg), yielding standardized uptake values (g/mL).
4.8.7. Kinetic Modelling of PET Data
The PET imaging data were analysed with the Logan graphical analysis (LGA) model, using
the metabolite corrected arterial plasma concentration to calculate the primary outcome measure:
total distribution volume (VT). The secondary outcome measure was VT values corrected for free
fraction in plasma (VT/fP). The parent fraction curve for [18F]ASEM was fitted with a Watabe fit.
Both curves were constrained to 1.0 at time = 0. Kinetic modeling was performed in PMOD version 3.0
(PMOD Technologies).
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Abstract: The orexin receptor (OX) is critically involved in motivation and sleep−wake regulation
and holds promising therapeutic potential in various mood disorders. To further investigate the
role of orexin receptors (OXRs) in the living human brain and to evaluate the treatment potential of
orexin-targeting therapeutics, we herein report a novel PET probe ([11C]CW24) for OXRs in the brain.
CW24 has moderate binding affinity for OXRs (IC50 = 0.253 μM and 1.406 μM for OX1R and OX2R,
respectively) and shows good selectivity to OXRs over 40 other central nervous system (CNS) targets.
[11C]CW24 has high brain uptake in rodents and nonhuman primates, suitable metabolic stability,
and appropriate distribution and pharmacokinetics for brain positron emission tomography (PET)
imaging. [11C]CW24 warrants further evaluation as a PET imaging probe of OXRs in the brain.
Keywords: orexin receptors; PET; radiotracer; imaging
1. Introduction
Orexin (OX) is a hypothalamic hypocretin peptide that mediates multiple functions such as
arousal, attention, neuroendocrine, water balance, and pain modulation [1–6]. The orexin system has
two peptide members, orexin-A and orexin-B with 33 amino acids and 28 amino acids, respectively [7].
Orexin receptors (OXRs) also have two subtypes (OX1R and OX2R). Orexin-A has similar binding
affinities to OX1R and OX2R, while orexin-B has a 10-fold higher affinity for OX2R compared with
OX1R. OXRs are differently expressed throughout the brain. OX1R is mainly expressed in the prefrontal
and infralimbic cortex, hippocampus, paraventricular thalamic nucleus, and locus coeruleus [8].
OX2R is mainly distributed in the cerebral cortex, septal nuclei, lateral hypothalamus, hippocampus,
and hypothalamic nuclei [9]. The differential distribution of OXRs in the brain may be responsible for
the various physiological and psychiatric functions mediated by the OXR system [10–12].
Therapeutics targeting the orexin system have been investigated for various brain disorders
such as insomnia [1,3], cluster headache [13], substance abuse [4,14], and maladaptation to
stress [15,16]. This has led to the design and evaluation of orexin antagonists, including dual-OX1R
and OX2R antagonists (DORA) and selective OX1R and OX2R antagonists (SORA). [7] Almorexant [5]
(ACT-426606) [17] from Actelion, SB-649868 [18] from GSK, and Suvorexant [6] from Merck are a few
examples demonstrating the efforts from pharmaceutical companies. Among these compounds,
many have entered into clinical trials, however, Suvorexant is the only U.S. Food and Drug
Administration (FDA) approved orexin drug for the insomnia market. The discovery of ORX
Molecules 2020, 25, 1018; doi:10.3390/molecules25051018 www.mdpi.com/journal/molecules83
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antagonists provided powerful tool compounds to investigate the roles of the orexin system in a variety
of biological processes. However, the roles of the orexin system in the brain are not well understood
and further investigations with translational methods, such as in vivo imaging, are warranted.
A non-invasive molecular imaging with positron emission tomography (PET) is a unique tool to
study the living brain, which provides a distinct advantage to quantify receptor expression and/or
drug occupancy of novel ligands in vivo. Over the last decade, though there have been major advances
in the development of orexin antagonists [19–25], no PET radiotracer is available for OXR imaging
in the human brain. This limits our ability to investigate the orexin system in the human brain and
hinders the potential of orexin-targeting neurotherapeutics for brain disorders.
To bridge the gap, several orexin antagonists have been radiolabeled by our group, as well
as others. Most of the early discovery attempts resulted in compounds with low brain uptake or
strong P-glycoprotein (P-gp) binding, including [11C]MK-1064 [26], [11C]EMPA [27], [11C]BBAC [28],
and [11C]CW4 [29] (Figure 1). Towards the development of a successful OXR brain-PET imaging probe,
we report the discovery and evaluation of [11C]CW24 with good brain uptake, suitable metabolic
stability, and pharmacokinetics based on animal imaging studies in rodents and non-human primates.
 
Figure 1. Structures of orexin receptor radioligands.
2. Results and Discussion
2.1. Selection of Scaffold for Orexin Imaging Probe Development
Several small molecules have been reported as DORA or SORA [20,30,31]. Previously, our group
has radiolabeled several DORAs based on a 1,4-diazepane scaffold [27,29]. However, the low brain
uptake limited their further evaluation as a brain-PET radiotracer. Recently, IPSU was reported as
an OX2R selective antagonist with good brain uptake [32,33]. It has been studied in rodents, including
blood and brain pharmacokinetics, as well as EEG (electrocorticogram/electroencephalogram) and
EMG (electromyogram) recordings following treatment with these OXR antagonists in mice. Based on
the structure-activity relationship (SAR) study of ISPU analogs, methylation of the indole imine does
not disrupt OXR antagonism [32]. Hence, we chose the indole imine of IPSU as the radiolabeling
site and synthesized CW24. The affinity of CW24 for orexin receptors (OX1R and OX2R) in cells was
measured in a competition binding assay against [125I] orexin. CW24 displayed potent activity at OXRs
(IC50 0.253 μM OX1R, 1.406 μM OX2R). Compared to IPSU binding, this was ~5 fold (OX1R) and ~2
fold (OX2R) increase in potency, warranting further evaluation.
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2.2. Physicochemical Properties of CW24
Lipophilicity (logP) and molecular weight need to be optimized for sufficient blood-brain barrier
(BBB) penetration while also avoiding high non-specific binding. Studies have shown that it is preferred
for clogP ≤ 4, clogD ≤ 3, total polar surface area (tPSA) between 30–75 and molecular weight (M.W.) <
500 for successful brain-PET imaging probes [34,35]. IPSU is reported as a non-selective OXR antagonist
with good brain uptake [33]. CW24, the methylated form of IPSU, had favorable properties for CNS
penetration (M.W. = 419.5, Log D(7.4) = 2.3, tPSA = 60.74, IC50 = 0.253 μM and 1.406 μM for OX1R and
OX2R, respectively) (Figure 2). Furthermore, we tested the off-target binding of CW24 in vitro, [36]
and were pleased to see that CW24 was selective for OXRs compared to 40 other CNS targets(National
Institute of Mental Health Psychoactive Drug Screening Program, NIMH PDSP) (Table S1).
Figure 2. Structures and physicochemical properties of IPSU and CW24 (n.t. = not tested). IC50 of
IPSU, CW24 and suvorexant were measured by a radioligand competition binding assay.
2.3. Chemical Synthesis for CW24 and [11C]CW24
CW24 was prepared from IPSU via direct methylation in the presence of a base (Figures S1 and S2).
[11C]CW24 was radiosynthesized from IPSU (0.5 mg) in DMF (1 mL) with KOH (10 mg) and allowed
to react with [11C]CH3I for 3 min at 100 ◦C (Scheme 1). The average synthesis time was 30–35 minutes
from end of cyclotron bombardment (EOB) to end of synthesis (EOS), the radiochemical yield (RCY)
was 10–21% (non-decay corrected, from trapped [11C]CH3I), the specific activity (As) was 1.28 ± 0.2
mCi/nmol (EOS), the chemical and radiochemical purities of [11C]CW24 were ≥ 97%.
Scheme 1. Radiolabeling condition: IPSU (precursor, 0.5 mg), [11C]CH3I, KOH (10 mg), in 1.0 mL DMF,
3 min, 100 ◦C. Radiochemical yield (RCY): 10–21% (non-decay corrected from trapped [11C]CH3I).
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2.4. Mouse Imaging with [11C]CW24
We performed PET-computed tomography (CT) imaging on mice to test [11C]CW24 as
a neuroimaging probe for OXR imaging in vivo. [11C]CW24 exhibited high brain uptake (%ID/cc = 3.5%
at Cmax, 1.5 min post-injection). In general, %ID/cc above 0.1% in rat or 0.01% in non-human primate
within 5 min post-injection is above the threshold for suitable BBB penetration for CNS PET imaging
studies [37]. Next, to evaluate the specificity of [11C]CW24 for OXRs, PET-CT imaging studies were
performed in mice after 5 min pretreatment with IPSU (0.5 and 2.0 mg/kg; i.v.) or Suvorexant (5.0 mg/kg;
i.v.). Time-activity curves (TACs) were normalized for peak uptake (~20 seconds post-injection in
these studies) (Figure 3). Approximately 10% reduction in [11C]CW24 uptake with 0.5 mg/kg IPSU
administration in 30–60 mins post-injection of [11C]CW24. In addition, approximately 50% reduction
was found when the blocking dose of IPSU was increased to 2.0 mg/kg. Suvorxant (5.0 mg/kg)
administration at 30–60 mins post-injection of [11C]CW24 also showed ~50% reduction in the mouse
brain. Following IPSU pretreatment, [11C]CW24 binding was reduced in a dose-dependent manner in
the brain for the relative radioactivity changes after administration. These results strongly support
that [11C]CW24 binds selectively to the OXRs in vivo.
Figure 3. (A) The PET/CT imaging of [11C]CW24 focused on mice brain (20-60 min after intravenous
administration (i.v.)); (B) baseline and blocking time-activity curve (TAC) of [11C]CW24 and (C) TAC
after normalized the brain uptake curves with the highest uptake time point (20 seconds post-injection).
2.5. Non-human Primate (NHP) Imaging with [11C]CW24
Encouraged by the promising imaging results of [11C]CW24 in mice, we performed PET- Magnetic
resonance imaging (MR) imaging in a NHP (Figures 4 and 5). In macaque, [11C]CW24 demonstrated
high brain uptake. We observed a peak standard uptake value (SUV) (SUV=C(T)/(injected dose/body
weight) between 1.5–3.0 for all brain regions examined (Figure 4A). Furthermore, relatively higher
uptake was observed in the midbrain and the thalamus and lower uptake in the hippocampus which
suggests heterogenous expressions of OXR in the macaque brain. To further investigate the specific
binding of [11C]CW24, a blocking study was performed in which 2.0 mg/kg IPSU was administered
5 min prior the PET-MR acquisition. Similar to the blocking results shown in mice, a reduction of
radioactivity uptake was found in several brain regions including hippocampus, nucleus accumbens,
thalamus, hypothalamus, putamen and cerebellum (Figure 4B). Using the arterial blood data as input
function, Logan graphical analysis was applied to quantify volume of distribution (VT, mL/cm3) of
[11C]CW24 (Figure 5). The metabolite-corrected arterial plasma after [11C]CW24 bolus injection is
showed in Figure 5C.
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Figure 4. (A) Positron emission tomography (PET)-Magnetic resonance (MR) Imaging (macaque brain).
Summed PET images (30–90 min after [11C]CW24 injection) superimposed structural MRI from the
same macaque. (B) Time−activity curves for brain regions of interest from baseline and blocking scans
are shown (2.0 mg/kg IPSU) (a) hippocampus, (b) nucleus accumbens, (c) thalamus, (d) hypothalamus,
(e) putamen and (f) cerebellum.
Figure 5. Kinetic modeling results with [11C]CW24 in the macaque brain. (A) The total volume of
distribution (VT) images derived from Logan plot with arterial blood data as input function (color bar
indicates VT values from 1–2.5 mL/cm3 (blue to red); (B) Regional VT values showed that the expression
difference in brain regions; (C) Arterial plasma analysis showed that [11C]CW24 radioactivity was
rapidly cleared from blood and [11C]CW24 stability evaluated in plasma over time showed lasting
presence of ~47% of parent compound at 30 min.
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Based on our evaluation both in rodents and NHPs in vivo, [11C]CW24 is a promising OXR PET
radioligand candidate. It has been reported that OXR was typically present in the cerebral cortex,
septal nuclei, hippocampus, medial thalamic groups, raphe nuclei, and abundantly expressed in
hypothalamic nuclei that regulate the homeostasis in rodents [12]. In addition, OX2R was found to have
expression in the hypothalamus that enables its unique role of sleep-wake regulation [11]. Compare to
the previous OXR probes we developed [27,29] [11C]CW24 had higher brain uptake, increased isoform
selectivity over IPSU, appropriate kinetics and distribution, which warrants further development of
OXR PET radioligands based on [11C]CW24.
3. Materials and Methods
3.1. Synthesis of Compound CW24
A mixture of IPSU (5 mg, 0.012 mmol, purchased form MedChemExpress), KOH (4 mg, 0.06 mmol),
and CH3I (5 mg, 0.036 mmol) in DMF (0.1 mL) were reacted at room temperature overnight. The reaction
mixture was purified by reverse phase chromatography (H2O: CH3CN = 1:1) to give the desired
product (2 mg, 0.005 mmol, 39% yield) as a white solid. 1H-NMR (500 MHz, Chloroform-d) δ 8.04 (d, J
= 5.6 Hz, 1H), 7.64 (d, J = 7.9 Hz, 1H), 7.29 (d, J = 8.2 Hz, 1H), 7.22 (t, J = 7.7 Hz, 1H), 7.10 (t, J = 7.4 Hz,
1H), 7.02 (s, 1H), 5.93 (s, 1H), 4.72 (s, 2H), 4.40 (dt, J = 13.7, 4.7 Hz, 2H), 3.87 (s, 3H), 3.75 (s, 3H), 3.38
(m, 2H), 3.24 (t, J = 6.1 Hz, 2H), 2.24 (m, 2H), 1.83–1.77 (m, 2H), 1.73 (m, 2H), 1.50 (m, 2H).13C-NMR
(125 MHz, Chloroform-d) δ 174.50, 169.94, 161.78, 157.98, 137.12, 128.79, 127.61, 121.89, 119.68, 119.41,
110.84, 109.29, 95.96, 53.00, 46.79, 41.77, 40.27, 39.80(2), 33.84(2), 32.82, 30.61, 18.91. LC-MS [M]+ 419.85.
3.2. Radiosynthesis of [11C]CW24
[11C]CH3I was trapped in a reactor (TRACERlab FX-M synthesizer, General Electric) preloaded
with the precursor (0.5 mg), KOH (5.0 mg) in 1.0 mL dry DMF. The mixture was stirred for 3 min
at 100 ◦C and followed by adding water (1.2 mL). The product was separated by reverse phase
semi-preparative HPLC (Phenomenex Luna 5u C8(2), 250 mm × 10 mm, 5 μm; 5.0 mL/min; 60% H2O
+ ammonium formate (0.1 M)/ 40% CH3CN; isocratic). The collected final product was loaded onto
a C-18 sep-pak cartridge, and rinsed with water (5 mL), eluted with EtOH (0.3 mL), and saline (0.9%,
2.7 mL). The average time required for the synthesis from EOB to EOS was 30–35 min. The average
radiochemical yield (RCY) was 10%–21% (non-decay corrected to trapped [11C]CH3I). Chemical and
radiochemical purities were ≥ 95 % (measured with HPLC equipped with a UV detector and a gamma
detector) with a specific activity (As) of 1.28 ± 0.2 mCi/nmol (EOS).
3.3. Assessment of Lipophilicity (Log D; pH 7.4)
Log D was determined according to methods identical to those we previously reported [38].
3.4. Human Orexin GPCR Binding (Agonist Radioligand) Assay
Radioligand competition binding assays were performed by Panlabs, Eurofins Pharma Discovery
Services. Briefly, human recombinant orexin OX1 receptors expressed in CHO-S cells were used in
modified HEPES buffer pH 7.4. An aliquot was incubated with 0.1 nM [125I] Orexin A for 60 minutes
at 25 ◦C. Receptors were filtered and then counted to determine [125I] Orexin A specifically binding.
Human recombinant OX2 receptors were used in modified HEPES buffer pH 7.4. An aliquot was
incubated with 0.04 nM [125I] Orexin A for 180 minutes at 25 ◦C. Membranes were filtered and then
counted to determine [125I] Orexin A specifically bound.
3.5. Rodent PET/CT Acquisition
The Subcommittee on Research Animal Care (SRAC) serves as the Institutional Animal Care
and Use Committee (IACUC) for the Massachusetts General Hospital (MGH). SRAC reviewed and
approved all procedures detailed in this paper. B6C3F1/J mice (male, 18-month old; n = 4 total) were
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utilized in this study. IPSU and Suvorexant were purchased form MedChemExpress and dissolved in
1.0 % DMSO + 1.0 % Tween 80 + 98.0 % saline to make a solution of 1.0 mg/mL.
Animals were anesthetized with 1–1.5% isoflurane and maintained with isoflurane during the
imaging scan. In a single imaging session, mice were arranged in a Triumph PET/CT scanner (Gamma
Medica, Northridge, CA). The mice were administered [11C]CW24 (3700–7400 KBq per animal) after
5-min pre-treatment of IPSU (0.5 and 2.0 mg/kg; n = 1 for each dose; i.v.), Suvorexant (5.0 mg/kg; n = 1;
i.v.), or vehicle (n = 1) via a lateral tail vein catheter. Animals underwent a 60 min dynamic PET scan
followed by computed tomography (CT).
3.6. Rodent PET/CT Image Analysis
PET data were reconstructed using a 3D-MLEM method resulting in a full width at half-maximum
resolution of 1 mm. PET and CT images in DICOM format were imported to PMOD (PMOD
Technologies, Ltd. Zürich, Switzerland) and co-registered to the brain atlas. Volumes of interest
(VOIs) were drawn as spheres in brain regions guided by CT structural images and summed PET data.
Time-activity curves (TACs) were exported as activity per unit volume (%ID/cc) for analysis.
3.7. Macaque PET-MR Acquisition
A male rhesus macaque (14.4 kg) was included in this study. After endotracheal intubation,
the macaque was catheterized antecubitally for radiotracer injection and a radial arterial line was
placed for arterial blood sampling and radiometabolite analysis. The animal was anesthetized with
1.2–1.3% Isoflurane in medical oxygen throughout the imaging session. PET-MR data was acquired
on a 3T Siemens MRI scanner (Munich, Germany) with a BrainPET insert. A baseline and a blocking
scan were performed on the same animal. Dynamic PET image acquisition was initiated followed by
a bolus administration of [11C]CW24 (179 MBq for the baseline scan and 192 MBq for the blocking
scan). To characterize the specific binding of [11C]CW24, a blocking study was carried out in which
2.0 mg/kg IPSU (1.0 % DMSO + 1.0 % Tween 80 + 98.0 % saline to make a solution of 1.0 mg/mL) was
administered 5 min prior the acquisition. A T1-weighting multi-echo magnetization-prepared rapid
gradient-echo (MEMPRAGE) sequence began as the PET scan for anatomic co-registration. Dynamic
PET data were corrected for decay, scatter, and attenuation and reconstructed using methods similar to
our previous studies [39].
3.8. PET-MR Imaging Data Analysis for the Macaque Study
Motion-corrected PET data were registered to the INIA19 macaque MRI Template. VOIs were
selected according to the INIA19 Template and NeuroMaps Atlas [40]. TACs from the whole Macaque
brain as well as a few brain regions were exported. With the availability of a metabolite-corrected
arterial plasma data, the regional volume of distribution (VT) was calculated using Logan Plot analysis
(with a fixed t* of 40 min).
3.9. Plasma and Metabolite Analysis
Briefly, arterial blood samples collected (every 10 s at first 3 min post-administration of [11C]CW24,
then 5 min, 10 min, 20 min, 30 min, 45 min, 60 min, and 90 min) during macaque imaging were
centrifuged to separate plasma, which was then removed and placed in an automated gamma
counter [41]. Metabolite analysis of blood samples collected from 5 to 90 min was conducted on
a custom automated robot fitted with Phenomenex SPE Strata-X 500 mg solid phase extraction
cartridges that were primed with ethanol (2 mL) and deionized water (20 mL). Protein precipitation
was achieved by the addition of plasma (300 μL) to acetonitrile (300 μL), which was centrifuged for
1 min to obtain protein-free plasma (PFP). Three hundred microliters of PFP/acetonitrile solution
was diluted into deionized water (3 mL), loaded onto the C18 cartridge, and removed of polar
metabolites with 100% water. Next, a series of extractions was performed using water and acetonitrile.
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Each sample was counted in a WIZARD2 Automatic Gamma Counter to determine the presence of
radiolabeled metabolites.
4. Conclusions
In summary, our developed PET imaging radio-ligands, [11C]CW24, provides a non-invasive
quantitative imaging tool for evaluating OXR expression in the brain. Based on the in vitro and in vivo
evaluations, [11C]CW24 had high brain uptake and good target-selectivity, but suffers from high
non-specific binding. Therefore, [11C]CW24 could be used as a lead compound to develop brain-PET
probes for OXRs to investigate not only the roles of OXR in a variety of disease applications, but also
the development of OXR neurotherapeutics. In future studies, it is important that we characterize
and optimize [11C]CW24 to improve specific binding for developing potential PET imaging probes for
human imaging.
Supplementary Materials: The following are available online, Figure S1: Representative 1H, 13C-NMR and
HPLC data for CW24; Figure S2: The HPLC profile of CW24; Table S1: Off-target binding data of CW24.
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Abstract: The adenosine A2A receptor (A2AR) is regarded as a particularly appropriate target for
non-dopaminergic treatment of Parkinson’s disease (PD). An increased A2AR availability has been
found in the human striatum at early stages of PD and in patients with PD and dyskinesias. The aim
of this small animal positron emission tomography/magnetic resonance (PET/MR) imaging study
was to investigate whether rotenone-treated mice reflect the aspect of striatal A2AR upregulation in
PD. For that purpose, we selected the known A2AR-specific radiotracer [18F]FESCH and developed a
simplified two-step one-pot radiosynthesis. PET images showed a high uptake of [18F]FESCH in
the mouse striatum. Concomitantly, metabolism studies with [18F]FESCH revealed the presence of a
brain-penetrant radiometabolite. In rotenone-treated mice, a slightly higher striatal A2AR binding of
[18F]FESCH was found. Nonetheless, the correlation between the increased A2AR levels within the
proposed PD animal model remains to be further investigated.
Keywords: adenosine A2A receptor; Parkinson’s disease; rotenone-based mouse model; PET imaging;
[18F]FESCH; two-step one-pot radiosynthesis
1. Introduction
Parkinson’s disease (PD) is characterized by the degeneration of dopaminergic neurons in the
brain, especially in the substantia nigra, resulting in a decreased dopamine level in the striatum.
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Consequently, stimulation of the dopamine D2 receptor (D2R) is reduced and, further, the morphology
of striatal neurons and synaptic connections is changing. These effects lead to motor dysfunctions like
bradykinesia, tremor, rigor, and postural instability [1,2]. The standard therapy of PD is based on the
pharmacological increase of dopamine levels either by administration of L-DOPA as metabolic precursor
of dopamine or by dopamine agonists. Further strategies to raise or maintain the dopamine levels
are based on inhibitors for dopamine reuptake and dopamine-degrading enzymes (e.g., monoamine
oxidase B, catechol-O-methyl transferase) [2]. These dopamine- increasing drugs have only a positive
effect on motor functions at short-term treatment but cause undesirable side effects at long-term
treatment like dyskinesia, nausea, and hallucinations. Due to these limitations, the medicinal research
is currently focusing on non-dopaminergic therapies of PD [2,3].
The adenosine A2A receptor (A2AR) is a G-protein coupled receptor that is highly expressed in
the basal ganglia of the brain, mainly in striatopallidal GABAergic neurons. Furthermore, in this
brain area the A2AR and the D2R are co-localized and form heteromeric receptor complexes while
showing contradictory effects on motor functions [2]. For example, an L-DOPA-induced increase
of dopamine stimulates the D2R leading to enhanced motor activity. Activation of the A2AR by
adenosine or appropriate agonists results in the inhibition of the D2R and, thus, in reduced dopamine
binding [2,4,5]. Pharmacological inhibition of the A2AR amplifies the D2R-dependent signaling cascade
and improves motor symptoms [2,3,5,6]. Since the A2AR modulates the dopamine binding affinity
of the D2R, selective A2AR antagonists have great potential as appropriate non-dopaminergic PD
therapeutics [2,3,6]. In clinical phase II and III trials, the A2AR antagonists istradefylline, preladenant,
and tozadenant improved motor symptoms in PD patients [7–9]. Out of these, istradefylline
(Nourianz®) has already been approved in Japan [10] and currently by the U.S. Food and Drug
Administration (FDA) as an adjunctive treatment to L-DOPA.
Furthermore, a comparative neuropathological postmortem study on brain slices from healthy
subjects and PD patients showed a 2.5-fold increased striatal A2AR protein level already at early PD
stages pointing out that A2AR upregulation is an initial event in the pathogenesis of the disease [11].
Though, it remains unclear whether there is a correlation between altered A2AR expression and motor
symptoms in PD.
Molecular imaging of the A2AR with positron emission tomography (PET) enables the non-invasive
investigation of pathological changes of the receptor level in the human brain [12].
A clinical PET study using [11C]SCH442416 (Figure 1) revealed a 70–80% increased A2AR
availability in the striatum of PD patients with L-DOPA-induced dyskinesia [13]. This strongly
indicates a key role of A2AR not only in the development of PD [11] but also in the progression of
the disease and in association with the dopaminergic standard therapy [2,13]. Hence, A2AR-PET
is considered as an appropriate tool for early diagnosis and staging of PD as well as evaluation of
potential A2AR antagonists for PD treatment by means of receptor occupancy studies. The main
disadvantage of 11C-labeled radiotracers for clinical routine applications is the short half-life of the
nuclide (t1/2 = 20.3 min). To date, there is only one 18F-labeled (t1/2 = 109.7 min) A2AR radiotracer,
[18F]MNI-444 [14,15] (Figure 1), that has already been evaluated in a clinical PET study. In healthy
volunteers [15], a high uptake of activity in the striatum has been observed. However, no follow-up
studies have been published since 2015 and further data of [18F]MNI-444 regarding specificity of
A2AR binding in humans or selectivity over the adenosine A1 receptor (A1R), which is also highly
expressed in the brain [16,17], are not yet available. For that reason, we selected the well-studied
and highly A2AR-selective radiotracer [18F]FESCH [18–21] (Ki(hA2AR) = 12.4 nM, Ki(hA1R) ~ 10 μM,
former [18F]MRS5425 [18]) for our purposes, which is the [18F]fluoroethoxy analog of [11C]SCH442416
(Figure 1). [18F]FESCH has been evaluated in healthy rats and in rats with unilateral PD symptoms by
PET showing an A2AR-specific binding in the striatum and a significantly increased A2AR-mediated
uptake in the 6-hydroxydopamine-lesioned hemisphere of 9–12% [19,21]. Therefore, [18F]FESCH has
been stated as the most suitable radiotracer for quantification of the A2AR in the brain with PET [21].
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Figure 1. Molecular structures of the herein discussed radiotracers for positron emission tomography
(PET) imaging of the adenosine A2A receptor (A2AR).
The rotenone-based mouse model has been well established for pre-clinical investigations of
PD [22–24]. Chronic administration of the neurotoxin rotenone to mice leads to relapse of dopaminergic
neurons and changes in motor functions similar to the symptoms in PD patients [24–26]. In this small
animal PET/MR imaging study with [18F]FESCH, we aimed to validate if rotenone-treated mice reflect
the aspect of striatal A2AR upregulation in PD. In addition, we investigated [18F]FESCH by in vitro
autoradiography on mouse brain slices and in vivo metabolism as well as baseline and blocking PET
studies in healthy CD-1 mice.
2. Results and Discussion
The A2AR antagonist FESCH and the required known phenol precursor desmethyl SCH442416
for 18F-labeling were synthesized in three or two steps, respectively, from commercially available
2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine-5-amin and 1-(3-bromopropyl)-4-
methoxybenzene according to procedures described in the literature [18,27,28]. Evaluation of FESCH
in an established binding assay revealed high A2AR affinity (Ki(hA2AR) = 0.6 ± 0.1 nM, n = 4) and good
A1R selectivity (Ki(hA1R) = 203 ± 40 nM, n = 4).
The initially published radiosynthesis of [18F]FESCH comprises a two-step two-pot
procedure [19,20]. Briefly, the respective [18F]fluoroethyl intermediate from the 18F-labeling step
was isolated either by semi-preparative HPLC [19] or solid-phase extraction on a cartridge [20] and,
only then, reacted with the phenol precursor desmethyl SCH442416. To simplify the radiosynthesis
and avoid loss of activity through purification of the [18F]fluoroethyl intermediate, we developed a
two-step one-pot strategy for the production of [18F]FESCH [29] (see Scheme 1). First, ethane-1,2-diol
bis(4-methylbenzenesulfonate) was 18F-labeled via nucleophilic substitution of one tosylate group
using anhydrous K+/[18F]F-/K222-carbonate complex in acetonitrile. Notably, desmethyl SCH442416
was pre-treated with aqueous tetrabutylammonium hydroxide (TBAOH) in acetonitrile to generate
the activated phenolate which was directly reacted with the non-isolated 2-[18F]fluoroethyl tosylate.
Besides, further bases and solvents were tested for the [18F]fluoroethylation of desmethyl SCH442416
resulting in decreased yields of [18F]FESCH mainly due to partial decomposition of the phenol
precursor under these conditions. Preliminary experiments using potassium carbonate or cesium
carbonate (1.5–2.5 eq.) for activation of desmethyl SCH442416 (1–2 mg) and either acetonitrile or a
1:1 mixture of acetonitrile and N,N-dimethylformamide or tert-butanol as solvents revealed labeling
yields of 4–14% based on TLC analysis of the reaction mixtures after 10 min at 120 ◦C, respectively.
Replacement of the base by TBAOH (2.5 eq.) and the use of acetonitrile only resulted in a significantly
increased labeling yield of 25%. Final optimization was achieved by increasing the amount of the
phenol precursor to 2.5 mg leading to 46.4 ± 8.5% (n = 9) of non-isolated [18F]FESCH.
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Scheme 1. Simplified two-step one-pot radiosynthesis of [18F]FESCH. Reagents and conditions: (First
step) 2 mg ethane-1,2-diol bis(4-methylbenzenesulfonate) in 100 μL MeCN, ~ 3 GBq azeotropically dried
K+/[18F]F-/K222-carbonate complex in 400 μL MeCN, 90 ◦C, 10 min; (Second step) 2.5 mg desmethyl
SCH442416 pre-treated with 10 μL TBAOHaq. (40%) in 490 μL MeCN at 90 ◦C for 10 min, directly
added to 2-[18F]fluoroethyl tosylate, 120 ◦C, 10 min.
[18F]FESCH was purified by semi-preparative HPLC (see Figure 2) and concentrated via
solid-phase extraction on a pre-conditioned reversed-phase cartridge followed by elution with absolute
ethanol. After evaporation of the solvent, the radiotracer was finally formulated in sterile isotonic
saline with a maximum ethanol content of 10% for better solubility. The identity of [18F]FESCH was
confirmed by analytical HPLC using an aliquot of the final product spiked with the non-radioactive
reference compound (Figure 2).
Figure 2. (A) Semi-preparative HPLC profile of the crude reaction mixture for isolation of [18F]FESCH
(column: Reprosil-Pur 120 C18-AQ, 250 × 10 mm, particle size: 10 μm, eluent: 50% MeCN/20 mM
NH4OAcaq., flow: 7 mL/min). (B) Analytical HPLC profile of the formulated radiotracer [18F]FESCH
spiked with the non-radioactive reference FESCH (column: Reprosil-Pur 120 C18-AQ, 250 × 4.6 mm,
particle size: 5 μm; eluent: 26-90-26% MeCN/20 mM NH4OAcaq., flow: 1 mL/min).
The herein described one-pot radiolabeling strategy provided [18F]FESCH with a high molar
activity of 116 ± 18.5 GBq/μmol (n = 7, end of synthesis) and an overall radiochemical yield of
16.1 ± 1.5% (n = 9, end of bombardment), which is a significant improvement compared to the
published two-pot procedure (7 ± 2% [20]). The required total synthesis time of 114 ± 6 min and the
achieved radiochemical purity of ≥ 98% were very similar for both methods.
In vitro stability of [18F]FESCH was examined in isotonic saline and pig plasma. Samples of
each medium were analyzed by radio-HPLC after 60 min incubation at 37 ◦C and no degradation or
defluorination of the radiotracer was observed. This result is contradictory to the published stability
of [18F]FESCH especially in saline where only 85–90% of intact radiotracer have been detected by
radio-TLC while multiple spots were observed [20]. Thus, Khanapur et al. [20] formulated [18F]FESCH
in phosphate-buffered saline, but Bhattacharjee et al. [19] used a saline solution of [18F]FESCH for
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biological investigations. At present, we have no explanation for that and as we detected only the
intact radiotracer in isotonic saline (see Figure 2), formulation of [18F]FESCH in another medium was
not required.
The distribution coefficient of [18F]FESCH was determined by partitioning between n-octanol and
phosphate-buffered saline (PBS, pH = 7.4) at ambient temperature using the conventional shake-flask
method. The obtained logD7.4 value of 1.97 ± 0.17 (n = 4) emphasizes the lipophilic character of the
radiotracer which allows a passive diffusion through the blood–brain barrier [30–32]. However, there is
a discrepancy compared to the published logD value of 3.16 ± 0.03 [20] which might be caused by
different experimental setups.
In vitro autoradiography studies were accomplished by incubating sections of mouse brain with
[18F]FESCH. Non-specific binding was assessed by co-incubation with an excess of either FESCH or
ZM241385, respectively. The images demonstrated an A2AR-specific accumulation of [18F]FESCH in
the striatum (Figure 3), which is characterized by the binding parameters KD = 4.69 ± 1.17 nM and
Bmax = 497 ± 97 fmol/mg wet weight consistent with the literature [33].
 
Figure 3. Representative autoradiographic images of transversal CD-1 mouse brain slices. (A)
In vitro distribution of activity after incubation with 0.2 MBq/mL of [18F]FESCH (TB = total binding).
(B) Non-specific binding (NB) of [18F]FESCH determined in the presence of 1 μM of FESCH or
ZM241385, respectively, as blocking agents. (C) Nissl staining, St = Striatum, Cb = Cerebellum.
For in vivo imaging investigations in healthy CD-1 mice (n = 12, 10 weeks, 30–35 g), [18F]FESCH
was injected intravenously (baseline: 2.8 ± 2 MBq, vehicle: 5.8 ± 2 MBq, blocking: 6.4 ± 2.5 MBq
with n = 4, respectively) and whole body scans were performed for 60 min in listmode with a Mediso
nanoScan® PET/MR scanner followed by dynamic reconstruction. Time-activity curves (TACs) were
generated for regions of interest such as striatum and cerebellum as reference region. The obtained PET
images showed a high striatal uptake of [18F]FESCH with a standardized uptake value ratio (SUVR)
for striatum over cerebellum of > 5 (9–30 min post injection (p.i.)). In vivo selectivity for the A2AR was
highlighted by the significant reduction of the SUVR by 29–42% (9–30 min p.i. with p < 0.05) after
pre-injection of tozadenant as blocking agent (Figure 4). The highest achievable dose of tozadenant
was 2.5 mg/kg with respect to solubility and volume of injection as well as the concentrations of DMSO
and Kolliphor® EL suitable for in vivo application in mice. The herein observed blocking effect is in
accordance with the estimated A2AR occupancy for tozadenant in rhesus monkey of about 72% at
5 mg/kg [14]. These results indicate that [18F]FESCH is a promising radiotracer for molecular imaging
of the A2AR in the brain.
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Figure 4. (A) Representative horizontal PET images of [18F]FESCH uptake (average 10–30 min) in the
brain of healthy CD-1 mice under vehicle (15 min pre-injection of DMSO:Kolliphor® EL:0.9% NaCl, 1:2:7,
5 μL/g) and blocking conditions (15 min pre-injection of tozadenant 2.5 mg/kg in DMSO:Kolliphor®
EL:0.9% NaCl, 1:2:7, 5 μL/g; red = striatum; yellow = cerebellum). (B) Averaged TACs of [18F]FESCH
for vehicle (n = 4) and tozadenant pre-injected mice (n = 4) with SUVRs for striatum over cerebellum.
However, a representative metabolism study revealed only moderate in vivo stability of
[18F]FESCH. Analytical radio-HPLC (Figure 5) of the extracted mouse plasma sample showed 41%
of intact radiotracer at 15 min p.i. (recovery of total activity = 84%). In the analyzed brain sample,
one polar radiometabolite ([18F]M1) was detected accounting for 29% of the total extracted activity at
15 min p.i. (recovery = 98%).
Figure 5. Representative in vivo metabolism study of CD-1 mouse plasma and brain samples at 15
min p.i. of [18F]FESCH (~ 17 MBq): Analytical radio-HPLC profiles of extracted (A) brain and (B)
plasma sample (column: Reprosil-Pur 120 C18-AQ, 250 × 4.6 mm, particle size: 5 μm; eluent: 26-90-26%
MeCN/20 mM NH4OAcaq., flow: 1 mL/min).
Compared to the published study in Wistar-Unilever rats (46% intact radiotracer in plasma at
60 min p.i. [20]) the in vivo degradation of [18F]FESCH appears to be somewhat faster in mice. Notably
and to the best of our knowledge, the formation of brain-penetrating radiometabolites of [18F]FESCH
has not been regarded before. Based on our experiences with radiotracers bearing a [18F]fluoroethoxy
moiety [34,35], the herein observed radiometabolite [18F]M1 is proposed to be 2-[18F]fluoroethanol or
the oxidized 2-[18F]fluoroacetaldehyde and 2-[18F]fluoroacetate, resulting from a cytochrome P450
enzyme-induced metabolic degradation [36,37], which are able to cross the blood–brain barrier [38–41].
For PET/MR studies with [18F]FESCH in the rotenone-based mouse model of PD, the radiotracer
(9.7± 1.3 MBq) was administrated to C57BL/6JRj mice (control: n= 5; rotenone-treated: n= 7; 16 months,
28–35 g) followed by the same imaging protocol used for the baseline and blocking studies in CD-1
mice. Although statistically not significant, the averaged TACs between 2 and 61 min p.i. revealed a
slightly higher uptake of [18F]FESCH in the striatum of rotenone-treated mice compared to controls.
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An increase of the SUVR for striatum over cerebellum by 15–33% was observed, which was caused by
the elevated SUV for striatum of 11–27% (21–61 min p.i., respectively; Figure 6).
Figure 6. (A) Representative horizontal PET images of [18F]FESCH uptake (average 2–61 min) in
the brain of control and rotenone-treated C57BL/6JRj mice (red = striatum; yellow = cerebellum).
(B) Averaged TACs of [18F]FESCH for control (n = 5) and rotenone-treated mice (n = 7) with SUVs for
striatum and SUVRs for striatum over cerebellum.
These results are in accordance with the determined A2AR levels on C57BL/6JRj mouse brain
sections from a comparative in vitro immunofluorescence study. No significant difference in the
fluorescence signal of the A2AR between control and rotenone-treated mice was observed (Figure 7).
Figure 7. Mean fluorescence intensity of A2AR staining on the striatum of coronal C57BL/6JRj mouse
brain sections: (A) Control vs. rotenone-treated wild-type mice (n = 3, respectively); (B) Young
(39 weeks) vs. old (71–76 weeks) A30P transgenic mice (n = 3, respectively).
The increased A2AR availability in the striatum of PD patients appears to be related to
L-DOPA-induced dyskinesia. In the rotenone-treated mice, we did not identify any signs of dyskinesia
and, thus, it is not surprising that in this PD mouse model no significant increase in the A2AR
density was detected either by PET imaging or by immunofluorescence staining. With regard
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to dyskinesia, the rotenone model is comparable to another neurotoxin-based PD mouse model
using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), where only weak signs of dyskinesia
were observed and this exclusively under L-DOPA treatment [42]. To date, unilateral injection of
6-hydroxydopamine (6-OHDA) is the only effective neurotoxin-related approach to replicate evidently
some forms of dyskinesia in rats and mice. In the 6-OHDA mouse model, dyskinesia is detected
as abnormal involuntary movements (AIMs) with a more simplified range than in rats, presenting
more prominent rotational locomotion with less dystonic features, i.e., axial AIMs [42]. None of the
above-mentioned AIMs were detected in the rotenone-treated mice. Consequently, it remains to be
examined whether treatment with L-DOPA would lead to dyskinesia in the rotenone model as shown
for the MPTP model and if this would cause a quantifiable increase in striatal A2AR levels.
In contrast to the above-discussed neurotoxin-based PD animal models, the A30P mouse line
represents a transgenic model of PD. This mouse line overexpresses the human A30P mutation in the
α-synuclein gene, where the 30th amino acid residue alanine is replaced by proline, in all neurons.
The A30P mutation is associated with rare familial cases of PD. Since α-synuclein is a main constituent
of Lewy bodies, the A30P transgenic mice are characterized by Lewy body formation in neuronal
cell bodies and neurites throughout the brain [43]. The α-synuclein pathology and PD-associated
symptoms become prominent at about 69 weeks of age [43,44]. In an ongoing study, we detected
slightly, but due to the rather small and highly variable data set statistically non-significant, higher
striatal mean fluorescence intensities of the A2AR signal in older symptomatic A30P transgenic mice
compared to younger ones without symptoms (see Figure 7). We will further investigate this PD mouse
model by small animal PET/MR imaging studies using a novel derivative of [18F]FESCH currently
under development.
3. Summary and Conclusions
In this study, we investigated the suitability of the known radiotracer [18F]FESCH for in vitro
and in vivo imaging of the A2AR in the mouse brain by autoradiography and small animal
PET/MR. Contrary to previous estimations, the herein observed brain-penetrating radiometabolite
might limit the applicability of [18F]FESCH for valid quantification of A2AR levels in the striatum
with PET. One promising strategy to decelerate the degradation of 18F-labeled radiotracers is the
deuterium-hydrogen exchange at the metabolic labile position in the molecular structure of the
compound [45]. Thus, our recent efforts are focused on a deuterated derivative of [18F]FESCH with
enhanced in vivo stability particularly at the [18F]fluoroethoxy side chain.
In the investigated rotenone-based mouse model of PD, no significant difference in the striatal
A2AR density between rotenone-treated mice and controls was detectable by PET imaging or
immunofluorescence staining. These results indicate that the rotenone model does not reflect
upregulation of striatal A2AR in PD, which appears to be related to dyskinesia. Therefore, it remains
to be further examined whether treatment with L-DOPA could cause a detectable increase in A2AR
levels in the striatum, which would induce observable dyskinesia in this PD model. In a parallel and
ongoing study to characterize the A30P mouse model, initial findings reveal that this transgenic model
might be more suitable with regard to displaying PD-like pathological changes in A2AR availability.
4. Materials and Methods
4.1. General Information
Chemicals and solvents were purchased from standard commercial sources in analytical grade
and were used without further purification. Radio-TLCs were performed on pre-coated silica gel
plates (Alugram® Xtra SIL G/UV254, Polygram® SIL G/UV254; Carl Roth, Karlsruhe, Germany).
The compounds were localized at 254 nm (UV lamp). Radio-TLC was recorded using a bioimaging
analyzer system (BAS-1800 II, Fuji Photo Film, Co. Ltd., Tokyo, Japan) and images were evaluated
with Aida 2.31 software (raytest Isotopenmessgeräte GmbH, Straubenhardt, Germany). Column
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chromatography was conducted on silica gel (0.06–0.20 mm; Carl Roth, Karlsruhe, Germany). HPLC
separations were performed on JASCO systems equipped with UV detectors from JASCO Deutschland
GmbH (Pfungstadt, Germany) and activity detectors from raytest Isotopenmessgeräte GmbH (GABI
Star, Straubenhardt, Germany).
Semi-preparative HPLC conditions were: Column: Reprosil-Pur C18-AQ, 250 × 10 mm; particle
size: 10μm; eluent: 50% MeCN/20 mM NH4OAcaq.; flow: 7 mL/min; ambient temperature; UV detection
at 254 nm.
Analytical HPLC conditions were: Column: Reprosil-Pur C18-AQ, 250 × 4.6 mm; particle
size: 5 μm; gradient: 0–10 min: 26% MeCN, 10–35 min: 26%→ 90% MeCN, 35–45 min: 90% MeCN,
45–50 min: 90%→ 26% MeCN, 50–60 min: 26% MeCN/20 mM NH4OAcaq.; isocratic: 40% MeCN/20 mM
NH4OAcaq.; flow: 1 mL/min; ambient temperature; UV detection at 254 nm. Molar activity was
determined on the base of a calibration curve (0.05–2.0 μg FESCH) carried out under isocratic HPLC
conditions (36% MeCN/20 mM NH4OAcaq.) using chromatograms obtained at 264 nm as the maximum
of UV absorbance.
No-carrier-added (n.c.a.) [18F]fluoride (t1/2 = 109.8 min) was produced via the [18O(p,n)18F]
nuclear reaction by irradiation of [18O]H2O (Hyox 18 enriched water, Rotem Industries Ltd, Arava,
Israel) on a Cyclone®18/9 (IBA RadioPharma Solutions, Louvain-la-Neuve, Belgium) with fixed energy
proton beam using Nirta® [18F]fluoride XL target.
4.2. Radiosynthesis
The aqueous solution of no-carrier-added [18F]fluoride (~ 3 GBq) was trapped on a Chromafix®
30 PS-HCO3− cartridge (MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany). The activity was
eluted with 300 μL of an aqueous K2CO3-solution (1.78 mg, 12.9 μmol) into a 4-mL V-vial containing
Kryptofix 2.2.2 (K2.2.2, 5.6 mg, 14.9 μmol) in 1 mL MeCN. The K+/[18F]F−/K2.2.2-carbonate complex
was azeotropically dried under vacuum and argon flow within 7–10 min using a Discover PETwave
Microwave CEM® (75 W, 50–60 ◦C, power cycling mode, CEM GmbH, Kamp-Lintfort, Germany).
Two aliquots of MeCN (2 × 1 mL) were added during the drying procedure and the final complex was
dissolved in 400 μL MeCN ready for radiolabeling.
The aliphatic radiolabeling of ethane-1,2-diol bis(4-methylbenzenesulfonate) (Sigma-Aldrich,
Munich, Germany; 2 mg in 100 μL MeCN) was performed under conventional heating at 90 ◦C
for 10 min. After pre-heating of the phenol precursor desmethyl SCH442416 (2.5 mg in 490 μL
MeCN) with 10 μL TBAOHaq. (40%) at 90 ◦C for 10 min, this solution was directly added to the
crude 2-[18F]fluoroethyl tosylate and the reaction mixture was stirred for 10 min at 120 ◦C. Aliquots
of the reaction mixtures from both steps were analyzed by radio-TLC (EtOAc/petroleum ether; first
step = 1:1; second step = 6:1) or radio-HPLC (isocratic mode, see General Information) to determine the
radiochemical yields of crude 2-[18F]fluoroethyl tosylate (Rf = 0.7, 87.0 ± 2.3%; n = 9) and [18F]FESCH
(Rf = 0.5, 46.4 ± 8.5%; tR = 29.4 min, 34.4 ± 4.1%, decay corrected for tR = 0 min; n = 9), respectively.
After dilution with water (1:1), the crude reaction mixture was applied to an isocratic
semi-preparative HPLC (see General Information) for isolation of the desired radiotracer [18F]FESCH
(tR = 32–33 min). The collected fractions were diluted with water (total volume = 40 mL), passed
through a Sep-Pak® C18 Plus cartridge (Waters, Milford, MA, USA; pre-conditioned with 5 mL of
absolute EtOH and 60 mL water), and eluted with 1.5 mL of absolute EtOH. Evaporation of the solvent
at 70 ◦C under a gentle argon stream and subsequent formulation of the radiotracer in sterile isotonic
saline containing 10% EtOH afforded a [18F]FESCH solution usable for biological investigations.
The identity of the radiotracer was proved by analytical radio-HPLC (see General Information) of
samples of [18F]FESCH spiked with the non-radioactive reference compound FESCH using a gradient
and an isocratic mode.
101
Molecules 2020, 25, 1633
4.3. Investigation of In Vitro Stability and Lipophilicity (logD7.4)
The in vitro stability of [18F]FESCH (4–6 MBq) was studied by incubation in isotonic saline and pig
plasma (500 μL each) at 37 ◦C. Samples were taken at 60 min and analyzed by radio-HPLC (see General
Information).
The lipophilicity of [18F]FESCH was examined by partitioning between n-octanol and
phosphate-buffered saline (PBS, pH = 7.4) at ambient temperature using the conventional shake-flask
method. The radiotracer (65 μL, ~ 8 MBq) was added to a tube containing the n-octanol/PBS-mixture
(6 mL, 1:1, four-fold determination). The tubes were shaken for 20 min using a mechanical shaker
(HS250 basic, IKA Labortechnik GmbH & Co. KG, Staufen, Germany) followed by centrifugation
(5500 rpm for 5 min) and separation of the phases. Aliquots were taken from the organic and the aqueous
phase (1 mL each) and activity was measured with an automated gamma counter (1480 WIZARD,
Fa. Perkin Elmer, Waltham, MA, USA). The distribution coefficient (D7.4) was calculated as [activity
(cpm/mL) in n-octanol]/[activity (cpm/mL) in PBS, pH = 7.4] stated as the decade logarithm (logD7.4).
4.4. Binding Assay
Membrane homogenates prepared from stably transfected CHO-K1 cells (Chinese hamster ovary
cells, clone K1) with the human A1R or A2AR, provided by Prof. Klotz, University of Würzburg,
Würzburg, Germany, were used for the binding experiments. The following radioligands were
employed: [3H]ZM241385 for the A2AR and [3H]DPCPX for the A1R. For the determination of A2AR
and A1R binding affinity of reference compound, frozen cell suspensions were thawed, homogenized
by a 27-gauge needle, and diluted with 50 mM TRIS-HCl buffer (pH = 7.4, 100 mM NaCl, 5 mM MgCl2,
1 mM EDTA) containing 1 μU/mL adenosine deaminase (ADA). Membrane suspension was incubated
with 1.5 nM [3H]ZM241385 or 1 nM [3H]DPCPX and various concentrations of the test compound.
Non-specific binding was determined by co-incubation with 10 μM ZM241385 or 1 μM DPCPX.
The incubation was performed at room temperature for 90 min and terminated by rapid filtration
using Whatman GF/B glass-fiber filters, pre-soaked in 0.3% polyethyleneimine and a 48-channel
harvester (Biomedical Research and Development Laboratories, Gaithersburg, MD, USA) followed
by washing four times with ice-cold TRIS-HCl buffer. Filter-bound radioactivity was quantified by
liquid scintillation counting. At least two separate experiments were performed for determination of
Ki values. All data were analyzed with GraphPad Prism, Version 4.1 (GraphPad Inc., La Jolla, CA,
USA), according to the Cheng–Prusoff equation.
4.5. Animal Experiments
All experimental work including animals was conducted in accordance with the national legislation
on the use of animals for research (Tierschutzgesetz (TierSchG), Tierschutz-Versuchstierverordnung
(TierSchVersV)) and was approved by the responsible animal care committees of the Free State
of Bavaria and the Free State of Saxony (TVV 08/13, 24-9168.11/18/8, June 12th, 2013 and
TVV 18/18, DD24.1-5131/446/19, June 20th, 2018; Landesdirektion Sachsen). Female CD-1 mice,
10–12 weeks, were obtained from the Medizinisch-Experimentelles Zentrum at University of Leipzig,
Leipzig, Germany.
4.5.1. In Vitro Autoradiography
Cryosections of brains obtained from female CD-1 mice (10–12 weeks) were thawed, dried in a
stream of cold air, and pre-incubated in 50 mM TRIS-HCl buffer (pH = 7.4, 100 mM NaCl, 5 mM MgCl2,
1 mM EDTA) containing 1 μU/mL adenosine deaminase (ADA) for 15 min at ambient temperature.
Afterwards, brain sections were incubated with 0.1–0.2 MBq/mL [18F]FESCH in buffer for 90 min
at room temperature. Non-specific binding was determined in the presence of 1 μM of FESCH or
ZM241385, respectively. Subsequently, the sections were washed twice for 5 min in ice-cold TRIS-HCl
buffer, and dipped for 5 s in ice-cold deionized water. The sections were rapidly dried in a stream
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of cold air before being exposed overnight on an imaging plate (Fujifilm Corporation, Tokyo, Japan).
Developed autoradiographs were analyzed in a phosphor imager (HD-CR 35, Duerr NDT GmbH,
Bietigheim Bissingen, Germany). The quantification was performed by using 2D-densitometric analysis
(AIDA 2.31 software, raytest Isotopenmessgeräte GmbH, Straubenhardt, Germany). Further data
analysis was performed with GraphPad Prism, Version 4.1 (GraphPad Inc., La Jolla, CA, USA).
4.5.2. Rotenone-Based and A30P Transgenic Mouse Models of Parkinson’s Disease
Animal Housing
Male wild-type C57BL/6JRj mice (Janvier Labs, Le Genest-Saint-Isle, France) and male
(Thy1)-h[A30P]α-syn transgenic C57BL/6JRj mice (generated according to the protocol by Kahle
et al. [43], hereafter “A30P transgenic mice”) were housed at room temperature under a 12:12 h
dark:light cycle. Food and water was provided ad libidum.
Oral Rotenone Administration
Wild-type C57BL/6JRj mice (12 months) were divided into two groups and treated 5 days a week
for 4 months. A 1.2 mm × 60 mm gavage (Unimed, Lausanne, Switzerland) was used to administer
0.01 mL/g animal weight of rotenone (Sigma-Aldrich, Munich, Germany) solution corresponding to
a 5 mg/kg dose. Controls were treated only with the vehicle solution (2% carboxymethyl cellulose
(Sigma-Aldrich, Munich, Germany) and 1.25% chloroform (Carl Roth, Karlsruhe, Germany)).
4.5.3. Immunofluorescence Staining and Imaging
Immunostaining
Cryosections of brains obtained from wild-type C57BL/6JRj mice (16 months, vehicle and
rotenone-treated) or A30P transgenic mice (young group = 39 weeks; old group = 71–76 weeks)
were immunostained using the free-floating technique and all procedures took place in a well of a
12-well plate. Briefly, brain sections were washed with PBS (pH = 7.4) for 10 min, then blocked with
blocking solution (PBS, 0.02% Triton-X and 5% donkey serum) for 1 h, and incubated in the first antibody
(1:100, rabbit anti-adenosine receptor A2A, ab3461, Abcam, Cambridge, UK) in blocking solution at
4 ◦C overnight. On the next day, sections were washed in PBS (4 × 15 min) and incubated with the
secondary antibody (1:500, donkey Alexa® 555 anti-rabbit, Invitrogen/Thermo Fisher Scientific Inc.,
Waltham, MA, USA) for three hours at room temperature. Sections were washed in PBS (4 × 15 min),
transferred to the slide, and mounted with Mowiol mounting medium (50% PBS, 25% ethylenglycol
and 25% glycerol).
Microscopy and Image Analysis
Images were obtained with an Apotome.2 fluorescence microscope (Carl Zeiss Microscopy GmbH,
Jena, Germany). Mean fluorescence intensity (MFI) in the striatum was measured using Fiji-ImageJ,
a free-software for image analysis (ImageJ v1.52p, National Institutes of Health (NIH), Bethesda, MD,
USA). MFI values were normalized to background signal.
4.5.4. Small Animal PET/MR Studies
For the time of the experiments, female CD-1 mice (n = 12; age = 10 weeks; weight = 30–35 g)
and male C57BL/6JRj mice (control with n = 5; rotenone-treated with n = 7; age = 16 months;
weight = 28–35 g) were kept in a dedicated climatic chamber with free access to water and food
under a 12:12 h dark:light cycle at a constant temperature of 24 ◦C. The animals received an injection
of [18F]FESCH into the tail vein (5.0 ± 2.5 MBq for CD-1 mice) or retro-orbital (9.7 ± 1.3 MBq for
C57BL/6JRj mice) followed by a 60-min PET/MR scan (Mediso nanoScan®, Budapest, Hungary).
Each PET image was corrected for random coincidences, dead time, scatter, and attenuation (AC),
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based on a whole body (WB) MR scan. The reconstruction parameters for the list mode data were
the following: 3D-ordered subset expectation maximization (OSEM), 4 iterations, 6 subsets, energy
window = 400–600 keV, coincidence mode = 1–5, ring difference = 81. The mice were positioned prone
in a special mouse bed (heated up to 37 ◦C), with the head fixed to a mouth piece for the anesthetic gas
supply with isoflurane in 40% air and 60% oxygen (anesthesia unit: U-410, Agnthos, Lidingö, Sweden;
gas blender: MCQ, Rome, Italy). The PET data were collected by a continuous WB scan during the
entire investigation. Following the 60-min PET scan, a T1-weighted WB gradient echo sequence (GRE,
repetition time = 20 ms, echo time = 6.4 ms) was performed for AC and anatomical orientation. Image
registration and evaluation of the region of interest (ROI) were done with PMOD (PMOD Technologies
LLC, v. 3.9, Zurich, Switzerland).
The respective brain regions were identified using the mouse brain atlas template
Ma–Benveniste–Mirrione–FDG. The activity data are expressed as mean standardized uptake value
(SUV) of the overall ROI.
4.5.5. In Vivo Metabolism Study
The radiotracer [18F]FESCH (~ 17 MBq in 150 μL isotonic saline) was injected into a female CD-1
mouse via the tail vein. Brain and blood samples were obtained at 15 min p.i., plasma separated by
centrifugation (14,000 × g, 1 min), and brain homogenized in ~ 1 mL isotonic saline on ice (10 strokes
of a polytetrafluoroethylene (Teflon®) plunger at 1000 rpm in a borosilicate glass cylinder; Potter S
Homogenizer, B. Braun Melsungen AG, Melsungen, Germany).
Two consecutive extractions were performed as duplicate (plasma) or triplicate (brain)
determinations. Plasma (50 μL) and brain samples (250 μL) were added to an ice-cold acetone/water
mixture (4:1; plasma or brain sample/organic solvent = 1:4). The samples were vortexed for 1
min, incubated on ice for 10 min (first extraction) or 5 min (second extraction) and centrifuged at
10,000 rpm for 5 min. Supernatants were collected and the precipitates were re-dissolved in 100
μL of the ice-cold acetone/water mixture (4:1) for the second extraction. Activity of aliquots from
supernatants of each extraction step and of the precipitates was quantified using an automated gamma
counter (1480 WIZARD, Fa. Perkin Elmer). The supernatants from both extractions were combined,
concentrated at 70 ◦C under argon stream, and analyzed by radio-HPLC (gradient mode, see General
Information). By this protocol, [18F]FESCH was quantitatively extracted from the biological material
as proven by in vitro incubation of the radiotracer in pig plasma.
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Abstract: Phosphodiesterase 2A (PDE2A) is highly expressed in distinct areas of the brain, which are
known to be related to neuropsychiatric diseases. The development of suitable PDE2A tracers for
Positron Emission Tomography (PET) would permit the in vivo imaging of the PDE2A and evaluation
of disease-mediated alterations of its expression. A series of novel fluorinated PDE2A inhibitors on
the basis of a Benzoimidazotriazine (BIT) scaffold was prepared leading to a prospective inhibitor
for further development of a PDE2A PET imaging agent. BIT derivatives (BIT1–9) were obtained
by a seven-step synthesis route, and their inhibitory potency towards PDE2A and selectivity over
other PDEs were evaluated. BIT1 demonstrated much higher inhibition than other BIT derivatives
(82.9% inhibition of PDE2A at 10 nM). BIT1 displayed an IC50 for PDE2A of 3.33 nM with 16-fold
selectivity over PDE10A. This finding revealed that a derivative bearing both a 2-fluoro-pyridin-4-yl
and 2-chloro-5-methoxy-phenyl unit at the 8- and 1-position, respectively, appeared to be the most
potent inhibitor. In vitro studies of BIT1 using mouse liver microsomes (MLM) disclosed BIT1 as
a suitable ligand for 18F-labeling. Nevertheless, future in vivo metabolism studies are required.
Keywords: Phosphodiesterase 2A (PDE2A); Positron Emission Tomography (PET); Benzoimidazotriazine
(BIT); fluorinated; Mouse Liver Microsomes (MLM)
1. Introduction
Cyclic nucleotide Phosphodiesterases (PDEs) represent a class of enzymes catalyzing the hydrolysis
of the intracellular second messengers, cyclic Adenosine Monophosphate (cAMP) and cyclic Guanosine
Monophosphate (cGMP) [1]. cAMP and cGMP are involved in a great variety of cellular functions
related to physiological and pathophysiological processes in brain and periphery [2–6].
The 11 family members of PDEs are encoded by 21 genes and classified by their substrate
specificity [7–10]. PDEs 4, 7, and 8 are cAMP-specific and PDEs 5, 6, and 9 cGMP-specific, and others
(PDEs 1, 2, 3, 10, and 11) hydrolyze both substrates [7,9,11].
The dual substrate enzyme PDE2A is highly expressed in some brain areas, such as nucleus
accumbens, cortex, hippocampus [7], striatum, amygdala [12], substantia nigra, and olfactory
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neurons [13–15], thus being involved in complex neuronal processes like learning, concentration,
memory, emotion, and related diseases [8,9]. The inhibition of PDE2A will increase the intracellular
levels of cGMP and cAMP in PDE2A-abundant tissues and may result in improvement of neuroplasticity
and memory function [8].
The activity of PDE2A inhibitors related to cognitive improvement has been evaluated in animal
models [1,7,16,17]. These results suggest the use of PDE2A inhibitors for treatment of neuropsychiatric
diseases such as Alzheimer’s disease and schizophrenia [18].
Up to now, there have been several PDE2A inhibitors reported. BAY 60-7550 (Figure 1), the first
highly-selective PDE2A inhibitor, has been widely used to evaluate PDE2A activity. However,
this compound shows a poor pharmacokinetic profile, as well as poor ability to cross the blood-brain
barrier [11,16]. The finding of BAY 60-7550 triggered many pharmaceutical companies to discover
potent PDE2A inhibitors for potential use in treating a variety of brain diseases [11].
 
Figure 1. Different PDE inhibitors [15,19–27].
In 2010, Biotie Therapies and Wyeth claimed a series of 1,2,4-triazine- and pyrazine-containing
tricyclic compounds exhibiting dual inhibition against both PDE2A and PDE10A as therapeutic
targets [25–28]. The triazine series comprises benzo- and pyridine-fused imidazo[5,1-c][1,2,4]triazine
derivatives [27], some of which are depicted in Figure 1 (Compounds I (TA1), II, and III), along with
their binding affinities. In 2015, our group reported on the first PDE2A PET tracers on the basis
of a Pyridoimidazotriazine (PIT) scaffold starting from I (TA1, Figure 1), as the lead compound.
Two fluoroalkyl derivatives, TA3 and TA4 (Figure 1), demonstrated high affinity towards PDE2A
with 28-fold and 125-fold selectivity over PDE10A, respectively [15,21]. More recently, we gained
a further improvement in terms of in vitro PDE2A binding via replacement of the 1-methoxy in TA1
by 1-(2-fluoroethoxy), resulting in the compound TA5, (Figure 1) [15,21,22]. However, after successful
18F-labeling, the obtained tracers, [18F]TA3 and [18F]TA4, did not entirely succeed and were proven
to be suitable only for in vitro autoradiographic PDE2A imaging. Beyond that, [18F]TA5 failed to
demonstrate specific binding in vitro [22]. The formation of brain-penetrating radiometabolites due
to the O-defluoroalkylation limited their application for in vivo PDE2A imaging. Therefore, further
structural modifications of tricyclic lead are inevitably required to allow appropriate in vivo PDE2A
imaging [21,22]. A further tracer, [18F]AQ28A, obtained as a developmental compound from our
PDE10 program (AQ28A, Figure 1), was proven to be sufficiently metabolically stable and to enable
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in vivo imaging of PDE10A in rodents by PET [24]. As one feature, the fluorinated aromatic ring of
this compound was ascribed to its performance as a promising tracer.
As part of our ongoing commitment in 18F-PET tracer development devoted to PDE imaging
(2A, 5A, and 10A) [21,22,24,29], we focused on Benzoimidazotriazine (BIT) as the scaffold, which differs
in a benzo ring formally replacing the pyrido ring of our hitherto investigated TA compounds.
Because of our findings from AQ28A, we felt encouraged to combine a 2-fluorpyridine moiety as
a fluorine-bearing group with structural features required for PDE2A binding (Figure 2). Herein,
we report the synthesis and in vitro evaluation of fluorinated derivatives containing a BIT scaffold and
the selection of a promising ligand for the development of a 18F-labeled ligand for PDE2A imaging
with PET. The use of a benzo fused imidazo[2,1-c][1,2,4]triazine allows us to readily perform structural
modification in the six-membered benzo ring (8-position) while retaining the structural modifiability of
the imidazole portion (1-position) of the tricycle (Figure 2). An example of this BIT series, compound
III (Figures 1 and 2), bearing no substituent at the 6-position, was more potent to PDE2A in comparison
to II and served as the lead in our studies [26].
 
Figure 2. Approach for structural modification of the lead structure III.
Therefore, our strategy was to modify this structure by changing the substituents at 1-(phenyl) and
the 8-position (pyridinyl instead of F) in order to obtain potent and selective PDE2A inhibitors
(Figure 2). These can be established via a standard palladium (Pd)-catalyzed Suzuki coupling
reaction [30]. Our main interest was to obtain fluorinated compounds for the development of PDE2A
PET tracers. Therefore, the introduction of fluorine-containing groups particularly at the 8-position
(pyridinyl) is required. According to our previous work, several fluorinated pyridinyl substituents
may enhance the potency and selectivity to PDE2A, and the incorporation of the pyridine moiety is
tolerable. Besides, pyridine, as an electron-deficient aromatic ring, offers a convenient way to perform
radiofluorination via nucleophilic aromatic substitution [31]. Furthermore, fluorinated pyridinyl
substituents are relatively more stable towards metabolic degradation compared with fluoroalkyl
groups, which were found to be more prone to defluoroalkylation [15,21,22,24].
2. Results and Discussion
2.1. Chemistry
The first of our synthetic approaches focused on bromo-3-methylbenzo[e]imidazo[5,1-c][1,2,4]triazine
(Scheme 1, Compound 5) as the key intermediate for further conversions into the desired final products
(BIT derivatives). The 8-bromo-substituted tricycle 5 was synthesized in four steps starting from
4-bromo-2-fluoro-aniline (1) as depicted in Scheme 1.
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Scheme 1. Synthesis of Compound 5. (i) Oxidation, NaBO3·4H2O, acetic acid, 65 ◦C, 2–3 d;
(ii) 4-methyl-1H-imidazole, K2CO3, DMF, room temperature (rt), 1–2 d; (iii) Fe (5 eq), HOAc/EtOH,
reflux, 2.5 h; (iv) NaNO2, acetic acid, H2O, rt, 1 h.
The oxidation of the aromatic amino group with sodium perborate tetrahydrate (NaBO3·4H2O)
in acetic acid afforded nitro compound 2 in a 51% yield. To avoid significant by-product formation,
the reaction temperature was kept below 65 ◦C, and the aniline 1 was slowly added to the oxidizing
agent [23]. The obtained 4-bromo-2-fluoro-nitrobenzene (2) was reacted with 4-methyl-1H-imidazole
to provide the corresponding N-aryl-4- and N-aryl-5-methylimidazoles 3 and 3b. This nucleophilic
aromatic substitution (SNAr) employed 1.2 eq of 4-Me-imidazole and 2.0 eq of K2CO3 in DMF and
formed a mixture of 3 and 3b in a ratio of ~4:1 [32,33]. However, the main regioisomer 3 could
be purified via repeated recrystallization from methanol (50% yield). The reduction of 3 using iron
afforded aniline 4 in high yield (92%). The iron powder represents a preferred reducing agent for nitro
compounds bearing sensitive functional groups such as halides and/or other reducible groups [34].
A subsequent one-pot diazotation-intramolecular azo coupling of compound 4 by use of aqueous
sodium nitrite in acetic acid gave the intermediate 5 in a satisfactory yield of 93%. The overall yield
was 22%.
The synthesis of diaryl-substituted compounds (BIT derivatives) starting from 5 is depicted in
Scheme 2. Positions 1 and 8 were substituted with different aryl moieties by two independent Suzuki
couplings, possible through an intermediate bromination on position 1. The first Suzuki coupling
was used to introduce a substituted pyridine ring to the 8-position. Six different Boronic Acids (BAs),
including fluoropyridinyl boronic acids (8a–8d) and pyridinyl boronic acids (8e and 8f) as well,
were coupled in the presence of K2CO3 as a base and Pd(Ph3)4 as a catalyst under standard conditions
(Scheme 1, Table 1).
Cross-coupling products 6a–6f were obtained after flash column chromatography purification in
yields from 28%–98%, as depicted in Table 1. Afterwards, the bromination of the imidazo fused ring in
the 1-position was carried out using N-bromosuccinimide (NBS) in acetonitrile at room temperature
and provided Compounds 7a–7f in moderate to high yields (Table 1).
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Scheme 2. Approach to achieve a series of nine BIT derivatives. (i) R1B(OH)2 (8a–8f), K2CO3, Pd(PPh3)4,
1,4-dioxane:H2O (4:1), reflux, 1–2 d; (ii) NBS, MeCN, rt 4–6 h; (iii) R2B(OH)2 (9a [phe-1-B(OH)2],
9b [phe-2-B(OH)2]), or R2B(pin) (9c, [phe-3-B(pin)]), K2CO3, Pd(PPh3)4, dioxane:H2O (4:1), reflux,
1–2 d.
Table 1. Yields of Suzuki coupling with compound 5 (products: 6a–6f) and of bromination (products:
7a–7f).







1 2-fluoro-pyridine-4-yl-BA (8a) 6a 76% 7a 79%
2 6-fluoro-pyridine-3-yl-BA (8b) 6b 28% 7b 63%
3 2-fluoro-pyridine-3-yl-BA (8c) 6c 98% 7c 88%
4 3-fluoro-pyridine-5-yl-BA (8d) 6d 56% 7d 98%
5 pyridine-3-yl-BA (8e) 6e 77% 7e 87%
6 pyridine-4-yl-BA (8f) 6f 87% 7f 92%
By a second Suzuki coupling, the five-membered imidazole portion was functionalized (Scheme 2).
Initially, two ortho-chlorophenyl boronic acid (BA) derivatives 9a and 9c were used for coupling
with 7a and 7b, as well. In addition, to include the 5′′-methoxy substituted BA 9a, we investigated
a derivative with a modified propoxy substitution by using 9c with a (3-methyloxetan-3-yl)methoxy
moiety at the C-5′′-position (Scheme 2, 9c [phe-3-B(pin)]). It has been reported that an oxetane residue
may modulate and positively influence physicochemical, as well as biological properties of a drug
candidate [35,36]. Besides, an oxetane moiety is regarded to induce stability towards metabolic attack
similar to a corresponding geminal dimethyl unit (gem-Me2) [37], but in contrast will not increase the
lipophilicity of the compound [35,36]. To make this oxetane derivative available, we prepared boronic
ester 9c in three steps, starting from 3-bromo-phenol (10) (Scheme 3).
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Scheme 3. Preparation of 9c. (i) 3-methyloxetan-3-yl-methyl-mesylate, Cs2CO3, K2CO3, MeCN,
75–79 ◦C, 18 h; (ii) B2pin2, PdCl2(dppf), KOAc, 2-Me-THF, Ar; (iii) NCS, DMF, rt.
First, phenol 10 was reacted with 3-methyloxetan-3-yl-methyl-mesylate to provide aryl ether 11
(85% yield). Afterwards, Miyaura-borylation was performed to react 11 with bis(pinacolato)diboron
(B2pin2) in the presence of PdCl2(dppf) and KOAc as a catalyst and base, respectively, providing
boronate ester 12 in a good yield of 81%. Finally, the chlorination of 12 ortho to the boronate ester by
means of N-chloro-succinimide (NCS) in DMF at room temperature afforded 9c in a yield of 56% [38].
Boronic acid derivatives 9a and 9c were reacted with 7a and 7b via cross-coupling under conditions
similar to those described for the reactions of BAs 8a–8f with compound 5. Reaction products BIT1,
BIT2, and BIT3 were obtained in satisfactory yields, as depicted in Table 2 (Entries 1–3).





1 7a 9a 2-F-pyr-4/phe-1 BIT1 80%
2 7b 9c 6-F-pyr-3/phe-3 BIT2 79%
3 7a 9c 2-F-pyr-4/phe-3 BIT3 68%
4 7b 9a 6-F-pyr-3/phe-1 BIT4 64%
5 7c 9a 2-F-pyr-3/phe-1 BIT5 69%
6 7a 9b 2-F-pyr-4/phe-2 BIT6 72%
7 7d 9a 5-F-pyr-3/phe-1 BIT7 56%
8 7e 9b pyr-3/phe-2 BIT8 82%
9 7f 9b pyr-4/phe-2 BIT9 39%
In vitro evaluation data of the first series of final compounds revealed BIT1 to have a higher
inhibitory potency towards PDE2A in contrast to BIT2 and BIT3 (see the In Vitro Evaluation section).
Therefore, on the basis of this first finding, we prepared further BIT derivatives and investigated the
effect of an alteration of the pyridinyl substitution in 8-position on the PDE2A inhibition. For that
purpose, we synthesized BIT4–BIT9 with the methoxy group in the 5′′-position, since this substitution
appeared to be the most promising for the inhibition of PDE2A. Of the newly-synthesized compounds,
BIT6, BIT8, and BIT9 possessed the fluoro substitution in position 2′′ of the phenyl residue. BIT4–BIT9
were obtained in moderate to good yields as shown in Table 2 (Entries 4–9). After characterization by
one- and two-dimensional NMR spectroscopy and HR-MS (see Supplementary Materials), the new
derivatives were evaluated in vitro (see the In Vitro Evaluation Section).
2.2. In Vitro Evaluation: Structure-Activity Relationships of BIT Derivatives
Final products (BIT derivatives) were evaluated in vitro towards PDEs by means of radioligand
binding assays. Inhibition of PDE2A was measured at an inhibitor concentration of 10 nM and those
of other PDEs at a concentration of 1 μM for each BIT derivative. The inhibitory potencies of all BIT
compounds are summarized in Table 3.
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Table 3. Percentage inhibition of PDE sub-types from synthesized compounds; for PDE2A3,
the compounds were measured at a concentration of 10 nM and for PDE4A1, PDE5A1, PDE9A1,
and PDE10A1 at 1 μM.
Inhibition of PDE Sub-Types (%)
2A3 4A1 5A1 9A1 10A1
BIT1 82.9 58.6 29.3 NI 32.4
BIT2 8.52 64.1 NI NI 2.46
BIT3 13.2 72.7 NI NI 28.2
BIT4 2.63 NI NI NI 10.8
BIT5 NI NI NI NI 22.1
BIT6 56.6 54.2 13.6 28.4 74.0
BIT7 50.6 65.7 25.1 11.5 87.0
BIT8 NI 13.9 36.2 NI 55.5
BIT9 80.5 86.8 57.7 17.5 96.6
TA1 93.5 24.9 3.08 NI 41
NI: No Inhibition
We first focused our attention on modifications at the 1-position while keeping the
2-fluoropyridin-4-yl (2-F-pyr-4) fixed at the 8-position as for compounds BIT1 and BIT3. According
to our previous work [21], a longer alkyl side chain length (3-fluoropropoxy to 4-fluorobutoxy,
as TA3–TA4) contributes to improved potency, as well as selectivity towards PDE2A, as was also
shown for TA1 (Figure 1) [15,21]. However, the substitution of the 5′′-methoxy group (BIT1) by
a (3-methyloxetan-3-yl)methoxy moiety (BIT3) in the 1-phenyl moiety resulted in a strong reduction of
inhibitory potency towards PDE2A3 from 82.9% to 13.2% (at 10 nM). One possible explanation for
that result might be the increased polarity of the chosen oxetanyl-methoxy residue compared with
alkoxy groups, which possibly is unfavorable for key interactions towards PDE2A. It was reported
that the phenylpropyl portion in the imidazole ring of BAY 60-7550 interacts with Leu770, one of
the amino acids that is known to be responsible for hydrophobic pocket (H-pocket) formation in the
PDE2A active site [39]. Moreover, BAY 60-7550 binding to the PDE2A active site suggested that the
selectivity for PDE2A was generated from the ability of the ligand to induce a conformational change
of Leu770 [1,39]. Therefore, it is hypothesized that BIT3 may not induce the conformational change of
the Leu770 amino acid that generates the selectivity pocket formation, thus leading to potency losses
towards PDE2A [1,39].
In the case of a pair of 6-F-pyr-3-substituted products, BIT2 and BIT4, a weak inverse effect of
PDE2A binding was observed [40], depending on the nature of the 5′′ substituent and in comparison
to BIT3/BIT1. Strikingly, the much lower inhibition displayed by BIT4 (2.63%) in contrast to BIT1
(82.9%), bearing the same phe-1 substituent, points to the impact of the pyridine substitution pattern in
exerting inhibition on PDE2A.
In this connection, another factor that contributes to the selectivity of BAY 60-7550 is
a glutamine-switch mechanism [39], which is generally proposed for dual substrate-specific PDEs,
such as PDE2A [1,39]. We assume that triazine N-5 in our scaffold might accept a hydrogen bond from
Gln859 in a similar mode as described for the pyrazine portion in bioisosteric triazoloquinoxaline-based
PDE2A inhibitors [16,20]. We further investigated the influence of different pyridinyl substituents at
the 8-position on PDE2A inhibition while keeping the phe-1 fixed at the 1-position. In addition to
BIT4, containing a 6-F-pyr-3, the PDE2A inhibition also dropped significantly with BIT5, containing
a 2-F-pyr-3 at the 8-position. Interestingly, a potency of at least 50% remained with the introduction of
the 5-F-pyr-3 residue (BIT7) at the 8-position. It is not unambiguously clear whether this was caused
only by the position of the pyridine nitrogen, which may affect rotational freedom of the ring via
active site H-bonding to the pyridine N [16], or in the case of BIT1 and BIT7, additionally by X-H···F-C
interactions with fluorine [41,42]. Considering this, we found an influence of substituent variation at
the 8-position while keeping phe-1 at the 1-position in decreasing order of activity towards PDE2A
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as 2-F-pyr-4 > 5-F-pyr-3 > 6-F-pyr-3 > 2-F-pyr-3. It was supposed that 2-F-pyr-4 and 5-F-pyr-3 likely
maintained the conformational locking by the H-bond, resulting in higher PDE2A potency of BIT1 and
BIT7. Moreover, compared to BIT7, both BIT4 and BIT5 demonstrated eight- and four-fold selectivity
over PDE10A, respectively.
We then directed our attention to investigate the influence of ortho-fluorophenyl (phe-2) at the
1-position. In the case of BIT6, having a 2-F-pyr-4 at the 8-position, a weakly lower potency towards
PDE2A of 56% was observed, when compared to BIT1, which is in accordance with the known positive
PDE2A inhibitory effect of 2′′-Cl in comparison to 2′′-F [20,28]. A non-fluorinated pyridine (pyr-4
in BIT9) also maintained the inhibitory activity towards PDE2A of 80.5%, close to BIT1 (82.9%),
however at the expense of increasing inhibition towards PDE10A and PDE4A (96.6% and 86.8% at
a 1 μM inhibitor concentration) in contrast to BIT1 (32.4% and 58.6% at 1 μM). Incorporation of pyr-3
resulted in a significant loss of PDE2A inhibition, which is consistent with the result of BIT2, BIT4,
and BIT5, having also a substituted pyridin-3-yl at the 8-position, but not with BIT7, which may be
due to reasons discussed above. Again, the strong effect of the N-atom position in the pyridine ring
on PDE2A inhibition may be explained by differing conformational preferences between pyr-4 and
pyr-3 [11]. It was assumed that pyr-3 allows more rotational freedom, resulting in energy loss of
binding [16]. The selectivity towards certain PDEs was decreased when exchanging phe-1 with phe-2.
Thus, in addition to lower potency towards PDE2A, BIT6 displayed higher inhibition of PDE10A when
compared to BIT1 (74% vs. 32%, at 1 μM). Therefore, these results suggest that the ortho-chlorophenyl
(phe-1) at 1-position was useful for PDE2A potency and selectivity.
Three compounds, BIT1, BIT6, and BIT9, were selected for estimation of IC50 values of PDE2A
and PDE10A inhibition, to determine the potency in more detail and also the PDE10A/PDE2A selectivity
ratio. The related IC50 values are shown in Table 4.







BIT1 3.33 53.23 16
BIT6 65.06 168.4 2.5
BIT9 17.7 20.24 1.1
Finally, the potencies of BIT1 towards a range of other PDEs were evaluated as depicted in Table 5.
BIT1 showed a good selectivity over other PDEs (12.6%–23.3% for other PDEs, measured at 1 μM).
Summarizing, BIT1 had a good selectivity over PDE10A (16-fold), while BIT6 and BIT9 had 2.5-fold
and 1.1-fold selectivity over PDE10A, respectively. Applying similar assay conditions, TA1 and BAY
60-7550 displayed an IC50 value towards PDE2A of 10.8 nM and 0.66 nM, respectively. Thus, BIT1,
possessing phe-1 and 2-F-pyr-4 at the 1- and 8-positions, proved to be a prospective ligand for labeling
with 18F for PDE2A PET imaging.
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2.3. Incubations with Mouse Liver Microsomes
To gain first information about whether BIT1 is prone to metabolic degradation, the compound
was investigated in an in vitro test system. Briefly, BIT1 was incubated with Mouse Liver Microsomes
(MLM), in the presence of NADPH, at 37 ◦C for 90 min [43]. After protein precipitation by addition of
acetonitrile and subsequent centrifugation, the supernatant was examined by HPLC-UV-MS.
After incubation with MLM for 90 min, unchanged BIT1 could still be detected in high amounts
(Figure 3). The main fractions of in vitro metabolites were products of a mono-oxygenation of BIT1,
namely Metabolites M3, M5, and M6 (see Table 6).
Figure 3. HPLC-UV chromatogram after incubation of BIT1 with MLM in the presence of NADPH
(for conditions, see the experimental part): (a) UV chromatogram (partial) recorded during gradient
elution (Method A); (b) UV chromatogram recorded during isocratic elution (Method B).














BIT1 11.28 16.10 420.7 420.1 parent (M + H)+
M1 8.47 2.85 422.7 422.1 reduction(M + 2H + H)+
M2 9.05 4.24 452.8 452.1 di-oxygenation(M + 2O + H)+
M3 9.33 5.02 436.7 436.1 mono-oxygenation(M + O + H)+
M4 9.86 7.03 406.6 406.1 demethylation(M-CH3 + H)+
M5 10.67 12.04 436.7 436.1 mono-oxygenation(M + O + H)+
M6
not
detected 17.89 436.7 436.1
mono-oxygenation
(M + O + H)+
The metabolite M6 was detectable only by an HPLC method with isocratic elution as shown
in Figure 3b. Furthermore, one metabolite resulting from a two-fold oxygenation (M2) was found.
Due to the limitations of a single quadrupole MS, it was not possible to obtain information regarding
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the sites of functionalization in the molecule, neither to distinguish products from N-oxidation or
C-hydroxylation [44]. In contrast, for the formation of M1 and M4 by reduction and demethylation,
respectively, the chloro(methoxy)-phenyl moiety is expected to undergo these reactions under the
conditions applied.
The considerable metabolic stability of BIT1 in vitro supports the potential suitability of the
corresponding 18F-labelled compounds as a radioligand for PET. However, due to the retention
properties of the metabolite M6 in HPLC this metabolite may have a similar or higher lipophilicity in
comparison to BIT1. Therefore, of the metabolites detected, M6 most likely bears the risk of passing the
blood-brain barrier and influencing brain PET results. Hence, future in vivo metabolism studies should
pay attention to the occurrence of this metabolite, as well as to distinguish it chromatographically from
the parent compound.
3. Materials and Methods
3.1. General Information
Chemicals were purchased from following suppliers: Manchester Organics, abcr, VWR, Fluka,
Acros, Roth, ChemPure, Merck, Sigma Aldrich, Apollo scientific, and Fluorochem. Solvents were
dried before use, if required. Air- and moisture-sensitive reactions were carried out under argon
atmosphere. Room temperature (rt) refers to 20–25 ◦C. The progress of a reaction was monitored
by thin layer chromatography using pre-coated TLC sheets POLYGRAM® SIL G/UV254 purchased
from Macherey-Nagel. Detected spots were observed under UV light at λ 254 nm and 365 nm.
Flash chromatography was performed with silica gel 40–63 μm from VWR Chemicals.
NMR spectra (1H, 13C, 19F) were recorded on Mercury 300/Mercury 400 (Varian, Palo Alto,
CA, USA) or Fourier 300/Avance DRX 400 Bruker (Billerica, MA, USA) instruments. Signals of solvents
were used as internal standards for 1H-NMR (CDCl3, δH = 7.26; DMSO-d6, δH = 2.50) and 13C-NMR
(CDCl3, δC = 77.16; DMSO-d6, δC = 39.52). The chemical shifts (δ) are reported in ppm as follows: s,
singlet; d, doublet; t, triplet; m, multiplet; and the coupling constants (J) are reported in Hz. Mass
spectra were recorded on an ESQUIRE 3000 Plus (ESI, low resolution) and a 7 T APEX II (ESI, high
resolution) from Bruker Daltonics.
3.2. Syntheses
4-Bromo-2-fluoro-nitrobenzene (2): A suspension of sodium perborate tetrahydrate (20.24 g, 0.13 mol)
in glacial acetic acid (80 mL) was stirred at 65 ◦C. 4-Bromo-2-fluoro-aniline (5 g, 26.31 mmol, 1 eq) in
35 mL acetic acid was dropwise added over 5 h. The reaction was heated overnight, and subsequently,
another portion of NaBO3·4H2O (12.2 g, 78.9 mmol) was added. After full consumption of the
starting material, the reaction mixture was cooled to room temperature, the solid filtered off, and the
filtrate quenched with ice-cold water (600 mL). Then, the precipitate was filtrated and purified with
column chromatography (hexane/chloroform, 2:1) to give the product as yellow solid 2 (2.96 g, 51%).
TLC (hexane/CHCl3 (2:1)): Rf = 0.32. 1H-NMR (400 MHz, CDCl3) δH = 8.01–7.93 (m, 1H), 7.50 (dd,
J = 10.1, 1.9 Hz, 1H), 7.48–7.44 (m, 1H). 13C-NMR (101 MHz, CDCl3) δC = 155.48 (d, J = 269.9 Hz),
136.60 (d, J = 7.2 Hz), 129.56 (d, J = 8.9 Hz), 128.24 (d, J = 4.3 Hz), 127.28 (d, J = 2.5 Hz), 122.21
(d, J = 23.6 Hz). LR-MS (EI): m/z = 219 (calcd. 219 for C6H379BrFNO2+ [M]+)
4-Bromo-2-(4-methyl-1H-imidazol-1-yl) nitrobenzene (3): A mixture of compound 2 (9.46 g, 43 mmol) and
K2CO3 (11.9 g, 86 mmol) in DMF (40 mL) was stirred at 4 ◦C, while a solution of 4-methyl imidazole
(3.78 g, 46 mmol) in DMF (10 mL) was slowly added in the course of 2 h. Afterwards, stirring was
continued for 10 h at room temperature. The reaction mixture was poured into water (250 mL), and the
formed precipitate was filtered off, washed, and dried to give a brown yellow solid (10.47 g), which was
found to be an impure mixture of regioisomeric Products 3 and 3b in a ratio of ~4:1, according to
1H-NMR. The solid was dissolved in CHCl3 (80 mL) and filtered through a plug of silica gel (2 g).
The solvent was evaporated, and the remaining solid was recrystallized twice from aqueous EtOH
118
Molecules 2019, 24, 2791
(80%) to give pure 3, as bright yellow crystals (7.09 g, 58%). Mp. 151–152.5 ◦C; TLC (CHCl3/MeCN
(10:1)]: Rf = 0.33. 1H-NMR (400 MHz, CDCl3) δH = 7.85 (d, J = 8.7 Hz, 1H), 7.70 (dd, J = 8.7, 2.0 Hz, 1H),
7.61 (d, J = 2.0 Hz, 1H), 7.52 (d, J = 0.9 Hz, 1H), 6.75 (s, 1H), 2.27 (d, J = 0.9 Hz, 3H). 13C-NMR (101 MHz,
CDCl3) δC = 143.91, 140.24, 136.31, 132.37, 131.95, 131.47, 127.95, 126.68, 116.35, 13.71. LR-MS (ESI+):
m/z = 282, (calcd. 282 for C10H979BrN3O2+ [M + H]+).
The minor regioisomer was isolated from a sample (0.36 g) of the filtrate obtained from the first
recrystallization. It was purified via flash purification applying a gradient from CHCl3 (100%) to
CHCl3/MeCN (30:1) to give pure 3b, as a yellow solid (0.11 g). Mp. 107.5–109 ◦C; TLC [CHCl3/MeCN
(10:1)]: Rf = 0.26. 1H-NMR (400 MHz, CDCl3) δH = 7.97 (d, J = 8.7 Hz, 1H), 7.81 (dd, J = 8.7, 2.1 Hz, 1H),
7.59 (d, J = 2.1 Hz, 1H), 7.46 (s, 1H), 6.91 (s, 1H), 2.04 (s, 3H). 13C-NMR (101 MHz, CDCl3) δC = 145.38,
136.78, 133.60, 133.54, 131.16, 128.99, 128.22, 127.82, 126.78, 9.24.
4-Bromo-2-(4-methyl-1 H-imidazol-1-yl) aniline (4): Nitro compound 3 (4.42 g, 15.7 mmol, 1 eq) was
dissolved under argon in a 1:1 mixture of ethanol (50 mL) and acetic acid (50 mL). Iron powder (5.25 g,
94 mmol) was added, and the reaction mixture was stirred under reflux for 2.5 h (bath temperature
115–120 ◦C). The mixture was filtered through celite, and the filtrate was adjusted to pH 8 with Na2CO3
until a greenish solid formed. The mixture was extracted with Ethyl Acetate (EE, 3 × 100 mL), and the
organic phase was washed with water (2 × 100 mL) and saturated NaCl solution (100 mL), and dried
(Na2SO4). The solvent was evaporated to give a beige solid (3.64 g, 92%). TLC (CHCl3/MeOH/30%
NH3 (10:1:0.1)): Rf = 0.41. 1H-NMR (400 MHz, CDCl3) δH = 7.52 (d, J = 1.0 Hz, 1H), 7.30 (dd, J = 8.6,
2.3 Hz, 1H), 7.23 (d, J = 2.2 Hz, 1H), 6.80 (s, 1H), 6.71 (t, J = 8.0 Hz, 1H), 3.68 (d, J = 48.0 Hz, 2H),
2.30 (d, J = 0.6 Hz, 3H).13C-NMR (101 MHz, CDCl3) δC = 141.22, 139.48, 136.72, 132.47, 129.50, 124.52,
117.94, 116.32, 109.38, 13.77. LR-MS (ESI+): m/z = 274, (calcd. 274 for C10H1079BrN3Na+ [M + Na]+).
8-Bromo-3-methylbenzo[e]imidazo[5,1-c][1,2,4]triazine (5): A solution of NaNO2 (1.28 g, 18.6 mmol) in
H2O (10 mL) was added to a stirred solution of 4 (3.13 g, 12.4 mmol) in acetic acid (60 mL) at room
temperature. A yellow precipitate formed immediately. After 5 h of stirring, the reaction mixture
was evaporated to half of its original volume and diluted with H2O (50 mL). The pH was carefully
adjusted to pH 8 by the addition of solid NaHCO3. The yellow solid was filtered off and dried to give 5
(3.24 g, 98% sufficiently pure for the next step). The solid was dissolved in CHCl3 (150 mL) and filtered
through a plug of silica gel (2 g). The filtrate was concentrated and triturated with CHCl3/heptane
mixtures to afford a yellow powder (2.9 g, 89%). TLC (hexane/ethyl acetate (1:3)): Rf = 0.45. 1H-NMR
(400 MHz, DMSO-d6) δH = 9.16 (s, 1H), 8.70 (d, J = 2.0 Hz, 1H), 8.29 (d, J = 8.6 Hz, 1H), 7.88 (dd, J = 8.6,
2.0 Hz, 1H), 2.74 (s, 3H). 13C-NMR (101 MHz, DMSO-d6) δC = 137.71, 135.87, 134.37, 131.40, 130.55,
127.23, 126.01, 123.04, 118.35, 12.39. LR-MS (ESI+): m/z = 263 (calcd. 263 for C10H879BrN4+ [M + H]+).
3.2.1. General Procedure A for the Suzuki Coupling of Bromo Derivatives 5, 7a, 7b, 7c, 7d, 7e, and 7f
Brominated compound (1 eq), boronic acid derivative (BA, 8a–8f, 9a–9c, 1.1–1.3 eq), and K2CO3 (2–3 eq)
were combined in a mixture of 1,4-dioxane and water (4:1). The suspension was degassed with argon
for 5–10 min, and Pd(PPh3)4 (5–10 mol%) was added. The mixture was refluxed (bath temperature
102–108 ◦C) for 1–2 days until completion of the reaction (as indicated by TLC). The solvent was
removed, and the residue was partitioned between CHCl3 and water. The aqueous layer was extracted
twice with CHCl3, and the combined organic layers were dried (Na2SO4) and the solvent evaporated.
Unless stated otherwise, the obtained residue was purified by flash chromatography on silica gel using
CHCl3/MeOH (10:1) as the eluent. The following products were isolated:
8-(2-Fluoropyridin-4-yl)-3-methylbenzo[e]imidazo[5,1-c][1,2,4]triazine (6a): Based on General Procedure
A of Suzuki coupling, a mixture of compound 5 (101 mg, 0.38 mmol,1 eq), BA 8a (65 mg,0.46 mmol,
1.2 eq), and K2CO3 (131 mg, 0.95 mmol, 2.5 eq), in dioxane/water (5 mL) were reacted in the presence
of Pd(PPh3)4 (44 mg, 10 mol%) to give after purification compound 6a (81 mg, 76%) as a yellow solid.
TLC (hexane/ethyl acetate (1:1)): Rf = 0.25. 1H-NMR (400 MHz, DMSO-d6) δH = 9.28 (s, 1H), 8.92
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(d, J = 1.9 Hz, 1H), 8.52 (d, J = 8.5 Hz, 1H), 8.46 (d, J = 5.3 Hz, 1H), 8.25 (dd, J = 8.5, 1.9 Hz, 1H), 7.97
(dt, J = 5.3, 1.8 Hz, 1H), 7.82 (s, 1H), 2.79 (s, 3H). LR-MS (ESI+): m/z = 280, (calcd. 280 for C15H11FN5+
[M + H]+).
8-(6-Fluoropyridin-3-yl)-3-methylbenzo[e]imidazo[5,1-c][1,2,4]triazine (6b): According to General Procedure
A, compound 5 (500 mg, 1.9 mmol,1 eq), BA 8b (321 mg, 2.28 mmol, 1.2 eq), K2CO3 (788 mg, 5.7 mmol,
3 eq), and Pd(PPh3)4 (220 mg, 10 mol%) were reacted in dioxane/water (24 mL) to yield after purification
compound 6b (150 mg, 28%), as a yellow powder. TLC (CH3Cl3/MeOH (10:1)): Rf = 0.38. 1H-NMR
(400 MHz, CDCl3) δH = 8.62–8.52 (m, 3H), 8.12 (ddd, J = 8.4, 7.4, 2.7 Hz, 1H), 7.98 (d, J = 1.8 Hz, 1H),
7.82 (dd, J = 8.4, 1.8 Hz, 1H), 7.13 (dd, J = 8.5, 3.1 Hz, 1H), 2.91 (s, 3H). LR-MS (ESI+): m/z = 280, (calcd.
280 for C15H11FN5+ [M + H]+).
8-(2-Fluoropyridin-3-yl)-3-methylbenzo[e]imidazo[5,1-c][1,2,4]triazine (6c): According to General Procedure
A, compound 5 (501 mg, 1.9 mmol, 1 eq), BA 8c (325 mg, 2.28 mmol, 1.2 eq), K2CO3 (661 mg, 4.75 mmol,
2.5 eq), and Pd(PPh3)4 (219 mg, 10 mol%) were reacted in dioxane/water (15 mL) to afford after
purification compound 6c (0.52 g, 98%), as a yellow solid. TLC (CHCl3/MeOH (10:1)): Rf = 0.38.
1H-NMR (400 MHz, CDCl3) δH = 8.58–8.52 (m, 1H), 8.34 (dt, J = 5.0, 1.5 Hz, 1H), 8.10–7.99 (m, 1H),
7.85 (dd, J = 8.4, 1.6 Hz, 1H), 7.71–7.62 (m, 1H), 7.58–7.37 (m, 2H), 2.92 (s, 3H). LR-MS (ESI+): m/z = 280
(calcd. 280 for C15H11FN5+ [M + H]+).
8-(5-Fuoropyridin-3-yl)-3-methylbenzo[e]imidazo[5,1-c][1,2,4]triazine (6d): According to General Procedure
A, compound 5 (200 mg, 0.76 mmol, 1 eq), BA 8d (118 mg, 0.84 mmol, 1.1 eq), K2CO3 (315 mg,
2.28 mmol, 3.0 eq), and Pd(PPh3)4 (44 mg, 5 mol%) were reacted in dioxane/water (10 mL) to give after
purification Compound 6d (0.12 g, 56%), as a yellow powder. TLC (CHCl3/MeOH (10:1)): Rf = 0.29.
1H-NMR (400 MHz, DMSO-d6) δH = 9.26 (s, 1H), 9.09 (d, J = 1.9 Hz, 1H), 8.88 (d, J = 1.8 Hz, 1H), 8.71
(d, J = 2.7 Hz, 1H), 8.49 (d, J = 8.5 Hz, 1H), 8.36 (dt, J = 10.3, 2.3 Hz, 1H), 8.19 (dd, J = 8.5, 1.9 Hz, 1H),
2.77 (s, 3H).
3-Methyl-8-(pyridin-3-yl)benzo[e]imidazo[5,1-c][1,2,4]triazine (6e): According to General Procedure A,
compound 5 (1.0 g, 3.8 mmol, 1 eq), BA 8e (0.61 mg, 4.94 mmol, 1.3 eq), K2CO3 (1.58 g, 11.4 mmol,
3 eq), and Pd(PPh3)4 (220 mg, 5 mol%) were reacted in dioxane/water (50 mL) to give after purification
by flash chromatography compound 6e (0.76 g, 77%), as a yellow solid. TLC (CHCl3/MeOH (10:1)):
Rf = 0.20. 1H-NMR (400 MHz, DMSO-d6) δH = 9.23 (s, 1H), 9.16 (d, J = 2.1 Hz, 1H), 8.77 (d, J = 1.8 Hz,
1H), 8.69 (dd, J = 4.8, 1.6 Hz, 1H), 8.45 (d, J = 8.4 Hz, 1H), 8.35–8.30 (m, 1H), 8.11 (dd, J = 8.5, 1.8 Hz,
1H), 7.60 (ddd, J = 8.0, 4.8, 0.9 Hz, 1H), 2.75 (s, 3H). LR-MS (ESI+): m/z = 262, (calcd. 262 for C15H12N5+
[M+H]+).
3-Methyl-8-(pyridin-4yl)benzo[e]imidazo[5,1-c][1,2,4]triazine (6f): According to General Procedure A,
compound 5 (200 mg, 0.76 mmol, 1 eq), K2CO3 (265 mg, 1.92 mmol, 2.52 eq), BA 8f (119 mg, 0.968
mmol, 1.27 eq), and Pd(PPh3)4 (44 mg, 0.038 mmol, 5 mol%) were reacted in dioxane/water (5 mL) to
afford after purification compound 6f (173 mg, 87%), as a yellow solid. TLC (CHCl3/MeOH (10:1)):
Rf = 0.23. 1H-NMR (300 MHz, DMSO-d6) δH = 9.26 (s, 1H), 8.82 (d, J = 1.8 Hz, 1H), 8.78–8.75 (m, 2H),
8.47 (d, J = 8.5 Hz, 1H), 8.15 (dd, J = 8.5, 1.9 Hz, 1H), 7.96–7.92 (m, 2H), 2.75 (s, 3H).
3.2.2. General Procedure B for Bromination of Compounds 6a, 6b, 6c, 6d, 6e, and 6f
N-Bromosuccinimide (NBS, ~1.5 eq) was added to a suspension of compounds 6a–6f in acetonitrile.
The reaction mixture was protected from light and stirred at room temperature for 1–2 d. After the
full conversion of the starting material, the mixture was partitioned between CHCl3 and H2O.
The organic layer was washed with aqueous NaHCO3 (5%), water, and saturated NaCl solution.
After drying (Na2SO4) and evaporation, the residue was purified by flash chromatography, eluting
with CHCl3/MeOH (10:1).
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1-Bromo-8-(2-fluoropyridin-4-yl)methylbenzo[e]imidazo[5,1-c][1,2,4]triazine (7a): According to General
Procedure B, for bromination, compound 6a (300 mg, 1.07 mmol) and NBS (287 mg, 1.61 mmol) were
reacted in acetonitrile (20 mL) to give after purification compound 7a, as a yellow solid (306 mg, 79%).
TLC (CHCl3/MeOH (10:1)): Rf = 0.74. 1H-NMR (400 MHz, CDCl3) δH = 9.25 (t, J = 10.2 Hz, 1H), 8.59
(d, J = 8.4 Hz, 1H), 8.42 (t, J = 8.7 Hz, 1H), 7.94 (dd, J = 8.4, 1.8 Hz, 1H), 7.55–7.48 (m, 1H), 7.25 (s, 1H),
2.89 (d, J = 3.6 Hz, 3H). LR-MS (ESI+): m/z = 358 (calcd. 358 for C15H1079BrFN5+ [M + H]+)
1-Bromo-8-(6-fluoropyridin-3-yl)-3-methylbenzo[e]imidazo[5,1-c][1,2,4]triazine (7b): According to General
Procedure B, compound 6b (354 mg, 1.27 mmol) and NBS (338 mg, 1.9 mmol) were reacted in acetonitrile
(16 mL) to give after purification Compound 7b, as a yellow solid (290 mg, 63%). TLC (CHCl3/MeOH
(10:1)): Rf = 0.71. 1H-NMR (400 MHz, CDCl3) δH = 9.15 (d, J = 1.8 Hz, 1H), 8.59 (d, J = 2.6 Hz, 1H), 8.56
(d, J = 8.4 Hz, 1H), 8.12 (ddd, J = 8.5, 7.4, 2.7 Hz, 1H), 7.87 (dd, J = 8.4, 1.8 Hz, 1H), 7.13 (dd, J = 8.5, 3.0
Hz, 1H), 2.88 (s, 3H). LR-MS (ESI+): m/z = 358 (calcd. 358 for C15H1079BrFN5+, [M + H]+).
1-Bromo-8-(2-fluoropyridin-3-yl)-3-methylbenzo[e]imidazo[5,1-c][1,2,4]triazine (7c): According To General
Procedure B, compound 6c (169 mg, 0.61 mmol) and NBS (162 mg, 0.91 mmol) were reacted in acetonitrile
(6 mL) to give after purification compound 7c, as a yellow solid (192 mg, 88%). TLC (CHCl3/MeOH
(10:1)), Rf = 0.66. 1H-NMR (400 MHz, CDCl3) δH = 9.23 (t, J = 1.5 Hz, 1H), 8.54 (d, J = 8.4 Hz, 1H), 8.34
(dt, J = 4.9, 1.5 Hz, 1H), 8.08–8.00 (m, 1H), 7.89 (dt, J = 8.4, 1.6 Hz, 1H), 7.46–7.37 (m, 1H), 2.88 (s, 3H).
LR-MS (ESI+): m/z = 358, (calcd. 358 for C15H1079BrFN5+ [M + H]+).
1-Bromo-8-(5-fluoropyridin-3-yl)-3-methylbenzo[e]imidazo[5,1-c][1,2,4]triazine (7d): According to General
Procedure B, compound 6d (120 mg, 0.43 mmol) and NBS (115 mg, 0.65 mmol) were reacted in
acetonitrile (4 mL) to afford after purification Compound 7d, (151 mg, 98%), as a yellow solid.
TLC (CHCl3/MeOH (10:1)), Rf = 0.71. 1H-NMR (300 MHz, CDCl3) δH = 9.20–9.19 (m, 1H), 8.83–8.81
(m, 1H), 8.61–8.59 (m, 1H), 8.56 (d, J = 0.4 Hz, 1H), 7.90 (dd, J = 8.4, 1.8 Hz, 1H), 7.73 (ddd, J = 9.1, 2.7,
1.9 Hz, 1H), 2.88 (s, 3H). LR-MS (ESI+): m/z = 358, (calcd. 358 for C15H1079BrFN5+ [M + H]+).
1-Bromo-3-methyl-8-(pyridin-3-yl)benzo[e]imidazo[5,1-c][1,2,4]triazine (7e): According to General
Procedure B, compound 6e (300 mg, 1.15 mmol, 1 eq) and NBS (306 mg, 1.72 mmol) were reacted
in acetonitrile (8 mL) to afford after purification compound 7e (343 mg, 87%), as a yellow solid.
TLC (CHCl3/MeOH (10:1)): Rf = 0.47. 1H-NMR (400 MHz, CDCl3) δH = 9.19 (d, J = 1.7 Hz, 1H), 9.00
(dd, J = 2.5, 0.9 Hz, 1H), 8.73 (dd, J = 4.8, 1.6 Hz, 1H), 8.55 (d, J = 8.4 Hz, 1H), 8.03 (ddd, J = 8.0, 2.5,
1.6 Hz, 1H), 7.91 (dd, J = 8.4, 1.8 Hz, 1H), 7.50 (ddd, J = 8.0, 4.8, 0.9 Hz, 1H), 2.87 (s, 3H). LR-MS (ESI+):
m/z = 340, (calcd. 340 for C15H1179BrN5+ [M + H]+).
1-Bromo-3-methyl-8-(pyridin-4-yl)benzo[e]imidazo[5,1-c][1,2,4]triazine (7f): According to General Procedure
B, compound 6f (100 mg, 0.383 mmol, 1 eq) and NBS (102 mg, 0.573 mmol) were reacted in MeCN
(4 mL) to give after purification compound 7f (120 mg, 92%), as a yellow powder. TLC (CHCl3/MeOH
(10:1)): Rf = 0.54. 1H-NMR (400 MHz, DMSO-d6) δH = 9.27 (d, J = 1.8 Hz, 1H), 8.85–8.78 (m, 2H), 8.58
(d, J = 8.4 Hz, 1H), 8.24 (dd, J = 8.4, 1.8 Hz, 1H), 7.97–7.91 (m, 1H), 2.76 (s, 3H). LR-MS (ESI+): m/z = 340,
(calcd. 340 for C15H1179BrN5+ [M + H]+).
3.2.3. Synthesis of Oxetanyl Building Block 9c
3-((3-Bromophenoxy)methyl)-3-methyloxetane (11): A mixture of (3-methyloxetan-3-yl) methanol (2.09 g,
20.4 mmol) and triethylamine (TEA, 3.2 mL, 23 mmol) in MeCN (8 mL) was stirred and cooled at
15–25 ◦C, while a solution of methanesulfonyl chloride (1.55 mL, 20 mmol) in MeCN (3 mL) was
dropwise added in the course of 20 min. The mixture was stirred at 22 ◦C for 4 h and at 0–2 ◦C for
30 min. The precipitated TEA hydrochloride was filtered off and washed with MeCN (2 × 2.5 mL).
To the filtrate was successively added 3-bromophenol (10, 3.46 g, 20 mmol) and Cs2CO3 (3.26 g,
10 mmol) along with K2CO3 (2.07 g, 15 mmol). The resulting suspension was stirred and heated at
75–79 ◦C for 18 h (progress monitored by TLC). Upon completion, the suspension was stirred with
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methyl tert-butyl ether (MTBE, 50 mL) for 2 h. The solid was filtered off and the filtrate washed with
sodium hydroxide solution (0.8 M, 1 × 20, 2 × 10 mL) and dried (Na2CO3). The solvent was evaporated
and the remaining oil bulb-to-bulb distilled (4 mbar, air bath 150–190 ◦C) to afford compound 11,
as a colorless oil (4.35 g, 85%). TLC (heptane/MTBE (3:2)): Rf = 0.4. 1H-NMR (400 MHz, CDCl3)
δH = 7.18–7.12 (m, 1H), 7.12-7.08 (m, 2H), 6.87 (ddd, J = 8.1, 2.5, 1.3 Hz, 1H), 4.61 (d, J = 6.0 Hz, 2H),
4.46 (d, J = 6.0 Hz, 2H), 4.00 (s, 2H), 1.43 (s, 3H). 13C-NMR (101 MHz, CDCl3) δC = 159.86, 130.70,
124.24, 122.94, 117.97, 113.62, 79.81 (2C), 73.06, 39.74, 21.33.
4,4,5,5-Tetramethyl-2-(3-((3-methyloxetan-3-yl) methoxy) phenyl)-1,3,2-dioxaborolane (12): A mixture of
3-bromophenylether 11 (1.75 g, 6.8 mmol), KOAc (1.5 g, 15.3 mmol), and bis(pinacolato)diboron (1.77 g,
15 mmol, in 2-methyltetrahydrofuran (24 mL)) was degassed with argon for 10 min. After addition
of Pd(dppf)Cl2 (0.07 g, 0.096 mmol), the mixture was refluxed for 7 h. Upon completion (monitored
by TLC), CH2Cl2 (25 mL) was added, the resulting suspension stirred for 1 h, and the solid filtered
off. The filtrate was evaporated, and the viscous residue (3.2 g) was dissolved in MTBE (70 mL)
and subsequently filtered through a short silica gel column (H 2 cm × D 2 cm). The filtrate was
extracted with aqueous NaOH (0.75 M, 4 × 12 mL). The alkaline extract was neutralized by slow
addition of aqueous HCl (4 M) at 0–2 ◦C (→ pH 6–7). The separated oil was extracted with MTBE
(3 × 15 mL), and after drying (MgSO4), the solvent was evaporated to leave a viscous residue (2.15 g).
Crystallization was achieved by trituration with MTBE/heptane to yield 12, as a colorless solid (1.67 g,
81%). TLC (heptane/MTBE (2:1)): Rf = 0.38. 1H-NMR (300 MHz, CDCl3) δH = 7.42 (dt, J = 7.3, 1.1 Hz,
1H), 7.38–7.35 (m, 1H), 7.31 (t, J = 7.7 Hz, 1H), 7.04 (ddd, J = 8.2, 2.8, 1.2, 30 Hz, 1H), 4.63 (d, J = 5.9 Hz,
2H), 4.45 (d, J = 5.9 Hz, 2H), 4.06 (s, 2H), 1.44 (s, 3H), 1.35 (s, 12H). 13C-NMR (75 MHz, CDCl3)
δC = 158.65, 129.15, 127.59, 119.86, 118.27, 84.01, 80.01, 72.87, 39.86, 25.01, 21.47 (the boron-substituted
carbon atom was not detectable).
2-(2-Chloro-5-((3-methyloxetan-5 3-yl) methoxy) phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (9c):
N-Chlorosuccinimide (NCS, 0.4 g, 3.0 mmol) was added to a solution of compound 12 (0.73 g,
2.4 mmol) in DMF (7 mL). The mixture was stirred at room temperature for 20 h (monitored by TLC).
The solvent was removed in vacuo, and the viscous residue was dissolved in MTBE (20 mL). The solution
was successively washed with aqueous Na2S2O3 (10%, 9 mL) and water (6 mL) and extracted with
aqueous NaOH (0.75 M, 3 × 6 mL). The alkaline extract was neutralized (→ pH 7–8) by slow addition
of aqueous HCl (4 M) at 0–2 ◦C. The separated oil was extracted with MTBE (3 × 10 mL), and after
drying (MgSO4), the solvent was evaporated to leave a viscous residue. Crystallization was achieved
by trituration with MTBE/heptane to yield 9c, as a colorless solid (0.45 g, 56%). TLC (heptane/MTBE
(2:1)): Rf = 0.30. 1H-NMR (300 MHz, CDCl3) δH = 7.25 (d, J = 8.8 Hz, 1H), 7.23 (d, J = 3.2 Hz, 1H), 6.90
(dd, J = 8.8, 3.2 20 Hz, 1H), 4.61 (d, J = 5.9 Hz, 2H), 4.44 (d, J = 5.9 Hz, 2H), 4.01 (s, 2H), 1.42 (s, 3H), 1.37
(s, 12H). 13C-NMR (75 MHz, CDCl3) δC = 157.11, 131.36, 130.49, 121.90, 121.88, 118.33, 84.39, 79.90,
79.88, 73.15, 39.82, 24.95, 21.40.
3.2.4. Synthesis of Compounds BIT1–BIT9 via Suzuki Coupling According to General Procedure A
1-(2-Chloro-5-methoxyphenyl)-8-(2-fluoropyridin-4-yl)-3methylbenzo[e]imidazo[5,1-c][1,2,4]triazine (BIT1):
Based on General Procedure A for Suzuki coupling, a mixture of compound 7a (100 mg, 0.28 mmol,
1 eq), BA 9a (63.4 mg,0.34 mmol, 1.2 eq), and K2CO3 (97 mg, 0.7 mmol, 2.5 eq) in dioxane/water
(5 mL) was reacted in the presence of Pd(PPh3)4 (33 mg, 10 mol%) to give after purification by flash
chromatography (gradient: hexane/ethyl acetate, 9:1→ ethyl acetate, 100%) compound BIT1 (92 mg,
80%) as a yellow powder. TLC (hexane/ethyl acetate (1:1)): Rf = 0.33. 1H-NMR (400 MHz, CDCl3)
δH = 8.55 (d, J = 8.4 Hz, 1H), 8.27 (d, J = 5.2 Hz, 1H), 7.85 (dd, J = 8.4, 1.7 Hz, 1H), 7.56 (d, J = 8.8 Hz,
1H), 7.48 (d, J = 1.6 Hz, 1H), 7.21 (d, J = 3.0 Hz, 1H), 7.19 (d, J = 3.1 Hz, 1H), 7.16 (d, J = 3.0 Hz, 1H),
6.88 (s, 1H), 3.87 (s, 3H), 2.99 (s, 3H). 13C-NMR (75 MHz, CDCl3) δC = 164.59 (d, J = 239.3 Hz), 159.09,
151.71 (d, J = 8.1 Hz), 148.68 (d, J = 15.4 Hz), 140.20 (d, J = 3.3 Hz), 139.84, 137.41, 136.98, 136.18, 131.51,
131.44, 130.81, 126.00, 124.05, 119.38 (d, J = 4.1 Hz), 118.56, 117.68, 113.90, 107.44 (d, J = 38.7 Hz), 56.01,
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12.89. 19F-NMR (282 MHz, CDCl3) δF = −66.98 (s, br). HR-MS (ESI+): m/z = 420.1025 and 442.0848
(calcd. 420.1022 for C22H16ClFN5O+ [M+H]+ and 442.0841 for C22H15ClFN5NaO+ [M + Na]+).
1-(2-Chloro-5-((3-methyloxetan-3-yl)methoxy)phenyl)-8-(6-fluoropyridin-3-yl)-3-methylbenzo[e]imidazo[5,1-c]
[1,2,4]triazine (BIT2): According to General Procedure A, compound 7b (144 mg, 0.40 mmol,1 eq), BA
9c (163 mg, 0.48 mmol, 1.2 eq), K2CO3 (157 mg, 1.14 mmol, 2.84 eq), and Pd(PPh3)4 (23 mg, 5 mol%)
were reacted in dioxane/water (5 mL) to give a raw product, which was purified by two-times column
chromatography (CHCl3/MeOH (10:1) to yield compound BIT2 (155 mg, 79%), as a yellow solid.
TLC (hexane/ethyl acetate (1:3)): Rf = 0.29. 1H-NMR (400 MHz, CDCl3) δH = 8.52 (d, J = 8.3 Hz,
1H), 8.21 (d, J = 2.5 Hz, 1H), 7.90–7.81 (m, 1H), 7.77 (dd, J = 8.3, 1.8 Hz, 1H), 7.55 (d, J = 8.8 Hz,
1H), 7.45 (d, J = 1.8 Hz, 1H), 7.27 (s, 1H), 7.17 (dd, J = 8.9, 2.9 Hz, 1H), 7.02 (dd, J = 8.5, 3.0 Hz, 1H),
4.57 (dd, J = 6.0, 2.0 Hz, 2H), 4.44 (d, J = 5.9 Hz, 2H), 4.17–3.99 (m, 2H), 2.96 (s, 3H), 1.41 (s, 3H).
13C-NMR (101 MHz, CDCl3) δC = 163.85 (d, J = 242.3 Hz), 158.37, 146.27 (d, J = 15.2 Hz), 140.19,
139.79 (d, J = 8.1 Hz), 139.45, 137.37, 136.39, 135.92, 133.01 (d, J = 4.7 Hz), 131.74, 131.46, 130.85, 126.38,
125.94, 124.10, 118.73 (d, J = 41.2 Hz), 113.32, 110.38, 110.00, 79.66 (d, J = 3.4 Hz), 73.58, 39.77, 21.28,
12.87. 19F-NMR (282 MHz, CDCl3) δF = −67.82 (dd, J = 7.4, 3.2 Hz). HR-MS (ESI+): m/z = 490.1442
and 512.1260 (calcd. 490.1441 for C26H22ClFN5O2+ [M+H]+ and 512.1260 for C26H21ClFN5NaO2+
[M + Na]+).
1-(2-Chloro-5-((3-methyloxetan-3-yl)methoxy)phenyl)-8-(2-fluoropyridin-4-yl)-3-methylbenzo[e]imidazo[5,1-c]
[1,2,4]triazine (BIT3): According to General Procedure A, compound 7a (100 mg, 0.279 mmol, 1 eq), BA
9c (104 mg, 0.307 mmol, 1.1 eq), K2CO3 (93 mg, 0.642 mmol, 2.3 eq), and Pd(PPh3)4 (16 mg, 5 mol%)
were reacted in dioxane/water (5 mL) to give after purification by flash chromatography (gradient:
hexane/ethyl acetate, 1:2→ ethyl acetate, 100%) compound BIT3 (93 mg, 68%), as a yellow solid. TLC
(hexane/ethyl acetate (1:3)): Rf = 0.29. 1H-NMR (400 MHz, CDCl3) δH = 8.55 (d, J = 8.4 Hz, 1H), 8.27
(d, J = 5.2 Hz, 1H), 7.86 (dd, J = 8.4, 1.8 Hz, 1H), 7.58 (d, J = 8.9 Hz, 1H), 7.52 (d, J = 1.8 Hz, 1H), 7.28
(d, J = 3.0 Hz, 1H), 7.23–7.18 (m, 2H), 6.89 (d, J = 1.6 Hz, 1H), 4.60–4.55 (m, 2H), 4.44 (d, J = 6.0 Hz, 2H),
4.15–4.03 (m, 2H), 2.97 (s, 3H), 1.42 (s, 3H). 13C-NMR (101 MHz, CDCl3) δC = 164.60 (d, J = 239.3 Hz),
158.47, 151.79 (d, J = 8.2 Hz), 148.72 (d, J = 15.5 Hz), 140.25 (d, J = 3.4 Hz), 139.92, 137.45, 137.02,
136.10, 131.68, 131.49, 130.91, 126.37, 125.90, 124.06, 119.44 (d, J = 4.1 Hz), 118.91, 118.56, 114.00, 107.49
(d, J = 38.7 Hz), 79.63 (d, J = 4.1 Hz), 73.61, 39.77, 21.26, 12.90. 19F-NMR (282 MHz, CDCl3) δF = −66.93
(s, br). HR-MS (ESI+) m/z = 490.1443 and 512.1261 (calcd. 490.1441 for C26H22ClFN5O2+ [M + H]+ and
512.1260 for C26H21ClFN5NaO2+ [M + Na]+).
1-(2-Chloro-5-methoxyphenyl)-8-(6-fluoropyridin-3-yl)-3 methylbenzo[e]imidazo[5,1-c][1,2,4]triazine (BIT4):
According to General Procedure A, compound 7b (111 mg, 0.308 mmol, 1 eq), BA 9a (69 mg,
0.370 mmol, 1.2 eq), K2CO3 (107 mg, 0.77 mmol, 2.5 eq), and Pd(PPh3)4 (36 mg, 10 mol%) were reacted
in dioxane/water (5 mL) to give after purification by flash chromatography (gradient: CHCl3/MeOH,
50:1→ CHCl3/MeOH, 30:1) compound BIT4 (83 mg, 64%), as a yellow solid. TLC (hexane/ethyl acetate
(1:1)): Rf = 0.37. 1H-NMR (400 MHz, CDCl3) δH = 8.51 (d, J = 8.4 Hz, 1H), 8.20 (d, J = 2.3 Hz, 1H), 7.82
(ddd, J = 8.6, 7.3, 2.7 Hz, 1H), 7.76 (dd, J = 8.4, 1.8 Hz, 1H), 7.52 (d, J = 8.9 Hz, 1H), 7.39 (d, J = 1.8 Hz,
1H), 7.19 (d, J = 3.1 Hz, 1H), 7.13 (dd, J = 8.9, 3.0 Hz, 1H), 7.01 (dd, J = 8.5, 3.1 Hz, 1H), 3.84 (s, 3H), 2.96
(s, 3H).13C-NMR (75 MHz, CDCl3) δC = 163.82 (d, J = 242.0 Hz), 159.00, 146.24 (d, J = 15.0 Hz), 140.19,
139.76 (d, J = 8.1 Hz), 139.38, 137.33, 136.36, 136.00, 132.98 (d, J = 4.7 Hz), 131.58, 131.43, 130.77, 126.04,
125.87, 124.10, 118.64, 117.62, 113.26, 110.16 (d, J = 37.5 Hz), 55.99, 12.86. 19F-NMR (282 MHz, CDCl3)
δF = −67.90 (dd, J = 7.4, 3.1 Hz). HR-MS (ESI+): m/z = 420.1010 (calcd. 420.1022 for C22H16ClFN5O+
[M + H]+).
1-(2-Chloro-5-methoxyphenyl)-8-(2-fluoropyridin-3-yl)-3 methylbenzo[e]imidazo[5,1-c][1,2,4]triazine (BIT5):
According to General Procedure A, compound 7c (115 mg, 0.322 mmol, 1 eq), BA 9a (72 mg, 0.386 mmol,
1.2 eq), K2CO3 (115 mg, 0.832 mmol, 2.58 eq), and Pd(PPh3)4 (37 mg, 10 mol%) were reacted in
dioxane/water (5 mL) to give after purification by flash chromatography (gradient: light petroleum
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ether/ethyl acetate, 1:1 → light petroleum ether/ethyl acetate, 1:2) compound BIT5 (93 mg, 69%),
as a yellow solid. TLC (light petroleum ether/ethyl acetate (1:2)): Rf = 0.43. 1H-NMR (300 MHz, CDCl3)
δH = 8.51 (d, J = 8.4 Hz, 1H), 8.22 (dd, J = 4.8, 0.7 Hz, 1H), 7.83–7.73 (m, 2H), 7.52–7.45 (m, 2H), 7.32–7.27
(m, 1H), 7.17 (d, J = 3.0 Hz, 1H), 7.10 (dd, J = 8.9, 3.0 Hz, 1H), 3.83 (s, 3H), 2.97 (s, 3H). 13C-NMR
(75 MHz, CDCl3) δC = 160.19 (d, J = 242.0 Hz), 158.95, 147.84 (d, J = 15.0 Hz), 140.67 (d, J = 3.5 Hz),
139.44, 137.51, 137.42 (d, J = 2.1 Hz), 136.37, 136.21, 131.33, 131.01, 130.93, 127.58 (d, J = 2.8 Hz), 126.05,
123.76, 122.28 (d, J = 4.6 Hz), 121.95 (d, J = 27.2 Hz), 118.72, 117.03, 115.51 (d, J = 5.2 Hz), 55.95, 12.88.
19F-NMR (282 MHz, CDCl3) δF = −70.11 (d, J = 9.8 Hz). HR-MS (ESI+): m/z = 420.1014 (calcd. 420.1022
for C22H16ClFN5O+ [M + H]+).
1-(2-Fluoro-5-methoxyphenyl)-8-(2-fluoropyridin-4-yl)-3-methylbenzo[e]imidazo[5,1-c][1,2,4]triazine (BIT6):
According to General Procedure A, compound 7a (100 mg, 0.279 mmol, 1 eq), BA 9b (62 mg, 0.365
mmol, 1.3 eq), K2CO3 (97 mg, 0.698 mmol, 2.58 eq), and Pd(PPh3)4 (32 mg, 10 mol%) were reacted in
dioxane/water (5 mL) to give after purification by flash chromatography (gradient: light petroleum
ether/ethyl acetate, 1:1 → light petroleum ether/ethyl acetate, 1:2) compound BIT6 (81 mg, 72%),
as an orange solid. TLC (petroleum ether/ethyl acetate (1:2)): Rf = 0.54. 1H-NMR (300 MHz, CDCl3)
δH = 8.55 (d, J = 8.4 Hz, 1H), 8.27 (dd, J = 5.3, 0.7 Hz, 1H), 7.86 (dd, J = 8.4, 1.9 Hz, 1H), 7.73 (dd, J = 3.5,
1.8 Hz, 1H), 7.30–7.27 (m, 1H), 7.25–7.14 (m, 3H), 6.94–6.91 (m, 1H), 3.88 (s, 3H), 2.97 (s, 3H).13C-NMR
(75 MHz, CDCl3) δC = 164.61 (d, J = 239.5 Hz), 156.62 (d, J = 7.1 Hz), 153.86 (d, J = 246.3 Hz), 153.58,
151.80, 148.73 (d, J = 15.4 Hz), 140.32, 140.24 (d, J = 2.9 Hz), 137.50 (d, J = 62.8 Hz), 133.85, 131.56, 125.94,
124.28, 120.00 (d, J = 16.3 Hz), 119.46 (d, J = 4.1 Hz), 118.76 (d, J = 7.9 Hz), 117.03 (d, J = 22.7 Hz), 116.44,
113.90 (d, J = 2.2 Hz), 107.56 (d, J = 38.8 Hz), 56.21, 12.88.19F-NMR (282 MHz, CDCl3) δF =−66.90—-66.97
(m), −121.68–121.78 (m). HR-MS (ESI+): m/z = 404.1325 (calcd. 404.1317 for C22H16F2N5O+ [M + H]+).
1-(2-Chloro-5-methoxyphenyl)-8-(3-fluoropyridin-5-yl)-3 methylbenzo[e]imidazo[5,1-c][1,2,4]triazine (BIT7):
According to General Procedure A, compound 7d (100 mg, 0.279 mmol, 1 eq), BA 9a (62 mg,
0.335 mmol, 1.2 eq), K2CO3 (116 mg, 0.839 mmol, 3.0 eq), and Pd(PPh3)4 (17 mg, 5 mol%) were reacted
in dioxane/water (5 mL) to give after purification by flash chromatography (gradient: hexane/ethyl
acetate, 1:2 → hexane/ethyl acetate, 1:3) compound BIT7 (79 mg, 67%), as a yellow solid. TLC
(hexane/ethyl acetate (1:2)): Rf = 0.38. 1H-NMR (400 MHz, CDCl3) δH = 8.53 (d, J = 8.4 Hz, 1H), 8.48
(d, J = 2.7 Hz, 1H), 8.46–8.45 (m, 1H), 7.81 (dd, J = 8.4, 1.9 Hz, 1H), 7.55 (d, J = 8.9 Hz, 1H), 7.44–7.38
(m, 2H), 7.20 (d, J = 3.0 Hz, 1H), 7.14 (dd, J = 8.9, 3.0 Hz, 1H), 3.85 (s, 3H), 2.97 (s, 3H). 13C-NMR
(101 MHz, CDCl3) δC = 159.71 (d, J = 258.4 Hz), 159.05, 143.99 (d, J = 4.0 Hz), 139.77, 139.56, 138.21
(d, J = 23.1 Hz), 137.37, 136.58, 136.23 (d, J = 3.8 Hz), 136.09, 131.52, 131.48, 130.84, 126.02, 125.99, 124.10,
121.21 (d, J = 19.0 Hz), 118.59, 117.70, 113.68, 55.99, 12.87. 19F-NMR (377 MHz, CDCl3) δF = −125.95
(d, J = 9.2 Hz). HR-MS (ESI+): m/z = 420.1024 (calcd. 420.1022 for C22H16ClFN5O+ [M + H]+).
1-(2-Fluoro-5-methoxyphenyl)-3-methyl-8-(pyridin-3-yl)benzo[e]imidazo[5,1-c][1,2,4]triazine (BIT8): According
to General Procedure A, compound 7e (100 mg, 0.294 mmol, 1 eq), BA 9b (60 mg, 0.353 mmol, 1.2 eq),
K2CO3 (110 mg, 0.796 mmol, 2.7 eq), and Pd(PPh3)4 (17 mg, 5 mol%) were reacted in dioxane/water
(5 mL) to give after purification by flash chromatography (gradient: hexane/ethyl acetate, 1:3→ ethyl
acetate, 100%) compound BIT8 (93 mg, 82%), as an orange solid. TLC (hexane/ethyl acetate (1:3)):
Rf = 0.35. 1H-NMR (300 MHz, CDCl3) δH = 8.69–8.62 (m, 2H), 8.53 (d, J = 8.4 Hz, 1H), 7.83 (dd, J = 8.4,
1.8 Hz, 1H), 7.77 (ddd, J = 8.0, 2.4, 1.6 Hz, 1H), 7.70 (dd, J = 3.5, 1.8 Hz, 1H), 7.39 (ddd, J = 8.0, 4.8,
0.8 Hz, 1H), 7.30–7.23 (m, 2H), 7.18–7.11 (m, 1H), 3.86 (s, 3H), 2.97 (s, 3H). 13C-NMR (75 MHz, CDCl3)
δC = 156.52 (d, J = 1.8 Hz), 154.85 (d, J = 243.0 Hz), 149.93, 148.39, 140.58 (d, J = 125.3 Hz), 137.76, 136.60,
134.74, 134.53, 133.64, 131.43, 128.62 (d, J = 12.4 Hz), 126.12, 124.28, 123.94, 120.12 (d, J = 16.6 Hz),
118.83 (d, J = 7.9 Hz), 117.01 (d, J = 22.9 Hz), 116.29 (d, J = 2.0 Hz), 113.35 (d, J = 1.9 Hz), 56.18, 12.86.
19F-NMR (282 MHz, CDCl3) δF = −121.71 (td, J = 9.0, 4.0 Hz). HR-MS (ESI+): m/z = 386.1400 (calcd.
386.1412 for C22H17FN5O+ [M + H]+).
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1-(2-Fluoro-5-methoxyphenyl)-3-methyl-8-(pyridin-4-yl)benzo[e]imidazo[5,1-c][1,2,4]triazine (BIT9): According
to General Procedure A, compound 7f (100 mg, 0.294 mmol, 1 eq), BA 9b (61 mg, 0.366 mmol, 1.2 eq),
K2CO3 (103 mg, 0.745 mmol, 2.53 eq), and Pd(PPh3)4 (19 mg, 5 mol%) were reacted in dioxane/water
(5 mL) to give a raw product, which was purified by two-times flash chromatography: CHCl3/MeOH
(10:1) was used first, followed by hexane/ethyl acetate (gradient 1:3→ ethyl acetate, 100%) to obtain
compound BIT9 (44 mg, 39%), as a yellow solid. TLC (hexane/ethyl acetate (1:1)): Rf = 0.29. 1H-NMR
(300 MHz, CDCl3) δH = 8.68–8.65 (m, 2H), 8.53 (d, J = 8.5 Hz, 1H), 7.87 (dd, J = 8.4, 1.8 Hz, 1H), 7.74
(ddd, J = 3.5, 1.9, 0.5 Hz, 1H), 7.33–7.30 (m, 2H), 7.29–7.22 (m, 2H), 7.19–7.13 (m, 1H), 3.87 (s, 3H),
2.96 (s, 3H). 13C-NMR (101 MHz, CDCl3) δC = 156.57 (d, J = 2.0 Hz), 154.85 (d, J = 243.4 Hz), 150.60,
146.38, 141.51, 140.07, 137.81, 137.04, 133.73, 131.46, 125.98, 124.28, 121.65, 120.11 (d, J = 16.6 Hz),
118.86 (d, J = 7.9 Hz), 117.01 (d, J = 22.6 Hz), 116.24 (d, J = 2.0 Hz), 113.67 (d, J = 2.3 Hz), 56.21, 12.87.
19F-NMR (282 MHz, CDCl3) δF = −121.63—121.71 (m). HR-MS (ESI+): m/z = 386.1404 (calcd. 386.1412
for C22H17FN5O+ [M + H]+).
3.3. Biology
3.3.1. In Vitro Evaluation of BIT Derivatives Towards PDEs
The inhibitory potency of BIT derivatives against the human recombinant PDE subtype was
determined in enzyme assays, conducted by SB Drug Discovery (Scotland, U.K.). The phosphodiesterase
assays were performed using recombinant human PDE enzymes expressed in a baculoviral system.
This had similarity to PDE enzymes taken from human tissue using known inhibitor standards
where available. The radiometric assay was a modification of the two-step method of Thompson and
Appleman [45], which was adapted for 96-well plate format.
Firstly, tritium-labeled cyclic AMP or cyclic GMP was hydrolyzed to 5′-AMP or 5′-GMP by
phosphodiesterase. The 5′-AMP or 5′-GMP was then further hydrolyzed to adenosine or guanosine
by nucleotidase in snake venom. An anion-exchange resin bound all charged nucleotides and left
[3H]adenosine or [3H]guanosine as the only labeled compound to be counted by liquid scintillation.
Briefly, 50 μL of diluted human PDE enzyme were incubated with 50 μL of [3H]-cAMP or [3H]-cGMP
and 11 μL of 50% DMSO (or compound dilution) for 20 min (at 30 ◦C). Reactions were carried out
in a Greiner 96-deep well 1-mL master-block. The enzyme was diluted in 20 mM Tris HCl pH 7.4
and [3H]-cAMP or [3H]-cGMP are diluted in 10 mM MgCl2, 40 mM Tris HCl pH 7.4. The reaction is
terminated by denaturing the PDE enzyme (at 70 ◦C for 2 min), after which 25 μL of snake venom
nucleotidase were added and incubated for 10 min (at 30 ◦C). Plates were centrifuged for 9 seconds
before incubation. After incubation, 200 μL of Dowex resin were added, and the plate was shaken for
20 min then centrifuged for 3 min at 2500 r.p.m. Fifty microliters of supernatant were removed and
added to 200 μL of MicroScint-20 in white plates (Greiner 96-well Optiplate) and shaken for 30 min
before reading on a Perkin Elmer TopCount Scintillation Counter.
Compounds were tested at a concentration of 10 nM against human PDE2A3 and at 1 μM for
PDE4A1, PDE5A, PDE6AB, PDE9A1, and PDE10A1. The percentage of inhibition of the compounds
and standard inhibitors was determined and compared to historical assay data to ensure that they fell
within acceptable ranges. For IC50 values’ measurements, BIT1 was tested at concentrations of 0.1,
0.5, 1.0, 5.0, 10.0, and 100 nM, and BIT6 and BIT9 were tested at concentrations of 0.5, 1.0, 5.0, 10.0,
100, and 1000 nM against PDE2A3, while the concentration against PDE10A1 at 0.25, 5.0, 10, 100, 250,
and 1000 nM (n = 2).
Data generated were analyzed using Prism software (GraphPad Inc.).
3.3.2. Incubations with Mouse Liver Microsomes
For microsome experiments, the following instruments were used: BioShake iQ (QUANTIFOIL
Instruments, Jena, Germany), Centrifuge 5424 (Eppendorf, Hamburg, Germany), DB-3D TECHNE Sample
Concentrator (Biostep, Jahnsdorf, Germany), and UltiMate 3000 UHPLC System (Thermo Scientific,
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Germering, Germany) including a DAD detector (DAD-3000RS) coupled to an MSQ Plus Single
Quadrupole Mass Spectrometer (Thermo Scientific, Austin, Texas, USA).
NADPH (Nicotinamide Adenine Dinucleotide Phosphate) and testosterone were purchased from
Sigma-Aldrich (Steinheim, Germany). GIBCO Mouse Liver Microsomes (MLM, 20 mg/mL) were
purchased from Life Technologies (Darmstadt, Germany). Dulbecco’s Phosphate-Buffered Saline (PBS)
(without Ca2+, Mg2+) was purchased from Biochrom (Berlin, Germany).
Incubations had a final volume of 250 μL and were performed in PBS (pH 7.4). BIT1 was freshly
dissolved in DMSO to provide a stock solution of 2 mM that was used for the experiments and resulted
in an amount of DMSO of 1% in each incubation mixture. In the following, final concentrations are
provided in brackets [43]. PBS, MLM (1 mg/mL), and BIT1 (20 μM) were mixed and preincubated at
37 ◦C for 5 min. Analogously, preincubated NADPH (2 mM) was added, and the mixtures were gently
shaken at 37 ◦C. After 90 min, portions of 1.0 mL of cold acetonitrile (−20 ◦C) were added, respectively,
followed by vigorous shaking (30 s), cooling on ice (4 min), and centrifugation at 14,000 rpm (10 min).
Supernatants were concentrated at 50 ◦C under a flow of nitrogen to provide residual volumes of
40–60 μL, which were reconditioned by adding acetonitrile/water 1:1 (v/v) to obtain samples of 100 μL,
which were stored at 4 ◦C until analyzed by HPLC-UV-MS. As a positive control, testosterone was
used as the substrate and incubated at an appropriate concentration, similar to the protocol described
above, to give complete conversion confirmed by HPLC. Furthermore, incubations without NADPH,
microsomal protein, and BIT1, respectively, were performed as negative controls.
HPLC-UV-MS analyses were performed on a ReproSil-Pur 120 C18-AQ-column, 125 mm × 3 mm,
3 μm (Dr. Maisch GmbH, Ammerbuch, Germany) equipped with an appropriate precolumn at 25 ◦C
and a flow rate of 0.7 mL/min. The solvent system consisted of Eluent A: water, containing 2 mM
ammonium acetate, and Eluent B: water/acetonitrile 20/80 (v/v), containing 2 mM ammonium acetate.
Two methods were applied. Method A (gradient elution, % acetonitrile): 0–1.5 min, 10%; 1.5–10 min,
10–80%; 10-13 min, 80%; 13–16 min 10%. Method B (isocratic elution, % acetonitrile): 0–25 min, 42%.
For both methods, UV detection was performed at a wavelength of 228 nm (maximum UV absorbance
of BIT1) and a bandwidth of 20 nm. MSQ Plus single quadrupole mass spectrometer was operated in
positive electrospray ionization mode: probe temperature 500 ◦C, needle voltage 5 V, cone voltage 75 V.
4. Conclusions
A series of novel fluorinated PDE2A inhibitors based on a BIT (benzoimidazotriazine) scaffold
was successfully prepared and evaluated in vitro. The binding results revealed that a modification
with a 2,2-oxetanyl propoxy portion on the phenyl (phe-3) at the 1-position led to a potency loss
towards PDE2A. However, a small methoxy group at the same position (phe-1) led to a significant
increase of potency towards PDE2A. It appeared that a higher inhibition towards PDE2A was
obtained by pyridine-4-yl residues in this position, either fluorinated or non-fluorinated. Furthermore,
the introduction of ortho-fluorophenyl at the 1-position, instead of o-chlorophenyl, showed a lack
of selectivity towards PDE2A. The introduction of the 2-fluoropyridin-4-yl residue at the 8-position
provided us a promising candidate for future labeling with fluorine-18.
In vitro metabolism studies of BIT1 with MLM showed that BIT1 was sufficiently stable and
suitable for the development of an 18F-labeled radioligand. This should further be proven by in vivo
investigations in the future. Taken together, BIT1 might be a prospective ligand to be developed as
a radioligand for PDE2A-PET imaging.
Supplementary Materials: Supplementary Materials including NMR spectra of final compounds BIT1–BIT9,
and dose response curves (BIT1, BIT6, and BIT9) can be accessed at.
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Abstract: A specific radioligand for the imaging of cyclic nucleotide phosphodiesterase 2A
(PDE2A) via positron emission tomography (PET) would be helpful for research on the physiology
and disease-related changes in the expression of this enzyme in the brain. In this report,
the radiosynthesis of a novel PDE2A radioligand and the subsequent biological evaluation were
described. Our prospective compound 1-(2-chloro-5-methoxy phenyl)-8-(2-fluoropyridin-4-yl)-3-
methylbenzo[e]imidazo[5,1-c][1,2,4]triazine, benzoimidazotriazine (BIT1) (IC50 PDE2A = 3.33 nM;
16-fold selectivity over PDE10A) was fluorine-18 labeled via aromatic nucleophilic substitution of
the corresponding nitro precursor using the K[18F]F-K2.2.2-carbonate complex system. The new
radioligand [18F]BIT1 was obtained with a high radiochemical yield (54 ± 2%, n = 3), a high
radiochemical purity (≥99%), and high molar activities (155–175 GBq/μmol, n = 3). In vitro
autoradiography on pig brain cryosections exhibited a heterogeneous spatial distribution of [18F]BIT1
corresponding to the known pattern of expression of PDE2A. The investigation of in vivo metabolism
of [18F]BIT1 in a mouse revealed sufficient metabolic stability. PET studies in mouse exhibited
a moderate brain uptake of [18F]BIT1 with a maximum standardized uptake value of ~0.7 at
5 min p.i. However, in vivo blocking studies revealed a non-target specific binding of [18F]BIT1.
Therefore, further structural modifications are needed to improve target selectivity.
Keywords: cyclic nucleotide phosphodiesterase; PDE2A radioligand; nitro-precursor; fluorine-18;
in vitro autoradiography; PET imaging
1. Introduction
The cyclic nucleotide phosphodiesterases (PDEs) are a superfamily of enzymes catalyzing the
hydrolysis of the intracellular secondary messengers, cyclic adenosine monophosphate (cAMP) and
Molecules 2019, 24, 4149; doi:10.3390/molecules24224149 www.mdpi.com/journal/molecules131
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cyclic guanosine monophosphate (cGMP) [1–3]. These secondary messengers are involved in a great
variety of cellular functions associated with normal and pathophysiological processes in the brain and
periphery [3–6].
The 11 family members of PDEs are encoded by 21 genes and classified by their substrate
specificity [3,7]. PDE 4, 7, and 8 are only cAMP-specific, PDE 5, 6, and 9 are cGMP-specific, and the
remaining PDE 1, 2, 3, 10, and 11 hydrolyze both substrates [3,6,7].
The dual-substrate enzyme PDE2A is abundantly expressed in brain, in particular, in caudate,
nucleus accumbens, cortex, hippocampus [3,8,9], amygdala [10,11], substantia nigra, as well as olfactory
tubercle [11,12], while the expression in the midbrain, hindbrain, and cerebellum is comparatively
low [8,11,12]. This specific distribution indicates a role of PDE2A in the modulation of complex
neuronal processes, such as learning, concentration, memory, emotion, depression, anxiety, and CNS
related disorder [10,13,14]. The pharmacological inhibition of PDE2A has been evaluated in preclinical
studies, thus suggesting PDE2A inhibitors as a potential treatment for neurodegenerative diseases,
such as Alzheimer’s disease, schizophrenia, and dementia [15,16]. PDE2A inhibition has the potential
to prolong the duration of cAMP- and cGMP-dependent signaling pathways, eventually improving
neural plasticity and memory function [3,13,17].
Positron emission tomography (PET) is a molecular imaging modality that enables the visualization,
characterization, and measurement of molecular targets and biochemical processes in living systems [18].
Accordingly, a PDE2A specific radiotracer would allow quantification of PDE2A expression, as well as
disease-related changes thereof.
The so far most developed PDE2A radioligands are shown in Figure 1. The first highly potent
PDE2A compound [18F]B-23 (IC50 hPDE2A = 1 nM; IC50 rPDE10A = 11 nM) was developed by Janssen
Pharmaceutica NV (Beerse, Belgium) [10,19]. Biodistribution and microPET imaging studies in rats
demonstrated high uptake of activity in the striatum; however, brain-penetrating radio-metabolites
limited further evaluation. Pfizer Inc. (New York, NY, USA) also reported on a highly affine PDE2A
radioligand, [18F]PF-05270430 (IC50 hPDE2A = 0.5 nM; IC50 hPDE10A >3000 nM) [10,20], which has
been evaluated in monkeys [20] and translated to clinical trials [21,22]. [18F]PF-05270430 showed
high target-specific accumulation in the putamen, caudate, and nucleus-accumbens, as well as good
metabolic stability and a favorable kinetic profile, pointing out [18F]PF-05270430 as a promising PDE2A
PET ligand [21]. However, using the cerebellum as a reference region, the estimated binding potential
of [18F]PF-05270430 was low, and the authors concluded that further studies are required to validate
the suitability of the cerebellum as a reference region [21].
In parallel to Pfizer, our group developed further PDE2A radioligands on the basis of
pyridoimidazotriazine. The recently published compounds [18F]TA3 (IC50 PDE2A = 11.4 nM; IC50
PDE10A = 318 nM) and [18F]TA4 (IC50 PDE2A = 7.3 nM; IC50 PDE10A = 913 nM) (Figure 1) were
characterized by high potency and selectivity towards PDE2A [24]. Notably, both radiotracers were
found to be suitable radioligands for in vitro imaging of PDE2A; however, in vivo metabolism studies
revealed a high fraction of polar radio-metabolites in the brain limiting their use for in vivo PDE2A
imaging. The latest radioligand out of this series, [18F]TA5 ((IC50 PDE2A = 3.0 nM; IC50 PDE10A >1000
nM, Figure 1), exhibited the highest potency towards PDE2A and selectivity over PDE10A. However,
autoradiographic studies of [18F]TA5 showed a homogenous and non-displaceable binding in rat
and pig brain cryosections, indicating an insufficient specificity of this radioligand [25]. In addition,
[18F]TA5 is degraded extremely fast in the mouse. Therefore, we decided to perform further structural
modifications to develop fluorine-18 labeled PET tracers with improved metabolic stability for the
molecular imaging of PDE2A.
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Figure 1. Selected phosphodiesterase 2A (PDE2A) PET radioligands [10,19,20,23–25].
In our continuous effort to develop fluorine-18 labeled PET tracers dedicated to molecular imaging
of PDE2A, we selected the benzoimidazotriazine (BIT) scaffold (Figure 1) as lead structure by replacing
the pyrido ring of the TA compounds with a benzo ring [26,27]. As a first result, we very recently
reported on the synthesis and inhibitory potency of nine new fluorinated derivatives based on this BIT
scaffold [28]. In order to increase the metabolic stability of the corresponding PDE2A radioligands,
the fluorine was introduced by substituting a fluoropyridine ring at the benzene moiety. Out of this
series, derivative BIT1 (Figure 1) was selected as the most suitable candidate for 18F-labeling and
biological investigation (IC50 PDE2A = 3.33 nM; 16-fold selectivity over PDE10A) [28].
Herein, we reported on the development and the evaluation of [18F]BIT1, including the synthesis
of the corresponding nitro precursor, the manual radiosynthesis, and the transfer to an automated
synthesis module, and the subsequent in vitro and in vivo investigations.
2. Results and Discussion
2.1. Precursor Synthesis and Radiochemistry
2.1.1. Synthesis of the Labeling Precursor 5
The synthesis of the reference compound BIT1 has been reported previously [28]. For an efficient
radiosynthesis of [18F]BIT1, we selected the nitro precursor 5 because of its higher reactivity
to nucleophilic aromatic substitutions in comparison to a bromo-substituted precursor [29,30].
As depicted in Scheme 1, 5 was prepared in four steps starting from the BIT key intermediate
1 [28]. Firstly, Miyaura borylation of 1 with bis(pinacolato)diboron, using potassium acetate and
[Pd(dppf)Cl2] as base and catalyst, afforded the pinacol boronic ester 2 in a satisfactory yield of
85% [31]. By palladium-catalyzed Suzuki coupling with 4-bromo-2-nitropyridine, compound 3 was
obtained in 63% yield. This 4-bromo-2-nitropyridine was synthesized according to a slightly modified
procedure, already described in the literature [32]. Thereafter, the bromination at 1-position of the
imidazole ring using N-bromo-succinimide (NBS) afforded compound 4 in an excellent yield of 97%.
Finally, the subsequent Suzuki coupling with 2-chloro-5-methoxy-phenyl boronic acid gave the nitro
precursor 5 in 68% yield (NMR spectrums of precursor 5 see in the Supplementary Materials).
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Scheme 1. Synthesis of precursor 5. Reagents and conditions: (i) Bis(pinacolato)diboron [Pd(dppf)Cl2],
KOAc, 2-methyltetrahydrofuran (2-MeTHF), 100 ◦C (6 h), 85 ◦C (12 h), 85%; (ii) 4-bromo-2-nitropyridine,
K2CO3, Pd(PPh3)4, 1,2-dimethoxyethane, 63%; (iii) N-bromo-succinimide (NBS), acetonitrile (MeCN),
room temperature (RT), 4–6 h, 97%; (iv) 2-chloro-5-methoxy-phenyl-1-yl-boronic acid, K2CO3,
[Pd(PPh3)4], 1,4-dioxane/H2O (4:1), reflux, 1–2 d, 68%.
2.1.2. Radiosynthesis and Characterization of [18F]BIT1
Manual Radiosynthesis
The new PDE2A radioligand [18F]BIT1 was prepared by heteroaromatic nucleophilic substitution
of 5 using a classical anhydrous K[18F]F-K2.2.2 carbonate complex. The radiolabeling process of
[18F]BIT1 was carried out under thermal heating applying a constant amount of 1.0 mg of precursor
5 by using different (i) polar aprotic solvents dimethylsulfoxide (DMSO), N,N-dimethylformamide
(DMF), and acetonitrile (MeCN), (ii) temperatures, and (iii) reaction times.
As shown in Figure 2, after 5 min (min) reaction time, a radiochemical yield (RCY) of ~57% was
obtained when DMF was used at 150 ◦C. According to radio-TLC, besides [18F]fluoride, three radioactive
by-products were observed, which accounted for 10% of total radioactivity. When the temperature was
reduced to 120 ◦C, an increase of the RCY up to 93% was observed at this early time point. However,
the RCY decreased with increasing the reaction time, indicating a decomposition of [18F]BIT1 under
these conditions. The highest RCY in DMF (~94%) was achieved when the reaction temperature was
further reduced to 100 ◦C. At this temperature, the product remained stable over 20 min reaction
time. By contrast, almost no radiofluorination could be observed when MeCN was used (RCY ≤1%).
With DMSO as a solvent, high RCYs (>85%) were obtained at 150 ◦C and 120 ◦C, which remained
constant up to 20 min reaction time in contrast to the findings with DMF. A further decrease to
100 ◦C resulted in an increase of the RCY (>95%) after 10 min of reaction time. The precursor 5 was
stable throughout the time of analysis, as proven by HPLC (data not shown). Based on these results,
DMSO was selected for the production of [18F]BIT1.
Due to the similarity of the chromatographic behavior of the nitro precursor and the corresponding
18F-radiotracer, the use of a low amount of precursor is beneficial for subsequent isolation of the
radiotracer via semi-preparative HPLC [33,34]. Accordingly, the further reduction of the amount of
the nitro precursor 5 up to 0.5 mg was investigated, achieving an excellent RCY of ≥95% (DMSO,
100 ◦C, 5 min reaction time). The selection of a suitable column for semi-preparative HPLC was also
somewhat crucial in order to have a separation of the radiotracer and its nitro precursor in a reasonable
time [33]. According to our previous experiences [33], a slightly polar C18 phase turned out to be most
appropriate for the isolation of [18F]BIT1 using a mixture of MeCN/water and ammonium acetate as
a buffer.
[18F]BIT1 was successfully isolated under the aforementioned conditions and further purified
by solid-phase extraction (SPE). After formulation in 0.9% saline containing 10% ethanol, [18F]BIT1
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was obtained with an RCY of 38% (decay corrected to the end of the bombardment, EOB), and molar
activities in the range of 38 GBq/μmol (at the end of synthesis, EOS).
Figure 2. The radiochemical yield of [18F]BIT1 depending on reaction time, temperature, and solvent.
(Conditions: K[18F]F-K2.2.2, thermal heating, 1.0 mg of 5). BIT, benzoimidazotriazine.
Automated Radiosynthesis of [18F]BIT1
By using the most appropriate conditions of the manual procedure, the automated radiosynthesis
of [18F]BIT1 (Scheme 2) was established using a TRACERlab FX2 N synthesis module (GE Healthcare,
Waukesha, WI, USA). The detailed configuration is shown in theexperimental part. Briefly, the [18F]F-
was firstly trapped on an anion exchange cartridge and then eluted into the reactor using an aqueous
potassium carbonate solution. The reaction took place with the [18F]F-/K2.2.2./K2CO3 system and
the nitro precursor 5 (0.5 mg) in DMSO at 100 ◦C for 5 min. After the isolation of [18F]BIT1 via
semi-preparative RP-HPLC (Figure 3A), the product was purified via SPE on an RP cartridge and
formulated in sterile isotonic saline containing 10% of EtOH. The total synthesis time of [18F]BIT1 was
approximately 75 min. Analytical radio- and UV-HPLC of the final product, spiked with the non-labeled
reference compound BIT1, confirmed the identity of [18F]BIT1 (Figure 3B). Finally, the radiotracer was
obtained with a radiochemical purity of ≥99%, an RCY of 54 ± 2% (EOB, n = 3), and molar activities in
the range of 155–175 GBq/μmol (EOS, n = 3).
 
Scheme 2. 18F-labeling of [18F]BIT1.
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Figure 3. (A) Semi-preparative radio- and UV-HPLC chromatograms of [18F]BIT1 (conditions:
Reprosil-Pur C18-AQ, 250 × 10 mm, 46% MeCN/20 mM NH4OAcaq., 5.5 mL/min); (B) Analytical
radio- and UV-HPLC chromatograms of the final product of [18F]BIT1 spiked with the non-radioactive
reference BIT1 (conditions: Reprosil-Pur C18-AQ, 250 × 4.6 mm, gradient system with eluent mixture
of MeCN/20 mM NH4OAcaq., 1.0 mL/min).
In vitro Stability and Lipophilicity of [18F]BIT1
The radioligand [18F]BIT1 was stable (radiochemical purity ≥99%) in phosphate-buffered saline
(PBS), pig plasma, n-octanol, as well as in the saline formulation containing 10% ethanol at 40 ◦C for
up to 1 h. The lipophilicity was determined by the shake-flask method in the n-octanol/PBS system.
With a logD7.4 value of 1.81 ± 0.05, [18F]BIT1 falls within the range of radiotracers with optimal
brain passive diffusion [35–37]. However, the calculated coefficient distribution value (ACD/Labs,
Version 12.0, Advanced Chemistry Development, Inc.) displayed value of 4.03. The significant
deviations between the calculation and experimental methods were observed in particular when the
pattern of connectivity and non-bonded intramolecular interactions are not included in the applied
database [38–41]. Moreover, the big discrepancy between the experimental and the calculated logD7.4
value was already observed for our PDE2 tracer [18F]TA5 and has been previously discussed [25]. It is
assumed that the experimentally determined higher hydrophilicity of [18F]TA5 might be due to the
solvation effect related to hydrogen bonding and ionization of the radioligand in the aqueous buffered
system [25,35]. Whereas with the software-based determination, this effect may be underestimated [25].
Therefore, the calculated logD value is often higher than the experimentally determined value [25,35].
Since TA5 and BIT1 are rather structurally similar, we assume the apparent strong discrepancy of logD
for [18F]BIT1 might also be caused by the same reasons as those for [18F]TA5.
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2.2. In Vitro and In Vivo Characterization of [18F]BIT1
2.2.1. In Vitro Autoradiography of [18F]BIT1
To investigate the distribution of binding sites of [18F]BIT1 in the brain, in vitro autoradiographic
studies using cryosections of pig brain were performed. As depicted in Figure 4B, the distribution
pattern of [18F]BIT1 corresponds to the known spatial distribution of PDE2A with a high density of
binding sites in the caudate nucleus (Cd), nucleus accumbens (Acb), cortex (Cx), and hippocampus
(Hip) (Nissl staining of the corresponding slice is shown in Figure 4A). However, [18F]BIT1 also binds
to the non-PDE2A specific regions cerebellum (Cb) and thalamus (Th), indicating binding of [18F]BIT1
to other targets.
Figure 4. In vitro autoradiography of [18F]BIT1 in pig brain slices, (A) Nissl staining, (B) Total binding
of 1.72 nM of [18F]BIT1, (C) Blocking studies (10 μM of TA1), (D) Self-blocking (10 μM of BIT1).
Abbreviations: (Acb: nucleus accumbens; Cb: cerebellum; Cd: nucleus caudatus; Cx: cortex; Hip:
hippocampus; Th: thalamus).
To verify these findings, blocking studies with 10μM of TA1 (a potent PDE2 ligand) [42] (Figure 4C)
and BIT1 (Figure 4D) were performed. The decrease of [18F]BIT1 binding of ~50% and ~30% in PDE2A
specific regions Cd and Acb, respectively, observed for both TA1 and BIT1 indicated in vitro specificity
of the radiotracer. However, the simultaneous decrease of [18F]BIT1 binding in the range of 20–30% in
Cb by TA1, as well as BIT1, suggested further non-specific binding of the radiotracer. We hypothesized
the high non-specific binding of [18F]BIT1 could be related to the moderate selectivity of BIT1 over
PDE10A. Accordingly, these results limited the suitability of [18F]BIT1 for in vitro molecular imaging
of PDE2A.
2.2.2. In Vivo Metabolism of [18F]BIT1
The in vivo metabolism of [18F]BIT1 was investigated in plasma and brain homogenate obtained
from mice at 30 min p.i.. Prior to the analysis with RP-HPLC, the samples were treated with a mixture
of MeCN/H2O (4:1, v/v) to precipitate the proteins. The recovery of radioactivity in plasma and brain
samples was 96% and 99%, respectively. Intact tracer accounted for 43% and 78% of total activity in
plasma and brain, respectively, indicating higher metabolic stability of [18F]BIT1 in comparison to our
previous PDE2A radioligands [18F]TA3, [18F]TA4, and [18F]TA5 [23]. As shown in the chromatograms
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(Figure 5), the two radio-metabolites ([18F]M1 and [18F]M2) found in the brain were also observed in the
corresponding plasma sample, indicating their ability to penetrate the blood-brain barrier. For further
clarification, samples obtained as previously described in our in vitro metabolism study with BIT1
using mouse liver microsomes [28] were investigated similarly by HPLC, but with UV detection
(Figure 5C). On the basis of the in vitro metabolites M1 and M2, both elucidated by LC-MS in the
mentioned study, we can conclude about the brain penetrating radio-metabolites [18F]M1 and [18F]M2
as products of N-oxidation or C-hydroxylation. Besides, some of the more polar radio-metabolites
detected in plasma could only tentatively be assigned as formed by mono-oxygenation, di-oxygenation,
reduction, and demethylation, but were not investigated further.
Figure 5. Representative analytical HPLC chromatogram: (A) plasma and (B) brain samples at 30 min
p.i of [18F]BIT1 in a CD-1 mouse; (C) sample from incubation of BIT1 with mouse liver microsomes
(MLM) in the presence of NADPH for 90 min at 37 ◦C (UV detection: 228 nm; axis of retention time
was adjusted). Conditions: isocratic system, column: Reprosil-Pur C18-AQ, 250 × 4.6 mm; eluent: 42%
MeCN in 20 mM NH4OAcaq., flow: 1.0 mL/min.
2.3. In Vivo PET-MRI Studies of [18F]BIT1
Dynamic PET-MRI studies were performed in female CD-1 mice after intravenous administration
of [18F]BIT1. As reflected by the time-activity curves (TACs) shown in Figure 6, the radioactivity
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uptake in the whole brain, striatum, and cerebellum reached standardized uptake values (SUVs) of
about 0.7 at 5 min p.i., indicating blood-brain barrier penetration. Since there is no difference in the
TACs between the whole brain, striatum, and cerebellum, [18F]BIT1 is assumed to possess low specific
binding also in vivo.
Figure 6. Averaged time-activity curves of [18F]BIT1 in CD-1 mice (n = 2) with standard uptake values
(SUV) in the whole brain, striatum, and cerebellum.
To further investigate this hypothesis, blocking studies were performed by concomitant injection
of TA1 and [18F]BIT1. However, since no significant reduction of radioactivity uptake in the
PDE2A-specific region striatum was detectable (data not shown), the high non-specific binding
of [18F]BIT1 already observed in vitro was confirmed.
Overall, the herein reported potential PDE2A radioligand, selected from a new class of
8-pyridinyl-BIT compounds, demonstrated sufficient blood-brain barrier (BBB) permeability. However,
[18F]BIT1 was found to be insufficient for in vivo imaging of PDE2A with PET. Further structural
modifications are needed to obtain PDE2A selective radioligands for in vitro and in vivo research.
Extensive structure-activity relationship (SAR) studies could lead to the improvement of the selectivity
and specificity of compounds. In particular, modifications of the set substituents at 1- and 8-positions
of the BIT scaffold might result in additive as well as nonadditive effects in compound potency [43].
3. Materials and Methods
3.1. General Methods
All chemicals were purchased from commercial sources and used without further purification.
Solvents were dried before used if required. Air and moisture-sensitive reactions were carried
out under argon atmosphere. Room temperature (RT) refers to 20–25 ◦C. Reaction mixtures were
monitored by thin-layer chromatography (TLC) using pre-coated TLC-plates POLYGRAM® SIL
G/UV254 (Macherey-Nagel GmbH & Co. KG, Düren, Germany). The spots were detected under
UV light at λ 254 nm and 365 nm. For the purification of final products, flash chromatography was
performed with silica gel 40–63 μm (Merck KGaA, Darmstadt, Germany). Radio-TLC was performed
on Polygram SIL G/UV254 plates (Macherey-Nagel GmbH & Co. KG, Düren, Germany) pre-coated
plates with a mixture of chloroform/methanol (10:1, v/v) as eluent. The radio-TLC plates were exposed
to storage phosphor screens (BAS-IP MS 2025, FUJIFILM Co., Tokyo, Japan) and recorded using the
AmershamTyphoon RGB Biomolecular Imager (GE Healthcare Life Sciences, Freiburg, Germany),
and the images were quantified with ImageQuant TL8.1 software (GE Healthcare Life Sciences,
Freiburg, Germany).
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NMR spectra (1H and 13C) were recorded on Mercury 300/Mercury 400 (Varian, Palo Alto, CA,
USA) or Fourier 300/Avance DRX 400 Bruker (Billerica, MA, USA) instruments. Residual solvent proton
(1H) and carbon (13C) resonances were used as internal standards for 1H-NMR (CDCl3, δH = 7.26;
DMSO-d6, δH = 2.50) and 13C-NMR (CDCl3, δC = 77.16; DMSO-d6, δC = 39.52). The chemical shifts (δ)
were reported in ppm as follows: s, singlet; d, doublet; t, triplet; m, multiplet, and the coupling constants
(J) are reported in Hz. Mass spectra were recorded on an ESQUIRE 3000 Plus (ESI, low resolution) and
a 7 T APEX II (ESI, high resolution) (Bruker Daltonics, Bruker Corporation, Billerica, MA, USA).
For semi-preparative HPLC, the following conditions were used. Column: Reprosil-Pur C18-AQ,
250 × 10 mm, particle size: 10 μm; eluent: 46% MeCN/20 mM NH4OAcaq.; flow: 5.5 mL/min;
ambient temperature; UV detection at 254 nm. The semi-preparative HPLC separations in the manual
radiosynthesis were performed on a JASCO LC-2000 system, using a PU-2080-20 pump, an UV/VIS-2075
detector coupled with a radioactivity HPLC flow monitor (Gabi Star, raytest Isotopenmessgeräte
GmbH, Straubenhardt, Germany) and a fraction collector (Advantec CHF-122SC, Dublin, CA, USA).
Data recording was performed with the Galaxie chromatography software (Agilent Technologies,
Santa Clara, USA).
Analytical chromatographic separations were performed on a JASCO LC-2000 system,
incorporating a PU-2080Plus pump, AS-2055Plus auto-injector (100 μL sample loop), and a UV-2070 Plus
detector coupled with a gamma radioactivity HPLC detector (Gabi Star, raytest Isotopenmessgeräte
GmbH, Straubenhardt, Germany). Data analysis was performed with the Galaxie chromatography
software (Agilent Technologies, Santa Clara, USA) using the chromatogram obtained at 254 nm.
A Reprosil-Pur C18-AQ column (250× 4.6 mm; 5 μm; Dr. Maisch HPLC GmbH, Ammerbuch-Entringen,
Germany) with MeCN/20 mM NH4OAcaq. (pH 6.8) as eluent mixture and a flow of 1.0 mL/min was
used (gradient: eluent A 10% MeCN/20 mM NH4OAcaq.; eluent B 90% MeCN/20 mM NH4OAcaq.;
0–10 min 100% A, 10–40 min up to 100% B, 40–45 min 100% B, 45–50 min up to 100% A, 50–60 min
100% A; isocratic system 42% MeCN/20 mM NH4OAcaq.; flow: 1.0 mL/min; ambient temperature).
The molar activities were determined on the basis of a calibration curve (0.1–6 μg of BIT1)
performed under isocratic HPLC conditions (46% MeCN/20 mM NH4OAcaq.) using chromatograms
obtained at 228 nm as the maximum of UV absorbance of compound BIT1.
No-carrier-added (n.c.a.) [18F]fluoride (t1/2 = 109.8 min) was produced by irradiation of [18O]H2O
(Hyox 18 enriched water, Rotem Industries Ltd., Arava, Israel) via [18O(p,n)18F] nuclear reaction by
irradiation of on a Cyclone®18/9 (iba RadioPharma Solutions, Louvain-la-Neuve, Belgium).
Remote-controlled automated syntheses were performed using a TRACERlab FX2 N synthesizer
(GE Healthcare, USA) equipped with a N810.3FT.18 pump (KNF Neuburger GmbH, Freiburg, Germany),
a BlueShadow UV detector 10D (KNAUER GmbH, Berlin, Germany), NaI(Tl)- counter, and the
TRACERlab FX Software.
3.2. Precursor Synthesis and Radiochemistry
The final compounds described in this manuscript meet the purity requirement (>95%) determined
by UV-HPLC.
3.2.1. Synthesis of Precursor
3-Methyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[e]imidazo[5,1-c][1,2,4]triazine (2)
A mixture of bromo derivative 1 [28] (1.32 g, 5 mmol), potassium acetate (1.1 g, 11.2 mmol),
and bis(pinacolato)diboron (1.3 g, 5.11 mmol) in 2-MeTHF (20 mL) was degassed with argon for 10 min.
After the addition of Pd(dppf)Cl2 (0.055 g, 0.075 mmol), the mixture was refluxed at 100 ◦C for 6 h and
at 85 ◦C for 12 h. Upon completion of the reaction (monitored by TLC), CH2Cl2 (25 mL) was added,
and the reaction mixture was stirred for 1 h. The solid was filtered off, and the filtrate was evaporated.
The dark brown semi-solid residue (2.5 g) was dissolved in MTBE (60 mL) and filtered through a
short silica gel column (H: 3 cm × D: 2 cm). Heptane (30 mL) was added to the eluate, followed by
concentration to a volume of approximately 20 mL. The precipitated solid was filtered and dissolved
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in MTBE (120 mL), and the solution obtained was filtered again through a short silica gel column (H:
2 cm × D: 2 cm). The yellow eluate was concentrated (→ ~15 mL) and treated with n-heptane (30 mL).
The solid obtained was filtered and dried under reduced pressure to afford a yellow solid 2 (1.32 g,
85%). TLC [CHCl3/MeCN (10:1)]: Rf = 0.26 (strong tailing). 1H NMR (400 MHz, CDCl3) δH = 8.57
(s, 1H), 8.41 (d, J = 8.0 Hz, 1H), 8.25 (s, 1H), 8.05 (dd, J = 8.0, 1.1 Hz, 1H), 2.89 (s, 3H), 1.40 (s, 13H).
3-Methyl-8-(2-nitropyridin-4-5 yl)benzo[e]imidazo[5,1-c][1,2,4]triazine (3)
A mixture of boronic ester 2 (470 mg, 1.5 mmol, 1 eq) and 4-bromo-2-nitropyridine (243 mg,
1.2 mmol) in 1,2-dimethoxyethane (6 mL) and an aqueous solution of K2CO3 (2 M, 1.75 mL, 3.5 mmol)
was degassed with argon for 20 min. Pd(PPh3)4 (50 mg, 0.043 mmol) was added, and the reaction
mixture was heated at 95 ◦C for 1 h and 88 ◦C for 14 h. Upon full conversion of starting material
(monitored by TLC), the solvent was evaporated, and the residue was partitioned between water
(30 mL) and CHCl3 (50 mL). After separation of the organic layer, the aqueous layer was extracted
with CHCl3/MeCN (8:1, 6 × 30) and CHCl3 (5 × 30 mL). The combined organic layers were dried over
Na2CO3, and the solvent was evaporated to leave a solid residue (370 mg). The residue was refluxed
in MeCN (50 mL) for 5 min, and after cooling to 0–2 ◦C, the product was filtered and dried to give 3 as
yellow solid (233 mg, 63%). TLC [CHCl3/MeOH/30% NH3 (10:1:0.1)]: Rf = 0.35. 1H NMR (300 MHz,
DMSO-d6) δH = 9.26 (s, 1H), 8.96 (dd, J = 2.0, 0.5 Hz, 1H), 8.85 (dt, J = 5.1, 0.8 Hz, 1H), 8.82–8.80
(m, 1H), 8.52 (dd, J = 8.7, 1.5 Hz, 1H), 8.42 (dd, J = 5.1, 1.7 Hz, 1H), 8.28 (dd, J = 8.5, 2.0 Hz, 1H), 2.78
(d, J = 1.7 Hz, 3H). 13C NMR (75 MHz, DMSO-d6) δC = 157.67, 149.59, 149.28, 138.82, 138.14, 136.18,
135.67, 130.31, 127.22, 127.17, 126.02, 122.45, 115.55, 114.35, 12.18.
1-Brom-3-methyl-8-(2-nitropyridin-4-yl)benzo[e]imidazo[5,1-c][1,2,4]triazine (4)
N-Bromosuccinimide (NBS) (48 mg, 1.58 eq) was added to a suspension of compound 3 (52 mg,
1 eq) in 2.5 mL MeCN. The reaction mixture was protected from light and stirred at RT for 1–2 d.
After the complete conversion of starting material (monitored by TLC), the mixture was partitioned
between CHCl3 (15 mL) and water (15 mL). The organic layer was washed with aqueous NaHCO3
(5%, 15 mL) and Na2SO3 (5%, 15 mL). The aqueous layer was extracted again with CHCl3 (4x5 mL).
The combined organic layers were dried (Na2SO4) and evaporated. The crude product was purified by
column chromatography (CHCl3/MeOH, 20:1) to afford compound 4 as a yellow solid (64 mg, 97%).
TLC [CHCl3/MeOH (20:1)]: Rf = 0.59. 1H NMR (400 MHz, CDCl3) δH = 9.31 (d, J = 1.8 Hz, 1H), 8.84 (d,
J = 5.0 Hz, 1H), 8.65 (d, J = 8.4 Hz, 1H), 8.59 (d, J = 1.6 Hz, 1H), 8.04–7.98 (m, 2H), 2.90 (s, 3H).
1-(2-Chloro-5-methoxyphenyl)-3-methyl-8-(2-nitropyridin-4-yl)benzo[e]imidazo[5,1-c][1,2,4]triazine (5)
Brominated compound 4 (43 mg, 0.112 mmol, 1 eq), 2-chloro-5-methoxyphenyl boronic acid
(27 mg, 0.145 mmol, 1.29 eq), and K2CO3 (44 mg, 0.318 mmol, 2.8 eq) were combined in a mixture
of 1,4-dioxane and H2O (4:1). Under argon atmosphere, [Pd(PPh3)4] (13 mg, 10 mol%) was added.
After refluxing at 101–105
◦
C for 3 h, the reaction mixture was stirred at RT for 16 h. Afterward, the
residue was partitioned between CHCl3 (20 mL) and water (20 mL). The organic layer was washed
with water (20 mL) and brine (20 mL). The aqueous layer was extracted with CHCl3 (3 × 10 mL),
and the combined organic layers were dried over Na2SO4, and the solvent was evaporated under
reduced pressure. The crude product was purified by column chromatography using a gradient system
(n-hexane/ethyl acetate from 1:1 to 1:3) to get the corresponding precursor 5 as a yellow solid (34 mg,
68%). TLC [n-hexane/ethyl acetate (1:2)]: Rf = 0.38. 1H NMR (400 MHz, CDCl3) δH = 8.71 (dd, J = 5.0,
0.6 Hz, 1H), 8.60 (d, J = 8.4 Hz, 1H), 8.15 (dd, J = 1.6, 0.6 Hz, 1H), 7.95 (dd, J = 8.4, 1.9 Hz, 1H), 7.77
(dd, J = 5.0, 1.6 Hz, 1H), 7.67–7.64 (m, 1H), 7.58 (d, J = 1.9 Hz, 1H), 7.24–7.20 (m, 2H), 3.87 (s, 3H), 3.00
(s, 3H). 13C NMR (101 MHz, CDCl3) δC = 159.24, 157.85, 150.52, 149.96, 140.32, 138.66, 137.53, 137.22,
136.47, 131.76, 131.27, 131.11, 126.50, 125.79, 125.61, 124.31, 118.59, 117.99, 115.77, 114.21, 56.06, 12.94.
ESI (+): m/z = 447.10 (calcd. 447.10 for C22H16ClN6O3+ [M + H]+).
3.2.2. In Vitro Metabolism of BIT1
BIT1 was incubated with mouse liver microsomes in the presence of NADPH, including positive
and negative controls, for 90 min at 37 ◦C, as previously described [28]. Obtained samples were
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investigated by analytical HPLC with an isocratic system (42% MeCN/20 mM NH4OAcaq; flow rate of
1.0 mL/min) and UV detection (228 nm).
3.2.3. Radiochemistry
Manual Radiosynthesis
No carrier added [18F]fluoride in 1.5 mL water and was trapped on a Chromafix® 30 PS-HCO3−
cartridge (Macherey-Nagel GmbH & Co. KG, Düren, Germany). The activity was eluted with 300 μL
of an aqueous solution of potassium carbonate solution (K2CO3, 1.8 mg, 13 μmol) into a 4 mL V-vial,
and Kryptofix2.2.2. (K2.2.2) (11 mg, 29 μmol) in 1.0 mL MeCN was added. The aqueous [18F]fluoride was
azeotropically dried under vacuum and nitrogen flow within 7–10 min using a single-mode microwave
(75 W, at 50–60 ◦C, power cycling mode). Two aliquots of MeCN (2 × 1.0 mL) were added during
the drying procedure, and the final complex was dissolved in 500 μL of solvent (DMSO, DMF, and
MeCN) ready for labeling. Thereafter, 0.5–1.0 mg of precursor in 500 μL labeling solvent was added,
and the 18F-labeling was performed at different temperatures (100 ◦C, 120 ◦C, and 150 ◦C). To analyze
the reaction mixture and to determine radiochemical yields, samples were taken for radio-HPLC and
radio-TLC at different time points (5, 10, 15, and 20 min).
After cooling to <30 ◦C, the reaction mixture was diluted with 1.0 mL water and 2.0 mL of
MeCN/H2O (1:1) and directly applied to an isocratic semi-preparative RP-HPLC for isolation of
[18F]BIT1 (46% MeCN/20 mM NH4OAcaq., 5.5 mL/min, Reprosil-Pur C18-AQ column, 250 × 10 mm;
10 μm; Dr. Maisch HPLC GmbH, Ammerbuch-Entringen, Germany). The collected radiotracer fraction
was diluted with 35 mL water to perform purification by sorption on a Sep-Pak® C18 light cartridge
(Waters, Milford, MA, USA) and successive elution with 0.75 mL of ethanol.
Automated Radiosynthesis of [18F]BIT1
The automated radiosynthesis was performed in a TRACERlab FX2 N synthesis module (GE
Healthcare, Waukesha, WI, USA). About 2–4.5 GBq of aqueous n.c.a [18F]fluoride was trapped on a
Chromafix® 30 PS-HCO3- cartridge (Figure 7, Macherey-Nagel GmbH & Co. KG, Düren, Germany,
entry 1) and eluted with K2CO3 (1.8 mg, 13 μmol, entry 2) in 400 μL water. Kryptofix K2.2.2 (11 mg,
29 μmol, in 1.0 mL MeCN, entry 3) was directly added. Afterward, azeotropic drying was performed at
60 ◦C and 85 ◦C under a vacuum. Thereafter, 0.5 mg of 5 in 1.0 mL DMSO (entry 4) was transferred to
the reactor, and subsequently, the reaction was performed at 100 ◦C for 5 min. After cooling the reactor
to 30 ◦C, 1.0 mL of H2O and 2.0 mL of MeCN/H2O (1:1) (entry 5) were added and transferred into the
injection vial (entry 6). The semi-preparative HPLC was performed using a Reprosil-Pur C-18 AQ
column (250 × 10 mm; 10 μM) using 46% MeCN in aqueous 20 mM ammonium acetate at a flow rate
of 5.5 mL/min (entry 7). The [18F]BIT1 fraction was pooled in 35 mL H2O (entry 8) and then loaded on
a preconditioned Sep-Pak® C18 light cartridge (Waters, Milford, MA, USA, entry 9), and washed with
2.0 mL of H2O (entry 10). Afterward, the trapped [18F]BIT1 was eluted with 1.2 mL EtOH (entry 11)
into the product vial (entry 12). The product was transferred out of the hot cell, and the solvent was
reduced under a gentle argon stream at 70 ◦C to a final volume of 10–50 μL. Afterward, the radiotracer
was diluted in isotonic saline to obtain a final product containing 10% of EtOH (v/v). The identity of
the final product was confirmed using radioanalytical HPLC.
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Figure 7. Scheme of the synthesis module TRACERlab FX2 N for the radiosynthesis of [18F]BIT1.
(1) Chromafix® 30 PS-HCO3−, (2) K2CO3 (1.8 mg in 400 μL water), (3) K2.2.2. (11 mg, 29 μmol in 1.0
mL MeCN), (4) precursor (0.5 mg of 5 in 1.0 mL DMSO), (5) 1.0 mL H2O and 2.0 mL MeCN/H2O (1:1),
(6) injection vial, (7) Reprosil-Pur C18-AQ column (46% MeCN/20mM NH4OAcaq., flow 5.5 mL/min),
(8) 35 mL water, (9) Sep-Pak® C18 light, (10) 2.0 mL water, (11) 1.2 mL EtOH, (12) product vial.
The molar activity of [18F]BIT1 was determined by analytical HPLC (isocratic mode: 46%
MeCN/20 5mM NH4OAcaq., Reprosil-Pur C18-AQ column 250 × 4.6 mm, flow rate: 1.0 mL/min). The
UV/Vis detection was carried out at 228 nm as the absorption maximum of BIT1.
Determination of Stability
In vitro stability of [18F]BIT1 was investigated by incubation of the radioligand in
phosphate-buffered saline (PBS, pH 7.4), n-octanol, and pig plasma at 40 ◦C for 60 min (~5 MBq of the
radioligand was added to 500 μL of each medium). Samples were taken at 30 and 60 min and analyzed
by radio-TLC and radio-HPLC.
Determination of log D
The lipophilicity of [18F]BIT1 was determined by partitioning between n-octanol and
phosphate-buffered saline (PBS, pH 7.4) at ambient temperature using the conventional shake-flask
method. An aliquot of 10 μL of the formulated solution containing ~500 kBq of [18F]BIT1 was added
to a tube containing 6 mL of the n-octanol/PBS-mixture (1:1, v/v, four-fold determination). The tubes
were shaken for 20 min using a mechanical shaker (HS250 basic, IKA Labortechnik GmbH & Co. KG,
Staufen, Germany) followed by centrifugation (5000 rpm for 5 min) and separation of the phases.
Aliquots of 1 mL of the organic and the aqueous phase were taken, and the activity was measured using
an automated gamma counter (1480 WIZARD, Fa. Perkin Elmer, Waltham, MA, USA). The distribution
coefficient (D) was calculated as [activity (cpm/mL) in n-octanol]/[(activity (cpm/mL) in PBS], specified
as the decadic logarithm (logD).
3.3. Animal Studies
All experimental work, including animals, was conducted in accordance with the
national legislation on the use of animals for research (Tierschutzgesetz (TierSchG), Tierschutz-
Versuchstierverordnung (TierSchVersV)) and was approved by the responsible research ethics committee
(TVV 18/18, DD24.1-5131/446/19, Landesdirektion Sachsen, 20th June 2018). Female CD-1 mice,
10–12 weeks, were obtained from the Medizinisch-Experimentelles Zentrum at Universität Leipzig.
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For the time of the experiments, the animals were kept in a dedicated climatic chamber with free access
to water and food under a 12:12 h dark:light cycle at a constant temperature of 24 ◦C. Piglet brains
were obtained from anesthetized and euthanized juvenile female German landrace pigs (Lehr- und
Versuchsgut Oberholz, Universität Leipzig).
3.3.1. In Vitro Autoradiography of [18F]BIT1
Pig brain cryosections (16 μm; Microm HM560 Cryostat, FischerScientific GmbH, Schwerte,
Germany) were thawed, dried in a stream of cold air, and preincubated for 10 min with buffer (50 mM
TRIS-HCl, pH 7.4, 120 mM NaCl, 5 mM KCl, 2 mM MgCl2) at room temperature. Afterward, brain
sections were incubated with 1.72 nM of [18F]BIT1 in the buffer for 60 min at room temperature.
The sections were then washed twice with ice-cold 50 mM TRIS-HCl (pH 7.4), dipped in ice-cold
deionized water, dried in a stream of cold air, and exposed for 60 min to an image plate. The analysis
was performed using an image plate scanner (HD-CR 35; Duerr NDT GmbH, Bietigheim Bissingen,
Germany). Non-specific binding was determined using 10 μM TA1 and BIT1 as blocking compounds.
3.3.2. In Vivo Metabolism of [18F]BIT1
[18F]BIT1 (~19 MBq) was injected in female CD-1 mice (10–12 weeks old) via the tail vein. Brain
and blood samples were obtained at 30 min p.i., plasma separated by centrifugation (14,000 rpm,
1 min), and brain homogenized in ~1 mL isotonic saline on ice (10 strokes of a PTFE plunge at 1000 rpm)
in borosilicate glass.
Protein precipitation of plasma and brain samples was performed in duplicate with ice-cold
MeCN/H2O (8:2, v/v), which was added to the samples (sample/solvent, 1:4, v/v). The samples were
vortexed for 1 min, followed by resting on ice for 10 min. Afterward, the samples were centrifuged for
5 min at 10,000 g. Supernatants were collected, and 100 μL ice-cold MeCN/H2O (8:2, v/v) was added to
the pellets for the second extraction, applying the same treatment as before. The combined supernatants
were concentrated at 70 ◦C under nitrogen stream until a remaining volume of 100 μL and subsequently
quantified by analytical radio-HPLC with an isocratic system (42% MeCN/20 mM NH4OAcaq.; flow
rate: 1.0 mL/min). The activity recovery was determined by measuring the radioactivity of aliquots
taken from supernatants and the pellets using a gamma counter.
3.4. PET-MRI Studies of [18F]BIT1
PET/MRI scans were performed using a preclinical PET/MRI system (nanoScan, Mediso Medical
Imaging Systems, Budapest, Hungary). Animals were anesthetized with a mixture of air/isoflurane
(2.0%, 200 mL/min) (Anesthesia Unit U-410, agntho’s, Lidingö, Sweden), and their body temperature
maintained at 37 ◦C with a thermal bed system. [18F]BIT1 (2 MBq, Am: 155 GBq/μmol, EOS) was
injected via the tail vein, either without (baseline study, n = 2) or with TA1 (2 mg/kg, DMSO/NaCl
(1:25); blocking study, n = 2). A dynamic 60-min PET scan was started 20 sec before radioligand
injection. The list-mode data were reconstructed into 33 frames (12 × 10 sec, 6 × 30 sec, 5 × 1 min,
10 × 5 min) with 3D-ordered subset expectation maximization, 4 iterations, and 6 subsets, using an
energy window of 400 to 600 KeV and coincidence mode of 1–5. After the PET scan, an MRI scan was
performed for anatomical orientation and attenuation correction on a 1T magnet using a T1-weighted
gradient-echo sequence (TR = 15 ms, TE = 2.6 ms). The data analysis was done with PMOD (PMOD
Technologies Ltd., Zurich, Switzerland, v. 3.6), and an atlas-based method was used to obtain SUV
time-activity curves for the striatum, cerebellum, and the whole brain.
4. Conclusions
In our efforts to develop a specific radioligand for PET imaging of PDE2A in the brain on the basis
of a benzoimidazotriazine scaffold, we successfully prepared the novel PDE2A radioligand [18F]BIT1
with a high radiochemical yield, radiochemical purity, as well as molar activity. Our findings showed
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that this class of compound demonstrated good brain penetration and sufficient in vivo metabolic
stability. However, [18F]BIT1 was not suitable for the molecular imaging of PDE2A in the brain because
of a high non-specific binding. Further structural modifications are required to obtain more satisfactory
PDE2A specific radioligands.
Supplementary Materials: The following are available online, Figures S1–S2: NMR spectra of precursor 5 (1H
and 13C), Figure S3. The calibration curve of molar activity of reference BIT1.
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Abstract: The discovery of endogenous peptide ligands for morphine binding sites occurred in
parallel with the identification of three subclasses of opioid receptor (OR), traditionally designated as
μ, δ, and κ, along with the more recently defined opioid-receptor-like (ORL1) receptor. Early efforts
in opioid receptor radiochemistry focused on the structure of the prototype agonist ligand, morphine,
although N-[methyl-11C]morphine, -codeine and -heroin did not show significant binding in vivo.
[11C]Diprenorphine ([11C]DPN), an orvinol type, non-selective OR antagonist ligand, was among the
first successful PET tracers for molecular brain imaging, but has been largely supplanted in research
studies by the μ-preferring agonist [11C]carfentanil ([11C]Caf). These two tracers have the property
of being displaceable by endogenous opioid peptides in living brain, thus potentially serving in a
competition-binding model. Indeed, many clinical PET studies with [11C]DPN or [11C]Caf affirm the
release of endogenous opioids in response to painful stimuli. Numerous other PET studies implicate
μ-OR signaling in aspects of human personality and vulnerability to drug dependence, but there have
been very few clinical PET studies of μORs in neurological disorders. Tracers based on naltrindole, a
non-peptide antagonist of the δ-preferring endogenous opioid enkephalin, have been used in PET
studies of δORs, and [11C]GR103545 is validated for studies of κORs. Structures such as [11C]NOP-1A
show selective binding at ORL-1 receptors in living brain. However, there is scant documentation of
δ-, κ-, or ORL1 receptors in healthy human brain or in neurological and psychiatric disorders; here,
clinical PET research must catch up with recent progress in radiopharmaceutical chemistry.
Keywords: opioid receptors; positron emission tomography; radiotracers; μOR-, δOR-, κOR- and
ORL1-ligands; epilepsy; movement disorders; pain; drug dependence
1. Introduction
The analgesic and soporific properties of opium have been known since antiquity, perhaps first
attested in the detached reveries of Homer’s Lotophagi. The sinister side of opium dreams is depicted
in Tennyson’s version of that story, and more distinctly in the memoires of Thomas de Quincy, who
may have had the distinction of establishing a genre of literature, the addiction diary. A key active
constituent of the sap of Papaver somniferum was first isolated in 1804 by the apothecary Friedrich
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Wilhelm Sertürner, who named it morphium, later morphine (1). Chemists identified its elemental
composition in the 19th century, and efforts to determine its structure were rewarded in 1925, when
Gulland and Robinson [1] recommended a structure consistent with the characteristics of morphine
and codeine and their degradation products. Subsequent investigations confirmed the correctness
of the analytically deduced structure of morphine, culminating in its total synthesis, achieved in the
1950s by Gates and Tschudi [2,3]. The absolute stereochemistry of morphine’s five chiral carbons (5, 6,
9, 13 and 14) was reported by Bentley and Cardwell [4] in 1955, and the first practically realizable
morphine total synthesis with reasonable yields was reported by Rice in 1980 [5]. To this day, it is more
economical to allow the poppy plant to do the main work of morphine (1) synthesis, although chemists
have since produced so many structural variants that one might consider opioid pharmacology to be a
discipline in its own right. There have been several reviews of opioid receptor imaging in the past
decade [6–8], but we now present a comprehensive update on the the main classes of opioid receptor
(OR) ligands used for positron emission tomography (PET), and review clinical findings with this
technology. Relevant chemical structures of endogenous opioid peptides and representative small
























































































Figure 1. Chemical structures of endogenous opioid peptides and selected opioid receptor ligands.
The modern era of opioid pharmacology began with the identification of an opioid binding
site in brain tissue in studies with tritiated naloxone [9]. Soon thereafter, opioid peptides were
isolated from pig brain [10], which famously involved whisky as an emolument for the slaughterhouse
workers. The pentapeptides Met5-enkephalin (2) and Leu5-enkephalin (3) both had morphine-like
effects in inhibiting the electrically stimulated contraction of the vas deferens, with the latter compound
being somewhat less potent. The enkephalins were most abundant in striatum and hypothalamus
of rat, guinea pig and calf, and Met5-enkephalin (2) was generally 3–6 times more abundant than
Leu5-enkephalin (3) [11,12]. An additional higher molecular weight opioid (β-endorphin) isolated and
sequenced from camel pituitary extracts proved to be a 31 amino acid polypeptide possessing homology
with Met5-enkephalin (2) [13]. A trypsin-sensitive opioid activity (dynorphin-A) isolated from pituitary
is a 17 amino acid polypeptide possessing N-terminal homology with Leu5-enkephalin (3), with the
shorter peptide dynorphin-B [1-13] having almost 1000-fold higher potency than Leu5-enkephalin (3) in
the guinea pig ileum muscle preparation [14]. Soon after these discoveries, bovine DNA sequences were
cloned for the β-endorphin precursor corticotropin-β-lipotropin [15], the Met5/Leu5-enkephalin (2, 3)
precursor preproenkephalin-A [16] (which proved to contain four copies of Met5-enkephalin (2) and
one copy of Leu5-enkephalin (3), consistent with the ratio of their tissue concentrations), and the closely
related preproenkephalin-B [17]. Other researchers cloned porcine preprodynorphin, the precursor for
dynorphin A [1-17], dynorphin-A [1-8], dynorphin B [1-13], and other opioid peptides [18].
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It was soon apparent that the endogenous opioid peptides bound to at least three distinct sites
in the brain and peripheral tissues, known as μ-, δ-, and κORs. For a time, the orphaned σ receptors
were thought to comprise another type of OR [20], due to the analgesic (and hallucinogenic) action
of pentazocine at κORs in brain. However, binding of σOR ligands is not displacable by the opioid
antagonist naloxone, nor do σORs bind opioid peptides with high affinity, such that the σ- receptor
is now recognized as a pharmacological class in its own right. The μOR gene has at least 14 exons
that can give rise to diverse splice variants, and at least three pharmacologically distinct subtypes are
recognized: μ1, μ2 and μ3. Displacement studies in vitro and in vivo with the μ-selective competitive
antagonist cyprodime (6) and the μ1-specific competitor naloxonazine (7) showed that [11C]carfentanil
([11C]Caf, 8) binds predominantly to the μ1 subtype [21]. The μ3 subtype is alkaloid sensitive and
opioid peptide insensitive; it couples to nitric oxide generation, and, extraordinarily, its endogenous
agonist in amygdala seems to be morphine (1) [22]. There is also an opioid receptor-like receptor
1 (ORL1), which is activated by the 17 amino acid polypeptide known as nociceptin/ orphanin FQ
(N/OFQ) [23].
Opioid signaling has an important function in the modulation of pain processing at the spinal
level. ORs synthetized in the dorsal root ganglion are transported to peripheral nerve endings and to
the superficial layers of the spinal cord dorsal horn. In the dorsal horn, μORs are the most densely
expressed subtype, followed by δ-, and κORs. Over 70% of the ORs there are located on the central
terminals of small-diameter (mostly C and A-delta fibres) primary afferent neurons. A main mechanism
of opioid analgesia lies in the activation of presynaptic μORs in the spinal cord, leading to decreased
release of excitatory transmitters and nociceptive transmission. Unforunately, PET methods do not
suffice for detecting ORs in the human spinal cord.
Figure 2 shows PET images of the distributions in human telencephalon of binding sites for the four
main classes of ORs, μ, δ, κ, and ORL1. The pattern of μORs in Figure 2A encompasses the telencephalic
pain pathway of limbic brain regions. Supraspinal μORs in the nucleus accumbens and amygdala
have a role in the analgesic and reinforcing properties of opioids. The thalamus, especially the medial
structures, relay nociceptive spinothalamic input from the spinal cord to higher structures. μORs also
have a prominent distribution in the brainstem, with high density in several structures associated with
analgesia, such as the periaqueductal gray, rostroventral medulla, the reticular formation, and locus
coeruleus [24–26]. From these structures, efferent outflow descends to the spinal cord where it acts to
inhibit nociceptive transmission in afferent fibres. μORs are also abundant in the hypothalamus, where
they might affect hormonal regulation. Receptors in the medullary vagal complex, area postrema, and
nucleus tractus solitarius, can mediate endocrine actions and nausea.
As seen in Figure 2B, the δOR has high expression in the cerebral cortex, nucleus accumbens, and
the caudate putamen. This receptor is involved in analgesic activity at both spinal and supraspinal sites.
Similarly as μORs, agonists of central δORs contribute to respiratory depression, whereas receptors
in the gut mediate constipation, an important side effect of morphine. The δORs receptors localize
presynaptically where they inhibit the release of excitatory neurotransmitters [27]. Despite these
properties, δ-selective drugs have not yet found clinical application.
The κORs have wide expression in rat brain, with highest levels in the ventral tegmental area,
substantia nigra, nucleus accumbens, caudate putamen, claustrum, endoperiform nucleus, various
hypothalamic nuclei, and the amygdala [28]. A similar expression profile occurs in the human
brain [29,30], as seen in Figure 2C. Activation of κORs does not produce respiratory depression, but
typical adverse effects include sedation and dysphoria, limiting the clinical use of κOR targeting
drugs [27]. Despite generally dysphoric effects in humans, the κOR agonist Salvinorin-A, which is
obtained from the leaves of Salvia divinorum, finds a niche market in the drug subculture for those
seeking to briefly experience a dissociative state.
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Figure 2. Human brain opioid receptor PET images in coronal (upper row) and axial (lower row)
planes. Modified and reproduced with permission from Peciña et al. [19]. From left to right, we see (A)
the μOR agonist [11C]carfentanil, binding most abundantly in the caudate nucleus, anterior cingulate
cortex, thalamus, and pituitary gland; (B) the δOR antagonist N1′-([11C]methyl)natrindole, which has
diffuse binding throughout neocortex; (C) the κOR antagonist [11C]LY2795050, which has high binding
in the insular cortex, lateral frontal cortex and amygdala; (D) the NOP antagonist [11C]NOP-1A, which
binds abundantly throughout the brain. Binding sites of μ-, κ- and NOP-OR ligands are expressed as
binding potential relative to the cerebellum (BPND), whereas binding of the δ-ligand (which has no
non-binding reference region) is expressed as net influx (Ki,) in units of perfusion (mL cm−3 min−1).
The color scale in the lower right indicates (for A, C, and D) BPND ranging from 0 to 2, or (B) Ki ranging
from 0–0.1 mL cm−3 min−1
Figure 2D shows a widespread and abundant expression of NOP binding sites in human brain.
Agonists of the NOP receptor, unlike μOR agonists, are devoid of reinforcing or motivational properties,
but are implicated in homeostatic functions such as feeding and body weight, as well as anxiety, stress,
and alcohol dependence [31].
2. Radiotracers for the PET Imaging of ORs
2.1. μOR Ligands and Non-Selective Ligands
The era of OR PET imaging was preceded by a phase of studies ex vivo with tritiated ligands
such as the antagonist [3H]diprenorphine ([3H]DPN), which accumulated in striatum, locus coeruleus,
substantia nigra pars compacta, and substantia gelatinosa of the living rat [32]. A similar pattern was
revealed with the antagoninst [3H]naloxone, which showed sodium-dependent saturable binding ex
vivo, with a Bmax close to that seen in vitro [33]. In contrast, the agonist [3H]Foxy bound with low
nM affinity at μORs in vitro, but failed to accumulate in brain of living rats, a property which was
attributed to the presence of high sodium in the living organism. The presence of sodium in the biding
medium enhanced antagonist binding in vitro but decreases agonist binding [34]. However, addition of
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Na+ to the incubation medium had little effect on the affinity of the morphiceptin analog μOR agonist
Tyr-Pro-(NMe)Phe-D-Pro-NH2 in vitro ([3H]PL017) [35]. Unpredictable sensitivity of binding to the
presence of sodium in the medium seems mainly to be a property of agonist ligands.
OR PET imaging began with the introduction of 3-O-acetyl-[18F]cyclofoxy (3-O-Ac-[18F]FcyF),
(10). 3-O-Ac-[18F]FcyF (10, Figure 3) is an opioid antagonist radiotracer, which was prepared
from 3-O-acetyl-6α-naltrexol triflate via direct nucleophilic substitution with tetraethylammonium
[18F]fluoride in anhydrous acetonitrile at 80 ◦C for 15 min [36,37]. Based on displacement studies with
CyF, binding of 3-O-Ac-[18F]FcyF (10) is likely to reveal the composite of μ- and κOR binding [38],
despite the qualitatively μOR-like binding pattern reported in living baboon brain examined with
3-O-Ac-[18F]FcyF (10) [36], and the pattern of [3H]cyclofoxy retention in rat brain analysed ex vivo [39].
However, in a rat study, the increased [3H]cyclofoxy binding provoked by chronic treatment with
morphine (1) could be attributed to upregulation of μOR sites [40]. Saturation binding PET studies
with [18F]FcyF (11) in awake rat indicated a single binding site with apparent affinity of 2 nM and Bmax
ranging from 15 pmol/g in white matter to 74 pmol/g in striatum; these results matched closely the
































































































































Figure 3. Structures of μ-selective and non-selective opioid receptor radioligands.
PET studies with N-[methyl-11C]-labelled morphine, codeine, heroin and pethidine indicated
distinct differences in uptake and kinetics in rhesus brain [42], all seemingly in relation to lipophilicity of
the various drugs. A more detailed kinetics analysis of N-[methyl-11C]pethidine (12) in brain of rhesus
monkey indicated a very low binding potential [43]. The methadone analogue [11C]L-α-acetylmethadol
([11C]LAAM, 13) had moderate uptake in brain of mice, but its specific binding was not reported [44].
These observations are a case in point supporting the generalization that effective pharmaceuticals do
not necessary make good ligands for molecular imaging of their targets.
The displaceability of OR ligands by competitors in vivo is a complex matter, and one increasingly
relevant given the current opioid abuse crisis in some countries. Whereas antagonists such as naloxone
are effective in rescuing addicts from death by overdose, naloxone also finds experimental use in
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molecular imaging studies to confirm binding of PET tracers to ORs. Thus, the BPND of [11C]Caf (8)
to μORs in human brain, which ranged from 1.0 in cerebellum to 2.7 in caudate nucleus, was nearly
completely displaced throughout in brain by a 50-mg dose of naltrexone (NTX, 5) [45], closely matching
the dose used for resuce from opioid agonist overdose. In humans, intranasal naloxone administration
caused a rapid displacement of [11C]Caf (8), in accordance with the rapid response seen in treatment
for overdose [46].
Buprenorphine (BPN) [47–49] is a narcotic analgesic used since the 1970s in the low dose
management of post-operative pain. Since 2002, BPN has approval in the United States at higher dose
or in combination with naloxone (Suboxone®) for substitution therapy in the management of opiate
addiction. BPN contains the same 6,14-ethenomorphinan skeleton as diprenorphine (DPN), and both
compounds have an N17-cyclopropylmethyl substituent, although BPN contains a tert-butyl group in
position-20 instead of methyl. Interestingly, BPN has a completely different pharmacological profile
than DPN. Whereas DPN is a mixed antagonist, BPN is a partial μOR agonist and κOR antagonist, and
displays some affinity for the NOP receptor [50] (Table 1).
Table 1. Binding profile of selected ligands at the human opioid receptors [51] .
Ki [nM] Compound
Ligand




Met5-enkephalin 261 9.9 - - agonist δOR EOP Stefanucci [52]
Leu5-enkephalin 513 10.7 - - agonist δOR EOP Stefanucci [52]
β-Endorphin 2.1 2.4 96 - agonist μOR, κOR EOP Corbett [53]
Dinorphin A 1.6 1.25 0.05 386 agonist κOR EOP Zhang [54]
Nociceptin 437 2846 147 0.08 agonist EOP Cami-Cobeci [50]
Morphine 2.06 >10,000 134 >10,000 agonist μOR EM Valenzano [55]
Oxycodone 16 7680 43,000 - agonist μOR EM Miyazaki [56]
Naltrexone 0.62 12.3 1.88 - antagonist EM Zheng [57]
Carfentanil 0.07 - - - agonist μOR 4-AP Henriksen [58]
Carfentanila 0.051 4.7 13 - agonist μOR 4-AP Frost [59]
Carfentanilb 0.024 3.28 43.1 - agonist μOR 4-AP Cometta [60]
Cyclofoxya 2.62 89 9.3 - antagonist μOR, κOR EM Rothman [38]
DPN 0.07 0.23 0.02 - antagonist orvinol Raynor [61]
BPN 1.5 6.1 2.5 77.4 partial μOR agonist, κOR antagonist orvinol Cami-Cobeci [50]
PEO 0.18 5.1 0.12 - full agonist orvinol Marton [62]
FE-DPN 0.24 8.00 0.20 - antagonist orvinol Schoultz [63]
FE-BPN 0.24 2.10 0.12 - mixed agonist/antagonist orvinol Schoultz [63]
FE-PEO 0.10 0.49 0.08 - full agonist orvinol Schoultz [63]
NTIb 3.8 0.03 332 - antagonist δOR EM Portoghese [64]
MeNTIb 14 0.02 65 - antagonist δOR EM Portoghese [64]
GR103545 16.2 536 0.02 - agonist κOR ArAP Schoultz [65]
LY2459989a 7.68 91.3 0.18 - antagonist κOR APPB Zheng [66]
LY2795050 25.8 153 0.72 - antagonist κOR APPB Zheng [57]
FEKAP 7.4 139 0.43 - agonist κOR ArAP Li [67]
EKAP 8.6 386 0.28 - agonist ArAP Li [68]
MeJDTic 8.88 118 1.01 - antagonist κOR JDTic Poisnel [69]
Salvinorin A >1000 5790 1.9 - agonist κOR NND Harding [70]
NOP-1A - - - 0.15 antagonist NOP FDPTP Pike [71]
MK-0911 94 - - 0.6 antagonist NOP SPB Hostetler [72]
EOP: Endogenous opioid peptide, EM: 4,5-Eopxy-morphinan, 4-AP: 4-Anilidopiperidine, orvinol: 6,14-
ethenomorphinan, Bentley-compound, ArAP: Arylacetamidopiperazine, APPB: Aryl-phenylpyrrolidinylmethyl-
phenoxy-benzamide, JDTic: trans-3,4-dimethyl-4-(3-hydroxyphenyl)- piperidine, NND: “non nitrogenous” diterpene,
FDPTP: 2′-fluoro-4′,5′-dihydrospiro[piperidine- 4,7′-thieno [2,3-c]pyran]- derivative, SPB: [[spiro[2.5]octan-8-
yl]-methyl]piperidin-4-yl] benzimidazol-2-one, a: in the rat brain b: in guinea pig brain membranes.
Luthra et al. [73] synthesized N17-cyclopropyl[11C]methyl-buprenorphine starting from
N17-nor-buprenorphine. Analogously to the N17-cyclopropyl[11C]methyl-diprenorphine synthesis [74]
the corresponding precursor, nor-BPN, was reacted with cyclopropyl[11C]carbonyl chloride and
the carbonyl functional group of the resulting intermediate was reduced with LiAlH4. Lever
et al. [75] developed a metabolically stable radiotracer, 6-O-(methyl-11C)-BPN, at Johns Hopkins
University in 1990 in a two-step synthesis from 3-O-TBDMS-6-O-desmethyl-BPN. The precursor
was selectively alkylated in position-6 with [11C]iodomethane/NaH in DMF at 80 ◦C for two min.
Following desilylation, [11C]BPN (14) was produced in 10% radiochemical yield with molar activity
of 41 GBq/μmol. Subsequently, Luthra et al. [76], aiming to avoid the formation of 3-O-alkylated
by-products, introduced the base-stable, acid labile trityl protecting group to protect the phenolic
hydroxyl in position-3. Applying 3-O-trityl-6-O-desmethyl-BPN in a two-step, fully-automated
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radiosynthesis (11C-methylation/deprotection), yielded [11C]BPN (14) in 15% radiochemical yield
and with a molar activity of 13-22 GBq/μmol. In 2014, Schoultz et al. [63] reported a procedure for
the radiosynthesis of 6-O-(2-[18F]fluoroethyl)-6-O-desmethyl-BPN ([18F]FE-BPN (19)) via 18F-fluoro-
alkylation of 3-O-trityl-6-O-desmethyl-BPN (TDBPN) precursor with [18F]fluoroethyl tosylate and
subsequent trityl deprotection. The decay corrected formulated product yield was 26 % and the molar
activity 50–300 GBq/μmol.
DPN, a semisynthetic thebaine/oripavine derivative with a methyl group amenable for labelling in
position-20, belongs structurally to the ring-C bridged morphinans (6,14-ethenomorphinans, orvinols,
Bentley-compounds) [48]. DPN is a nonselective OR antagonist with affinity in the nanomolar range
(Table 1), 100 times more potent than nalorphine. Indeed, DPN is used in the veterinary medicine
as an antidote/reversing agent/antagonist for remobilizing large African animals (rhinos/elephants,
Revivon®), which had been immobilized with the astonishingly potent agonists etorphine or carfentanil.
The first attempt at labelling of DPN with carbon-11 in postition-20 was reported by Burns et al. [77],
who used N-cyclopropylmethyl-dihydronororvinone as precursor. The reaction of the precursor bearing
an acetyl group in position-7-alpha with [11C]methyllithium yielded 20-[11C]methyl-DPN ([11C]DPN
(15)). Luthra et al. [74] developed cyclopropyl[11C]methyl-DPN by alkylating N17-nor-DPN with
cyclopropane[11C]carbonyl chloride and then reducing the N-cyclopropyl[11C]carbonyl intermediate
with LiAlH4 in THF. The radiochemical yield of the corresponding radioligands were low in both
cases [74,77].
In 1987, Lever et al. [78] developed a [11C]DPN (15) synthesis by alkylating the precursor
3-O-TBDMS-6-O-desmethyl-DPN in position-6 with [11C]iodomethane in DMF containing sodium
hydride at 80 ◦C for two min. After cleavage of the TBDMS protecting group, [11C]DPN (15) was
obtained with 10 % radiochemical yield and 64 GBq/μmol molar activity. In 1994, Luthra and her
associates at the Hammersmith Hospital developed a new precursor for the radiosynthesis of [11C]DPN
(15) [76]. Selective alkylation of 3-O-trityl-6-O-desmethyl-DPN (TDDPN) with [11C]iodomethane
in the presence of NaH/DMF (95 ◦C, five min). Upon deprotection with 2 M hydrochloric acid (95
◦C, two min) the radiotracer 15 was obtained with a radiochemical yield of 13–19% and a molar
activity of 16–24 GBq/μmol. Recently, Fairclough et al. [79] at the University of Manchester reported a
modified synthetic method also starting from TDDPN, yielding [11]DPN (15) with ten times higher
molar activity (240 GBq/μmol) [76] and a radiochemical yield of 32%. The non-selective OR partial
mixed agonist/antagonist 6-O-(methyl-11C)-BPN ([11C]BPN, 14) accumulated in striatum, thalamus
and cingulate cortex in living baboon brain. Analysis of the dynamic PET data with a model assuming
irreversible trapping gave a net blood-brain clearance (Ki) of about 0.064 mL cm−3 min−1, which was
halved by administration of naloxone, indicating substantial displaceability [80]. In a study in heroin
addicts, the BPN occupancy at [11C]Caf (8) binding sites was estimated relative to the drug-free baseline.
An oral dose of 2 mg BPN had an occupancy of about 50% throughout brain, whereas 16 mg had 85%
global occupancy [81]. On the other hand, therapeutic methadone (18–90 mg/day) did not provoke
any discernible occupancy at 6-O-(methyl-11C)-diprenorphine ([11C]DPN, 15) binding sites, neither in
human opioid addicts, nor in mice, a phenomenon attributed to high agonist potency of methadone,
such that withdrawl effects are averted with a rather low occupancy [82]. In further preclinical studies
from the same research group, binding of [11C]DPN (15) in mouse brain was unaltered by treatment
with oxycodone (4) or morphine (1) (full agonists at μORs), but was reduced by approximately 90% by
BPN (partial agonist at μORs and antagonist at the δ- and κORs).
A comparative OR PET study in humans compared the distributions of the μOR-selective agonist
[11C]Caf (8) and the mixed antagonist [11C]DPN (15) [83]. Qualitatively, [11C]DPN (15) binding in
the striatum, cingulate and frontal cortex exceeded that of [11C]Caf (8) (which had highest binding
in the μOR-rich thalamus), consistent with labeling of additional non-μOR sites by [11C]DPN (15).
An investigation of ORs in human cerebellum showed abundant binding of a μOR-specific ligand in
the molecular layer, moderate binding of a κOR-selective ligand, but a near absence of δOR binding
sites, which was consistent with the observations of [11C]DPN (15) binding in vivo [84]. The presence
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of binding sites in cerebellum can be an obstacle to the valid use of reference tissue methods of
PET quantitation.
As a longer-lived alternative to [11C]DPN, (15), Wester et al. developed
6-O-(2-[18F]fluoroethyl)-6-O-desmethyl-DPN ([18F]FE-DPN (16)) [85], which contains a 2-fluoroethoxy
group in position-6 instead of an OCH3. [18F]FE-DPN (16) was synthesized from TDDPN, the so
called “Luthra-precursor” [76], the same precursor as for [11C]DPN (15). For the synthesis of 16,
TDDPN was reacted with [18F]fluoroethyl tosylate ([18F]FE-Tos) in DMF in the presence of sodium
hydride for five min at 100 ◦C. The trityl protecting group was removed with 2 N hydrochloric
acid, yielding [18F]FE-DPN (16) with a radiochemical yield of 22 ± 7% and the molar activity was
37 GBq/μmol [85]. In 2013, Schoultz et al. [86] reported an automated radiosynthesis of 16 from
TDDPN with a decay-corrected radiochemical yield of 25 ± 7%. [18F]FE-DPN (16) has similar uptake as
[11C]DPN (15) in mouse brain, and obtained a BPND in human thalamus of about 2 relative to occipital
cortex, versus only 0.3 in somatosensory cortex [87]. Women showed faster plasma metabolism
[18F]FE-DPN (16) than men, which might contribute to apparent gender differences in binding [88].
The first instance of full compartmental analysis of an opioid PET ligand in living brain was for the
case of [11C]Caf, as described below. This fentanyl analogue belongs to the 4-anilidopiperidine (4AP)
class of OR ligands, which are potentμOR-selective agonists. Since 1960, numerous 4AP-type OR ligands
were synthesized and their structure-activity-relationship at ORs were recently summarized [89,90].
Caf is structurally different from fentanyl in that it contains an additional carboxymethyl group in
position-4 of the piperidine ring. Caf is a μOR-selective full agonist of extreme potency, being almost
10,000 times more potent than morphine (1) [58,91]. In 1985, [11C]Caf (8) radiotracer was applied in the
first human PET study [59,92]. For the radiosynthesis of [11C]Caf, desmethyl-Caf sodium carboxylate
was alkylated with [11C]iodomethane in DMF at 35 ◦C for five min [92]. This procedure gave molar
activity at the end of synthesis of 122 GBq/μmol, which would correspond to mass dose of about 500
pg in a human PET study, which is too low to have any effect on particpants. According to a novel
version of the radiosynthesis, desmethyl-Caf free acid serves as precursor in a reaction performed in
dimethylsulfoxide with [11C]methyl triflate in the presence of tetrabutylammonium hydroxide [93].
This procedure gave a molar activity of 5 GBq/μmol, which would correspond to a mass dose of 100 μg,
certainly intruding into the range causing some pharmacological effects. Risk of toxicity is a serious
matter in PET imaging with potent agonists, and for society in general, given the weaponization [94]
(figurative and literal) that is possible with Caf.
For the compartmental analysis of [11C]Caf (8), two models were fitted to dynamic time activity
curves (TACs) measured by PET in human brain relative to a metabolite-corrected arterial input
function [95]; this approach is the gold standard for PET quantitation. The input function obtained by
HPLC analysis of plasma extracts showed that untransformed parent fractions declined to 50% at 25
min post injection. The authors estimated microparameters for the reversible transfer of the tracer
across the blood-brain barrier (K1/k2), the reversible binding to a receptor compartment (k3/k4), and
the reversible association to a non-specific compartment in brain (k5/k6). The mean binding potential
(BP; k3/k4) was 1.8 in frontal cortex and 3.4 in thalamus at baseline, versus only 0.16 and 0.26 after
treatment with naloxone (0.1 mg/kg). This study set a very high standard for quantitative PET analysis,
although the molar activity of the tracer may not have been completely adequate. The amount of
mass injected corresponded to about 5 μg Caf per scan, which could cause some analgesia in humans,
although being less than 10% of the dose causing loss of consciousness. Nonetheless, this again raises
the issue of safety in PET studies with the using of high-potency full agonist ligands, as noted above.
Unless the the highest possible molar activity is obtained, pharmacologically significant occupancy can
occur, bringing a risk of toxicity. Test-retest studies with [11C]Caf (8) showed admirable low variability
(< 6%) and high intraclass correlation coefficients (ICC > 0.90) of the total distribution volume (VT)
relative to the metabolite-corrected arterial input, and likewise BPND relative to a reference tissue [96].
Phenethyl-orvinol (PEO) [97] shares the same in ring-C bridged morphinan scaffold as
DPN and BPN. PEO contains a 6,14-etheno-bridge, an N17-methyl substituent and a 2-phenethyl
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group in position-20. It is a full agonist with higher affinity at μOR (0.18 nM) and κORs
(0.12 nM) than to δORs (5.1 nM). The radiosynthesis of 6-O-(methyl-11C)-phenethyl-orvinol
([11C]PEO, 18) was reported by Marton et al. [62] in 2009. The Luthra-type trityl-protected
precursor (3-O-trityl-6-O-desmethyl-phenethyl-orvinol, TDPEO) was alkylated in position-6 with
[11C]iodomethane in the presence of 8-10 equiv. sodium hydride. The protecting group was removed
with 1 M hydrochloric acid in ethanol, yielding [11C]PEO (18) with a radiochemical yield of 57 ± 16%
and a molar activity of 60 GBq/μmol.
In 2012, Marton and Henriksen [98] reported the preliminary results of the synthesis
of 6-O-(2-[18F]fluoroethyl)-6-O-desmethyl-phenethyl-orvinol ([18F]FE-PEO, 17) starting from
6-O-(2-tosyloxyethyl)-6-O-desmethyl-phenylethyl-orvinol (TE-TDPEO) via direct nucleophilic
fluorination and subsequent deprotection. This procedure gave [18F]FE-PEO (17) in an isolated
preparative yield of 35 ± 8% with a molar activity of 55–130 GBq/μmol. In 2013, a research group
of the University of Cambridge [99] investigated [18F]FE-PEO (17) as a candidate OR PET-ligand,
obtained by an automated cGMP-compliant method the [18F]FE-PEO at 28 ± 15% yield and 52–224
GBq/μmol molar activity. In 2014, Schoultz et al. [63] reported the synthesis and biological evaluation
of three structurally-related 6-O-(2-[18F]fluoroethyl)-6-O-desmethy-orvinols, i.e. [18F]FE-DPN (16),
[18F]FE-BPN (19), and [18F]FE-PEO (17). The production of these 18F-fluoroethyl-orvinol radiotracers
(16,17,19) was accomplished from 3-O-trityl-6-O-desmethyl-orvinol precursors (TDDPN, TDBPN,
TDPEO) in a two-pot, three-step synthesis. [18F]FE-PEO (17) had a molar activity at end of synthesis
of 50–250 GBq/μmol [99], corresponding to an injected mass <1 μg in human PET studies. The total
distribution volume (VT) in rat brain ranged from 1 mL cm−3 in cerebellum to 8 mL cm−3 in thalamus;
displacement studies in vitro with the μOR-selective agonist DAMGO indicated high specificity in
certain brain regions. [18F]FE-DPN (16) had a molar activity of 37 GBq/μmol [85].
2.2. Delta Ligands
N1′-Methylnaltrindole (MeNTI, Figure 4) is a highly selective δOR antagonist (Table 1). MeNTI
was prepared from naltrexone (5) in a Fischer-indol synthesis with N-methyl-N-phenylhydrazine [64].
The radiosynthesis of [11C]MeNTI was reported by Lever et al. in 1995 [100]. In the first step,
3-O-benzyl-naltrindole was reacted with [11C]iodomethane in DMF in the presence of either sodium
hydride or tetrabutylammonium hydroxide at 80 ◦C for two min. The next step was hydrogenolysis of
the formed 3-O-benzyl-N1′-(methyl-11C)-naltrindole under heterogenous catalytic conditions (H2, 10%
Pd/C, DMF/ethanol, 80 ◦C, four min), or alternatively catalytic transfer hydrogenation (HCOONH4,























[11C]MeNTI [18F]FE-NTI N-substituted-[11C]quinolinimide  
Figure 4. Labeled δ-opioid receptor ligands.
Human PET studies with [11C]MeNTI (22) confirmed earlier demonstrations in living mice of
δOR-selectivity in vivo [101]. The binding ratio relative to cerebellum ranged from 1.1 in hippocampus
to 1.7 in striatum and insular cortex, regional values correlated rather precisely with known density
of δORs in vitro, and showed 50% displacement after administration of 50 mg NTX (5). The tracer
showed pseudo-irreversible binding characteristics over the course of 90 min, with net blood-brain
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clearance (Ki) ranging from 0.04 in cerebellum to 0.11 mL cm−3 min−1 in putamen [102]. The Ki for
[11C]MeNTI (22) in human brain declined by only about 20% after treatment with naloxone at a dose
completely displacing μOR sites [45]. The authors of that study suggested that incomplete and variable
δOR blockade might contribute to the success of NTX (5) as a treatment for alcoholism.
N1′-(2-[18F]fluoroethyl)naltrindole (23, [18F]FE-NTI, BU97001) was developed by Matthews et
al. in 1999 [103]. The precursor, N1′-[2-(tosyloxyethyl)]-3-O-benzyl-naltrindole, was prepared in
four consecutive transformations from naltrexone (5). In the first step, naltrexone (5) was reacted
in a Fischer-indol synthesis with 2-(N1-phenylhydrazino)acetic acid ethyl ester. The resulting
indolomorphinanyl-acetic ester was reacted with benzyl bromide to yield the 3-O-benzyl protected
NTI derivative, which was reduced with LiAlH4 in THF-toluene to afford the corresponding
indolomorphinanyl ethanol intermediate. This compound was reacted with tosyl chloride to
provide the appropriate precursor with a tosyloxy leaving group. For the radiosynthesis of
[18F]FE-NTI (23), the precursor was reacted in a direct nucleophilic reaction with potassium
[18F]fluoride/K2CO3/Kryptofix[2.2.2] in DMF to yield N1′-(2-[18F]fluoroethyl)-3-O-benzyl-naltrindole.
Final debenzylation by hydrogenolysis under heterogenous catalytical conditions (H2, Pd/C,
N,N-dimethyl formamide) gave [18F]FE-NTI (23) with a radiochemical yield of 10% and molar
activity of 31 GBq/μmol. [18F]FE-NTI (23) was an antagonist in mouse vas deferens with high selectivity
over μ- and κOR sites, and its tritiated version bound to rat whole brain as a single site with KD of 0.42
nM and Bmax of 3 pmol g−1 [104].
In 2007, Bourdier et al., [105] reported the radiosynthesis of a 2-[11C]methyl-
pyrrolo[3,4-b]pyridine-5,7-dione derivative (N-substituted-[11C]quinolinimide) (24). The radiotracer
containing a [11C]methyl-group on the pyridine ring was synthesized from a tributylstannyl precursor,
with introduction of the [11C]methyl group by the Stille reaction using [11C]iodomethane in the presence
of tris(dibenzylideneacetone)dipalladium, tri-o-tolylphosphine, K2CO3, and CuCl in DMF, heated at 90
◦C for five min. The labelled compound (24) was synthesized with a radiochemical yield of 60 ± 10%
and a molar activity of 30–56 GBq/μmol. The unlabelled version of the N-substituted quinolinimide
had higher δOR-selectivity than MeNTI, but its 11C-derivative (24) failed to label ORs in mouse brain,
due either to excessively rapid metabolism [105], or its only moderate affinity.
2.3. Kappa Ligands
GR89696 ((±)-methyl 4[(3,4-dichlorophenyl)acetyl]-3-(1-pyrrolidinylmethyl)- 1-piperazine-
carboxylate [106–108] (Glaxo Group Research Ltd.) is a κOR-selective agonist with an
arylacetamidopiperazine/diacylpiperazine structural core. GR103545, the biologically active
(R)-(−)-enantiomer of GR89696, displays subnanomolar affinity and 1000-fold selectivity for human
κOR (Ki = 0.02 nM), [65]. Ravert et al. [109] reported synthesis of both enantiomers of [11C]GR89696 (26,
Figure 5) from the corresponding chiral normethylcarbamoyl precursor [108,110]. The radiosynthesis
was accomplished by acylation of the secondary amine with [11C]methyl chloroformate in
dichloromethane in the presence of trimethylamine, giving product with molar radioactivity of
69 GBq/μmol. Mouse brain distribution of the synthesized enantiomers, ((R)-(−)-[11C]GR103545 (25)
and the (S)-(+)-enantiomer [11C]SGR) was determined in vivo, which showed the (S)-enantiomer
to be inactive. The low radiochemical yield of the radiosynthesis (2–14%) [110,111] motivated the
development of elaborate new radiochemical methods. In 2008, Schoultz et al. [112] developed a simple
[11C]methyl triflate mediated methylation of carbamino adducts. Normethylcarbamoyl-GR103545 was
converted to [11C]GR103545 (25) with [11C]CH3OTf under mild conditions in 64–91% radiochemical
yield. Wilson et al. [113] developed a method for preparing [11C-carbonyl]-methylcarbamates
directly from primary or secondary amines, applying either DBU or BEMP and cyclotron-produced
[11C]CO2. [11C-carbonyl]-GR103545 (25) was synthesized with high radiochemical purity (>98%) and
molar activity of 108–162 GBq/μmol. In 2011, Nabulsi et al. [114] reported an automated two-step,
one-pot procedure for the synthesis of [11C]GR103545 (25) from normethylcarbamoyl-GR103545 via
transcarboxylation using the zwitterionic carbamic complex DBU-CO2 and [11C]CH3OTf.
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Figure 5. Selected κOR ligands.
In PET studies, the κOR-agonist ligand [11C]GR103545 (25) had a VT in baboon brain ranging
from 3 mL cm−3 in cerebellum to 10 mL cm−3 in striatum and cingulate cortex [111]. Naloxone
homogeneously displaced tracer throughout brain, but had no effect on VT in cerebellum, which would
support use of that brain region as a reference tissue. The tracer had >100-fold selectivity for κ- over δ-
and μORs in vitro [65]. Much as in baboons, PET studies in rhesus monkey showed VT ranging from
8 mL cm−3 in cerebellum to 21 mL cm−3 in striatum. Other monkey studies showed BPND ranging
from 0.3 in amygdala to 2.2 in putamen [115]. This bolus plus infusion study with increasing mass
dose in monkeys indicated an in vivo KD of 2 nM and Bmax of 1–6 pmol g−1. In 2014, Naganawa et
al. [116] reported the first-in-human PET study with [11C]GR103545 (25). Test-retest variability of the
quantitative endpoint VT was about 15%, and binding ranged from 8 mL cm−3 in cerebellum to 41 mL
cm−3 in amygdala; Lassen plots with naltrexone blocking indicated a non-specific uptake (VND) of
only 3.4 mL cm−3, thus emphasizing the absence of any non-binding reference region.
Based on the substituted-diacylpiperazine scaffold of GR103545, researchers at Yale University
developed the new κOR agonist radiotracers [11C]EKAP (27) [68] and [11C]FEKAP (28) [67] with
improved pharmacological and PET-imaging profile compared with the native compound. In the
open-ring analogs of GR103545, the pyrrolidinyl-methyl group of the original molecule in position-3
was replaced by a diethylamino-methyl in EKAP and a ((ethyl)2-fluoroethyl)amino)methyl group in
FEKAP. Imaging studies [11C]EKAP (27) in rhesus monkey showed rapid metabolism in vivo and fast,
reversible binding kinetics in brain that was blockable with specific competitors. The BPND ranged
from 0.8 in frontal cortex to 1.8 in globus pallidus.
Researchers at Eli Lilly, in cooperation with the Yale University, developed κOR antagonist
radiotracers with the 3-pyridinyl-1-pyrrolidinylmethyl structural scaffold. Along these lines, in
2013, Zheng et al. [57] synthesized the selective κOR antagonist radiotracer [11C]LY2795050 (30)
from an iodophenyl precursor in a two-step procedure. The precursor was converted by transition
metal-mediated cyanation using H11CN and Pd2(dba)3/dppf to a [11C]nitrile intermediate. This latter
was partially hydrolysed with NaOH/H2O2 in DMF at 80 ◦C for five min, giving a 12% radiochemical
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yield with molar activity of 23.6 GBq/μmol. [11C]LY2459989 (31) was prepared in a two-step one-pot
radiosynthesis. In the first step, an aryl-iodide-type precursor was transformed in a palladium catalyzed
reaction (Pd2dba3/dppf) with H11CN to the corresponding [11C]nitrile, which was reacted with H2O2
under basic condition to afford 31 with 7.4% radiochemical yield and 23 GBq/μmol molar activity.
LY2459989 is the fluorine-containing analogue of LY2795050. Li et al. [117] synthesised the
18F-fluorine-labelled version of LY2459989 using two different methods. Using the nitro precursor, the
radiochemical yield was too low, but applying the iodonium ylide precursor, [18F]LY2459989 (30) was
prepared with 36% radiochemical yield and 1,175 GBq/μmol molar activity. While admirably high, this
molar activity falls far short of the theoretical maximium for 18F-, which is 63,000 GBq/μmol. Where
does all that non-radioactive fluoride come from?
As noted above, salvinorin A [118–120] is a naturally occurring non-alkaloid neo-clerodane
diterpenoid, isolated from Salvia divinorum. Also as noted above, smokings Salvinorin-A can provoke a
dissociative hallucinogenic experience distinct from that of the classical hallucinogens. It has a unique
structure with seven chiral carbons and is potent and highly selective κOR agonist; salvinorin A does
not display any significant activity at other OR subtypes. In 2008, Hooker et al. [121] synthesized the
carbon-11 labelled version of salvinorin A (33), using salvinorin B as precursor for the radiosynthesis.
The 2-alpha-hydroxyl group of the precursor was acylated with [11C]acetyl chloride in DMF in the
presence of DMAP at 0 ◦C for 7–10 min, giving a radiochemical yield of 3.5–10% with molar activity
7.4–28 GBq/μmol. PET studies in baboon brain showed rapid uptake and washout of [11C]salvinorin
A (33), matching the brief duration of the hallucinatory/dissociative experience reported by humans
users. Rat studies showed that acute doses of salvinorin A caused dose-dependent occupancy at brain
κORs labelled in vivo with [11C]GR103545 (25). Pretreatment with a high dose in the hours before PET
examination caused persistent reductions in receptor availability, despite the brief plasma half-life
of the drug, and despite the rather brief duration of the hallucinogenic experience. This suggests
that κOR activation by agonists such as salvinorin A provokes a delayed and persistent receptor
internalization [122].
In 2001, Thomas et al. [123] identified the first κOR-selective antagonist ligand,
trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine (JDTic, > 200-fold selective, Table 1), with non-opiate
structure. MeJDTic is a derivative of JDTic that is ring methylated on the nitrogen of the
tetrahydroisoquinoline. Poisnel et al. [69] prepared [11C]MeJDTic (29) from JDTic by methylation
with [11C]methyl triflate in acetonitrile at room temperature for three min. The radiochemical yield
was 78–98% and the molar activity 1.5–4.4 GBq/μmol. Recently, Schmitt et al. [124] synthesized
N-[18F]fluoropropyl-JDTic ([18F]FP-JDTic) (35)) from JDTic with [18F]fluoropropyl-tosylate in DMSO in
the presence of DIPEA and LiI at 150 ◦C for 30 min. In vivo studies in mouse showed accumulation of
[18F]FP-JDTic (35) in peripheral organs rich in κORs. [11C]MeJDTic (29) entered mouse brain in vivo,
albeit attaining a concentration of only 0.2–0.3% ID/g. Its binding was substantially reduced by
treatment with the κOR agonist U50,488, but was unaffected by morphine (1) or naltrindole (NTI), thus
attesting to its high selectivity for κOR sites [69]. The κOR-agonist [11C]LY2795050 (30) had an in vitro
binding affinity of 1 nM, and 25 fold selectivity over μORs (Table 1). It readily entered monkey brain,
and was substantially displacement by naloxone [57]. Displacement studies showed scant specific
binding in monkey cerebellum, which supports its use as a reference region for quantitation. The tracer
had a BPND as high as 1.0 in parts of the basal ganglia [125]. Dual tracer studies in monkey showed the
LY2795050 displaced [11C]Caf (8) from μOR sites with an ED50 of 119 μg/kg, whereas the ED50 at κOR
sites was 16 μg/kg, indicating 8-fold selectivity in vivo [125,126]. Corresponding human studies with
kinetic modelling showed VT ranging from 2 mL cm−3 in cerebellum to 4 mL cm−3 in amygdala, and
Lasson plots with partial NTX (5) blocking indicated a VND (non-specific binding) close to 1.6 mL cm−3,
thus giving a BPND of 1.5 in amygdala versus only 0.2 in cerebellum [126]. The test-retest reliability in
human brain was about 10% [127]. PET with [11C]LY2795050 (30) has revealed the dose-occupancy
relationship in human brain for the experimental κOR antagonist LY2456302 (34), which is under
development as a treatment of alcoholism [128].
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[11C]LY2459989 (31) had sub-nM affinity at κOR sites in vitro, with 30-fold selectivity over μOR
and 400-fold selectivity over δOR sites [66]. Preliminary PET studies in monkey showed rapid kinetics
and substantial displaceability in vivo, with BPND ranging from 0.5 in thalamus to 2.2 in globus pallidus.
A comparison of κOR ligands in rat showed that the agonist [11C]GR103545 (25) and the antagonist
[11C]LY2459989 (31) had similar displacement by various κOR antagonists. However, and of great
significance, the κOR agonists salvinorin A and U-50488, while displacing [11C]GR103545 (25) binding
in vivo, did not alter [11C]LY2459989 (31) binding [129], which may indicate an allosteric binding
mechanism. The novel κOR agonist tracer [11C]-EKAP (27) showed fast uptake kinetics and high
specific binding in monkey brain, with VT ranging from 12 mL cm−3 in cerebellum to mL cm−3 in
globus pallidus, corresponding to a BPND of 1.8, its binding was 95% displaced by pre-blocking with
the antagonists naloxone or LY2795050 [68].
The highly selective and potent κOR-ligand U-50488 served as a scaffold for developing
fluoro-alkylated PET ligands, but proved inappropriate due to 100-fold loss of affinity relative
to the starting compound [130]. The novel fluorinated κ-ligand [18F]LY2459989 (32) had similar kinetic
properties in monkey PET studies to those of [11C]LY2459989 (31) [117].
2.4. Nociceptin and Opioid-like 1 Receptors (ORL1)
Emerging evidence supports the use of agonists for the nociceptin/orphanin FQ peptide
receptor (NOP) in the clinical management of pain and for substance abuse [131], thus
presenting an attractive target for molecular imgaing A series of NOP ligands based on a
2′-fluoro-4′,5′-dihydrospiro[piperidine-4,7′-thieno[2,3-c]pyran]-scaffold were screened in rats [71].
Uptake in monkey brain in a baseline condition contrasted with a blocking condition
indicated specific binding of several of the [11C]-labelled compounds, of which [11C]NOP-1A
((2S)-2-[(2-fluorophenyl)methyl]- 3-(2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran- 7,4′-piperidine-1′-
yl)-N-methyl-propanamide (36, Figure 6) was selected for further investigations. In the synthesis
developed by Pike et al. [71], [11C]NOP-1A (36) was prepared from a primary-amide type precursor
by methylation with [11C]iodomethane in DMSO basified with potassium hydroxide at 80 ◦C for 5
min. PET imaging experiments with 36 showed a VT in monkey brain ranging from 13 mL cm−3
in cerebellum to 21 mL cm−3 in amygdala. This fell globally to 8 mL cm−3 after blocking with the
antagonist SB-612111, indicating a BPND of 1–2 [132]. A somewhat lower VT range was detected in






































Figure 6. Chemical structures of selected ORL1 receptor ligands.
The NOP/ORL1 antagonist LY2940094 (37) exerted a dose-dependent reduction in immobility
in the forced swim test, matching that provoked by imipramine, consistent with a potential
antidepressant action [23]. Changes in [11C]NOP-1A (36) binding in brain of living rats revealed
the ORL1 occupancy of orally administered LY2940094 (37) [135]. MK-0911 (1-(2-fluoroethyl)-
3-[(3R,4R)-3-(hydroxymethyl)-1-[[(8S)-spiro[2.5]octan-8-yl]methyl]piperidin-4-yl]benzimidazol-2- one)
is a high affinity, selective NOP receptor antagonist developed by Merck Pharmaceuticals.
The fluorine-18 labelled version [18F]MK-0911 (39) had a VT in human brain ranging from 5 mL cm−3
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in cerebellum to 7 mL cm−3 in temporal cortex, with excellent test-retest stability [72]. Displacement
studies with antagonists revealed the presence of a small specific binding component in cerebellum,
again raising a red flag about reference tissue quantitation. Studies with the nociceptine ligand
[3H]PF-7191 (38) showed sub-nM binding displacement in vitro (Ki = 0.1 nM) and high selectivity over
other OR types, as well as promising displaceable binding in rat brain measured ex vivo [136].
3. Clinical Studies
3.1. Age and Gender
The BPND of [11C]Caf (8) relative to occipital cortex was 20% lower in thalamus and amygdala of
healthy, aged women compared with young women, but tended to increase with age in frontal cortex,
whereas increases were more consistently seen in aged men [137]. This finding seems relevant to the
age-dependent changes in sensitivity to μOR agonists, compounded by possible gender differences in
hepatic tracer metabolism, noted above. Preliminary results with [11C]LY2795050 (30) PET did not
indicate any change in κOR availability with age in humans [138]. Another κ-OR PET study with that
ligand showed slightly higher (5–10%) VT in widespread brain regions of male subjects than that seen
in age-matched women [139].
3.2. Epilepsy
A dual tracer PET study of patients with temporal lobe epilepsy showed increased binding of
[11C]Caf (8) to μORs in the temporal neocortex and decreased binding in the amygdala ipsilateral
to the epileptic focus [140]. However, binding of [11C]DPN (15) to μ- and other OR subtypes did
not differ between affected and unaffected cerebral hemipsheres, emphasizing the importance of
subtype selectivity in PET studies. Another multi-tracer PET study in temporal lobe epilepsy showed
increased μOR binding ([11C]Caf (8)) in medial inferior temporal cortex and a more widespread
increase in δOR binding ([11C]MeNTI (22)) in the affected temporal lobe [141]. Increased [11C]DPN (15)
binding in temporal pole and fusiform gyrus of epilepsy patients declined with time since last seizure,
indicating a transient response of the opioid system [142]. Applying a partial volume correction
revealed small post-ictal increases in [11C]DPN (15) VT in the (sclerotic) hippocampus relative to the
interictal state [143], possibly indicating reduced competition from endogenous opioids. Thus, there
may be reduced opioid transmission in the post-ictal period.
A study of five patients with reading epilepsy (i.e. seizures provoked by reading text) revealed
very circumscribed 10% reductions in [11C]DPN binding the temporal parietal cortex in the activation
condition compared to non-reading baseline, whereas no such changes was seen in control subjects [144].
In the context of a competition model, the authors interpreted this to indicate task-dependent release
of opioid peptides in the patients, but it is difficult to determine the causal relationship between this
release and the seizures.
3.3. Movement Disorders
In an MPTP model of acquired parkinsonism, a substantial striatal dopamine depletion to
FDOPA–PET was associated with a 20–30% reduction in the VT of [18F]FcyF, (11) in opioid-receptor
rich areas, i.e., caudate, anterior putamen, thalamus, and amygdala relative to intact animals [145].
These animals had recovery of their motor function, suggesting that the μOR changes were an adaptive
response to dopamine depletion. The same group reported that this effect was (paradoxically) bilateral
in animals with unilateral dopamine lesions [146]. In patients with Parkinson’s disease, the [11C]DPN
(15) binding relative to occipital cortex was 20–30% reduced in striatum and thalamus only in those
patients with iatrogenic DOPA-dyskinesia, but was unaffected in nondyskinetic Parkinson’s disease
patients [147]. This observation seems to merit further investigation, given the disabling effect of
dyskinesias often encountered in the treatment of Parkinson’s disease. On the other hand, there was no
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difference in [11C]DPN (15) binding in symptomatic DYT1 primary torsion dystonia patients relative
to controls [148].
Regional [11C]DPN (15) binding was unaffected in patients with restless legs syndrome (which,
like, Parkinson’s disease, is responsive to levodopa treatment). However, there was a negative
correlation between VT and motor symptom severity, and a negative correlation between severity of
pain and ligand binding in the medial pain system (medial thalamus, amygdala, caudate nucleus,
anterior cingulate gyrus, insular and orbitofrontal cortex). The authors interpreted this result in
relation to pain-induced release of endogenous peptides, rather than a primary aspect of restless legs
syndrome [149].
Binding of the non-selective OR ligand [11C]DPN PET was reduced by 31% in the caudate nucleus
and 26% in putamen of a small group of symptomatic Huntington’s disease patients compared to
age-matched healthy controls [150]. This effect was less pronounced than was the loss of dopamine
transporters seen in the same patients, suggesting that the reduction in ORs may partially accommodate
the nigrostriatal degeneration. Despite this finding, there has been no indication for opioid medications
in the symptomatic treatment of HD.
3.4. Pain
A qualitative study of post pontine infarct central pain showed a reduction in [11C]DPN (15) uptake
in the lateral cerebral cortex on the side contralateral to the main symptoms [151]. A more detailed
study indicated [11C]DPN (15) binding reductions in contralateral thalamus, parietal, secondary
somatosensory, insular and lateral prefrontal cortices; these reductions were similar irrespective of
the site of the lesion causing the central pain syndrome [152]. Indeed, this network of brain regions is
recognized as comprising a central pain pathway. Another [11C]DPN (15) study of central neuropathic
pain showed 15–30% lower OR-binding within the medial pain system (cingulate, insula and thalamus),
as well as the inferior parietal cortex of the lateral system (Brodman area 40). Patients with peripheral
neuropathic pain had bilateral and symmetrical decreases in [11C]DPN (15) binding in contrast to
the hemispheric changes seen in central pain patients [153]. As always, these binding reductions are
ambiguous, perhaps due to reduced receptor expression, increased occupancy, or internalization.
Poor sleep quality in relation to topical application of 10% capsaicin cream (which directly activates
cutaneous pain receptors) was associated with higher baseline [11C]Caf (8) BPND in the frontal lobe [154].
Thus, we suppose that baseline cortical binding may reflect a tradeoff between pain sensitivity and
some cognitive or resilience function subserved by μ-ORs. Capsaicin-induced pain provoked a decrease
in [11C]Caf (8) binding in the contralateral thalamus by as much as 50%, increasing as the subjective
severity of the pain [155]. Heat pain reduced the [18F]FE-DPN (16) binding in limbic and paralimbic
brain areas including the rostral ACC and insula [156]. Application of sustained painful stimulus of the
jaw muscle with saline injection provoked bilateral reductions in [11C]Caf (8) binding in the ipsilateral
amygdala (5%) and contralateral ventrolateral thalamus (7%) [157]. The same painful stimulus that
provoked 5–10% decreases in [11C]Caf (8) binding in healthy young men tended to increase binding in
women; this gender difference was most pronounced in the ventral striatum ipsilateral to the pain [158].
A small group of patients with trigeminal neuralgia had reduced [11C]Caf (8) binding in left nucleus
accumbens, a brain region earlier implicated in pain modulation and response to reward or aversive
stimuli [159]. It would be interesting to test if this phenomenon correlated with individual differences
in affective state or trait neuroticism.
In another [11C]Caf (8) study, the reduced binding provoked soon after administration of a
sustained pain of moderate intensity had normalized in the hours after cessation of the stimulus [160].
In general, painful stimuli do not desensitize with time, so the relationship between temporal dynamics
of opioid signaling and pain perception must be complex. Indeed, pain researchers and clinicians alike
are familiar with the phenomenon of allodynia, which is a decrease in pain threshold, or the conversion
of previously non-painful stimuli to pain. In a sciatic nerve stimulation model, pain conditioning some
hours after stimulation was associated with increased C-fibre response and reduced C-fibre threshold,
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as well as supraspinal changes marked by increased binding of [11C]PEO (18) in ipsilateral and bilateral
structures of the rat brain [161]. Thus, allodynia may indicate inactivation of pain-mediated opioid
release in brain, resulting in greater OR availability. On the other hand, an [18F]FE-DPN (16) PET
study in athletes contrasting receptor availability at rest with the condition immediately after running
a half marathon showed reduced binding in various paralimbic and prefontal cortical structures, to an
extent correlation with post-running euphoria (“runner’s high”) [162]. Similarly, a [11C]Caf (8) study
in recreationally active men showed a relationship between post-exercising euphoria with decreased
μOR binding in widespread cortical areas after high intensity exercise, although effects were less clear
after moderate intensity exercise [163].
Prolonged electrical stimulation of the motor cortex for relief of neuropathic pain caused reductions
in [11C]DPN (15) binding in part of the cingulate cortex, prefrontal cortex, the periaqueductal gray
prefrontal cortex, and cerebellum [164]. Some of these changes correlated with the extent of pain relief.
In a case study, a single session of motor cortex stimulation improved the cold pain threshold, while
decreasing [11C]Caf (8) binding in pain-network brain regions [165]. Other studies showed that low
cerebral binding of [11C]DPN (15) predicted for poor response to motor cortex stimulation for the
treatment of neuropathic pain [166]. Stimulation of the central grey for treatment of phantom limb
pain provoked a focal decrease in midbrain [11C]DPN (15) binding, indicating endogenous opioid
release [167].
Visceral pain applied by gastric inflammation was without effect on cerebral [11C]Caf (8) binding
in healthy volunteers [168], this standing in contrast to findings with somatic pain as described above.
On the other hand, vestibular stimulation provoked decreased [18F]FE-DPN (16) binding in parts of
the right dominant cortical vestibular network [169].
A [11C]Caf (8) study in which painful heat was applied after administration of supposedly
analgesic cream indicated a placebo-mediated reduction in receptor availability [170]. The same
group later showed that placebo transcranial direct current stimulation (tDCS) reduced [11C]Caf (8)
BPND in the periaqueductal gray matter (PAG), precuneus, and thalamus, indicating endogenous
opioid release [171]. This placebo effect apparently increased upon administration of verum tDCS.
In another study, acupuncture administered according to an authentic analgesic procedure had only
slight effects on the binding of [11C]DPN (15) in human brain [172]. However, a study with [11C]Caf
(8) showed acupuncture therapy to provoke short-term and persistent 10–30% increases in μOR
binding in pain-related brain regions; importantly the verum acupuncture condition was contrasted
with a sham acupuncture condition in that study [173]. Thus, while acupuncture analgesia may
be “in one’s head”, there seems to be a real component mediated by increased opioid transmission.
Transcutaneous electrical acupoint stimulation (TEAS) is an analogue of the electrical acupuncture
technique. Administration of TEAS at 2 Hz to anesthetized monkey provoked reductions in [11C]Caf
(8) binding in striatum, amygdala and ACC, whereas 100 Hz stimulation had no effect relative to
baseline PET recordings [174].
Reminiscent of the findings in the study of pain-induced sleep disturbance noted above, a
cross sectional study of sensory processing in healthy volunteers showed lower baseline binding
of [18F]FE-DPN (16) in regions such as insular cortex and orbitofrontal cortex of those with greater
sensitivity to cold pain. In addition, there were negative correlations between regional binding
and sensory thresholds for non-painful stimuli [175]. Similarly, the individual striatal binding of
[11C]Caf (8) BPND predicted cold pressor pain threshold, but not cold pressor pain tolerance or tactile
sensitivity [176]. A longitudinal [18F]FE-DPN (16) PET study in neuropathic pain model rats showed
lower μ+κ OR availability in the insula, caudate putamen, and motor cortex at three months after the
injury [177]. These reductions occurred in association with anhedonia (disinterest in sucrose solution).
Overall, these studies suggest that individual differences in OR signaling may mediate vulnerability to
environmental stressors, a topic to be elaborated in Section 3.5 below.
Binding of [11C]DPN (15) was reduced in pineal gland (but not in the brain per se) of patients who
had been experiencing cluster headache attacks [178], said to be one of the most painful experiences.
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The authors suggested that inputs from trigeminal nerve to the pineal gland might mediate this change.
A group of seven spontaneous migrainers showed ictal reductions in [11C]Caf (8) binding in the medial
prefrontal cortex, which correlated with the baseline or intra-ictal binding [179]. The [11C]DPN (15)
BPND in brain did not differ between migrainers and healthy controls, nor was there any effect of
placebo treatment in either group [180].
3.5. Personality, Drug Dependence, and Psychiatric Disorders
Scores in the personality trait of harm avoidance in a group of 23 healthy males correlated
positively with binding of [18F]FE-DPN (16) in the bilateral ventral striatum, suggesting a link with
predisposition to substance abuse [181]. It might follow that drug abuse is a kind of self-medication
for those with pronounced harm avoidance trait. A comparison of [11C]Caf (8) uptake in healthy
individuals showed that high scores in the harm avoidance trait were associated with high μOR
availability in frontal and insular cortex [182], again linking the hard avoidance trait with lower tonic
opioid transmission. Score in a scale of behavioral activation, which conceptually guides approach
behavior, and notably in a scale designated “fun-seeking”, correlated positively with [11C]Caf (8)
in widespread brain regions [183]. A [11C]Caf (8) study in 49 healthy volunteers showed an inverse
relationship between μOR availability in various brain regions and individual scores in the avoidance
dimension of interpersonal attachment [184]. Considering the harm avoidance findings, baseline μOR
availability may mediate a trade-off between harm avoidance and avoidant behavior in interpersonal
relationships, in a psychological analogue of pain or cold sensitivity.
In a large group of healthy women, [11C]Caf (8) binding had a negative correlation with BOLD
signal responses in amygdala, hippocampus, thalamus, and hypothalamus to viewing emotionally
arousing scenes [185]. Non-sexual, albeit pleasurable social touch from a partner provoked widespread
increases in [11C]Caf (8) binding, suggesting reduced opioid signaling [186], whereas social laughter
provoked by viewing comedic film clips decreased [11C]Caf (8) binding in thalamus, caudate nucleus,
and anterior insula. Furthermore, baseline μOR availability in some regions was associated with the
rate of social laughter [187]. These results are difficult to reconcile, since pleasurable social experiences
can seemingly have opposite effects on μOR availability. Contrasting the [11C]Caf (8) binding in
euthymic and unhappy states (provoked by autobiographical reflection) in young women showed
higher μOR availability in the rostral anterior cingulate, ventral pallidum, amygdala, and inferior
temporal cortex in the unhappy state [188]. This kind of sad reflection provoked greater increases in
[11C]Caf (8) binding in widespread brain regions of women with major depression [189], suggesting an
exaggerated opioid response in relation to mood disorder, as distinct from ordinary sadness. A pilot
PET study with the κOR-ligand [11C]GR103545 (25) did not reveal any binding differences between
healthy control and patients suffering from major depression [190]. However, a [11C]EKAP (27) κOR
study in healthy volunteers showed an inverse correlation between social status and [11C]salvinorin A
(33) binding in widespread brain areas, with a special association occurring in brain regions mediating
reward or aversion [191]. Given the association between social stress and depression, one might have
expected covariance κORs in the two studies.
A recent [11C]Caf (8) PET study of 19 schizophrenia patients and 20 controls showed a 10% lower
(Cohen’s d = 0.7) μOR -availability in striatium of the patient group. While such a decrease can hardly
be pathogonomic of disease, the authors also reported considerably higher inter-regional covariance
of the [11C]Caf (8) binding in the patients, which might indicate an aberent spatial pattern of opioid
signalling in schizophrenia [192]. There have been no OR PET studies in bipolar disorder.
A [11C]Caf (8) study showed that circulating levels of the anti-nociceptive cytokine IL-1ra (which
correlated with neuroticism scores) predicted for the pain response to a standard stimulus (saline
infusion to the masseter muscle), and likewise the reduction in μOR availability in the basal ganglia
during the painful stimulus [193]. In a group of female patients suffering from fibromyalgia, [11C]Caf
(8) binding correlated with pain-evoked BOLD signal changes in several brain regions, including
dorsolateral prefrontal cortex and nucleus accumbens [194]. Overall, these studies suggest some
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linking between opioid transmission, mood, and inflammatory markers, which returns to the the
notioin that OR signaling may mediate personality traits and vulnerability to stresses of various sorts.
[11C]Caf (8) PET showed persistently increased μOR binding in frontal and cingulate cortex of
acutely detoxified cocaine addicts, which correlated with the extent of craving [195]. Elevated [11C]Caf
(8) binding in frontal and temporal cortical regions was a significant predictor of time to relapse
to cocaine use among abstinent addicts [196]. Binge cocaine users showed a significant association
between [11C]GR103545 (25) binding to κORs with the amount of drug consumed. Furthermore, a
three-day cocaine binge reduced binding by about 15% [197]. The cerebral binding (VT) of the ORL1
ligand [11C]NOP-1A (36) was globally elevated 10% in detoxified cocaine users [198].
One [11C]Caf (8) PET study showed persistently increased μOR binding in striatum of detoxified
alcoholics, which furthermore correlated with the extent of craving [199]. Abstinent alcoholics showed
significantly higher [11C]Caf (8) binding compared to controls, but a blunting of the response to
amphetamine (which indirectly displaces μOR binding), resembling that seen by the same research
group in compulsive gamblers [200]. However, others saw only a small increase in [11C]DPN (15) VT
in brain of acutely withdrawn alcoholics, although there was a correlation between individual PET
results and craving scores at the time of scanning [201]; the combined (μ+κ) PET signal in that study
makes difficult a comparison with [11C]Caf (8) studies. Post mortem autoradiographic examination of
[3H]DAMGO binding in brain of a large group of alcoholics showed substantial reductions in μOR
binding sites, whereas low [11C]Caf (8) BPND in ventral striatum of acutely detoxified patients predicted
high risk of relapse and poor response to naloxone in interaction with the μOR rs1799971 allele [202].
The disagreement between μOR findings in vivo and post mortem could indicate low tonic occupancy in
alcohol dependent patients, since competition effects would disappear in autoradiographic studies.
In a [11C]MeNTI (22) PET study, there was globally 10–20% higher δOR binding in brain of a
large group of alcohol-dependent subjects; which reached significance upon correcting for age, gender,
and smoking status; there was an inverse relationship between binding in some regions and intensity
of craving [203]. The VT of the κOR-selective ligand [11C]LY2795050 (30) was significantly lower in
amygdala and pallidum of alcohol-dependent subjects [138]. This stands in contrast to the usual
finding of increased μOR binding and the single report of elevated δOR binding.
The naloxone challenge paradigm has a long history in investigations of the regulation of
the neuroendocrine axis, but it has been uncertain if naloxone-induced increases in ACTH and
cortisol secretion bear any relation to central OR pathways. In a [11C]Caf (8) PET study of healthy
volunteers there were negative relationships between cortisol (but not ACTH) response to naloxone
and ligand BPND in ventral striatum, putamen and caudate [204]. The inverse relationship between
naloxone-induced cortisol secretion and [11C]Caf (8) BPND in various brain regions of healthy volunteers
was absent in alcohol dependent subjects [205]. This suggests that central ORs exert a top-down
regulation of the neuroendocrine axis, which might contribute to individual differences in stress
response, and that the normal regulation of this axis is disprupted in alcohol dependence.
There was only a slight difference in [11C]Caf (8) binding between non-smoking carriers of the
μOR rs1799971 allelic variants, but this allelic difference was greater among smokers. Furthermore,
the contrast in PET results between active and denicotinized cigarette conditions revealed a positive
relationship between reward and altered μOR availability in the smokers [206]. An apparent
re-analysis of the same data showed widespread reductions in [11C]Caf (8) binding after smoking
a nicotine-containing cigarette; this effect was moderated by the rs1799971 polymorphism, where
carriers of the A allele showed greater response to active cigarette smoking, and higher baseline
μOR binding [207]. The authors conceded that non-nicotinergic factors, i.e. conditioning, could be
contributing to aspects of smoking related opioid transmission [208].
Smoking subjects with higher dependence, craving, and cigarette consumption rates showed
lower baseline [11C]Caf (8) BPND in limbic brain regions. There was bluniting of this association during
NTX (5) treatment [209], but there was very low residual specific binding in the NTX condition, which
must have compromised the sensitivity of the method. Another [11C]Caf (8) PET study showed no
166
Molecules 2019, 24, 4190
difference in BPND between placebo and active nicotine cigarette conditions, and no difference between
smokers and nonsmokers. However, there was a negative correlation in the smokers between BPND in
bilateral superior temporal cortex with scores in an index of nicotine dependence [210].
As noted above, challenge with amphetamine can indirectly provoke increased opioid peptide
release. However, in a placebo-controlled, double-blinded and randomized [11C]Caf (8) PET study,
amphetamine challenge (0.3 mg/kg) did not alter μOR availability in healthy male volunteers [211].
This stands in contrast to another study, wherein a high dose of amphetamine (0.5 mg/kg) provoked
reductions in [11C]Caf (8) binding in widespread brain regions, i.e. frontal cortex, putamen, caudate,
thalamus, anterior cingulate, and insula, whereas a sub-pharmacological dose was without such
an effect [212,213]. Preclinical studies point to the importance of receptor internalization on the
vulnerability of OR-receptor binding to challenge with amphetamine [214]. Notwithstanding this
caveat, amphetamine induced reductions in [11C]Caf (8) binding were blunted in compulsive gamblers
compared to that in a healthy control group controlled for smoking and drinking [215]. There was a
general correlation between dopamine synthesis capacity to FDOPA PET and [11C]Caf (8) binding in
putamen of healthy controls, and likewise in pathological gamblers, consistent with a tight relationship
between dopamine and opioid systems in relation to compulsive behaviors [216].
Women with bulimia nervosa had reduced [11C]Caf (8) binding in the left insula, to an extent
correlating with their duration of fasting [217]. Obese patients (BMI 40) had globally 20% lower
[11C]Caf (8) BPND compared to lean volunteers; contrary to some reports, the same obese subjects had
normal dopamine D2 receptor levels in striatum [218]. There were similar reductions in [11C]Caf (8)
binding in morbidly obese subjects and patients with binge eating disorder [219]. Weight loss after
bariatric surgery for the treatment of obesity resulted in a global 25% increase of μOR binding [220].
A dual tracer study with [11C]Caf (8) and the dopamine receptor ligand [11C]raclopride showed a
high correlation in the striatum of lean subjects, whereas this correlation was considerably weaker in
the ventral (limbic) striatum of the morbidly obese, suggesting an uncoupling of opioid/dopamine
interactions in that condition [221]. This finding might predict analogous results in gambling and
substance abuse disorders, which likewise may involve dysregulation opioid/dopamine interactions.
Feeding, regardless of the hedonic experience (palatable versus unpalatable meal), provoked
widespread decreases in [11C]Caf (8) binding in non-obese healthy subjects, suggesting that OR
transmission mediates some aspect of the rewarding properties of food [222]. Also in non-obese
subjects, [11C]Caf (8) BPND in amygdala correlated inversely with BMI in the range 20–27 [223]. In that
study, BPND in other brain regions correlated with the BOLD signal response in orbitofrontal cortex
upon viewing palatable food. In a group of lean subjects, the [11C]Caf (8) BPND at baseline in widespread
brain regions correlated with BOLD responses to viewing palatable food [224], suggesting that low
basal occupancy increases the response to cues. Interestingly, exercise increased or decreased thalamic
μOR binding in these subjects; the direction of this change correlated with the individual BOLD signal
in the contrast between viewing palatable and non-palatable food. This draws attention to individual
differences in effects of exercise on the hedonic response to food, which may have some bearing on
the relationship between exercise and weight loss, with the caveat that only intense exercise may
significantly engage opioid transmission, as claimed above. Other studies show widespread reductions
in μOR availability in frontolimbic regions after high intensity aerobic exercise, in correlation with
negative affect. In contrast, mean binding was unaltered after moderate-intensity exercise, although
there was some positive association with euphoria [225]; too much of a good thing spoils runner’s
high, it seems.
4. Conclusions and Outlook
The past decades have seen extraordinary progress in the development of ligands for PET studies
of ORs. Early radiopharmaceutical research focused on studies with the antagonist [11C]DPN (15)
and the μOR-selective agonist [11C]Caf (8), and the great preponderance of human PET studies
have employed these and closely related tracers. While studies with non-selective tracers reveal the
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composite of OR binding sites, specific tracers may be more indicative of physiological changes in
disease states. Attaining high molar activity is of great importance in PET studies with [11C]Caf (8)
and other highly potent agonist ligands; fortunately, most tracers described in this review have molar
activities of at least 50 GBq/μmol, corresponding to an injected mass of about 1 μg of the drug. This is
hardly a relevant dose in the case of antagonist ligands, and would give a comfortable 100-fold margin
of safety with the potent μOR agonist [11C]Caf (8).
The μOR ligands have the useful property of binding in competition with endogenous opioid
peptides, such that changes in the uptake in PET studies can reveal altered endogenous opioid release
under various physiological conditions. This model has been particularly useful in studies of pain
pathways, which largely involve μORs in telencephalon, and in some pharmacological or behavioral
activation studies. However, the simple competition model may be inadequate to account for all
observations. Thus, one of the [11C]Caf (8) studies noted above reports widespread reductions in μOR
availability after smoking [207], despite the 30–3000-fold lower affinity of endogenous opioid peptides
at μOR. This would seem to imply an implausibly enormous increase in peptide release to effect such
changes by competition alone.
Pain studies have so far dominated the field of clinical PET research with OR-ligands, with
relatively few reports on other models or conditions, as summarized in Table 2. For example, there in
only one PET study of opioid receptors in schizophrenia, and only scant documentation in depression,
or for that matter, in a range of common neurological disorders. In several human diseases noted
above, the OR binding may be only 10% higher or lower than in the control group; while these small
differences can have a large effect size, it is perhaps difficult to argue that such small differences can be
causative of complex disorders or symptoms.
Table 2. A summary of the key results with opioid PET in clinical research.
















20–30% decrease in striatum and thalamus only in those




30% reduced in caudate/putamen [150]
Pontine infarct central pain [
11C]DPN (15)
(mixed ligand)
Reduced throughout pain network [151]
Capsaicin-induced acute pain [
11C]Caf (8)
(μOR)
Up to 50% decrease contralateral thalamus, in proportion to
subjective severity [155]
Sustained painful stimulus of the jaw
muscle with saline injection
[11C]Caf (8)
(μOR)
Blateral decrease in binding in the ipsilateral amygdala (5%)




Placebo effect on binding changes [170]




Persistent 10–30% increases in μ-OR binding in pain-related
brain regions [173]
Harm avoidance trait in healthy males [
18F]FE-DPN (16) (mixed
ligand)
Trait correlated positively with binding in vental striatum,
suggesting link with substance abuse [181]
Correlation with BOLD signal responses
A large group of healthy women, binding.
to viewing emotionally arousing scenes
[11C]Caf (8)
(μOR)
Negative correlation in amygdala, hippocampus, thalamus,
and hypothalamus [185]
Major depressive disorder [
11C]GR103545 (25)
(κOR)
No difference from controls [190]
Detoxified cocaine addicts [11C]Caf (8) (μOR)
Increased in frontal and cingulate cortex, which correlated
with the extent of craving [195]
Detoxified alcohol-dependent subjects [11C]MeNTI (22) (δOR)
Globally 10–20% increased binding inverse relationship in
some regions with intensity of craving [203]
Obesity (BMI > 40) [
11C]Caf (8)
(μOR)
Globally 20% lower compared to lean volunteers [218]
Feeding, regardless of the hedonic
experience in non-obese subjects
[11C]Caf (8)
(μOR)
Widespread decreases in binding [222]
Addiction research using PET studies of ORs are so far mostly confined to alcohol, cocaine, and
nicotine abuse and (strangely, perhaps), opioid addiction has hardly been a research theme, other than in
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a few occupancy studies. Since antagonists are relatively safe at doses provoking high occupancy (viz 50
mg naloxone for opioid overdose), we suppose that the Bmax of ORs might be determinable in relation to
opioid addiction and withdrawal by conducting serial PET studies over a range of molar activity, even in
the presence of significant agonist occupancy. Indeed, chronic morphine was reported 45 years ago to
increase the abundance of [3H]naloxone binding sites in rat brain [226], but no such studies are reported
in human opioid users, despite the catastrophe of the current opioid addiction epidemic. This kind of
information might help to understand better the correlates of addiction and relapse. In addition, genetic
studies of dopaminergic and opioid systems in relation to addiction [227], in conjunction with molecular
imaging studies, could help to establish better the risk factors for opioid addiction. Endomorphins
and other novel opioid petpides may present new avenues for obtaining opioid analgesia [228], while
moderating the risk of “iatrogenic opioid addiction”. The development of PET tracers with good binding
properties in vivo and high selectivity for ORs other than the μ-type has accelerated in the past decade.
However, there remain relatively few clinical molecular imaging studies of these important targets. Thus,
developments in radioligand chemistry have for the presence to read for the present presence outpaced
clinical PET imaging, a state of affairs that could enable and motivate a broad range of studies focusing on
non-μORs over the coming decades. Just for example, κORs have an established role in the reinstatement
of stress induced drug use in experimental animals, i.e. nicotine use [229], and very recent results indicate
a relationship between κORs and stress-induced binge cocaine use [197].
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Abbreviations
Compound Name, Synonyms








[11C]BPN (14) [11C]buprenorphine, [6-O-methyl-11C]buprenorphine
Caf
carfentanil, 1-(2-phenylethyl)-4-[(1-oxopropyl)phenylamino]-4-piperidine




DBU 1,8-diazabicyclo[5.4.0]undec-7-ene, CAS RN: [6674-22-2]
DIPEA ethyldiisopropylamine, N,N-diisopropylamine, Hünig’s base
DMF N,N-dimethylformamide
[11C]DPN (15) [11C]diprenorphine, [6-O-methyl-11C]diprenorphine
dppf 1,1’-ferrocenediyl-bis(diphenylphosphine), CAS RN: [121450-46-8]
Dynorphin A [1-17] Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-T rp-Asp-Asn-Gln CAS RN: [80448-90-4]














FDOPA 6-fluoro-L-dopa, 2-Fluoro-5-hydroxy-L-tyrosine, CAS RN: [144334-59-8]
[18F]FE-DPN (16) 6-O-(2-[18F]fluoroethyl)-6-O-desmethyl-diprenorphine
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[11C]GR103545 (25) [(3,4-dichlorophenyl)acetyl]-(3R)-(1-pyrrolidinylmethyl)-1-piperazine carboxylic acid methyl-11C ester
[11C]GR89696 (26) 4-[(3,4-dichlorophenyl)acetyl]-3-(R,S)-(1-pyrrolidinylmethyl)-1-piperazine carboxylic acid methyl-11C ester
HD Huntington’s disease
[11C]LAAM (13)
N-(methyl-11C)-L-α-acetoxymethadol, N-(methyl-11C)-levo-alpha-acetyl methadol, N-(methyl-11C)-levomethadyl
acetate





















MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, CAS RN: [28289-54-5]


















[11C]PEO (18) [11C]phenethyl-orvinol, [6-O-methyl-11C]phenethyl-orvinol
PET positron emission tomography






4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate, CAS RN: [83729-01-5]
TBDMS tert-butyldimethylsilyl protecting group
TDBPN 3-O-trityl-6-O-desmethyl-buprenorphine, CAS RN: [157891-93-5]
TDDPN
3-O-trityl-6-O-desmethyl-diprenorphine, CAS RN: [157891-92-4],
“Luthra-precursor”, TDDPN was the first product of the company ABX advanced biochemical compounds
Biomedizinische Forschungsreagenzien GmbH, Radeberg in 1997
TDPEO 3-O-trityl-6-O-desmethyl-phenethyl-orvionol, CAS RN: [1187551-69-4]
U-50488
3,4-dichloro-N-methyl-N-[(1R,2R)-2-(1-pyrrolidinyl)cyclohexyl]- benzene acetamide, NIH10533, CAS RN:
[67198-13-4]
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Abstract: The number of positron-emission tomography (PET) tracers used to evaluate patients
with brain tumors has increased substantially over the last years. For the management of patients
with brain tumors, the most important indications are the delineation of tumor extent (e.g., for
planning of resection or radiotherapy), the assessment of treatment response to systemic treatment
options such as alkylating chemotherapy, and the differentiation of treatment-related changes (e.g.,
pseudoprogression or radiation necrosis) from tumor progression. Furthermore, newer PET imaging
approaches aim to address the need for noninvasive assessment of tumoral immune cell infiltration
and response to immunotherapies (e.g., T-cell imaging). This review summarizes the clinical value of
the landscape of tracers that have been used in recent years for the above-mentioned indications and
also provides an overview of promising newer tracers for this group of patients.
Keywords: amino acid; FET; FACBC; FDOPA; immunoPET; molecular imaging; glioma; brain
metastases
1. Introduction
For the management of patients with brain tumors, clinicians frequently need to rely on imaging
information obtained from anatomical magnetic resonance imaging (MRI) before, during, and after
the treatment. While contrast-enhanced MRI is of paramount value in neuro-oncology, its specificity
for neoplastic tissue is low, and changes of the blood-brain barrier permeability as indicated by
contrast enhancement are not limited to tumor tissue [1–7]. Nevertheless, precise delineation
of tumor extent, including non-enhancing tumor subregions, is decisive for several diagnostic
and therapeutic steps (e.g., planning of biopsy, surgery, or radiotherapy) [7,8]. Following radio-
and/or chemotherapy, neurooncologists often encounter treatment-related changes. Some of these,
e.g., pseudoprogression, are difficult to differentiate from actual tumor progression with conventional
MRI alone [6–12]. Pseudoprogression describes a phenomenon characterized by an increase of
contrast enhancement without clinical deterioration, and which disappears again over time without
any treatment change [3,9,13–16]. Such treatment-related changes may occur early (in the case of
pseudoprogression typically within the first 12 weeks after chemoradiation completion) or late (several
months or even years after radiotherapy in the case 31 of radiation necrosis) [7,8,17].
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Furthermore, surrogates of treatment response or progression obtained from MRI (e.g., a decrease
of contrast enhancement or the fluid-attenuated inversion recovery (FLAIR) signal hyperintensity)
may be unspecific. They can be influenced by inflammation, infarction, and reactive changes after
surgery [2,6,12,18]. If treatment-related changes remain unidentified, an effective treatment may be
erroneously terminated prematurely. The latter may also harm survival and mislead study results
evaluating novel treatment approaches for tumor relapse [19].
To overcome these diagnostic challenges, imaging techniques with higher diagnostic accuracy than
conventional MRI offering more than just anatomical information are needed. Apart from advanced
MRI techniques, positron-emission tomography (PET) imaging has been evaluated over the past
decades. It has been shown that PET imaging offers additional value in neuro-oncology since it enables
the non-invasive evaluation of molecular and metabolic features of brain tumors. PET, therefore, is of
great value for the indications mentioned above, which are of particular clinical interest [7,8,10,20].
Consequently, the PET task force of the Response Assessment in Neuro-Oncology (RANO) working
group highlighted the additional clinical value of PET imaging using amino acid tracers compared to
anatomical MRI. Accordingly, its widespread clinical use was recommended in patients with glioma
and brain metastases [17,21].
The continuously growing landscape of PET tracers enables the evaluation of many biochemical
processes in patients with brain tumors. With the advent of newer treatment options in neuro-oncology,
in particular, targeted therapy and various immunotherapy options, the needs for additional information
derived from neuroimaging in terms of characterization of the tumor environment, the evaluation of
tumoral drug accumulation, immune cell infiltration, and the diagnosis of treatment-related changes
following these newer treatment options are steadily increasing. Some of these requirements may be
met by the existing landscape of well-established PET tracers, while others can be addressed by newer
ones [22,23].
This review summarizes the value of PET tracers that have been used in brain tumors in recent
years for the most relevant clinical indications. Furthermore, more unique but promising PET tracers
are summarized and discussed.
2. Methods
A PubMed search using the terms “PET”, “positron”, “tracer”, “glioma”, “brain metastases”,
“FDG”, “amino acid”, “methionine”, “FET”, “FDOPA”, “FACBC”, “AMT”, “TSPO”, “GE-180”, “FLT”,
“FAZA”, “EGFR”, “VEGF”, “immunoPET”, “isocitrate dehydrogenase”, “radiotherapy”, “T-cell
imaging”, “reporter gene”, “radiation necrosis”, “pseudoprogression”, “tumor extent”, “response
assessment”, “treatment-related changes”, and combinations thereof was performed until January
2020. The PET tracers were evaluated regarding their clinical value for the delineation of tumor extent,
diagnosis of treatment-related changes, the assessment of treatment response (Table 1), and according
to the information provided by newer PET probes (Table 2).
186






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Molecules 2020, 25, 1471
3. Current Landscape of PET Imaging
PET allows targeting metabolic and molecular processes in patients with brain tumors relevant to
diagnosis, treatment, and prognosis that cannot be assessed with anatomic computed tomography
(CT) or MR imaging. A variety of PET tracers have been evaluated predominantly in glioma patients
or patients with brain metastases with the main focus on glucose metabolism, amino acid transport,
proliferation, hypoxia, blood flow, or angiogenesis. This section will provide an overview of PET
tracers for brain tumors that have been evaluated in human subjects in the last years, especially for
those above mentioned highly relevant indications in clinical routine. An overview is presented in
Table 1.
3.1. PET Imaging of Glucose Metabolism
[18F]-2-Fluoro-2-deoxy-D-glucose ([18F]FDG) is the most widespread PET tracer in nuclear
medicine. In neoplastic tissue, the uptake of [18F]FDG reflects the increased expression of glucose
transporters and hexokinase. The latter enzyme phosphorylates glucose and [18F]FDG. In the central
nervous system, the physiologically high and varying uptake of [18F]FDG in healthy brain parenchyma
hampers the accurate delineation of the brain tumor. This limits the diagnostic accuracy for the correct
identification of treatment-related changes and assessment of treatment response in gliomas and brain
metastases [17,21]. It has repeatedly been shown that the diagnostic accuracy of [18F]FDG regarding the
differentiation of radiation-induced changes from glioma and brain metastases recurrence is inferior
to other imaging modalities, including advanced MRI and amino acid PET [17,24–26]. However,
[18F]FDG PET seems to be of value for the delineation of tumor extent and assessment of treatment
response in patients with primary central nervous system (CNS) lymphoma [27–30].
3.2. PET Using Amino Acid PET Tracers
Radiolabeled amino acid tracers (Figure 1) are of great interest in brain tumor imaging because of
the high tumor-to-brain contrast based on the relatively high specificity for neoplastic tissue and the
low uptake in healthy brain tissue [7,8,21,31–33].
Figure 1. Chemical structure of radiolabeled amino acids.
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3.2.1. Uptake Mechanisms of Amino Acid PET Tracers
The uptake of the amino acid tracers O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET),
[11C]methyl-L-methionine ([11C]MET), and 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine ([18F]FDOPA)
is mainly based on the increased expression of large neutral amino acid transporters of the l-type
(LAT) in gliomas and brain metastases (i.e., subtypes LAT1 and LAT2) [7,34–37]. Moreover, LAT1
overexpression correlates with malignant phenotypes and proliferation of gliomas. It is associated with
glioma angiogenesis [38,39]. A critical consideration for the practical application of [11C]MET compared
to [18F]FET or [18F]FDOPA is the half-life of the [11C]-isotope ([18F] 110 vs. [11C] 20 min) [40,41],
which allows the transport of [18F]FET and [18F]FDOPA to PET facilities. In contrast, the use of
[11C]MET necessitates an on-site cyclotron. In many European centers, this logistical disadvantage
has led to the replacement of [11C]MET predominantly by [18F]FET [7]. When using [18F]FDOPA, the
physiological uptake in the striatum may hamper the evaluation of tumor extent [7,42].
The L-tryptophan analogue α-[11C]-methyl-L-tryptophan ([11C]AMT) is another radiolabeled
amino acid with uptake via the LAT system. Additionally, [11C]AMT uptake is mediated via the
kynurenine pathway and has a rate-limiting enzyme indoleamine 2,3-dioxygenase [43]. Indoleamine
2,3-dioxygenase is upregulated in various cancers including gliomas [44], which prompted the use of
[11C]AMT PET in patients with brain tumors [45].
Other tracerssuchas thesyntheticaminoacidanaloganti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic
acid ([18F]FACBC or [18F]fluciclovine) are also LAT-mediated but use additionally the alanine, serine, and
cysteine transporter 2, which is upregulated in many human cancers [46–49].
3.2.2. Value of Amino Acid PET Tracers for Brain Tumor Patients
For the planning of diagnostic and therapeutic procedures, the precise delineation of tumor
spread is essential. For example, the tumor extent as assessed by amino acid PET provides valuable
information for planning stereotactic biopsies, resection, and radiotherapy [1,50–52]. For [11C]MET and
[18F]FET, it has been shown that the delineation of tumor extent, particularly in non-enhancing gliomas,
can be assessed with high accuracy using amino acid PET [51,53]. Preliminary data suggest that newer
tracers such as [18F]FACBC PET are also helpful in identifying metabolically active and non-contrast
enhancing tumor regions in glioma patients [54–56]. Moreover, it has been shown that in the majority
of cases, the metabolically active tumor burden as assessed by amino acid PET extends considerably
beyond the volume of MRI contrast enhancement, which is of significant relevance for subsequent
treatment planning [1,7,53,57]. Regarding the comparability of PET tracers for this indication, [11C]MET,
[18F]FET, and [18F]FDOPA seem to be equally informative [58–61]. Nevertheless, it has to be pointed
out that 20–30% of grade II gliomas, according to the World Health Organization (WHO) classification
of tumors of the central nervous system [62,63], show no amino acid uptake [64–66]. A negative amino
acid PET, therefore, does not exclude glioma [8].
For the differentiation of treatment-related changes from tumor relapse, amino acid PET also
provides valuable diagnostic information. Using [18F]FET or [18F]FDOPA, especially the differentiation
of radiation injury from tumor relapse in glioma patients, as well as in patients with brain metastases,
can be obtained with a relatively high diagnostic accuracy between 80–90% (Figure 2) [11,26,67–80].
Importantly, in glioma patients, parameters derived from dynamic [18F]FET PET acquisition may
further increase the diagnostic accuracy [67,74–76,78]. This has also been demonstrated in patients with
brain metastases who underwent radiosurgery for brain metastases treatment [80,81]. The diagnostic
accuracy of [11C]MET PET regarding this clinical question is slightly lower (approximately 75%) [8,82,83],
which is most probably related to the higher affinity of [11C]MET for inflammation [84]. First PET studies
using [11C]AMT or [18F]FACBC suggest that these tracers may also be of value for the differentiation
of radiation injury from glioma progression [85,86].
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Figure 2. Radiation necrosis and chronic inflammation in a patient with brain metastases of a
B-Raf proto-oncogene (BRAF)-mutated malignant melanoma who had been treated with whole-brain
radiation therapy combined with concurrent dabrafenib plus trametinib. Twenty-four months later, the
contrast-enhanced magnetic resonance imaging (MRI) indicates a recurrence of the brain metastases
(left panel), whereas the O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) positron-emission tomography
(PET) shows only insignificant metabolic activity and is consistent with the findings of treatment-related
MRI changes. Neuropathological findings (right panel) after stereotactic biopsy show signs of radiation
necrosis as well as considerable T-cell infiltration. (A) Hyaline, eosinophilic necrosis with evidence
of a necrotic vessel wall (arrowhead). (B) Vital brain parenchyma besides necrosis with activated
microglia cells (arrowhead), and blood vessels with lymphocyte infiltrates (arrows) without evidence
of tumor cells (inserted box). (C) Adjacent to inflamed blood vessels (arrows), a resorption of necroses
by macrophages (block arrows) as well as activated microglia cells (arrowheads) and astrocytes in the
brain parenchyma (inserted box). (D) The main population of intra- and perivascular T-cell infiltrates
are CD3+ (arrow), but also CD4+ (inserted box left) and CD8+ (inserted box right) T-cells contribute to
the infiltrates (modified from Galldiks et al. [10], with permission from Oxford University Press).
The advent of immunotherapy using immune checkpoint inhibitors and targeted therapy has
improved the survival of cancer patients, particularly in melanoma and lung cancer. Recent trials
suggest that patients with brain metastases from these tumor entities may also benefit from these
agents alone or in combination [87]. Regarding patients with brain metastases treated with checkpoint
inhibitors or targeted therapy (frequently combined with radiotherapy), initial data indicate that amino
acid PET may provide valuable information for differentiating relapse from equivocal MRI findings
related to immunotherapy-induced inflammation [10,88].
Recently, a variety of experimental treatment options has been introduced for treating patients
with high-grade glioma. [18F]FET PET was shown to differentiate benign MRI findings related to these
experimental therapies, e.g., immunotherapy with dendritic cell vaccination or targeted therapy with
regorafenib, from tumor relapse [89,90]. However, the number of patients treated with these therapies
and monitored with [18F]FET PET is still small, and the results should be interpreted with caution.
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The assessment of the response to a particular neurooncological treatment is of clinical relevance
since treatment decisions can be negatively affected by treatment-related changes. The accurate
assessment of response helps both to discontinue an ineffective treatment option as early as possible
and to prevent an effective treatment from being erroneously terminated prematurely with a potentially
harmful influence on survival. Furthermore, the evaluation of response also helps to avoid possible
treatment side effects, e.g., bone marrow depression or fatigue, and, therefore, to maintain or even
improve life-quality. It has been shown in glioma patients that the assessment of response to alkylating
chemotherapy (i.e., temozolomide or lomustine) using [11C]MET or [18F]FET PET provides valuable
additional information compared to contrast-enhanced MRI. Importantly, metabolic PET responders
(i.e., patients with a decrease of tumor-to-brain ratios or metabolically active tumor volumes at follow-up
relative to baseline imaging) had a significantly longer survival than metabolic non-responders [91–98].
Following antiangiogenic therapy using bevacizumab, the use of reduced contrast enhancement as
a surrogate marker for treatment response is not optimal due to a phenomenon called pseudoresponse [9].
Pseudoresponse describes a decrease of contrast enhancement related to a rapid restoration of the
blood-brain barrier by antiangiogenic drugs [9]. However, a clinical benefit is not infrequently lacking
in patients with an impressive radiological response (pseudoresponse). [18F]FET and [18F]FDOPA PET
may provide valuable information regarding the identification of pseudoresponse [99–102]. Moreover,
[18F]FDOPA and [18F]FET PET were also able to predict a favorable clinical outcome in bevacizumab
responders [101–104].
After chemoradiation completion, newly diagnosed glioblastoma patients can be treated with
tumor-treating fields therapy in addition to adjuvant temozolomide chemotherapy [105]. Initial studies
suggest that amino acid PET might identify responding patients undergoing tumor-treating fields
therapy, but it has to be considered that the response can also be related to the concurrently applied
chemotherapy or delayed chemoradiation effects [106,107].
3.3. PET Imaging of the Mitochondrial Translocator Protein
PET ligands targeting the 18 kDa mitochondrial translocator protein (TSPO), located at the
outer mitochondrial membrane and formerly known as the peripheral benzodiazepine receptor, are
also of interest in neuro-oncology [108,109]. TSPO is associated with neuroinflammation due to its
expression in activated microglia, endothelial cells, and infiltrating macrophages [109]. The PET ligand
[11C]PK11195 was one of the first ligands evaluated for TSPO expression in glioma patients [110–112].
The recently introduced TSPO ligand GE-180 labeled with [18F] offers an increased binding
specificity and was tested in patients with gliomas [113] and neuroinflammatory diseases such as
multiple sclerosis [114–116]. Regarding the delineation of glioma extent, it has been demonstrated that
the [18F]GE-180 uptake volume is significantly larger than the volume of contrast enhancement [113,117].
However, when comparing [18F]FET with [18F]GE-180 uptake volumes intraindividually in terms of
spatial distribution, the overlap is only moderate (Dice similarity coefficient, 0.55) despite comparable
tumor volumes [117]. These differences might help to characterize glioma heterogeneity and warrant
further studies with spatial correlation of imaging findings of [18F]FET uptake to [18F]GE-180 uptake
with neuropathology.
3.4. PET Imaging of Cellular Proliferation
The radiolabeled nucleoside 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT) is a pyrimidine analogue.
It is used to evaluate cellular proliferation because of its rapid incorporation into newly synthesized
DNA [118]. [18F]FLT is trapped intracellularly after phosphorylation by the thymidine kinase-1, a
cytoplasmatic enzyme expressed during cell proliferation [46,119]. However, the requirement of a
disrupted blood-brain barrier for [18F]FLT uptake may limit its diagnostic use [2,120]. For example,
in terms of tumor detection and delineation, [18F]FLT PET was less sensitive than [11C]MET PET to
detect WHO grade II gliomas, which usually show no contrast enhancement [121]. Furthermore,
a meta-analysis evaluating the value of [18F]FLT PET for the diagnosis of glioma recurrence based
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on approximately 800 patients showed no superiority of [18F]FLT (pooled sensitivity, 82%; pooled
specificity, 76%) compared to [18F]FDG (pooled sensitivity, 78%; pooled specificity, 77%) [122].
On the other hand, [18F]FLT PET seems to be useful for the assessment of response to antiangiogenic
therapy with bevacizumab in patients with recurrent malignant glioma. [18F]FLT PET was able to
identify a reduction of proliferative activity in responding patients with favorable outcome as an
indicator for response compared to metabolic non-responders [123–125]. Furthermore, [18F]FLT PET
was used in patients with malignant melanoma brain metastases treated with targeted therapy or
immunotherapy using checkpoint inhibitors [126]. In that study, responding patients showed a
clearer reduction of proliferative activity as assessed by [18F]FLT PET than the decrease of contrast
enhancement on standard MRI.
3.5. PET Imaging of Tumor Hypoxia
Hypoxia is a key factor in treatment outcome in various cancers, including glioma. It has been
shown that hypoxia is associated with tumor persistence and resistance to cancer treatment [127]. To
further evaluate this phenomenon using PET, the tracer [18F]fluoromisonidazole ([18F]FMISO) has
been developed, which is trapped in hypoxic but viable cells [46,128,129]. It has been demonstrated in
glioblastoma patients that [18F]FMISO PET delineates additional hypoxic tumor subregions which
exceed the contrast-enhancing tumor parts, indicating that hypoxia may induce peripheral tumor
growth [130]. A subsequent study showed that the metabolically active tumor volume in [11C]MET
PET strongly correlated with the hypoxic volume defined by [18F]FMISO [131]. Importantly, the tumor
area on [11C]MET PET exceeded the area of the contrast enhancement on MRI in the range of 20–30%.
More recently, [18F]FMISO PET has been used for monitoring the effects of antiangiogenic therapy
with bevacizumab in patients with recurrent malignant glioma [132,133]. It was shown that patients
who had a response in both contrast-enhanced MRI and [18F]FMISO PET had significantly longer
survival than patients who responded on MRI only [133].
[18F]-labeled flouroazomycin arabinoside ([18F]FAZA) may be a promising alternative to
[18F]FMISO offering an improved tumor-to-background ratio due to faster blood clearance [134,135].
Preliminary data in glioblastoma patients suggest that [18F]FAZA PET might be of value for radiotherapy
response assessment [136].
3.6. PET Imaging of Tumor Perfusion
The evaluation of regional cerebral blood flow (rCBF) allows identifying brain tumors with
high vascularization. rCBF can be measured by PET using [15O]-labeled water. However, [15O]H2O
requires an on-site cyclotron because of its very short half-life (2 min) [137]. The development and easy
accessibility of perfusion-weighted CT and MRI has led to various studies evaluating brain tumors
outnumbering [15O]H2O PET studies by far. In direct comparisons, it has been shown that rCBF values
differ considerably between CT- and MRI-based perfusion measurements and [15O]H2O PET [138,139].
In patients with malignant gliomas undergoing chemoradiation with nitrosoureas, a reduction of
rCBF was evaluated using [15O]H2O PET, but data on subsequent survival as an indicator for treatment
response are lacking [140,141].
3.7. PET Imaging of Angiogenesis
The vascular endothelial growth factor (VEGF) is overexpressed by most tumors, including
brain tumors, and an important trigger for neovascularization [142]. Bevacizumab is a recombinant
humanized monoclonal antibody against VEGF and appears to prolong progression-free survival
and decrease steroid usage in patients with malignant glioma [142,143]. Based on these properties,
[89Zr]-labeled bevacizumab PET imaging has been evaluated for tumoral drug accumulation in
pediatric patients with diffuse intrinsic pontine glioma [144]. That study demonstrated intertumoral
heterogeneity of drug accumulation and may aid in selecting those patients with the greatest chance
of benefit from bevacizumab [144,145]. Other studies have used [64Cu]-labeled conjugates of VEGF
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with DOTA (1,4,7,10-tetra-azacylododecane N,N′,N′′,N′′′-tetraacetic acid) for PET imaging in animal
models [146–148]. Similarly, these approaches suggest the clinical value for the identification of patients
who will benefit from anti-VEGF therapy.
In adult glioblastoma patients, it has been demonstrated that accumulation of [123I]VEGF in the
tumor region of glioblastomas can be assessed using single photon emission computed tomography
(SPECT) imaging [149]. Importantly, high uptake of [123I]VEGF was able to identify glioblastoma
patients with a poor clinical outcome.
4. Emerging Fields of PET Imaging
Currently, blockade of immune checkpoints and other immunotherapy options (i.e., vaccination
strategies, oncolytic virus approaches, cell-based immunotherapy such as chimeric antigen receptor
T-cells (CAR-T cells) are under evaluation in patients with brain cancer including glioma and brain
metastases. Furthermore, recent study results suggest that newer-generation targeted therapies are a
promising treatment option, especially in a subset of patients with brain metastases [150]. As a new
treatment option, mutations of the isocitrate dehydrogenase (IDH) gene, which frequently occur in
WHO grade II and III gliomas, have also gained interest as a potential treatment target [151,152]. All
these promising treatment options impose new demands on brain imaging (e.g., imaging of immune
reactions in the brain). The current body of literature suggests that PET has the potential to adapt to
these needs. An overview is presented in Table 2.
4.1. PET Imaging of the Epidermal Growth Factor Receptor Family
Both the epidermal growth factor receptor (EGFR) and the human epidermal growth factor
receptor 2 (HER2) are transmembrane protein receptors and belong to the EGFR family. These receptors
are targets for various growth factors that mediate various cellular processes such as differentiation or
proliferation. In clinical oncology, various gene mutations may lead to overexpression of these proteins
and are associated with the development of a variety of cancers. Importantly, these mutations also play
a significant role in various treatment options, including tyrosine kinase inhibitors and monoclonal
antibodies targeting EGFR, HER2, or both [153], as well as for imaging. Especially the evaluation of a
response to these targeted therapy options in patients with brain metastases (from melanoma, lung,
or breast cancer) as well as in glioma patients is the indication with the highest clinical potential for
EGFR- and HER2-targeted PET [154,155]. In recent years, radiolabeled EGFR and HER2 antibodies, as
well as tyrosine kinase inhibitors, have been used as PET imaging agents.
For identifying EGFR overexpression, PET ligands such as [11C]erlotinib, [11C]PD153035, and
[89Zr]Zr-DFO-nimotuzumab have been used [156–158]. The most relevant PET tracers for imaging of
HER2 overexpression are [64Cu]DOTA-trastuzumab and [89Zr]pertuzumab (Figure 3) [159,160].
4.2. Immuno-Imaging: Immuno-PET and Imaging of T-Cells
In recent years, immunotherapy with antibodies directed against immune checkpoints such as the
cytotoxic T-lymphocyte antigen-4 (CTLA-4; e.g., ipilimumab), the programmed cell death receptor-1
(PD-1; e.g., pembrolizumab, nivolumab), or the programmed cell death protein ligand 1 (PD-L1; e.g.,
atezolizumab) have gained paramount importance in clinical oncology and neuro-oncology. However,
the efficacy and responsiveness of these agents may vary considerably among different cancer types
and across individuals. Biomarkers obtained from tumor tissue, such as PD-1 and PD-L1 expression,
can help to select patients. However, these tissue biomarkers are limited, and some patients show no
response even if the target is present [161]. Therefore, the significance of PET for predicting response
to immunotherapy and patient selection increases. Among other methods, immuno-PET combines
antibodies or antibody fragments with a radionuclide and takes advantage of the specificity and affinity
of antibodies and the sensitivity of PET [162]. Generally, targets for immuno-PET can be T-cell markers
(e.g., CD4+, CD8+), immune checkpoints (e.g., CTLA-4, PD-1, PD-L1), or biomarkers of the immune
response (e.g., interferon-γ, interleukin-2) [23].
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Figure 3. [64Cu]-DOTA-trastuzumab positron-emission tomography (PET) and contrast-enhanced
magnetic resonance imaging (MRI) performed one day after initiation of treatment with trastuzumab
in a patient with a human epidermal growth factor receptor 2 (HER2)-positive breast cancer with
brain metastases. In single brain metastases, [64Cu]-DOTA-trastuzumab PET helps to improve lesion
detection (arrow) (modified from Tamura et al. [160], with permission from the Society of Nuclear
Medicine and Molecular Imaging).
First-in-human studies suggest that targeting PD-1 with [89Zr]nivolumab [163] or PD-L1 with
[89Zr]atezolizumab [164] is useful as imaging biomarkers to non-invasively evaluate the expression
of these immune checkpoints in patients with extra- and intracranial cancer [164,165]. Engineered
target-binding proteins (adnectins) for PD-L1 ligands such as [18F]BMS-986192 are currently under
evaluation [166].
Tumor-infiltrating T-cells (such as CD8+) play an essential role in the activation of immune
cells in response to checkpoint inhibition [167]. Recently, it has been shown that a radiolabeled
[89Zr]IAB22M2C has the potential to visualize CD8+ T-cell-enriched tumor tissue [168]. The assessment
of immune cells infiltrating tumors has also been investigated with PET using radiolabeled clofarabine
(2-chloro-2′-deoxy-2′-[18F]fluoro-9-b-D-arabinofuranosyl-adenine; [18F]CFA) [169]. [18F]CFA is a
substrate for the enzyme deoxy-cytidine kinase, which is overexpressed in immune cells such as CD8+
T-cells [169]. Importantly, [18F]CFA PET has shown a great clinical potential to localize and quantify
immune responses in glioblastoma patients undergoing dendritic cell vaccination treatment combined
with immune checkpoint blockade (Figure 4) [169].
Another interesting approach is the transfection of immune cells with a reporter gene that encodes
a protein that can be specifically targeted by a radiolabeled reporter probe [170]. Imaging of reporter
gene expression of cells transfected with the herpes simplex virus type 1 thymidine kinase reporter
gene has been demonstrated using 9-[4-[18F]fluoro-3-(hydroxymethyl)butyl]guanine ([18F]FHBG) [171].
Moreover, this technique has the potential to image recently introduced cell-based therapies with
CAR-T cells [23]. Accordingly, a study with recurrent high-grade glioma patients suggested that
[18F]FHBG PET can detect reporter gene expression in CAR-engineered cytotoxic T-lymphocytes [172].
4.3. PET Imaging of Isocitrate Dehydrogenase Mutations
In patients with malignant glioma, the modest outcome improvement following both standard
therapy (i.e., chemoradiation with temozolomide) and newer treatment options (e.g., tumor-treating
fields) has prompted various efforts to identify molecules that are fundamental to regulate tumor
progression and provide additional options for personalized therapy in this group of patients.
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Figure 4. Detection of immune response in a patient with recurrent glioblastoma
using 2-chloro-2′-deoxy-2′-[18F]fluoro-9-b-D-arabinofuranosyl-adenine ([18F]CFA) positron-emission
tomography (PET) and advanced magnetic resonance imaging (MRI) before (upper panel) and after
treatment with dendritic cell vaccination and programmed cell death receptor-1 (PD-1) blockade
using pembrolizumab (lower panel). Following treatment, [18F]CFA uptake is considerably increased,
indicating an immune-cell infiltration, and helps distinguishing tumor progression from inflammation
(modified from Antonios et al. [169], with permission from the National Academy of Sciences).
Accordingly, the enzyme isocitrate dehydrogenase (IDH) has gained interest as a potential
target. IDH is an enzyme of the Krebs cycle, catalyzing the oxidative decarboxylation of isocitrate
to alpha-ketoglutarate. Mutations in the IDH1 and IDH2 gene, frequently occurring in WHO grade
II or III astrocytomas and oligodendrogliomas, result in a significant increase of the oncometabolite
2-hydroxyglutarate (2-HG) [173,174]. In cells with IDH mutant enzymes, the accumulation of 2-HG
alters several downstream cellular activities, causing epigenetic dysregulation and, consequently,
a block in cellular differentiation, leading to oncogenesis [175].
Therefore, mutant IDH proteins are highly attractive targets for inhibitory drugs. In glioma
patients, selective oral IDH inhibitors of IDH1 (i.e., ivosidenib, BAY-1436032), pan-IDH1/2 (i.e., AG-881),
and vaccination strategies targeting the IDH1R132H mutation are currently under clinical evaluation.
Initial results predominantly from phase-1 studies are promising and suggest that these inhibitors
are safe and have antitumoral activity [151,152,176]. Although immunohistochemistry and genomic
sequencing are the methods of choice for the detection of an IDH mutation, these techniques are
invasive and are not appropriate for treatment monitoring, which requires continual assessment.
Furthermore, the use of magnetic resonance spectroscopy (MRS) to non-invasively evaluate 2-HG is
technically challenging, and may be false-positive in 20% of cases [177,178].
Newer PET probes for imaging mutant IDH expression in gliomas may be an alternative imaging
method. Recent radiochemical developments suggest that triazinediamine or butyl-phenyl sulfonamide
analogs labeled with [18F] are promising candidate radiotracers for noninvasive PET imaging of IDH
mutations in gliomas [179,180]. Furthermore, a [18F]-labeled IDH1 inhibitor (AGI-5198) has also been
investigated [181]. Interestingly, Koyaso and colleagues demonstrated that [11C]acetate uptake in IDH
mutant cells is significantly higher than in IDH wild-type cells because of metabolic trapping [182].
Taken together, further efforts to translate these promising approaches for IDH imaging into clinical
use are warranted.
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4.4. PET-Based Theranostics
The combination of therapeutics and diagnostics, also termed as theranostics, supports the concept
of precision oncology. One PET-based theranostic approach is the peptide receptor radionuclide
therapy (PRRT), in which overexpressed tumor-specific receptors are used as a therapeutic target.
By exchanging the radionuclide used for diagnostic PET such as [68Ga] with a radiation source, typically
ß-emitters like [177Lu] or [90Y], the same PET tracer can be used for therapy. Although there are currently
no theranostic approaches clinically established for gliomas or brain metastases, there are promising
concepts. For example in patients with glioblastoma, a potential target is the overexpressed chemokine
receptor-4 (CXCR4) which is associated with a poor clinical outcome [183–185]. Visualization of CXCR4
expression using diagnostic PET with CXCR4-directed [68Ga]Pentixafor® has been demonstrated in
glioblastoma patients [186].
Another potential target is the prostate-specific membrane antigen (PSMA) which may be
overexpressed in prostate cancer and also in predominantly malignant gliomas. Diagnostic PET
imaging of PSMA expression in patients with malignant glioma can be obtained using [68Ga]-labeled
PSMA ligands [187–189]. The use of the theranostic agent [177Lu]-PSMA-617 has demonstrated
favorable safety and efficacy in patients with advanced prostate cancer, indicating the potential to
be also of value for patients with malignant glioma [190]. Nevertheless, the potential of theranostics
needs to be further evaluated in patients with malignant gliomas.
5. Discussion
Anatomical MRI is currently the method of choice for neuroimaging of brain tumors, but PET
complements this technique and provides important biological information that cannot be obtained
from anatomical MRI alone. Currently, best-established PET tracers in neuro-oncology are radiolabeled
amino acids targeting L-system transporters. However, a considerable number of other PET tracers
have been developed for brain tumor patients and allow the evaluation of a wide range of biochemical
processes. A variety of PET biomarkers offers the potential to play a clinically significant role for the
monitoring of newer treatment options such as targeted therapy and immunotherapy, e.g., by providing
an early assessment of response to these options, and for a more accurate differentiation of viable
tumor from treatment-related changes. A major current shortcoming is the lack of large, prospective
clinical trials in patients with both glioma and brain metastases for many of these PET tracers. Despite
encouraging early study results in the field, it has to be further demonstrated that these tracers improve
considerably patient management and outcome.
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Abstract: Glioblastoma multiforme (GBM) is the deadliest type of brain tumor, affecting approximately
three in 100,000 adults annually. Positron emission tomography (PET) imaging provides an important
non-invasive method of measuring biochemically specific targets at GBM lesions. These powerful
data can characterize tumors, predict treatment effectiveness, and monitor treatment. This review
will discuss the PET imaging agents that have already been evaluated in GBM patients so far, and
new imaging targets with promise for future use. Previously used PET imaging agents include the
tracers for markers of proliferation ([11C]methionine; [18F]fluoro-ethyl-L-tyrosine, [18F]Fluorodopa,
[18F]fluoro-thymidine, and [18F]clofarabine), hypoxia sensing ([18F]FMISO, [18F]FET-NIM, [18F]EF5,
[18F]HX4, and [64Cu]ATSM), and ligands for inflammation. As cancer therapeutics evolve
toward personalized medicine and therapies centered on tumor biomarkers, the development
of complimentary selective PET agents can dramatically enhance these efforts. Newer biomarkers
for GBM PET imaging are discussed, with some already in use for PET imaging other cancers
and neurological disorders. These targets include Sigma 1, Sigma 2, programmed death ligand
1, poly-ADP-ribose polymerase, and isocitrate dehydrogenase. For GBM, these imaging agents
come with additional considerations such as blood–brain barrier penetration, quantitative modeling
approaches, and nonspecific binding.
Keywords: PET imaging; GBM; biomarkers; Sigma 1; Sigma 2; PD-L1; PARP; IDH
1. Introduction
Glioblastoma Multiforme (GBM) is a fast growing, invasive brain tumor that typically results in
death in the first 15 months after diagnosis [1]. It develops from glial cells, astrocytes or oligodendrocytes,
and can evolve from lower-grade tumors or de novo. Previously, GBM was characterized as ‘grade
IV’ astrocytoma. Recently, the World Health Organization (WHO) updated the classification of brain
tumors to include genotypic markers, building on the histological markers considered previously [2].
Glioblastoma can be classified by a single nucleotide polymorphism in the isocitrate dehydrogenase
(IDH) gene as wild-type or mutant. Approximately 10% of glioblastomas are IDH-mutant [2].
IDH-mutant status weakly predicts long-term survival (over 3 years post diagnosis) [3]. GBM tumors
are heterogenous in location (with 25%–43% incidence in frontal lobes), histopathology, and the
tumor microenvironment [4]. The first line of treatment for GBM is surgery, followed by radiation
and chemotherapy [1]. Temozolomide, a DNA alkylating agent is often used for chemotherapy.
In 2015, the vascular endothelial growth factor inhibitor Bevacizumab was fast-tracked for use in GBM
after demonstrating efficacy in shrinking or halting tumor growth. However, it has failed to show
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improvement in overall survival [5]. Patients with GBMs have a very low survival rate with very few
treatment options, making this a particularly acute health challenge.
Medical imaging provides critical information for diagnosing, staging, and monitoring the
treatment of GBM. While formal diagnosis relies on histopathology and genetic markers for grading,
structural magnetic resonance images (MRIs) are routinely acquired and can be used in guiding surgery.
Additional structural MRI methods can accurately classify and grade tumors with high accuracy,
though it has not been adopted yet as common practice [6]. Positron emission tomography (PET)
imaging provides important complementary information to anatomical MRI data. In this functional
type of imaging, biochemical information about the tumor and the tissue surrounding it can be
measured non-invasively. GBMs typically are fast growing, giving an important role for specific PET
radioligands to quantify proliferation. PET imaging is also uniquely positioned to identify ideal cases
for targeted treatments and evaluate treatment progression.
This article provides an overview of the novel imaging tracers used in PET imaging of brain
tumors. Discussion includes the strengths, limitations, and pitfalls of individual imaging biomarker
strategies, and general challenges associated with PET imaging of brain tumors. We first provide
a brief overview of established PET imaging biomarkers (glycolysis, amino acid metabolism, DNA
replication, hypoxia, and inflammation), followed by newer imaging targets (Sigma 1/ 2, programmed
death ligand 1, poly-ADP-ribose polymerase, and isocitrate dehydrogenase) with promise to image
glioblastoma lesions. None of these biomarkers are unique to glioblastoma, though their presence has
been found in resected brain tumors. This work concludes with important quantitative considerations
for use of these imaging biomarkers in the evaluation and treatment of GBM patients.
2. Overview of PET Imaging Agents for Brain Tumor
2.1. Sustained Proliferation Markers: Glycolysis, Amino Acid Transportation, and DNA Replication
The classic approach to imaging tumors in general, and in application to GBM, has been to
probe the functional necessities of proliferation. These necessities include glucose metabolism, protein
synthesis, and DNA replication. From a biochemical prospective, these functions highlight the ‘building
block’ small molecules that compose macromolecules: sugars, nucleotide bases, and amino acids.
Radionuclide-labeled forms of these building blocks have been employed to study these functions
with PET imaging. The gold standard of most cancer imaging is [18F]FDG (1), a fluorine-18 glucose
analogue. This radiotracer is actively taken up by the glucose transporter and participates in the first
step of glucose metabolism (phosphorylation), then becomes trapped in the cell [7]. [18F]FDG PET
allows for the functional imaging of glucose metabolism, a relative gold mine of information in most
cancers. However, the brain has naturally high uptake of [18F]FDG, which complicates interpretation
of GBM lesions near gray matter. Further efforts to image proliferation through the ‘building block’
strategy include neutral amino acid analogues ([11C]methionine (2); [18F]fluoro-ethyl-L-tyrosine (3);
[18F]Fluorodopa (4)) and deoxynucleoside bases ([18F]fluoro-thymidine (5); and [18F]clofarabine (6))
(Figure 1).
[11C]Methionine ([11C]MET) was developed shortly after [18F]FDG [8,9]; it was considered a
valuable tracer because methionine, an essential amino acid, can be used in protein synthesis. Both
L-and D-isomers were synthesized, and no difference in accumulation was observed [10]. This lack
of selectivity between stereoisomers indicated that [11C]MET was not being incorporated for protein
synthesis, as only L-amino acids are incorporated into proteins. Despite this, [11C]MET was still
used as an alternative to [18F]FDG PET imaging because it is more sensitive (see review [11]).
[18F]fluoroethyl-tyrosine ([18F]FET) was developed as another amino acid based alternative to
[18F]FDG [12]. Unlike [11C]MET, [18F]FET is a modified amino acid, which led to questions about
the radiotracer’s ability to be taken up into cells. In cellular experiments and tumor-bearing mice,
it was found that [18F]FET is actively transported into cells [13]. The transporter responsible was later
identified as l-amino acid transporter (LAT-1) [14]. [18F]FET PET combined with MRI can dramatically
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improve glioma identification and tumor diagnosis [15]. In terms of the diagnostic performance, MRI
alone yielded a 96% sensitivity and 53% specificity; the combined technique achieved 93% sensitivity
and 94% specificity [15]. While MRI is the gold standard for diagnosis and tumor staging, [18F]FET
PET imaging provides complementary information in the form of increased specificity.
 
Figure 1. Radiotracers for markers of cellular proliferation.
The nonessential amino acid and neurotransmitter dopamine has also been used as a PET tracer
in the form of [18F]L-fluoro-dihydroxyphenylalanine ([18F]FDOPA), which becomes a dopamine
analogue in vivo after decarboxylation. [18F]Fluoro-dopamine can then be further taken up into
vesicles by VMAT, or metabolized by monoamine oxidases or catechol-O-methyltransferase. This gives
[18F]FDOPA a particular utility in neuroendocrine tumors [16] in addition to the obvious neurological
application. [18F]FDOPA imaging in pre-operative glioma patients has shown a significant correlation
between WHO grade and the volume of MRI contrast enhancement, volume of T2 hyperintensity,
and [18F]FDOPA uptake (as SUVmax ratio of tumor to normal tissue) [17]. From this 45 patient cohort,
a multivariate Cox regression suggested that [18F]FDOPA PET and age were significant prognostic
factors for overall survival [17]. A major limitation of [18F]FDOPA use is the radiosynthesis. One of
the first described high yielding radiosynthesis involved electrophilic fluorination [18]. Electrophilic
fluorination is not a desirable method for routine clinical production because of the hazardous nature of
F2 gas, however, improved syntheses were recently published involving nucleophilic fluorination [19].
Concurrent with the use of amino acid analogues, the deoxynucleoside base derivative
[18F]fluorothymidine ([18F]FLT) was developed. [18F]FLT is trapped in tissues after phosphorylation
by thymidine kinase [20]. This trapping was thought to be due to accumulation into growing DNA
chains, as fluorothymidine was originally developed to terminate DNA, and used in HIV therapy.
In reality, less than 1% of [18F]FLT was found to be incorporated in DNA in cellular studies, though it
correlated highly with [3H]thymidine uptake [21]. Despite this lack of accumulation in DNA, [18F]FLT
imaging confirms cellular uptake and correlates to Ki-67 expression on the corresponding resected
tumor tissue [22]. Thymidine kinase is a principal enzyme in the DNA salvage pathway, and is most
active in G1 and S phases of the cell cycle [23]. Because of its lower uptake in normal brain than
[18F]FDG, glioma patients underwent [18F]FLT imaging and a similar correlation was observed with
proliferative tissue markers [24]. When [18F]FLT PET was used to monitor treatment in malignant
glioma trials and compared to MRI responses, [18F]FLT-PET was more predictive of overall survival
than MRI [25]. Despite this utility, [18F]FLT is less widely used because of nonspecific binding in
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individuals [26], and because blood–brain barrier (BBB) penetration is limited, which limits its use
specifically for glioma imaging.
An alternative method to [18F]FLT, which is phosphorylated by thymidine kinase, is to target
deoxycytidine kinase (dCK). The activity of dCK, TK, and the other deoxyribonucleoside kinases are to
provide an alternative pathway to de novo synthesis of DNA precursors [27]. Additionally, the activity
of these kinases is critical for the activation of nucleoside analogues that are used for chemotherapy, like
clofarabine [28]. Clofarabine is a chemotherapy used in pediatric patients with relapsed or refectory
acute lymphoblastic leukemia. The radiolabeled [18F]clofarabine ([18F]CFA) has been evaluated in
healthy humans and found to be BBB permeable [29]. Biodistribution of [18F]CFA showed uptake in
lymph nodes, consistent with known dCK activity being required for T- and B-cell development [30].
In two patients with recurrent GBM, PET imaging with MRI was able to delineate specific regions
of immune activity [31]. In one individual, the post-treatment PET-MRI scan demonstrated a 300%
increase in immune cells in the tumor microenvironment, with the tumor volume remaining consistent.
This combined technique has been shown in this preliminary data set to be useful in differentiating
tumor progression from immune cell infiltration in a treatment monitoring scenario.
PET imaging of these classic markers of proliferation is useful to image GBM due to their
simplistic design. However, changes in glucose metabolism, DNA replication, protein synthesis,
and neurotransmitter homeostasis are not unique to cancers; they can describe a number of disease
states. This generality makes these imaging approaches most appropriate for disease monitoring in
cancer treatments like chemotherapy and targeted radiation. For further discussion of these tracers
and their prognostic value in brain tumors, see a recent systematic review [32].
2.2. Hypoxia-Sensing Tracers
The first-line treatment strategy for gliomas is surgical resection if possible, followed by
chemotherapy and targeted radiation [33]. Chemotherapy and radiation are therapies that hinge on
cell death by damaging DNA and initiating apoptosis. However, some tumors are resistant to these
strategies. For example, it has been long known that poorly oxygenated tissue, or hypoxic tissue, is less
sensitive to radiation. Gray et al. confirmed in 1953 that X ray therapy was more effective in mice that
were breathing oxygen at a higher pressures than normal atmosphere [34]. Hypoxia has become a
recognized key feature of most solid tumors [35]. In a hypoxic tumor microenvironment, radiation
therapy could be more effective at a higher dose; however, this requires an accurate identification of
that cell population.
PET radiotracers that sense oxygen levels in cells can be used to visualize hypoxia (Figure 2).
[18F]Fluoromisoinodazole ([18F]FMISO; 7) contains a nitroimidazole which is reduced to RNO2 radical
after entering a viable cell. In the presence of oxygen, it will be re-oxidized and diffuse from the cell.
If the cell is hypoxic, however, the radiotracer will be trapped. This tracer was first evaluated in V-79
cells using low O2 levels in the incubation to mimic hypoxia [36] and followed up with cancer models
in animals [37]. Glioma patients have undergone [18F]FMISO PET imaging, though with limited
success [38]. Chakhoyan et al. were able to build ptO2 maps from [18F]FMISO PET images and compare
them to perfusion weighted imaging (MRI) and 1H-MR mono-voxel magnetic resonance spectroscopy
(MRS) [39]. The correspondence with MRI and MRS imaging confirms the direct relationship between
[18F]FMISO and oxygen levels in tissue. However, Valk et al. observed retention of [18F]FMISO in
a GBM subject and anaplastic astrocytoma subject, but no retention of [18F]FMISO in another GBM
subject [38]. [18F]FMISO PET imaging has a limited range in sensitivity between normoxic and hypoxic
tissue [40]. Additionally, BBB penetration is low for [18F]FMISO which does not make it attractive for
glioma imaging.
There are multiple hypoxia radiotracers developed around the same time as [18F]FMISO including
[18F]FET-NIM (8), [18F]EF5 (9), and [18F]HX4 (10) (see review [35]). All of these ligands use the
nitroimidazole moiety to sense oxygen level in vivo, and the differences in the chemical structures
are primarily focused on the linker groups and location of fluorine-18 label (Figure 2). [18F]EF5
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exhibits greater cell membrane permeability, slower clearance, and improved tumor uptake [41–44].
Its structurally very similar to [18F]FMISO and [18F]FETNIM, but incorporates a pentafluoro ethyl group
via an amide linker. Labeling at this position requires electrophilic fluorination in the radiosynthesis,
limiting regular production of this radiotracer. [18F]FETNIM was developed concurrently with
[18F]FMISO, and is the most structurally similar with the addition of a hydroxyl group alpha to the
nitroimidazole ring [45–47]. [18F]HX4 still contains the nitroimidazole, though added a triazole linker
between this and the fluorine-18 label [48–51]. When compared to [18F]FMISO, [18F]HX4 provides the
higher image contrast 4 h post-injection, but has high variability [52,53]. A second generation version
of [18F]FMISO, [18F]DiFA (12) is slightly less lipophilic. This radiotracer aims to have a faster clearance
rate, and thus improved signal-to-noise ratio over [18F]FMISO [54].
g g p
 
Figure 2. Hypoxia-sensing tracers.
An alternative to [18F]FMISO, and the other organic oxygen sensing compounds, is [64Cu]ATSM
(12), which uses a metal to sense oxidation changes (Cu(II) to Cu(I)) [55]. In comparison to [18F]FMISO,
it has faster tracer kinetics and can reveal ‘hypoxic’ tissues in 15 min post injection. [64Cu]ATSM
uptake is influenced not only by hypoxia, but also cellular concentrations of reducing species such as
NADH [56]. Using [64Cu]ATSM imaging in glioma patients, SUV was found to be an independent
predictor of both progression free survival and overall survival in this study [57]. In the GBM subgroup
analysis, however, max SUV only showed significant prediction of progression free survival [57], using
copper-64 allowed for synergy between PET and MRI, in this proof of concept using a closely related
[64Cu]ATSM compound ([64Cu]Cu(L2); 13), which has only been evaluated so far in vitro [58,59].
Though, it is likely to have similar BBB penetration issues as [64Cu]ATSM.
Hypoxia imaging techniques are important for the treatment planning of solid tumors to ensure
effective regression. While current therapies do not target the hypoxia machinery in cells, this
biochemical process remains a critical consideration for radiotherapy. Many tumor types, including
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gliomas, are described as being hypoxic and utilize PET or MR imaging methods for treatment
planning [60]. This method also serves to monitor treatment after targeted radiotherapies.
2.3. Inflammation
An important part of the immune response is inflammation and, like peripheral cancers,
brain cancer cells will trigger this response. A histological analysis of lesions from 1265 patients
with glioblastoma multiforme identified the presence of lymphocytes and reactive astrocytes [61].
Inflammation has been explored as a therapeutic target for such cases. Nonsteroidal anti-inflammatory
drugs (NSAIDs) have been evaluated to suppress the growth of tumor cells in vitro [62]. While NSAIDs
are an inappropriate therapy for GBM because of the lack of targeting, inflammation is a characteristic
of GBM pathology and could be useful for imaging.
Translocator protein (18 kDa), TSPO, is an integral mitochondrial membrane protein responsible
for cholesterol transport and responds to cell stress. Broadly, TSPO is treated as a biomarker sensitive to
pro-inflammatory stimuli, and small molecule inhibitors of TSPO have been utilized in PET imaging [63].
[11C]PK11195 (14, Figure 3) was developed for general use of inflammation imaging, and even in
glioma patients [64]. Immunohistochemical experiments with patient tissue further confirmed increase
TSPO mRNA and protein levels [65]. Furthermore TSPO PET imaging was correlated to outcome [66].
In a larger prospective trial which included tumor biopsy, imaging and histology were found to
correlate, and BPND in high-grade gliomas was significantly higher than in low-grade astrocytomas
and low-grade oligodendrogliomas [67]. Although second and third generation TSPO radioligands
with higher specific binding have since been developed, TSPO imaging in GBM has major limitations
including tumor heterogeneity and inability to distinguish signal caused by radiation therapy from
signal due to the tumor microenvironment.
Figure 3. TSPO ligand.
3. New Biomarkers for GBM PET Imaging
New strategies for cancer therapeutics target proliferation (sigma 2), immunity (sigma 1,
PD-L1), and genetic modification (PARP, IDH). PET imaging agents have developed in tandem
with advancement of these therapies. These therapies were initially designed to treat more prevalent,
peripheral tumors. The nature of heterogeneity in brain tumors inspires the use of biomarker
specific imaging agents, as opposed to the more general ligands for proliferation, hypoxia, and
inflammation. Applications to brain cancers comes with the significant considerations of blood–brain
barrier penetration and effectiveness. The PET imaging agents discussed in the following section are
not yet utilized in human brain imaging but represent promising candidates for the new therapeutic
and/or biomarker strategies.
3.1. Sigma 1
A key characteristic of GBMs is their invasiveness, which leads to the very low survival rate.
Sigma 1 and sigma 2 receptors are expressed in the human tumor cell lines: C6 glioma, NIE-115
neuroblastoma, and NG108-15 neuroblastoma- glioma hybrid [68]. While sigma 1 is associated with
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invasiveness, sigma 2 receptors have been associated with proliferation. Both receptors are interesting
PET imaging targets for glioblastoma.
Sigma 1 receptor (S1R) was identified as the site of action of the antipsychotic haloperidol [69].
Its role in the CNS has been investigated for neurodegenerative disorders [70] in addition to GBM.
The first PET ligand for S1R was [11C]1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine
([11C]SA4503: 15, Figure 4) [71]. While it showed nanomolar affinity to S1R, it
unfortunately has high affinities for other receptors, ion channels, and second messenger
systems [72]. Both S1R and S2R have structural similarity to opiate receptors, which necessitates
specificity and selectivity when designing ligands. Additionally, in the development of
fluorine-18 sigma-1 receptor ligands, very high binding affinity has corresponded to very
slow clearance rate. For example, [18F]1-3-fluoropropyl-4-((4-cyanophenoxy)-methyl)piperidine
([18F]FPS; 16) [73] did not reach pseudo-equilibrium by 4 h in human [74]. Another ligand,
[18F]6-(3-fluoropropyl)-3-(2-(azepan-1-yl)ethyl)benzo[d]thiazol-2(3H)-one ([18F]FTC-146; 17) was also
found to be irreversible and not suitable for neuroimaging [75]. Recently, [18F](S)-Fluspidine (18) [76]
was developed and evaluated in human [77]. The pharmacokinetics are improved, and with xenograft
mouse models of glioblastoma have visible increases in radioligand binding.
(S)
 
Figure 4. Sigma 1 receptor radioligands.
3.2. Sigma 2
The amino acid and nucleoside base PET imaging approach is a classic, straightforward way to
assess functional proliferation. The sigma-2 receptor (S2R; TMEM97) has recently been implicated in
cancer biology; S2R levels increased 5-fold in proliferating tumor cells compared to quiescent tumor
cells [78]. This allows for radioligand design for a specific protein more akin to drug design. For an
in-depth history of S2R ligand development, see references [79,80].
An early imaging effort for S2R was using 4-[125I]BP (19, Figure 5), a small molecule with high
affinity for both sigma 1 and 2 receptors [81]. Further efforts by these authors led to [125I]PIMBA
(20), though this radioligand suffered from high background binding [82]. [18F]RHM-4 (21) was
developed and demonstrated S2R overexpression in pancreatic cancer, though BBB penetration was
not investigated [83]. The radioligand [18F]ISO (22) was also developed, structurally similar to 21
except lacking the aryl methoxy group [84]. A positive correlation is observed between 22 binding and
tumor Ki67 expression [85]. In treatment monitoring of CDK4/6 inhibition plus endocrine therapy in
breast cancer xenograft animals, 22 was found to assess more delayed changes related to cell cycle
arrest compared to [18F]FLT [86]. However, 22 is not taken up into the brain, based on organ residence
studies in rodent [85]. This has inspired alternative ligands with BBB penetration as the design goal.
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Figure 5. Sigma 2 receptor radioligands.
A scaffold incorporating pthalimides (23 and 24) showed elevated brain uptake and specific
binding (displaceable with cold ligand and haloperidol), though the tumor to background ratio was
low [87]. Abate et al. described 25, which demonstrated good in vitro binding and specificity; however,
as a P-glycoprotein (PGP) substrate it is not suitable for brain imaging [88]. The same group continued
with a carbon-11 effort (26), based on the inhibitor PB28 and very similar to 19; however, brain uptake
was low and the compound did not display high enough specific binding [89]. Wang et al. reported
two fluorine-18 inhibitors, 27 and 28, with high brain uptake in mice in 2017, though it may be a PGP
substrate as well [90]. These efforts have demonstrated some challenges in the radioligand design of
sigma 2 receptor inhibitors for brain imaging, i.e., PGP efflux and limited specific binding.
3.3. PD-L1
Avoiding destruction by immune cells is a powerful strategy utilized by cancer cells. Until
recently, imaging research in this space has focused on antibody-based strategies, which is challenging
due to limited brain penetration. The molecules used in PET imaging for Programmed death ligand
1 (PD-L1) are large molecule therapeutics, including antibodies, antibody fragments, and peptides.
An early imaging effort developed at Johns Hopkins University adapted the therapeutic antibody for
PET imaging: [64Cu]Azetozolizumab [91]. The same group later developed a peptide, [64Cu]WL12,
although brain was not listed in the biodistribution study [92]. Another protein effort from the Gambhir
lab at Stanford, [64Cu]NOTA-HACA-PD1 and a gallium 68 version, determined no brain uptake
definitively [93]. Merck developed an affibody ZPD-L1_1 that was fluorine-18 labeled; however, brain
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penetration has not been demonstrated, though an affibody is more likely to be BBB penetrant than the
preceding antibodies [94].
Although small molecule inhibitors have been in development, to date no small molecule
radioligands have been described. Bristol Meyers Squib has the first small molecule inhibitor reported,
BMS-202 (29, Figure 6) [95] and has characterized the binding in a crystal structure [96]. The mechanism
of action is thought to be selectively induced dimerization of PD-L1, which inhibits binding to PD-1
(see reviews [97–99])
 
Figure 6. Small molecule PD-L1 inhibitor.
3.4. PARP
ADP-ribose polymerase (PARP) is the enzyme responsible for attaching linear or branched
polymers of ADP onto broken DNA and other biomolecules. PARP-1 recognizes single and
double-strand breaks, crossovers, cruciform, and supercoils. Additionally, PARP-1 maintains the
stability of replication forks, and the basal activity is very low [100]. In cancer cells containing a BRCA2
deficiency, inhibiting PARP causes synthetic lethality [101]. This treatment strategy has been used to
develop multiple small molecule therapeutics [102].
The first in-class inhibitor olaparib has been adapted for use in PET imaging: [18F]BO (biorthogonal
olaparib; 30, Figure 7) [103]. [18F]BO demonstrated ubiquitous distribution in cancer cells and
localization within the nucleus in cancer cells [104]. Structurally similar to olaparib, the inhibitor
radioligand [18F]PARPi (31), and corresponding fluorescent version (32), has been used in GBM cell
lines [104] and in rodent [105]. Although this shows specific binding in peripheral tumors, there was no
significant blocking with brain uptake at 2 h biodistribution. Brain penetration was very low initially.
In comparison to [11C]choline and [18F]FLT, PARPi demonstrated a lower mean uptake in tumor than
the other two PET ligands; however, the lower background uptake enabled PARPi to delineate brain
tumors in rodent models with more clear contrast [106]. The Gouverneur group recently radiolabeled
olaparib itself with fluorine-18, though limited imaging studies have been done with this tracer [107].
As expected, [18F]olaparib (33) was taken up selectively in PARP-1 expressing cells and in mouse
tumors. Additionally, radioligand uptake was increased by 70% after tumor irradiation, indicated a
great potential for monitoring radiation damage. However, brain was not included in biodistribution
calculations and there does not appear to be brain uptake in the dynamic PET images. Unlike the
preceding PARP radioligands, the inhibitor [18F]fluorthanatrace ([18F]FTT; 34) is not based on olaparib,
but rather rucaparib. This benzimidazole carboxamide derivative is highly potent with an IC50 of
6.3 nM [108]. It has been evaluated in humans, though with low brain penetration [109]. There remains
a need for BBB penetrating small molecule inhibitors of PARP in order to be useful specifically in
glioblastoma imaging.
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Figure 7. PARP ligands.
3.5. Isocitrate Dehydrogenase (IDH)
Through genome wide association studies (GWASs), the common mutation R132H, located
on the isocitrate dehydrogenase (IDH) 1 gene, was found in more than 70% of grade II and
III astrocytomas, oligodendrogliomas, and glioblastomas that developed from these lower-grade
lesions [110]. However, only 10% of glioblastomas are IDH mutant [1], and this is weakly associated
with tumor aggressiveness [3]. IDH- mutant GBM has a significantly longer survival rate compared to
IDH wild type, 31 months compared to 15 months with standard treatment.
The observed IDH mutation essentially eliminates all enzymatic activity [111]. In normal cells,
IDH1 converts isocitrate to α-ketoglutarate and form NADPH, which maintains a pool of reduced
glutathione and peroxiredoxin. When isocitrate cannot be converted to α-ketoglutarate, it instead
is converted to R(-)-2-hydroxyglutarate [112]. 2-Hyrdoxyglutarate and α-ketoglutarate are cofactors
for many enzymes and their availability influences DNA methylation status. 2-HG inhibits 5mC
hydroxylase (TET2) and lysine demethylases (KDM) leading to demethylation of DNA and histone,
respectively. This changes gene expression and thus tumorigenesis. R-2HG stimulates EgIN1, which
promotes HIF1a degradation by hydroxylation [113]. Therapeutic inhibitors are being developed for
IDH1 to influence this pathway and similarly slow tumorigenesis and promote survival.
Ivosidenib (AG-120) is the first in-class IDH1 reversible inhibitor [114]. In rats, some brain
penetration has been demonstrated, 4.1% after 50 mg/kg dose, which could indicate some effectiveness
in glioblastoma. The phase I trial in low grade glioma subjects is ongoing (NCT03343197). Another
inhibitor (IDH305) for mutant IDH1 is in development by Novartis, with strong data for binding
in brain homogenate [115]. In a phase I clinical trial, safety was evaluated in glioma, AML/MDS,
and other/ non-CNS solid tumors with IDH mutation [116]. However, phase II trials of IDH305 in
glioma has been withdrawn, possibly due to liver toxicity (NCT02977689 [117]).
Before small molecule inhibitors of IDH were available, PET radioligands were evaluated
for their relationship to IDH mutation status. While [18F]FDOPA does not correlate with IDH
mutation status [118], it appears that [18F]FET imaging does significantly associate with IDH mutation
status [119–121], although there does not appear to be a biochemical relationship between [18F]FET
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uptake and IDH mutation status. With the disclosure of small molecule IDH inhibitors came the
preliminary development of IDH-selective PET radioligands. Chitneni et al. utilized an iodine-131
and fluorine-18 version (35, Figure 8) of AGI-5198; however, these compounds lacked selectivity for
mutant IDH over wild type [122]. In a follow up from the same group, [18F]triazinediamine (36)
analogues were radiosynthesized, based on Enasidenib (AG-221) [123], The Kd (36) was calculated to
be 40 nM with a Bmax of 4426 gmol/mg in a mutant anaplastic astrocytoma cell line, which is promising.
However, biodistribution studies showed bone uptake from radiolytic defluorination, so further design
is required [123].
Figure 8. Isocitrate dehydrogenase (IDH) radioligands.
4. General Imaging Considerations
Brain PET imaging for any disease state is challenging. The blood–brain barrier (BBB) poses a
major obstacle for any successful radiotracer targeting glioblastoma. Even if the radiotracer enters the
brain, many compounds exhibit slow brain entry (i.e., small K1 values). Since glioblastoma lesions
often compromise BBB, increased radioactivity concentrations at the lesion site may reflect increased
nonspecific radiotracer instead of, or in addition to, increased target signal. For example, a combined
[18F]FMISO PET and MRI study noted high uptake of [18F]FMISO in areas of BBB disruption as
well as in necrotic tissue [124]. This raises a challenge in quantification at a suspected glioblastoma
lesion. Kinetic modeling approaches incorporating dynamic data, in some cases, may help distinguish
nonspecific signal from specific signal in some cases. Although these scanning protocols can require
longer scanning time and possibly arterial blood sampling, the potential for improved quantification
of specific radiotracer uptake offers important benefits to evaluating diagnosis, staging, or treatment
efficacy that must be considered when using PET to image GBM.
Reference region approaches offer alternatives for quantitative analyses that may shorten the
length of scanning time and do not require arterial blood sampling. While such approaches have major
limitations in cases of ubiquitously expressed targets, such as TSPO, in the case of brain tumor imaging
the reference region may be drawn as a larger region that is removed from the lesion. For example,
in a case of [18F]FET imaging a fixed-size reference ROI was placed in hemispheres contralateral
to tumorous tissue, which yielded fully image-derived measures that correlated with disease-free
survival [125]. Image-derived input function allow for alternative non-invasive modeling approaches.
For example, [18F]FMISO has no reference region, but image-derived tissue-to-blood ratios provide
reasonable proxies for measured parent radioactivity in venous blood [126]. Such approaches can
maintain quantitative accuracy while reducing logistical complexities introduced by full dynamic
scans with blood sampling.
A final major obstacle for PET radiotracers imaging GBM is high nonspecific binding. For example,
[18F]FMISO, [18F]FLT, and [64Cu]ATSM exhibit elevated nonspecific binding, which limits their
usefulness. Such radiotracers exhibit low signal to noise ratio (SNR), which makes it more difficult to
differentiate areas of low uptake from noise. In contrast, radiotracers with low nonspecific binding may
be amiable to reference region analysis if non-tumor brain regions exhibit negligible specific binding.
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Off-target binding poses another related challenge. For example, sigma 1 and sigma 2 receptors
have significant structural similarities to opiate receptors. These challenges highlight the need for
blocking studies with candidate radiotracers to confirm suitable sensitivity and specificity without
high nonspecific binding.
5. Conclusions
PET imaging provides important functional information about GBM tumors and surrounding
tissue environment. Markers of proliferation, hypoxia, and inflammation have been used to image the
lesions of GBM patients. Exciting new frontiers for PET imaging targets for GBM include PD-L1 for
immune status, PARP-1 for DNA damage, sigma 2 receptors as alternative markers of proliferation,
and isocitrate dehydrogenase for tumorigenesis activity. These PET imaging targets have the potential
to enhance diagnosis, staging, and treatment approaches for GBM. As GBM PET imaging techniques
advance, it is critical to consider blood brain barrier penetration and nonspecific binding in the
evaluation of new radioligands.
Author Contributions: L.R.D. performed literature search and drafted the initial manuscript. Z.C. and A.T.H.
revised and edited subsequent manuscript iterations. All authors have read and agreed to the published version
of the manuscript.
Funding: This research was supported by NIH grants K01AA024788, R21EB027872, R01AG058773. Z.C. is an
Archer Foundation Research Scientist.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Glioblastoma Multiforme. Available online: https://www.aans.org/Patients/Neurosurgical-Conditions-and-
Treatments/Glioblastoma-Multiforme (accessed on 15 November 2019).
2. Louis, D.N.; Perry, A.; Reifenberger, G.; Von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.;
Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization classification of tumors of the
central nervous system: A summary. Acta Neuropathol. 2016, 131, 803–820. [CrossRef] [PubMed]
3. Amelot, A.; De Cremoux, P.; Quillien, V.; Polivka, M.; Adle-Biassette, H.; Lehmann-Che, J.; Francoise, L.;
Carpentier, A.F.; George, B.; Mandonnet, E.; et al. IDH-mutation is a weak predictor of long-term survival in
glioblastoma patients. PLoS ONE 2015, 10, e0130596. [CrossRef]
4. Perrin, S.L.; Samuel, M.S.; Koszyca, B.; Brown, M.P.; Ebert, L.M.; Oksdath, M.; Gomez, G.A. Glioblastoma
heterogeneity and the tumour microenvironment: Implications for preclinical research and development of
new treatments. Biochem. Soc. Trans. 2019, 47, 625–638. [CrossRef] [PubMed]
5. Ozdemir-Kaynak, E.; Qutub, A.A.; Yesil-Celiktas, O. Advances in Glioblastoma Multiforme Treatment: New
Models for Nanoparticle Therapy. Front. Physiol. 2018, 9. [CrossRef] [PubMed]
6. Reza, S.M.S.; Samad, M.D.; Shboul, Z.A.; Jones, K.A.; Iftekharuddin, K.M. Glioma grading using structural
magnetic resonance imaging and molecular data. J. Med. Imaging 2019, 6, 024501. [CrossRef]
7. Som, P.; Atkins, H.L.; Bandoypadhyay, D.; Fowler, J.S.; MacGregor, R.R.; Matsui, K.; Oster, Z.H.; Sacker, D.F.;
Shiue, C.Y.; Turner, H.; et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic
tracer for rapid tumor detection. J. Nucl Med. 1980, 21, 670–675. [CrossRef]
8. Langstrom, B.; Lundqvist, H. The preparation of carbon-11-labeled methyl iodide and its use in the synthesis
of carbon-11-labeled methyl-L-methionine. Int. J. Appl. Radiat. Isot. 1976, 27, 357–363. [CrossRef]
9. Comar, D.; Cartron, J.C.; Maziere, M.; Marazano, C. Labeling and metabolism of methionine-methyl-11C.
Eur. J. Nucl. Med. 1976, 1, 11–14. [CrossRef]
10. Schober, O.; Duden, C.; Meyer, G.J.; Muller, J.A.; Hundeshagen, H. Non selective transport of
[11C-methyl]-L-and D-methionine into a malignant glioma. Eur J. Nucl. Med. 1987, 13, 103–105. [CrossRef]
11. Singhal, T.; Narayanan, T.K.; Jain, V.; Mukherjee, J.; Mantil, J. 11C-L-methionine positron emission tomography
in the clinical management of cerebral gliomas. Mol. Imaging Biol. 2008, 10, 1–18.
12. Wester, H.J.; Herz, M.; Weber, W.; Heiss, P.; Senekowitsch-Schmidtke, R.; Schwaiger, M.; Stocklin, G. Synthesis
and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J. Nucl. Med. 1999, 40,
205–212. [PubMed]
222
Molecules 2020, 25, 568
13. Heiss, P.; Mayer, S.; Herz, M.; Wester, H.-J.; Schwaiger, M.; Senekowitsch-Schmidtke, R. Investigation of
transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J. Nucl.
Med. 1999, 40, 1367–1373. [PubMed]
14. Habermeier, A.; Graf, J.; Sandhoefer, B.F.; Boissel, J.P.; Roesch, F.; Closs, E.I. System L amino acid transporter
LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET). Amino Acids 2015, 47, 335–344. [CrossRef] [PubMed]
15. Pauleit, D.; Floeth, F.; Hamacher, K.; Riemenschneider, M.J.; Reifenberger, G.; Muller, H.-W.; Zilles, K.;
Coenen, H.H.; Langen, K.-J. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the
diagnostic assessment of cerebral gliomas. Brain 2005, 128, 678–687. [CrossRef]
16. Minn, H.; Kauhanen, S.; Seppanen, M.; Nuutila, P. 18F-FDOPA: A multiple-target molecule. J. Nucl. Med.
2009, 50, 1915–1918. [CrossRef]
17. Patel, C.B.; Fazzari, E.; Chakhoyan, A.; Yao, J.; Raymond, C.; Nguyen, H.; Manoukian, J.; Nguyen, N.;
Pope, W.; Cloughesy, T.F.; et al. 18F-FDOPA PET and MRI characteristics correlate with degree of malignancy
and predict survival in treatment-naive gliomas: A cross-sectional study. J. Neuro-Oncol. 2018, 139, 399–409.
[CrossRef]
18. Chirakal, R.; Firnau, G.; Garnett, E. High yield synthesis of 6-[18F] fluoro-L-dopa. J. Nucl. Med. 1986, 27,
417–421.
19. Mossine, A.V.; Tanzey, S.S.; Brooks, A.F.; Makaravage, K.J.; Ichiishi, N.; Miller, J.M.; Henderson, B.D.;
Skaddan, M.B.; Sanford, M.S.; Scott, P.J.H. One-pot synthesis of high molar activity 6-[18F]fluoro-L-DOPA by
Cu-mediated fluorination of a BPin precursor. Org. Biomol. Chem. 2019. Ahead of Print. [CrossRef]
20. Rasey, J.S.; Grierson, J.R.; Wiens, L.W.; Kolb, P.D.; Schwartz, J.L. Validation of FLT uptake as a measure of
thymidine kinase-1 activity in A549 carcinoma cells. J. Nucl. Med. 2002, 43, 1210–1217.
21. Toyohara, J.; Waki, A.; Takamatsu, S.; Yonekura, Y.; Magata, Y.; Fujibayashi, Y. Basis of FLT as a cell
proliferation marker: Comparative uptake studies with [3H] thymidine and [3H] arabinothymidine, and
cell-analysis in 22 asynchronously growing tumor cell lines. Nucl. Med. Biol. 2002, 29, 281–287. [CrossRef]
22. Vesselle, H.; Grierson, J.; Muzi, M.; Pugsley, J.M.; Schmidt, R.A.; Rabinowitz, P.; Peterson, L.M.;
Vallieres, E.; Wood, D.E. In vivo validation of 3’deoxy-3’-[18F]fluorothymidine ([18F]FLT) as a proliferation
imaging tracer in humans: Correlation of [18F]FLT uptake by positron emission tomography with Ki-67
immunohistochemistry and flow cytometry in human lung tumors. Clin. Cancer Res. 2002, 8, 3315–3323.
[PubMed]
23. Been, L.B.; Suurmeijer, A.J.H.; Cobben, D.C.P.; Jager, P.L.; Hoekstra, H.J.; Elsinga, P.H. [18F]FLT-PET in
oncology: Current status and opportunities. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 1659–1672. [CrossRef]
[PubMed]
24. Yamamoto, Y.; Ono, Y.; Aga, F.; Kawai, N.; Kudomi, N.; Nishiyama, Y. Correlation of 18F-FLT uptake with
tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas.
J. Nucl. Med. 2012, 53, 1911–1915. [CrossRef] [PubMed]
25. Chen, W.; Delaloye, S.; Silverman, D.H.S.; Geist, C.; Czernin, J.; Sayre, J.; Satyamurthy, N.; Pope, W.; Lai, A.;
Phelps, M.E.; et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by
imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J. Clin.
Oncol. 2007, 25, 4714–4721. [CrossRef] [PubMed]
26. Shields, A.F. PET imaging with 18F-FLT and thymidine analogs: Promise and pitfalls. J. Nucl. Med. 2003, 44,
1432–1434.
27. Arner, E.S.; Eriksson, S. Mammalian deoxyribonuclease kinases. Pharmacol. Ther. 1995, 67, 155–186.
[CrossRef]
28. Ghanem, H.; Kantarjian, H.; Ohanian, M.; Jabbour, E. The role of clofarabine in acute myeloid leukemia.
Leuk. Lymphoma 2013, 54, 688–698. [CrossRef]
29. Barrio, M.J.; Spick, C.; Radu, C.G.; Lassmann, M.; Eberlein, U.; Allen-Auerbach, M.; Schiepers, C.; Slavik, R.;
Czernin, J.; Herrmann, K. Human biodistribution and radiation dosimetry of 18F-clofarabine, a PET probe
targeting the deoxyribonucleoside salvage pathway. J. Nucl. Med. 2017, 58, 374–378. [CrossRef]
30. Toy, G.; Austin, W.R.; Liao, H.-I.; Cheng, D.; Singh, A.; Campbell, D.O.; Ishikawa, T.-o.; Lehmann, L.W.;
Satyamurthy, N.; Phelps, M.E.; et al. Requirement for deoxycytidine kinase in T and B lymphocyte
development. Proc. Natl. Acad. Sci. USA 2010, 107, 5551–5556. [CrossRef]
223
Molecules 2020, 25, 568
31. Antonios, J.P.; Soto, H.; Everson, R.G.; Moughon, D.L.; Wang, A.C.; Orpilla, J.; Radu, C.; Ellingson, B.M.;
Lee, J.T.; Cloughesy, T.; et al. Detection of immune responses after immunotherapy in glioblastoma using
PET and MRI. Proc. Natl. Acad. Sci. USA. 2017, 114, 10220–10225. [CrossRef]
32. Treglia, G.; Muoio, B.; Trevisi, G.; Mattoli, M.V.; Albano, D.; Bertagna, F.; Giovanella, L. Diagnostic
Performance and Prognostic Value of PET/CT with Different Tracers for Brain Tumors: A Systematic Review
of Published Meta-Analyses. Int. J. Mol. Sci. 2019, 20, 4669. [CrossRef] [PubMed]
33. Omuro, A.; DeAngelis, L.M. Glioblastoma and other malignant gliomas: A clinical review. JAMA J. Am.
Med. Assoc. 2013, 310, 1842–1850. [CrossRef] [PubMed]
34. Gray, L.H.; Conger, A.D.; Ebert, M.; Hornsey, S.; Scott, O. The concentration of oxygen dissolved in tissues at
the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 1953, 26, 638–648. [CrossRef] [PubMed]
35. Horsman, M.R.; Mortensen, L.S.; Petersen, J.B.; Busk, M.; Overgaard, J. Imaging hypoxia to improve
radiotherapy outcome. Nat. Rev. Clin. Oncol. 2012, 9, 674–687. [CrossRef]
36. Rasey, J.S.; Grunbaum, Z.; Magee, S.; Nelson, N.J.; Olive, P.L.; Durand, R.E.; Krohn, K.A. Characterization of
radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat. Res. 1987, 111, 292–304. [CrossRef]
37. Rasey, J.S.; Koh, W.-J.; Grierson, J.R.; Grunbaum, Z.; Krohn, K.A. Radiolabeled fluoromisonidazole as an
imaging agent for tumor hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 1989, 17, 985–991. [CrossRef]
38. Valk, P.E.; Mathis, C.A.; Prados, M.D.; Gilbert, J.C.; Budinger, T.F. Hypoxia in human gliomas: Demonstration
by PET with fluorine-18-fluoromisonidazole. J. Nucl Med. 1992, 33, 2133–2137.
39. Chakhoyan, A.; Guillamo, J.-S.; Collet, S.; Kauffmann, F.; Delcroix, N.; Lechapt-Zalcman, E.; Constans, J.-M.;
Petit, E.; MacKenzie, E.T.; Barre, L.; et al. FMISO-PET-derived brain oxygen tension maps: Application to
glioblastoma and less aggressive gliomas. Sci. Rep. 2017, 7, 1–9. [CrossRef]
40. Bell, C.; Dowson, N.; Fay, M.; Thomas, P.; Puttick, S.; Gal, Y.; Rose, S. Hypoxia imaging in gliomas with
18F-fluoromisonidazole PET: Toward clinical translation. Semin. Nucl. Med. 2015, 45, 136–150. [CrossRef]
41. Koch, C.J.; Scheuermann, J.S.; Divgi, C.; Judy, K.D.; Kachur, A.V.; Freifelder, R.; Reddin, J.S.; Karp, J.;
Stubbs, J.B.; Hahn, S.M.; et al. Biodistribution and dosimetry of 18F-EF5 in cancer patients with preliminary
comparison of 18F-EF5 uptake versus EF5 binding in human glioblastoma. Eur. J. Nucl. Med. Mol. Imaging
2010, 37, 2048–2059. [CrossRef]
42. Komar, G.; Seppanen, M.; Eskola, O.; Lindholm, P.; Gronroos, T.J.; Forsback, S.; Sipila, H.; Evans, S.M.;
Solin, O.; Minn, H. 18F-EF5: A new PET tracer for imaging hypoxia in head and neck cancer. J. Nucl. Med.
2008, 49, 1944–1951. [CrossRef]
43. Ziemer, L.S.; Evans, S.M.; Kachur, A.V.; Shuman, A.L.; Cardi, C.A.; Jenkins, W.T.; Karp, J.S.; Alavi, A.;
Dolbier, W.R.; Koch, C.J. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5.
Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 259–266. [CrossRef]
44. Dolbier, W.R., Jr.; Li, A.-R.; Koch, C.J.; Shiue, C.-Y.; Kachur, A.V. [18F]-EF5, a marker for PET detection
of hypoxia: Synthesis of precursor and a new fluorination procedure. Appl. Radiat. Isot. 2001, 54, 73–80.
[CrossRef]
45. Lehtioe, K.; Oikonen, V.; Nyman, S.; Groenroos, T.; Roivainen, A.; Eskola, O.; Minn, H. Quantifying tumour
hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma
ratio. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 101–108. [CrossRef]
46. Gronroos, T.; Eskola, O.; Lehtio, K.; Minn, H.; Marjamaki, P.; Bergman, J.; Haaparanta, M.; Forsback, S.;
Solin, O. Pharmacokinetics of [18F]FETNIM: A potential hypoxia marker for PET. J. Nucl. Med. 2001, 42,
1397–1404. [PubMed]
47. Yang, D.J.; Wallace, S.; Cherif, A.; Li, C.; Gretzer, M.B.; Kim, E.E.; Podoloff, D.A. Development of F-18-labeled
fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995, 194, 795–800.
[CrossRef]
48. Verwer, E.E.; Windhorst, A.D.; Boellaard, R.; Verwer, E.E.; Zegers, C.M.L.; van, E.W.; Lambin, P.; Wierts, R.;
Mottaghy, F.M.; Mottaghy, F.M.; et al. Pharmacokinetic modeling of a novel hypoxia PET tracer [(18)F]HX4
in patients with non-small cell lung cancer. EJNMMI Phys. 2016, 3, 30. [CrossRef]
49. Dubois, L.J.; Lieuwes, N.G.; Janssen, M.H.M.; Peeters, W.J.M.; Windhorst, A.D.; Walsh, J.C.; Kolb, H.C.;
Oellers, M.C.; Bussink, J.; van Dongen, G.A.M.S.; et al. Preclinical evaluation and validation of [18F]HX4, a
promising hypoxia marker for PET imaging. Proc. Natl. Acad. Sci. USA. 2011, 108, 14620–14625. [CrossRef]
224
Molecules 2020, 25, 568
50. Van Loon, J.; Janssen, M.H.M.; Oellers, M.; Aerts, H.J.W.L.; Dubois, L.; Hochstenbag, M.; Dingemans, A.-M.C.;
Lalisang, R.; Brans, B.; Windhorst, B.; et al. PET imaging of hypoxia using [18F]HX4: A phase I trial. Eur. J.
Nucl. Med. Mol. Imaging 2010, 37, 1663–1668. [CrossRef]
51. Doss, M.; Zhang, J.J.; Belanger, M.-J.; Stubbs, J.B.; Hostetler, E.D.; Alpaugh, K.; Kolb, H.C.; Yu, J.Q.
Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and human determined
by using whole-body PET/CT. Nucl. Med. Commun. 2010, 31, 1016–1024. [CrossRef]
52. Wack, L.J.; Moennich, D.; van Elmpt, W.; Zegers, C.M.L.; Troost, E.G.C.; Zips, D.; Thorwarth, D. Comparison
of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia - a simulation study. Acta Oncol.
2015, 54, 1370–1377. [CrossRef] [PubMed]
53. Peeters, S.G.J.A.; Zegers, C.M.L.; Lieuwes, N.G.; van Elmpt, W.; Eriksson, J.; van Dongen, G.A.M.S.; Dubois, L.;
Lambin, P. A Comparative Study of the Hypoxia PET Tracers [18F]HX4, [18F]FAZA, and [18F]FMISO in a
Preclinical Tumor Model. Int. J. Radiat. Oncol. Biol. Phys. 2015, 91, 351–359. [CrossRef] [PubMed]
54. Watanabe, S.; Shiga, T.; Hirata, K.; Magota, K.; Okamoto, S.; Toyonaga, T.; Higashikawa, K.; Yasui, H.;
Kobayashi, J.; Nishijima, K.-I.; et al. Biodistribution and radiation dosimetry of the novel hypoxia PET probe
[18F]DiFA and comparison with [18F]FMISO. EJNMMI Res. 2019. [CrossRef] [PubMed]
55. Dunphy, M.P.S.; Lewis, J.S. Radiopharmaceuticals in preclinical and clinical development for monitoring of
therapy with PET. J. Nucl. Med. 2009, 50, 106S–121S. [CrossRef] [PubMed]
56. Floberg, J.M.; Wang, L.; Bandara, N.; Rashmi, R.; Mpoy, C.; Garbow, J.R.; Rogers, B.E.; Patti, G.J.; Schwarz, J.K.
Altering cellular reducing potential changes 64Cu-ATSM signal with or without hypoxia. J. Nucl. Med. 2019.
[CrossRef] [PubMed]
57. Toriihara, A.; Yoneyama, T.; Kitazume, Y.; Tateishi, U.; Ohtake, M.; Tateishi, K.; Kawahara, N.;
Hino-Shishikura, A.; Inoue, T. Prognostic implications of (62)Cu-diacetyl-bis (N(4)-methylthiosemicarbazone)
PET/CT in patients with glioma. Ann. Nucl Med. 2018, 32, 264–271. [CrossRef]
58. Xie, D.; Kim, S.; Kohli, V.; Banerjee, A.; Yu, M.; Enriquez, J.S.; Luci, J.J.; Que, E.L. Hypoxia-Responsive
19F MRI Probes with Improved Redox Properties and Biocompatibility. Inorg. Chem. 2017, 56, 6429–6437.
[CrossRef]
59. Xie, D.; King, T.L.; Banerjee, A.; Kohli, V.; Que, E.L. Exploiting Copper Redox for 19F Magnetic
Resonance-Based Detection of Cellular Hypoxia. J. Am. Chem. Soc. 2016, 138, 2937–2940. [CrossRef]
60. Challapalli, A.; Carroll, L.; Aboagye, E.O. Molecular mechanisms of hypoxia in cancer. Clin. Transl. Imaging
2017, 5, 225–253. [CrossRef]
61. Burger, P.C.; Vogel, F.S.; Green, S.B.; Strike, T.A. Glioblastoma multiforme and anaplastic astrocytoma.
Pathologic criteria and prognostic implications. Cancer 1985, 56, 1106–1111. [CrossRef]
62. King, J.G., Jr.; Khalili, K. Inhibition of human brain tumor cell growth by the anti-inflammatory drug,
flurbiprofen. Oncogene 2001, 20, 6864–6870. [CrossRef] [PubMed]
63. Roncaroli, F.; Su, Z.; Herholz, K.; Gerhard, A.; Turkheimer, F.E. TSPO expression in brain tumours: Is TSPO a
target for brain tumour imaging? Clin. Transl. Imaging 2016, 4, 145–156. [CrossRef] [PubMed]
64. Pappata, S.; Cornu, P.; Samson, Y.; Prenant, C.; Benavides, J.; Scatton, B.; Crouzel, C.; Hauw, J.; Syrota, A. PET
study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: A case report.
J. Nucl. Med. 1991, 32, 1608–1610. [PubMed]
65. Miettinen, H.; Kononen, J.; Haapasalo, H.; Helén, P.; Sallinen, P.; Harjuntausta, T.; Helin, H.; Alho, H.
Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human
astrocytomas: Relationship to cell proliferation. Cancer Res. 1995, 55, 2691–2695. [PubMed]
66. Vlodavsky, E.; Soustiel, J.F. Immunohistochemical expression of peripheral benzodiazepine receptors in
human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival. J.
Neuro-Oncol. 2007, 81, 1–7. [CrossRef]
67. Su, Z.; Roncaroli, F.; Durrenberger, P.F.; Coope, D.J.; Karabatsou, K.; Hinz, R.; Thompson, G.; Turkheimer, F.E.;
Janczar, K.; Du Plessis, D. The 18-kDa mitochondrial translocator protein in human gliomas: An 11C-(R)
PK11195 PET imaging and neuropathology study. J. Nucl. Med. 2015, 56, 512–517. [CrossRef]
68. Vilner, B.J.; John, C.S.; Bowen, W.D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human
and rodent tumor cell lines. Cancer Res. 1995, 55, 408–413.
69. Megalizzi, V.; Decaestecker, C.; Debeir, O.; Spiegl-Kreinecker, S.; Berger, W.; Lefranc, F.; Kast, R.E.; Kiss, R.
Screening of anti-glioma effects induced by sigma-1 receptor ligands: Potential new use for old anti-psychiatric
medicines. Eur. J. Cancer 2009, 45, 2893–2905. [CrossRef]
225
Molecules 2020, 25, 568
70. Jia, H.; Zhang, Y.; Huang, Y. Imaging sigma receptors in the brain: New opportunities for diagnosis of
Alzheimer’s disease and therapeutic development. Neurosci. Lett. 2019, 691, 3–10. [CrossRef]
71. Toyohara, J.; Kobayashi, T.; Mita, S.; Ishiwata, K. Application of [11C]SA4503 to selection of novel σ1 selective
agonists. Nucl. Med. Biol. 2012, 39, 1117–1121. [CrossRef]
72. Matsuno, K.; Nakazawa, M.; Okamoto, K.; Kawashima, Y.; Mita, S. Binding properties of SA4503, a novel
and selective σ1 receptor agonist. Eur. J. Pharmacol. 1996, 306, 271–279. [CrossRef]
73. Lee Collier, T.; O’Brien, J.C.; Waterhouse, R.N. Synthesis of
[18F]-1-(3-Fluoropropyl)-4-(4-cyanophenoxymethyl)-piperidine: A potential sigma-1 receptor radioligand
for PET. J. Label. Compd. Radiopharm. 1996, 38, 785–794. [CrossRef]
74. Waterhouse, R.N.; Chang, R.C.; Atuehene, N.; Collier, T.L. In vitro and in vivo binding of neuroactive steroids
to the sigma-1 receptor as measured with the positron emission tomography radioligand [18F]FPS. SYNAPSE
2007, 61, 540–546. [CrossRef] [PubMed]
75. James, M.L.; Shen, B.; Zavaleta, C.L.; Nielsen, C.H.; Mesangeau, C.; Vuppala, P.K.; Chan, C.; Avery, B.A.;
Fishback, J.A.; Matsumoto, R.R.; et al. New Positron Emission Tomography (PET) Radioligand for Imaging
σ-1 Receptors in Living Subjects. J. Med. Chem. 2012, 55, 8272–8282. [CrossRef] [PubMed]
76. Kranz, M.; Bergmann, R.; Kniess, T.; Belter, B.; Neuber, C.; Cai, Z.; Deng, G.; Fischer, S.; Zhou, J.; Huang, Y.; et al.
Bridging from brain to tumor imaging: (S)-(-)- and (R)-(+)-[18F]fluspidine for investigation of sigma-1
receptors in tumor-bearing mice. Molecules 2018, 23, 702. [CrossRef]
77. Kranz, M.; Sattler, B.; Wüst, N.; Deuther-Conrad, W.; Patt, M.; Meyer, P.; Fischer, S.; Donat, C.; Wünsch, B.;
Hesse, S. Evaluation of the enantiomer specific biokinetics and radiation doses of [18F] fluspidine—A new
tracer in clinical translation for imaging of σ1 receptors. Molecules 2016, 21, 1164. [CrossRef]
78. Wheeler, K.T.; Wang, L.M.; Wallen, C.A.; Childers, S.R.; Cline, J.M.; Keng, P.C.; Mach, R.H. Sigma-2 receptors
as a biomarker of proliferation in solid tumours. Br. J. Cancer 2000, 82, 1223–1232. [CrossRef]
79. Zeng, C.; McDonald, E.S.; Mach, R.H. Molecular probes for imaging the sigma-2 receptor: In vitro and
in vivo imaging studies. Handb. Exp. Pharmacol. 2017, 244, 309–330. [CrossRef]
80. Mach, R.H.; Zeng, C.; Hawkins, W.G. The σ2 Receptor: A Novel Protein for the Imaging and Treatment of
Cancer. J. Med. Chem. 2013, 56, 7137–7160. [CrossRef]
81. John, C.S.; Wilner, B.J.; Gulden, M.E.; Efange, S.M.N.; Langason, R.B.; Moody, T.W.; Bowen, W.D. Synthesis
and pharmacological characterization of 4-[125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide: A high
affinity or receptor ligand for potential imaging of breast cancer. Cancer Res. 1995, 55, 3022–3027.
82. John, C.S.; Bowen, W.D.; Fisher, S.J.; Lim, B.B.; Geyer, B.C.; Vilner, B.J.; Wahl, R.L.
Synthesis, in vitro pharmacologic characterization, and preclinical evaluation of
N-[2-(1’-piperidinyl)ethyl]-3-[125I]iodo-4-methoxybenzamide (P[125I]MBA) for imaging breast cancer. Nucl.
Med. Biol. 1999, 26, 377–382. [CrossRef]
83. Kashiwagi, H.; McDunn, J.E.; Simon, P.O., Jr.; Goedegebuure, P.S.; Xu, J.; Jones, L.; Chang, K.;
Johnston, F.; Trinkaus, K.; Hotchkiss, R.S.; et al. Selective sigma-2 ligands preferentially bind to pancreatic
adenocarcinomas: Applications in diagnostic imaging and therapy. Mol. Cancer 2007, 6, 48. [CrossRef]
[PubMed]
84. Dehdashti, F.; Laforest, R.; Gao, F.; Shoghi, K.I.; Aft, R.L.; Nussenbaum, B.; Kreisel, F.H.; Bartlett, N.L.;
Cashen, A.; Wagner-Johnston, N.; et al. Assessment of cellular proliferation in tumors by PET using 18F-ISO-1.
J. Nucl. Med. 2013, 54, 350–357. [CrossRef] [PubMed]
85. Shoghi, K.I.; Xu, J.; Su, Y.; He, J.; Rowland, D.; Yan, Y.; Garbow, J.R.; Tu, Z.; Jones, L.A.; Higashikubo, R.; et al.
Quantitative receptor-based imaging of tumor proliferation with the sigma-2 ligand [18F]ISO-1. PLoS ONE
2013, 8, e74188. [CrossRef]
86. Elmi, A.; Makvandi, M.; Weng, C.-C.; Hou, C.; Mach, R.H.; Mankoff, D.A.; Clark, A.S. Cell-Proliferation
Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer:
Comparison of [(18)F]FLT and [(18)F]ISO-1 PET/CT. Clin. Cancer Res. 2019, 25, 3063–3073. [CrossRef]
87. Nguyen, V.H.; Pham, T.; Fookes, C.; Berghofer, P.; Greguric, I.; Arthur, A.; Mattner, F.; Rahardjo, G.; Davis, E.;
Howell, N.; et al. Synthesis and biological characterization of 18F-SIG343 and 18F-SIG353, novel and high
selectivity σ2 radiotracers, for tumor imaging properties. EJNMMI Res. 2013, 3, 80. [CrossRef]
88. Abate, C.; Selivanova, S.V.; Muller, A.; Kramer, S.D.; Schibli, R.; Marottoli, R.; Perrone, R.; Berardi, F.; Niso, M.;
Ametamey, S.M. Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission
Tomography (PET) imaging of σ2 receptors. Eur. J. Med. Chem. 2013, 69, 920–930. [CrossRef]
226
Molecules 2020, 25, 568
89. Selivanova, S.V.; Toscano, A.; Abate, C.; Berardi, F.; Muller, A.; Kramer, S.D.; Schibli, R.; Ametamey, S.M.
Synthesis and pharmacological evaluation of 11C-labeled piperazine derivative as a PET probe for sigma-2
receptor imaging. Nucl. Med. Biol. 2015, 42, 399–405. [CrossRef]
90. Wang, L.; Ye, J.; He, Y.; Deuther-Conrad, W.; Zhang, J.; Zhang, X.; Cui, M.; Steinbach, J.; Huang, Y.;
Brust, P.; et al. 18F-Labeled indole-based analogs as highly selective radioligands for imaging sigma-2
receptors in the brain. Bioorg. Med. Chem. 2017, 25, 3792–3802. [CrossRef]
91. Lesniak, W.G.; Chatterjee, S.; Gabrielson, M.; Lisok, A.; Wharram, B.; Pomper, M.G.; Nimmagadda, S. PD-L1
Detection in Tumors Using [(64)Cu]Atezolizumab with PET. Bioconjug Chem. 2016, 27, 2103–2110. [CrossRef]
92. Chatterjee, S.; Lesniak, W.G.; Lisok, A.; Wharram, B.; Kumar, D.; Gabrielson, M.; Miller, M.S.; Sikorska, E.;
Pomper, M.G.; Gabelli, S.B.; et al. Rapid PD-L1 detection in tumors with PET using a highly specific peptide.
Biochem. Biophys. Res. Commun. 2017, 483, 258–263. [CrossRef]
93. Mayer, A.T.; Gambhir, S.S.; Mayer, A.T.; Natarajan, A.; Gambhir, S.S.; Gordon, S.R.; Maute, R.L.;
McCracken, M.N.; Weissman, I.L.; Gordon, S.R.; et al. Practical Immuno-PET Radiotracer Design
Considerations for Human Immune Checkpoint Imaging. J. Nucl. Med. 2017, 58, 538–546.
94. Gonzalez, T.D.E.; Meng, X.; McQuade, P.; Rubins, D.; Klimas, M.; Zeng, Z.; Connolly, B.M.; Miller, P.J.;
O’Malley, S.S.; Lin, S.-A.; et al. In Vivo Imaging of the Programmed Death Ligand 1 by (18)F PET. J. Nucl.
Med. 2017, 58, 1852–1857. [CrossRef]
95. Miller, M.M.; Mapelli, C.; Allen, M.P.; Bowsher, M.S.; Boy, K.M.; Gillis, E.P.; Langley, D.R.; Mull, E.;
Poirier, M.A.; Sanghvi, N. Macrocyclic inhibitors of the PD-1/PD-L1 and CD80 (B7-1)/PD-L1 protein/protein
interactions. US9308236B2, 7 July 2016.
96. Zak, K.M.; Grudnik, P.; Guzik, K.; Zieba, B.J.; Musielak, B.; Dömling, A.; Dubin, G.; Holak, T.A. Structural
basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget 2016, 7, 30323–30335.
[CrossRef]
97. Konstantinidou, M.; Zarganes-Tzitzikas, T.; Domling, A.; Magiera-Mularz, K.; Holak, T.A.; Holak, T.A.
Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies? Angew. Chem. Int. Ed. Engl. 2018, 57,
4840–4848. [CrossRef]
98. Chen, T.; Li, Q.; Liu, Z.; Chen, Y.; Feng, F.; Sun, H. Peptide-based and small synthetic molecule inhibitors on
PD-1/PD-L1 pathway: A new choice for immunotherapy? Eur. J. Med. Chem. 2019, 161, 378–398. [CrossRef]
99. Lee, H.T.; Lee, S.H.; Heo, Y.-S. Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4
in immuno-oncology. Molecules 2019, 24, 1190. [CrossRef]
100. Kim, M.Y.; Zhang, T.; Kraus, W.L. Poly(ADP-ribosyl)ation by PARP-1: ‘PAR-laying’ NAD+ into a nuclear
signal. Genes Dev. 2005, 19, 1951–1967. [CrossRef]
101. Ray Chaudhuri, A.; Nussenzweig, A. The multifaceted roles of PARP1 in DNA repair and chromatin
remodelling. Nat. Rev. Mol. Cell Biol. 2017, 18, 610–621. [CrossRef]
102. Jain, P.G.; Patel, B.D. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors
as anticancer agents—A recent update. Eur. J. Med. Chem. 2019, 165, 198–215. [CrossRef]
103. Reiner, T.; Lacy, J.; Keliher, E.J.; Yang, K.S.; Ullal, A.; Kohler, R.H.; Vinegoni, C.; Weissleder, R. Imaging
therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. Neoplasia
2012, 14, 169–177. [CrossRef]
104. Irwin, C.P.; Portorreal, Y.; Brand, C.; Zhang, Y.; Desai, P.; Salinas, B.; Weber, W.A.; Reiner, T. PARPi-FL-a
fluorescent PARP1 inhibitor for glioblastoma imaging. Neoplasia 2014, 16, 432–440. [CrossRef] [PubMed]
105. Carney, B.; Carlucci, G.; Salinas, B.; Di Gialleonardo, V.; Kossatz, S.; Vansteene, A.; Longo, V.A.; Bolaender, A.;
Chiosis, G.; Keshari, K.R. Non-invasive PET imaging of PARP1 expression in glioblastoma models. Mol.
Imaging Biol. 2016, 18, 386–392. [CrossRef] [PubMed]
106. Kossatz, S.; Carney, B.; Schweitzer, M.; Carlucci, G.; Miloushev, V.Z.; Maachani, U.B.; Rajappa, P.; Keshari, K.R.;
Pisapia, D.; Weber, W.A.; et al. Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse
Models. Cancer Res. 2017, 77, 2112. [CrossRef] [PubMed]
107. Wilson, T.C.; Xavier, M.-A.; Knight, J.; Verhoog, S.; Torres, J.B.; Mosley, M.; Hopkins, S.L.; Wallington, S.;
Allen, P.D.; Kersemans, V.; et al. PET Imaging of PARP Expression Using 18F-Olaparib. J. Nucl. Med. 2019,
60, 504–510. [CrossRef]
108. Zhou, D.; Chu, W.; Xu, J.; Jones, L.A.; Peng, X.; Li, S.; Chen, D.L.; Mach, R.H. Synthesis, [18F] radiolabeling,
and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using
positron emission tomography. Bioorg. Med. Chem. 2014, 22, 1700–1707. [CrossRef]
227
Molecules 2020, 25, 568
109. Michel, L.S.; Dyroff, S.; Brooks, F.J.; Spayd, K.J.; Lim, S.; Engle, J.T.; Phillips, S.; Tan, B.; Wang-Gillam, A.;
Bognar, C.; et al. PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First
In-Human Studies. Radiology 2016, 282, 453–463. [CrossRef]
110. Yan, H.; Parsons, D.W.; Jin, G.; McLendon, R.; Rasheed, B.A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.;
Riggins, G.J.; et al. IDH1 and IDH2 Mutations in Gliomas. New Engl. J. Med. 2009, 360, 765–773. [CrossRef]
111. Sanson, M.; Marie, Y.; Paris, S.; Idbaih, A.; Laffaire, J.; Ducray, F.; El Hallani, S.; Boisselier, B.; Mokhtari, K.;
Hoang-Xuan, K. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in
gliomas. J. Clin. Oncol. 2009, 27, 4150–4154. [CrossRef]
112. Ye, D.; Ma, S.; Xiong, Y.; Guan, K.-L. R-2-hydroxyglutarate as the key effector of IDH mutations promoting
oncogenesis. Cancer Cell 2013, 23, 274–276. [CrossRef]
113. Kaminska, B.; Czapski, B.; Guzik, R.; Krol, S.K.; Gielniewski, B. Consequences of IDH1/2 mutations in
gliomas and an assessment of inhibitors targeting mutated IDH proteins. Molecules 2019, 24, 968. [CrossRef]
114. Popovici-Muller, J.; Lemieux, R.M.; Artin, E.; Saunders, J.O.; Salituro, F.G.; Travins, J.; Cianchetta, G.; Cai, Z.;
Zhou, D.; Cui, D.; et al. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the
Treatment of IDH1 Mutant Cancers. ACS Med. Chem. Lett. 2018, 9, 300–305. [CrossRef] [PubMed]
115. Cho, Y.S.; Levell, J.R.; Liu, G.; Caferro, T.; Sutton, J.; Shafer, C.M.; Costales, A.; Manning, J.R.; Zhao, Q.;
Sendzik, M.; et al. Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1
Inhibitor. ACS Med. Chem. Lett. 2017, 8, 1116–1121. [CrossRef] [PubMed]
116. DiNardo, C.D.; Schimmer, A.D.; Yee, K.W.L.; Hochhaus, A.; Kraemer, A.; Carvajal, R.D.; Janku, F.; Bedard, P.;
Carpio, C.; Wick, A.; et al. A Phase I Study of IDH305 in Patients with Advanced Malignancies Including
Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations. Blood 2016, 128, 1073. [CrossRef]
117. Chi, A.S. Trial of IDH305 in IDH1 Mutant Grade II or III Glioma. Available online: https://clinicaltrials.gov/
ct2/show/NCT02977689 (accessed on 30 September 2019).
118. Cicone, F.; Carideo, L.; Scaringi, C.; Arcella, A.; Giangaspero, F.; Scopinaro, F.; Minniti, G. 18F-DOPA uptake
does not correlate with IDH mutation status and 1p/19q co-deletion in glioma. Ann. Nucl. Med. 2019, 33,
295–302. [CrossRef]
119. Blanc-Durand, P.; Van Der Gucht, A.; Verger, A.; Langen, K.-J.; Dunet, V.; Bloch, J.; Brouland, J.-P.;
Nicod-Lalonde, M.; Schaefer, N.; Prior, J.O. Voxel-based 18F-FET PET segmentation and automatic clustering
of tumor voxels: A significant association with IDH1 mutation status and survival in patients with gliomas.
PLoS ONE 2018, 13, e0199379. [CrossRef]
120. Unterrrainer, M.; Winkelmann, I.; Suchorska, B.; Giese, A.; Wenter, V.; Kreth, F.W.; Herms, J.; Bartenstein, P.;
Tonn, J.C.; Albert, N.L. Biological tumour volumes of gliomas in early and standard 20-40 min 18F-FET
PET images differ according to IDH mutation status. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 1242–1249.
[CrossRef]
121. Verger, A.; Stoffels, G.; Bauer, E.K.; Lohmann, P.; Blau, T.; Fink, G.R.; Neumaier, B.; Shah, N.J.; Langen, K.-J.;
Galldiks, N. Static and dynamic 18F-FET PET for the characterization of gliomas defined by IDH and 1p/19q
status. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 443–451. [CrossRef]
122. Chitneni, S.K.; Reitman, Z.J.; Spicehandler, R.; Gooden, D.M.; Yan, H.; Zalutsky, M.R. Synthesis and evaluation
of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors.
Bioorg. Med. Chem. Lett. 2018, 28, 694–699. [CrossRef]
123. Chitneni, S.K.; Yan, H.; Zalutsky, M.R. Synthesis and Evaluation of a 18F-Labeled Triazinediamine Analogue
for Imaging Mutant IDH1 Expression in Gliomas by PET. ACS Med. Chem. Lett. 2018, 9, 606–611. [CrossRef]
124. Preibisch, C.; Shi, K.; Kluge, A.; Lukas, M.; Wiestler, B.; Goettler, J.; Gempt, J.; Ringel, F.; Al Jaberi, M.;
Schlegel, J.; et al. Characterizing hypoxia in human glioma: A simultaneous multimodal MRI and PET study.
NMR Biomed. 2017, 30, e3775. [CrossRef]
228
Molecules 2020, 25, 568
125. Thiele, F.; Ehmer, J.; Piroth, M.D.; Eble, M.J.; Coenen, H.H.; Kaiser, H.-J.; Schaefer, W.M.; Buell, U.; Boy, C.
The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with
glioblastoma. Phys. Med. Biol. 2009, 54, 5525–5539. [CrossRef] [PubMed]
126. Muzi, M.; Peterson, L.M.; O’Sullivan, J.N.; Fink, J.R.; Rajendran, J.G.; McLaughlin, L.J.; Muzi, J.P.;
Mankoff, D.A.; Krohn, K.A. 18F-fluoromisonidazole quantification of hypoxia in human cancer patients
using image-derived blood surrogate tissue reference regions. J. Nucl. Med. 2015, 56, 1223–1228. [CrossRef]
[PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution







Tel. +41 61 683 77 34






St. Alban-Anlage 66 
4052 Basel 
Switzerland
Tel: +41 61 683 77 34 
Fax: +41 61 302 89 18
www.mdpi.com ISBN 978-3-03936-721-4 
